Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations.

Introduction

Cellular protein homeostasis, or proteostasis, is a cornerstone of normal cellular health and functionality in all living organisms. This term describes the delicate balance between protein synthesis, folding, modification, trafficking, and degradation, ensuring a stable and functional proteome capable of executing the myriad tasks essential for life. From catalyzing metabolic reactions to mediating signal transduction, proteins constitute the molecular machinery driving cellular processes, and their proper folding and function are paramount. The three-dimensional conformation of a protein, which is dictated by its amino acid sequence and influenced by various cellular factors, directly determines its activity and function. Maintaining this precise structural integrity is a continuous challenge in the face of both intrinsic and extrinsic factors that can disrupt the folding process or destabilize already folded proteins, leading to a state of imbalance in the cell known as dysproteostasis.

There are a range of perturbations that result in the loss of proteostasis, including genetic mutations that alter amino acid sequences, errors during protein synthesis and post-translational modifications (PTMs), dysfunction of the molecular chaperones responsible for assisting protein folding, and various cellular stresses, such as heat shock, oxidative stress, and nutrient deprivation. The accumulation of misfolded or unfolded proteins can trigger cellular dysfunction, activate stress response pathways, and ultimately contribute to the development of a wide spectrum of diseases. In neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease, metabolic diseases such as type 2 diabetes, and various cancers, disruption of proteostasis is a key pathological determinant. Understanding the complex mechanisms that underlie dysproteostasis, the cellular responses it activates, and the specific ways it contributes to disease pathology is crucial for developing effective therapeutic interventions.

This review provides a comprehensive exploration of the multifaceted nature of protein folding, from its historical roots to its implications for human health. We begin by tracing the historical trajectory of protein folding research, highlighting the key discoveries and milestones that have shaped our understanding. This includes seminal work on protein denaturation, the elucidation of secondary structure elements, and Anfinsen’s thermodynamic hypothesis, providing a foundation for exploring the complexities of protein folding. We then delve into the various factors that can disrupt protein folding, examining the molecular mechanisms by which these perturbations lead to protein misfolding and aggregation. This review also examines cellular stress response pathways, including the heat shock response (HSR) and the unfolded protein response (UPR), which act as critical defense mechanisms against protein folding defects in the cell. These pathways, which are activated by the accumulation of misfolded proteins, initiate a complex cascade of events aimed at restoring proteostasis by enhancing protein folding capacity, increasing the degradation of misfolded proteins, and attenuating protein synthesis.

Finally, we examine the specific roles of dysproteostasis in a range of diseases, with a particular emphasis on neurodegenerative diseases and cancer. Cancer cells, characterized by uncontrolled proliferation and metabolic reprogramming, often experience high levels of proteotoxic stress due to increased protein synthesis and an altered cellular environment. However, they also display a remarkable ability to adapt to and even exploit dysproteostasis for their survival and progression. We discuss the specific mechanisms by which cancer cells manipulate proteostasis networks, including the UPR, to support their growth, metastasis, and resistance to therapy. This review aims to provide a foundation for understanding the underlying causes of protein misfolding and aggregation, examining the molecular mechanisms involved, and exploring potential therapeutic strategies to mitigate their impact on various diseases.

Historical perspective and milestone events in protein folding

The study of protein folding began in the mid-20th century and has evolved significantly over the past several decades, driven by both experimental and theoretical advancements. This section traces key discoveries and models that shaped our understanding of how proteins attain their functional three-dimensional structures and maintain homeostasis (Fig. 1 ). Fig. 1 Timeline of key discoveries in protein folding research. Over the last two centuries, protein folding research has seen multiple major discoveries. Some of the central developments in the field are chronologically represented. These enabled the formation of theoretical models that best represent our understanding of the underlying mechanisms. Much of the progress is due to significant technological advancements that were developed and/or implemented along the way

Early discoveries and foundational work (1800–1950s)

Proteins were first recognized as distinct biomolecules by Berzelius in 1838, with the first amino acid, asparagine, discovered in 1806 and all others discovered by 1935. 1 , 2 Fischer and Hofmeister’s 1902 proposal of linear peptide-bonded chains laid the foundation for structural studies. 2 Chick’s work (1910–1912) distinguished denaturation (loss of structure/function) from coagulation, 3 whereas Anson and Mirsky (1925) reported reversible unfolding of hemoglobin. 4 Wu (1931) later linked denaturation to conformational changes, establishing that structure dictates function. 5

Pauling and Corey’s discovery of α-helices and β-sheets (1951) revealed protein secondary structure principles. 6 Sanger sequencing of insulin (1953) revealed that proteins have unique sequences. 7 Kendrew and Perutz’s X-ray crystallography breakthroughs (1958–1960) solved myoglobin and hemoglobin structures, earning the 1962 Nobel Prize and revealing atomic-level protein architecture. 8 , 9 In the 1960s, the work of Christian Anfinsen on ribonuclease A demonstrated spontaneous refolding, leading to the principle that the native structure of a protein is determined solely by its amino acid sequence and represents the most thermodynamically stable conformation under physiological conditions. 10 This “thermodynamic hypothesis” became foundational but left unresolved questions about folding pathways.

Levinthal’s 1969 paradox highlighted that random conformational sampling is implausible. 11 Ptitsyn’s framework model (1973) proposed early secondary structure formation, 12 whereas Karplus and Weaver’s diffusion-collision model (1979) emphasized the formation of transient multimicrodomain intermediates during the folding pathway. 13 Although both models posit that early local structure formation is critical, the diffusion‒collision model emphasizes the role of molecular diffusion and collision events in assembling the complete fold. Moreover, collisions may also occur between microdomains that are not adjacent in the linear sequence, shifting focus from the individual amino acids that make up the polypeptide chain to the characteristics and interactions of microdomains. 14 This model, refined and validated throughout the 1980s, provided a mechanistic explanation for rapid folding without exhaustive conformational searches. 13 , 14

The late 1970s and 1980s saw the development of new experimental techniques that revolutionized protein folding research. Circular dichroism (CD) spectroscopy, fluorescence spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy have emerged as powerful tools for probing protein structure and dynamics. In particular, the application of NMR to protein studies, pioneered by Kurt Wüthrich and others, enabled the exploration of protein structures in solution and the observation of folding intermediates, providing critical insights into the dynamic nature of this process. 15

In 1995, the “nucleation‒condensation model” was introduced as a refinement to the “diffusion‒collision model”. 16 , 17 Rather than requiring the independent formation of all secondary structures prior to assembly, this model suggests that a small region, formed through a combination of local and long-range interactions, rapidly attains a native-like conformation. This nucleus then serves as a condensation center that drives the cooperative formation of the remaining structure, effectively reducing the conformational search space.

The 1990s introduced energy landscape theory, framing folding as a funnel-guided process where native states occupy energy minima. 18 , 19 The ruggedness of the folding landscape—arising from the presence of partially folded states and misfolded conformations—accounts for the heterogeneity and complexity observed in folding pathways. The formation of a native-like nucleus, as posited by the nucleation‒condensation model, corresponds to the initial descent down the funnel, where the entropic cost of organizing the chain is minimized by the formation of local interactions. Once this nucleus is established, the funnel-shaped landscape guides the rapid and cooperative assembly of the remaining structure despite the presence of kinetic traps.

In the early 2000s, Englander and colleagues proposed the “foldon model,” which introduces foldons—independently folding units within a protein. 20 According to this model, proteins fold in a modular, hierarchical manner, with discrete segments attaining native-like conformations before being assembled into the complete structure. This modular organization reduces the overall conformational search space and facilitates the cooperative assembly of the folded protein, aligning rapid folding kinetics with the complexity of the final native state. Hydrogen–deuterium exchange and site-directed mutagenesis experiments provided evidence supporting the existence of foldons, indicating that certain segments stabilize early in the folding process, whereas others complete their structural formation later. 21

Molecular chaperones: Orchestrating protein folding in the cellular milieu (1990s-present)

As our understanding of protein folding has increased, it has become evident that intracellular conditions—such as macromolecular crowding, physiological temperatures, and rapid translation rates—present challenges that increase the risk of protein misfolding and aggregation. 22 To counteract these challenges, cells utilize molecular chaperones: proteins that assist in proper folding, prevent aggregation, refold misfolded proteins, and aid in protein transport and degradation, thereby maintaining proteostasis.

The discovery of molecular chaperones originated from studies on cellular stress responses. In 1962, Ferruccio Ritossa reported chromosomal “puffs” in the salivary glands of heat-shocked fruit flies, indicating increased expression of specific genes encoding heat shock proteins (HSPs). 23 Initially perceived as mediating general stress responses, the functional significance of HSPs became clearer through subsequent research.

In 1973, Georgopoulos and colleagues reported that mutations in the groE gene of E. coli led to protein aggregation, suggesting the role of specialized proteins in facilitating proper folding. 24 In 1980, Barraclough and Ellis provided additional evidence for this concept by showing that a binding protein in chloroplasts assists in the assembly and folding of Rubisco, a key enzyme in photosynthesis. 25 Further evidence emerged in 1978 when Laskey et al. introduced the term “molecular chaperone” to describe the role of nucleoplasmin in preventing histone aggregation during nucleosome assembly. 26 John Ellis expanded this definition in 1987 to include proteins that assist in the correct folding and assembly of other polypeptides without becoming part of the final structure. 27 This was followed by the finding that purified chaperones could prevent the aggregation of unfolded polypeptides and facilitate their refolding in a Mg-ATP-dependent manner, highlighting the active role that chaperones play in protein folding. 28

These findings showed that protein folding often requires assistance to prevent misfolding and aggregation. Molecular chaperones are highly conserved across species, highlighting their fundamental role in proteostasis. Dysfunction of chaperones has been linked to diseases such as Alzheimer’s disease and Parkinson’s disease, which are characterized by protein misfolding and aggregation. As discussed below in Section “Molecular chaperones: Facilitators of protein folding dynamics”, molecular chaperones are now recognized not only for their role in protein folding but also for their involvement in protein transport, degradation, and signaling pathways.

Evolution of experimental techniques in protein folding research

Protein folding research has evolved significantly, driven by continuous advances in experimental techniques. These tools have enabled high-resolution probing of protein structure, dynamics, and energetics. While comprehensive overviews are available elsewhere, 29 here, we briefly highlight the major methods and recent developments.

The structural exploration of proteins began with X-ray crystallography. Starting in the 1950s and 1960s, with the structures of myoglobin and hemoglobin, 9 it provided atomic-level insights. Despite its power, X-ray crystallography is limited to static, crystalline snapshots that may not reflect native conformations, and not all proteins crystallize easily. To overcome such limitations, CD spectroscopy emerged in the 1960s–70 s, enabling rapid estimation of secondary structure content. 30 , 31 The development of stopped-flow CD later allowed the capture of fast structural transitions that were previously inaccessible. 32 Simultaneously, fluorescence spectroscopy and Förster Resonance Energy Transfer (FRET) became essential for monitoring conformational changes. 33 FRET, introduced in the 1970s, functions as a “spectroscopic ruler,” measuring nanometer-scale distances to probe folding mechanisms. 34

Since the late 1980s, NMR spectroscopy has transformed the field, enabling the study of proteins in solution or membrane-like environments. 15 The development of multi-dimensional NMR techniques, such as two-dimensional (2D) NMR, has enabled the study of larger proteins and more complex structures in solution or in lipid environments under near-native conditions. 35 Unlike crystallography, NMR captures the dynamic behavior of proteins, making it especially valuable for examining intrinsically disordered proteins (IDPs) and fold-switching proteins that do not adopt a single stable structure. 36

Further improvements to X-ray crystallography came with synchrotron radiation in the 1970s–80 s, increasing resolution and speed. 37 Around the same time, early foundations were laid down for cryo-electron microscopy (cryo-EM) and single-molecule techniques such as optical tweezers, although their application to folding studies matured only in the 1990s, when several pivotal techniques emerged. 38 , 39 Cryocrystallography improved X-ray resolution by reducing radiation damage through cryogenic cooling. 40 Single-molecule FRET (smFRET) enabled real-time tracking of folding at the individual molecule level, revealing conformational heterogeneity. 41 , 42 In the meantime, a major leap in NMR came with the introduction of TROSY (transverse relaxation optimized spectroscopy) in 1997, allowing studies of larger proteins by mitigating signal broadening. 43 Moreover, fluorescence correlation spectroscopy (FCS) advanced the analysis of protein dynamics at low concentrations and fast timescales. 44

By the early 2000s, atomic force microscopy (AFM) enabled the mechanical manipulation of single proteins, the mapping of energy landscapes and rare folding events. 45 , 46 In parallel, advancements in hydrogen-deuterium exchange mass spectrometry (HDX-MS) and native MS have provided high-resolution data on protein stability and conformational dynamics. 47 The 2010s marked a turning point for cryo-EM with direct electron detectors and improved image processing. 48 , 49 This revolutionized 3D structural reconstruction at near-atomic resolution, capturing folding intermediates and dynamic complexes. Serial crystallography using XFELs further expanded time-resolved structural studies, revealing protein motion on femtosecond timescales. 50 Moreover, real-time NMR techniques have been developed and track folding pathways as they occur, whereas integrative approaches—combining multiple methods—have become central in the study of protein structure and dynamics. 51

In addition to direct folding studies, methods such as deep mutational scanning and display technologies (yeast, phage, ribosome) have emerged to evaluate the functional impact of mutations. 52 – 54 These approaches use large variant libraries and high-throughput selection to map sequence‒function relationships, which is particularly useful for protein engineering and understanding fitness landscapes. Most recently, cDNA proteolysis has enabled large-scale quantification of folding stability. 55 By combining cell-free systems with next-generation sequencing, researchers have assessed the thermodynamic stability of nearly one million protein variants in just one week. This technique offers insights into side chain thermodynamic couplings and generates rich datasets for protein design and machine learning models for folding prediction.

Experimental detection of protein aggregation and misfolding

In addition to structural techniques for probing protein structure and folding, a variety of chemical agents and imaging strategies have been developed to detect misfolded proteins and aggregates. These approaches, while often less structurally detailed than biophysical methods, offer highly practical tools for monitoring protein aggregation kinetics and studying the pathogenic roles of misfolded proteins in disease states.

Dyes such as Congo Red (CR) and Thioflavin T (ThT) remain among the most widely used tools for detecting amyloid fibrils and other β-sheet-rich aggregates. 56 , 57 These dyes exploit the structural hallmarks of aggregated proteins, including extended cross-β architectures, to produce characteristic optical signatures. The CR binds to β-sheet regions via hydrophobic and electrostatic interactions, yielding distinctive green birefringence under polarized light. 58 However, its labor-intensive staining protocols and limited sensitivity for early aggregates have motivated the search for alternative methods. 56

ThT offers a fluorescence-based approach, displaying strong signal enhancement upon binding to amyloid fibrils, likely due to restricted intramolecular rotation. 56 ThT is widely used to monitor amyloid formation kinetics, although its sensitivity for detecting early-stage oligomers is limited. 59 Structurally related dyes, including thioflavin S, and newly developed small-molecule probes with higher affinities for soluble oligomers, such as BD-Oligo and TAMAOP derivatives, have broadened the toolkit for studying early aggregation events. 57

More recent efforts have introduced luminescent conjugated oligothiophenes (LCOs), such as p-FTAA and hFTAA, which exhibit solvatochromic behavior (a reversible change in the absorption or emission spectrum of these probes that is induced by the action of solvents) and spectral shifts depending on the aggregation state or target protein. 60 , 61 Thiophene-based dyes with specificity for tau aggregates, such as bTVBTs and pTP-TFE, are particularly valuable in the study of tauopathies. 62 , 63 Near-infrared (NIR) probes and dual-emission dyes have further advanced real-time, in vivo imaging capabilities, offering deeper tissue penetration and reduced background fluorescence. 64 , 65

In clinical research, radiotracers derived from ThT, such as Pittsburgh compound B (PiB), pioneered noninvasive positron emission tomography (PET) imaging of amyloid deposits in the brain. 66 Subsequently, 18F-labeled tracers, including florbetapir and florbetaben, which have improved imaging protocols and are now used routinely for Alzheimer’s disease (AD) diagnostics, were developed. 67 – 69 Similar approaches have been applied to tau pathology, with first-generation tau PET tracers such as flortaucipir providing valuable but sometimes nonspecific imaging. 70 Second-generation tracers, including RO948 and PI-2620, aim to increase specificity, although off-target binding remains a challenge. 71 Promising candidates such as SNFT-1 are now emerging with improved sensitivity and reduced off-target effects for tau imaging. 72

Together, these methods complement advanced structural techniques by enabling the detection, quantification, and in vivo visualization of protein aggregates, bridging molecular insights with disease-relevant pathology.

Computational and theoretical approaches: simulating folding processes

In addition to experimental techniques, computational and theoretical methods have been central to elucidating the complex problem of protein folding—from early conceptual models to recent state-of-the-art AI-driven predictions that achieve near-atomic resolution.

Initial efforts in the mid-20th century employed simplified lattice models, notably the hydrophobic–polar (HP) model, which yielded fundamental insights into hydrophobic collapse and the role of energy landscapes in guiding folding. 73 These foundational approaches paved the way for molecular dynamics (MD) simulations in the 1970s, which utilized detailed force fields such as CHARMM and GROMOS to model atomic-level folding pathways. 74 By the late 20th century, advancements, including all-atom force fields, solvent models, enhanced sampling techniques (replica exchange, metadynamics), and distributed computing projects such as Folding@home, enabled MD simulations to explore larger systems and longer timescales. 75 , 76 Subsequent refinements, including coarse-grained models and GPU acceleration, have further improved the efficiency and scalability of computational folding studies. 77 , 78

A transformative breakthrough in computational methods for protein folding occurred with the advent of deep learning. Early machine learning efforts assisted in clustering conformational landscapes and analyzing simulation data. 79 , 80 Later, techniques such as support vector machines and decision trees were applied to predict structural features from sequence data via known protein structures. 81 However, a defining milestone was achieved with AlphaFold, which first participated in CASP13 in 2018 and revolutionized the field with AlphaFold2 at CASP14 in 2020. 82

AlphaFold2 introduces a transformer-based architecture that integrates attention mechanisms and evolutionary couplings to predict heavy-atom coordinates from sequences alone with near-experimental accuracy. 82 Prior to AlphaFold2, only approximately 17% of the human proteome had experimentally determined structures. Following its release, the publicly available AlphaFold protein structure database expanded structural coverage to over 200 million proteins, spanning nearly all known sequences, with built-in confidence scores that also enable identification of intrinsically disordered regions. 83

Building on this success, other deep learning models, such as RoseTTAFold, ESMFold, and OmegaFold, have emerged, offering diverse strengths, from rapid single-sequence predictions to modular frameworks capable of incorporating user-defined constraints. 84 – 86 Extending beyond single-protein predictions, AlphaFold-Multimer addresses protein complexes with improved interface predictions, which are especially effective for coevolved complexes but are currently limited in antibody‒antigen interactions. 87 , 88 To address many of these limitations, AlphaFold3 leverages diffusion-based neural networks to model complex biomolecular assemblies, markedly enhancing predictions for protein–ligand, protein–nucleic acid, and antibody–antigen interactions. 89 Similarly, complementary tools such as RoseTTAFold All‑Atom also extend predictions to heterogeneous biological complexes, bringing “color” to the “black‑and‑white” of prior protein-only models.

Despite the remarkable progress in AI-driven structure prediction, current models predominantly generate static conformations, leaving protein dynamics—including transient interactions, conformational ensembles, and intrinsically disordered regions—less well characterized. In this respect, AI models function as highly accurate “black boxes” for structure prediction but not for folding mechanisms. Therefore, traditional computational methods—MD simulations and physics-based coarse-grained models—are essential for investigating dynamic folding pathways and mechanistic insights. Recent innovations, such as the Wako-Saitô-Muñoz-Eaton (WSME-L) model, incorporate long-range interactions and disulfide bonding, rapidly generating interpretable folding landscapes and mechanisms that are consistent with experimental observations. 90 , 91

Furthermore, with this wealth of unprecedented knowledge, protein design has entered the spotlight. AlphaProteo, a recently introduced AI‑driven system, moves beyond prediction to generate novel, high‑affinity protein binders. 92 By leveraging extensive databases (including AlphaFold‑predicted structures), preliminary results from AlphaProteo have demonstrated remarkable success rates and significant improvements in binding affinities, opening new avenues for drug design and therapeutic development.

AI‑based predictions now routinely guide experimental design: static models provide blueprints for crystallography, cryo‑EM, and NMR, whereas MD and physics‑based simulations refine our understanding of protein dynamics and folding mechanisms. The feedback loop between computations and experiments is rapidly accelerating progress in structural biology, protein engineering, and drug discovery. Looking ahead, the trend is toward unified frameworks that predict not only a single static structure but also an entire conformational ensemble, accounting for dynamics, multicomponent interactions, and even co-translational effects. As AI methods converge with enhanced MD simulations and refined theoretical models, we approach a future where the complete biophysical behavior of proteins—including misfolding and functional modulation—can be predicted with high fidelity.

In summary, while early computational tools provided the theoretical foundation for understanding protein folding, the last five years—especially the last two—have seen an unprecedented transformation through AI. This revolution, together with evolving physics-based approaches, is not only enabling accurate structural predictions but also paving the way toward a deeper, mechanistic understanding of protein folding—and its rational manipulation for biomedical and biotechnological applications. As we better interpret these AI models, we might extract new principles of protein folding. A key emerging direction is the integration of structure prediction with the cellular context. Proteins fold in vivo within crowded, dynamic environments; future AI models will take this into account and may incorporate currently ignored biological constraints, enabling prediction of folding pathways as polypeptides emerge from the ribosome or modeling the effects of intermolecular interactions on folding efficiency and misfolding prevention.

Molecular chaperones: facilitators of protein folding dynamics

Molecular chaperones are essential for maintaining protein homeostasis by assisting in the correct folding of proteins, preventing aggregation, and facilitating the degradation of misfolded proteins. They are broadly categorized on the basis of their molecular weight, structure, and function. Major families include heat shock proteins (HSP40, HSP60, HSP70, HSP90, and HSP100), small HSPs (sHSPs), and chaperonin-containing TCP-1 (CCT) complexes. A detailed classification, including their specific functions, cellular localization, oligomeric forms, and mechanisms of action, is summarized in Table 1 . Table 1 Classification and functional overview of human molecular chaperone families Family Genes Oligomeric form Core mechanism Compartment(s) Functions/Targets HSP70 (17 members) HSPA1A/1B/1 L/2/4/4 L/5–9/12 A/12B/13/14; HSPH1; HYOU1 Monomer (forms transient complexes) ATP-dependent binding and release cycle for hydrophobic client regions Cytosol, ER (BiP), mitochondria (mtHSP70/Grp75) Nascent chains, stress-unfolded proteins, translocating polypeptides; prevents aggregation; co-translational folding and protein import, ERAD HSP90 family (5 members) HSP90A-A1/B1/A3P; HSP90B1;TRAP1 Obligate dimer ATP-driven conformational clamp for client maturation Cytosol, ER (GRP94), mitochondria (TRAP1), nucleus Kinases, hormone receptors, transcription factors; and assists in late folding Small HSPs (11 members) HSPB1-11 Dynamic oligomers (dimers → 24+mers) ATP-independent holdase, dynamic binding of misfolded proteins Cytosol, mitochondria, nucleus and other organelles Stress-denatured proteins, amyloidogenic proteins; prevents aggregation, aids in cytoskeletal stability, acts in oxidative stress HSP40 family (49 members) DNAJA1-4; DNAJB1-14 (except 10); DNAJC1-30; DNAJC5B/G Monomer (JC) or dimer (JA and JB) Co-chaperone of HSP70; substrate targeting and ATPase stimulation Cytosol, ER, mitochondria, nucleus, and other organelles Client delivery to HSP70, diverse isoform-specific functions including suppression of polyQ aggregation (DNAJB6), targets proteins for proteasomal degradation HSP110 HSPH1 Monomer NEF for HSP70; also has disaggregase activity Cytosol Key component in disaggregase triad with HSP70 and DNAJA1/B1 Chaperonins HSPD1/E1 HSPD1: two stacked heptameric rings; HSP10: 7-mer Encloses substrates for ATP-driven folding cycles Mitochondrial matrix Mitochondrial matrix proteins, folding imported proteins CCT1-8/6B (TRiC/CCT) Two stacked octameric rings Encloses substrates for ATP-driven folding cycles Cytosol Actin, tubulin, WD40 domain proteins, complex clients with β-propeller structures CLPB (HSP100 AAA⁺) Double hexamer ATP-dependent disaggregase Mitochondrial intermembrane space Misfolded or aggregated mitochondrial proteins NEFs BAG1–6, HSPBP1, SIL1, GRP170 Monomers or dimers Catalyze ADP → ATP exchange on HSP70; regulate client release Cytosol (BAG1–6), ER (SIL1, GRP170), nucleus Controls duration of HSP70 binding; regulates decision between folding and degradation

In the following subsections, we discuss the key members of these chaperone families in greater detail, highlighting their specialized roles and functional interplay during protein folding in specific cellular compartments (Fig. 2 ). Fig. 2 Protein folding, quality control mechanisms, and import into cellular organelles. Protein folding in the ER, mitochondria, and cytosol is tightly regulated by chaperones, co-chaperones and other regulatory proteins to ensure proteostasis. In the cytosol, newly synthesized proteins undergo folding with the assistance of molecular chaperones such as HSP70, which facilitates general protein folding with the aid of co-chaperones like BAG1 and HSPBP1. Some specialized clients require additional processing by HSP90, while others undergo folding via TRiC (TCP-1 Ring Complex). Misfolded proteins that cannot be refolded are targeted for proteasomal degradation or autophagy, with HSP110, small HSPs, and disaggregases playing key roles in aggregate clearance. In the ER, protein synthesis is coupled with folding, mediated by chaperones such as BiP (HSP70 family member), which prevents premature folding and regulates the UPR via IRE1, PERK, and ATF6. ERAD clears irreversibly misfolded proteins through retrotranslocation to the cytosol and proteasomal degradation. Folding of glycosylated proteins is assisted by calreticulin and calnexin, while GRP94 (HSP90 family member) and PDIs facilitate proper disulfide bond formation and stabilization. Mitochondrial protein import is mediated by the TOM/TIM complexes, with GRP75 facilitating the translocation into the mitochondrial matrix where proteins subsequently achieve their functional conformation with the aid of mitochondrial chaperones HSP60 and HSP10

Cytosolic folding and triage hub

HSP70

The HSP70 family members are highly conserved and central to protein folding, refolding, and translocation across membranes. 93 , 94 They represent up to 5% of total cellular proteins even under normal conditions. 95 Human HSP70 family members, encoded by 16 genes, exhibit distinct localizations and functions. For example, HSPA8 (HSC70) is constitutively expressed in the cytosol, whereas HSPA1A/B (HSP70) is stress inducible. Organelle-specific isoforms include HSPA5 (BiP/GRP78) in the ER and HSPA9 (mtHsp70/mortalin/GRP75) in the mitochondria.

Structurally, HSP70 proteins contain two main domains: an N-terminal nucleotide-binding domain (NBD) and a C-terminal substrate binding domain (SBD). 93 , 94 ATP binding and hydrolysis in the NBD drive conformational changes in the SBD, modulating its affinity for substrates. The SBD consists of a β-sheet region that captures hydrophobic stretches of unfolded proteins and an α-helical lid that controls substrate binding and release. ATP-bound HSP70 has lower substrate affinity, facilitating release, whereas hydrolysis to ADP stabilizes substrate binding, promoting protein folding. 96

A flexible linker region transmits allosteric signals between the NBD and SBD, coordinating substrate interactions with ATP hydrolysis cycles. 97 Co-chaperones, especially HSP40 members (J-domain proteins), stimulate ATP hydrolysis, enhance substrate binding, and facilitate client delivery to HSP70. 98 Conversely, nucleotide exchange factors (NEFs), such as BAG1 (BCL-2-associated athanogene 1) and HSPBP1 (HSP Binding Protein 1), promote ADP release and ATP rebinding, resetting the HSP70 cycle for new substrate interactions. 98 Since ADP release is often the rate-limiting step, NEFs play a central role in accelerating HSP70 turnover. By enhancing nucleotide exchange, NEFs facilitate timely substrate release and rebinding. Additionally, some NEFs, such as BAG1 and HSP110, link HSP70 to downstream pathways: BAG1 contains a ubiquitin-like domain that can recruit the proteasome, coupling failed folding attempts to protein degradation.

A critical function of HSP70 in cellular proteostasis is in making critical triage decisions regarding misfolded proteins—specifically, whether to attempt refolding or to target them for degradation (Fig. 2 ). 99 HSP70 does not actively “discern” between repairable and irreparable proteins; rather, the fate of a substrate is largely determined by how long it remains bound to HSP70. When a misfolded protein engages HSP70, the co-chaperone CHIP (C-terminus of HSP70 Interacting Protein)—which functions as an E3 ubiquitin ligase—stochastically interacts with the HSP70–substrate complex. 99 , 100 Because CHIP is present at a relatively low abundance (with estimates suggesting that only approximately 1–10% of HSP70 complexes are bound by CHIP at any given time), only a subset of substrates are ubiquitinated. The probability of ubiquitination increases with the duration of the substrate’s association with HSP70—that is, if the protein fails to achieve its proper conformation quickly, it remains bound longer and thus becomes more likely to be tagged for proteasomal degradation. In this way, CHIP-mediated ubiquitination is biased toward proteins that persistently misfold, serving as an intrinsic triage decision mechanism. Moreover, this process is fine-tuned by additional layers of regulation. Co-chaperones such as HOP and BAG1 promote protein folding by facilitating the transfer of certain substrates from HSP70 to HSP90. 101 In contrast, CHIP competes with these co-chaperones for binding to HSP70 and directs bound substrates toward degradation. 99 The mutual exclusivity of these interactions is due to overlapping binding sites on HSP70, particularly within its C-terminal EEVD motif, which is recognized by the tetratricopeptide repeat (TPR) domains of these co-chaperones. 98 , 102

Post-translational modifications provide additional regulatory complexity to HSP70 activity by modifying chaperone interactions and substrate affinities. 103 For example, phosphorylation at Thr636 of HSP70 shifts the substrate fate from degradation to refolding. 104 Similarly, the AMPylation of ER-resident HSP70 (BiP) at Thr518 reduces its activity under non-stress conditions, whereas stress-induced deAMPylation restores its protein-folding ability. 105 , 106 These reversible PTMs enable the dynamic adaptation of chaperone function to changes in the cellular environment.

HSP90

HSP90 functions downstream of HSP70, facilitating the maturation of specific client proteins, including kinases and steroid hormone receptors (Fig. 2 ). 107 , 108 It operates as an obligate dimer composed of three conserved domains: an N-terminal domain involved in nucleotide binding (NTD), a middle domain involved in client binding and ATP hydrolysis, and a C-terminal domain (CTD) responsible for dimerization. 107 , 108 Eukaryotic HSP90 isoforms also contain a flexible, charged linker between the NTD and middle domain, modulating conformational dynamics and co-chaperone interactions, and a conserved C-terminal MEEVD motif that binds TPR-domain co-chaperones such as HOP, CHIP, and immunophilins.

The HSP90 chaperone cycle is driven by ATP-dependent conformational changes: in the apo-protein or ADP-bound state, the dimer adopts an open, V-shaped conformation; ATP binding induces NTD dimerization, forming a closed clamp around the client protein. 109 This dynamic “molecular clamp” undergoes twisting and tightening movements that stabilize partially folded clients. Unlike HSP70, which binds short peptide motifs, HSP90 engages clients holistically, threading them through its dimer lumen. In addition, HSP90 can act as a holdase, sequestering aggregation-prone proteins in an ATP-independent manner and buying time for proper folding or degradation. 110 For further details, please see 109 , 111

The transfer of client proteins from HSP70 to HSP90 is typically mediated by the co-chaperone HOP (HSP70-HSP90 Organizing Protein). 107 HOP acts as a molecular bridge, simultaneously binding to HSP70 and HSP90 through its TPR domains, which specifically recognize the C-terminal EEVD motifs of both chaperones. 102 This ensures efficient client handover. However, recent findings revealed that HOP is not strictly essential for proteostasis: HOP knockout human cells retain viability and even display improved folding of many HSP90 substrates. 112 Immunoprecipitation experiments have shown that HSP70 and HSP90 can still interact in the absence of HOP, and only a subset of clients are negatively impacted, suggesting alternative pathways or compensatory mechanisms. 112 The precise nature and regulation of these alternative pathways remain open research questions.

Conformational transitions of HSP90 are further modulated by co-chaperones. p23 stabilizes the closed ATP-bound state, prolonging the folding window for sensitive clients. 111 Conversely, AHA1 accelerates ATP hydrolysis by interacting with the NTD and MD, shortening the closed-state dwell time—which is beneficial for some clients but detrimental if prematurely released. 113 CDC37, a kinase-specific co-chaperone, binds the HSP90 NTD and inhibits ATPase activity while tethering kinase clients, maintaining HSP90 in an open conformation until proper timing for activation is reached. 114 Collectively, these co‑chaperones fine‑tune the HSP90 clamp, ensuring that each client is released at the appropriate conformational stage for productive maturation—or, if necessary, directed toward degradation.

Mitochondrial protein import

Mitochondria import ~99% of their proteome from the cytosol, which necessitates a highly regulated system for importing nuclear-encoded proteins into various mitochondrial subcompartments. 115 – 118 Cytosolic HSP70, together with the mitochondrial import‑stimulating factor (MSF) and HSP90, recognizes N‑terminal presequences and maintains precursor polypeptides in an unfolded, import‑competent conformation. 118 These chaperone–precursor complexes dock on the outer‑membrane receptor TOMM70 (translocase of the outer mitochondrial membrane 70), thereby guiding substrates to the translocase of the outer membrane for passage (Fig. 2 ). 118

After traversing the outer membrane through the TOM complex, preproteins encounter the TIM23 (translocase of the inner membrane 23) complex, which works alongside the PAM (presequence translocase-associated motor) complex to facilitate their import into the mitochondrial matrix and inner membrane. 116 Here, another member of the HSP70 family, mtHSP70 (Mortalin/GRP75), takes center stage (Fig. 2 ). 115 , 116 mtHSP70, one of the most abundant proteins in the mitochondrial matrix, possesses a canonical HSP70 family structure but uniquely harbors a 46-residue mitochondrial presequence at its N-terminus and lacks the typical C-terminal EEVD motif. 119 mtHSP70 binds to incoming preproteins in an ATP-dependent manner, pulling them into the matrix via the TIM23 channel. 116 , 117 This energy-dependent translocation process is tightly regulated and facilitated by a coordinated network of co-chaperones. TIM44 anchors mtHSP70 to the TIM23 complex, ensuring its proper localization, whereas HEP1 prevents the aggregation of mtHSP70 and controls its ATPase activity. 116 , 120 J-proteins (TID-1L, TID-1S) mediate substrate binding to mtHSP70, while GRPEL1 and GRPEL2 regulate its ATPase activity and strengthen interactions with incoming substrates. 121 Importantly, while a fraction of mtHSP70 is dedicated to the import process, the majority of these proteins are involved in the folding of newly imported proteins. 93

Upstream of HSP70s, the HSP40 family of chaperones plays a crucial role in optimizing mitochondrial protein import. 93 For example, the deletion of Ydj1, the most abundant HSP40 homolog in yeast, significantly hinders this process. 122 Similarly, in mammalian cells, Ydj1 homologs, such as DNAJA1, support the import of matrix-targeted proteins into mitochondria. 122 , 123 The ER-bound J-domain protein Djp1, a yeast HSP40 homolog, directs certain proteins to the mitochondrial outer membrane via an unusual pathway termed ER surface-mediated protein targeting. 124 Collectively, these cytosolic and membrane‑bound J‑proteins ensure that precursors arrive in the matrix poised for encapsulation by the HSP60/HSP10 system discussed in the following section.

Mitochondrial protein folding-HSP60/HSP10 chaperonin machinery

After translocation into the matrix, many precursors achieve their native conformation inside the HSP60/HSP10 chaperonin cage (Fig. 2 ). Human HSP60 (HSPD1) is the mitochondrial member of the group I chaperonin family and works with its co‑chaperonin HSP10 (HSPE1), mirroring the GroEL/ES system first characterized in E. coli . 94 , 125 Two stacked heptameric HSP60 rings create a barrel that enfolds substrates up to ~60 kDa. Binding of an unfolded chain and ATP triggers HSP10 to cap the cavity; within this isolated, hydrophilic chamber, the client folds and is released after ATP hydrolysis. Multiple rounds can occur, although some substrates mature in a single cycle. 126

PTMs significantly enhance and regulate the functional versatility of HSP60 by modulating its activity, substrate specificity, and localization [for reviews, see 127 , 128 ]. The phosphorylation of HSP60 at Tyr227 and Tyr243 enhances chaperone activity, thus supporting cancer cell survival and proliferation through the activation of oncogenic signaling pathways. 129 Nitration of HSP60 under oxidative stress can impair its chaperone function by inducing conformational changes, leading to mitochondrial dysfunction due to the accumulation of misfolded proteins. 127 Nitrated HSP60 may also be translocated to exosomes for secretion, where it acts as a proinflammatory signal in the extracellular environment. 127

Intriguingly, the functions of HSP60 extend beyond the mitochondria, with its presence in various cellular compartments, such as the cytosol, plasma membrane, and extracellular environment. 130 – 132 These findings challenge the initial notion that HSP60 is solely a mitochondrial protein and suggest a multifaceted role in cellular physiology. Recent work has revealed that, under mild oxidative stress, mitochondrial HSP60 can be actively released into the cytosol through a p38/MK2–MFF1–VDAC–dependent pathway. 133 Once in the cytosol, HSP60 engages the IκB kinase complex, activating NF-κB–driven transcription of pro-survival genes. Blocking either its release or its interaction with IKK sensitizes cancer cells to oxidative stress and suppresses tumor growth in vivo, underscoring HSP60’s role as a messenger in a mitonuclear survival axis. Moreover, the presence of HSP60 on the cell surface and in the extracellular milieu has been linked with the activation of immune responses, where it acts as a damage-associated molecular pattern (DAMP) and signals to immune cells, thereby influencing inflammatory pathways, 134 , 135 which is particularly relevant in understanding autoimmune diseases and cancer.

Chaperones in the endoplasmic reticulum (ER)

The ER plays a central role in the synthesis, folding, modification, and trafficking of proteins destined for secretion, membrane insertion, or transport to other organelles, constituting approximately one-third of the cellular proteome. 136 Like mitochondria, the ER houses a complex network of molecular chaperones and folding enzymes that ensure proper protein conformation and function. Misfolded proteins within the ER can trigger stress responses and compromise cell viability. 137 , 138

ER chaperones can be grouped on the basis of their function in protein folding and quality control: ATP-dependent chaperones (e.g., BiP/HSPA5/GRP78), lectin chaperones (calnexin, calreticulin), and protein disulfide isomerases (PDIs) (Fig. 2 ). 139 These proteins cooperate to prevent aggregation, promote folding, and retain unfolded proteins until proper conformation is achieved.

BiP: The central regulator of folding in the ER

BiP (GRP78/HSPA5) is the most abundant luminal chaperone in the ER and the archetypal member of the HSP70 family. 140 By clamping exposed hydrophobic stretches on nascent or misfolded chains, BiP prevents premature aggregation, assists in folding, and acts as a molecular sentinel that gauges the protein folding load. 141 Its ATP‑driven open‑and‑closed cycle not only controls substrate binding and release but also modulates the activation state of the three canonical UPR sensors; this couples local proteostatic demand to global transcriptional and translational reprogramming. 142 , 143

The versatility of BiP is expanded by six ER‑resident J‑domain proteins (ERdjs) that stimulate its ATPase activity and target it to distinct client proteins. 141 ERdj1 (DNAJC1) and ERdj2/SEC63 anchor at the Sec61 translocon, synchronizing translation with chaperone availability and actively threading precursors with weak signal sequences into the lumen. 144 , 145 ERdj3 (DNAJB11) binds directly to unfolded proteins, facilitates their transfer to BiP, and stimulates the ATPase activity of BiP to enhance its chaperone function. 146 Persistent non‑native conformers are triaged by ERdj4 (DNAJB9) and ERdj5 (DNAJC10), in addition, ERdj4 escorts aberrant clients to the retro‑translocon and, under stress, attenuates IRE1 signaling. 147 , 148 ERdj5, an oxidoreductase of the PDI family, reduces incorrect disulfide bonds to prepare substrates for ER‑associated degradation (ERAD). 149 This reductase activity prepares misfolded proteins for dislocation from the ER and subsequent degradation by the proteasome in the cytosol. ERdj6 (DNAJC3), also known as p58 IPK , resides in the ER under normal conditions and binds to both unfolded protein substrates and BiP. 150 , 151 During stress, its translocation into the ER becomes less efficient, leading to its accumulation in the cytosol. 150 In the cytosol, p58 IPK inhibits the eIF2α protein kinases PKR, GCN2 and PERK, which are involved in regulating protein synthesis during stress responses. 152 – 154 Through this coordinated network of specialized J‑proteins, BiP forms the hub of a dynamic quality‑control grid that links co-translational translocation, luminal folding, disposal of chronic misfolds, and UPR signaling into an integrated proteostasis module.

GRP94: ER‑resident HSP90

GRP94 (glucose-regulated protein 94, also known as GP96 or HSP90B1) is the sole Hsp90 paralog in the ER and is specialized for the maturation of a select subset of secretory and membrane proteins, including integrins, Toll-like receptors (TLRs), and insulin-like growth factors (IGFs). 155 These clients are often large, multidomain proteins whose functional assembly depends on GRP94-mediated conformational refinement and quality control.

Structurally, GRP94 functions as an obligate homodimer composed of three domains per monomer: an N-terminal ATPase domain (NTD), a middle domain involved in client and co-chaperone interactions, and a C-terminal dimerization domain. 156 Its activity is regulated by a unique pre-N-terminal extension that acts as a molecular gatekeeper, suppressing premature ATP-driven closure and thereby stabilizing partially open conformations conducive to client engagement. 156 , 157 ATP binding triggers local conformational rearrangements, particularly in the NTD lid region, while ATP hydrolysis drives the transition into a catalytically competent closed state needed for productive client folding.

Recent structural and biophysical studies have mapped the conformational ensemble of GRP94 in solution, showing that even in the presence of ATP analogs or ADP, a substantial proportion ( ~60%) of the protein remains in a persistently open “V” state; the nucleotide state instead governs transitions among compact conformers (twist-V and closed-V). 158 Single-molecule FRET reveals that the transition toward a fully closed state is rate limited and can be specifically accelerated by BiP. 159 The Pre-N domain is essential in balancing this cycle—its removal increases the ATPase rate but impairs the maturation of authentic clients, confirming its allosteric regulatory role. 157

In contrast to cytosolic HSP90s, which rely on an extensive network of co-chaperones to regulate their conformational cycles, GRP94 interacts directly with BiP to form a minimal but highly coordinated Hsp70‒Hsp90 system in the ER (Fig. 2 ). 159 This collaboration does not require bridging co-chaperones like HOP. Instead, BiP, particularly in its ADP-bound state, binds to GRP94 via a conserved interface, stabilizing a partially closed GRP94 conformation and promoting dimer closure and ATP turnover. Structural and crosslinking studies have identified two functionally distinct BiP–GRP94 complexes: a “preloading” state involving the docking of BiP onto open GRP94 and a “loading” state stabilized by the engagement of a second BiP, which primes GRP94 for client capture. 160 The ER J-protein DNAJB11 enhances this interaction by accelerating BiP’s ATP hydrolysis and maintaining BiP in a client-bound, ADP-stabilized conformation optimal for GRP94 recruitment. 161

The chaperoning mechanism of GRP94 is multifaceted. Under mild stress conditions, it functions in tandem with BiP to support ATP-dependent folding. Under a heightened proteostatic burden, however, GRP94 can switch to an ATP hydrolysis–independent “holding” mode, buffering unfolded clients and preventing their aggregation until folding conditions improve. 156 , 161 This dual capacity underlines the unique position of GRP94 in the ER folding landscape—bridging the gap between generalist and specialist chaperone functions.

Importantly, the regulation of client affinity by the nucleotide state is a key feature of the mechanism of GRP94. 156 , 162 ATP binding reduces the substrate-binding affinity of GRP94, allowing for the release and subsequent maturation of clients, whereas loss of ATP binding results in persistent substrate retention and impaired folding. Recent structural studies have also revealed that BiP facilitates the conformational priming of GRP94 into a client-loading state, stabilizing intermediates that would otherwise be energetically inaccessible and enabling efficient handover of client proteins. 163 Taken together, these findings emphasize the specialized role of GRP94 in ER proteostasis and its ability to respond dynamically to fluctuations in folding demand.

Calnexin and calreticulin: key ER chaperones in glycoprotein folding

Calnexin (CANX) and calreticulin (CALR) are paralogous lectin chaperones that assist in glycoprotein folding within the ER (Fig. 2 ). 164 , 165 Calnexin is an integral membrane protein, whereas calreticulin is soluble; together, they form a membrane‑associated platform that recognizes monoglucosylated N‑linked glycans, a “fold‑me” tag displayed by proteins still going through maturation. Upon binding, chaperones shield hydrophobic patches, prevent premature exit from the ER, and recruit enzymatic partners that accelerate folding. 164 Both proteins harbor a carbohydrate‑binding globular lectin domain with a proline‑rich, hook‑shaped P‑domain that projects into the lumen and tethers folding catalysts such as ER protein‑disulfide isomerases and peptidyl‑prolyl isomerases. 166 This structural arrangement concentrates multiple activities on the client and increases the local catalyst concentration, thereby increasing the efficiency of glycoprotein maturation.

Entry into the calnexin/calreticulin cycle begins co-translationally, when the multi‑subunit oligosaccharyltransferase (OST) complex attaches a Glc₃Man₉GlcNAc₂ (G3M9) glycan to emerging polypeptides. 167 Glucosidase I (MOGS) and glucosidase II (GANAB‑PRKCSH) then remove two glucose residues, generating Glc₁Man₉ (G1M9), the high‑affinity ligand for calnexin/calreticulin. 167 , 168 While the client is bound, glucosidase II excises the final glucose, allowing release once the protein approaches its native state. If folding remains incomplete, UDP‑glucose:glycoprotein glucosyltransferase 1 (UGGT1) senses the misfolded conformation—often through exposed hydrophobics—reglucosylates the glycan and sends the substrate back for another round. Multiple iterations of this reglucosylation loop can occur until correct folding is achieved. 141 , 169

Persistent non‑native glycoproteins are rerouted: slow-acting mannosidases trim Man₉ to Man₇, a signal recognized by the lectins ERLEC1 and OS9 that deliver the substrate to the ERAD machinery. Clients too large or aggregated for ERAD may instead be dispatched via ER‑to‑lysosome‑associated degradation (ERLAD). 170

Recent work has expanded the portfolio of calnexins beyond lectin interactions. Its transmembrane domain can directly bind nonglycosylated, misfolded membrane proteins, stabilizing them until they engage canonical quality‑control pathways. 171 – 173 Moreover, calnexin partners with the ER‑phagy receptor FAM134B to escort refractory clients—such as aggregation‑prone α‑synuclein—into autophagosomes for lysosomal clearance. Loss of calnexin impairs this pathway, whereas FAM134B overexpression reduces the α‑synuclein burden and ER stress. 171 – 173 The nutrient‑responsive factor SESTRIN2 further couples ER stress to this degradative branch. Under XBP1‑driven stress, SESTRIN2 inhibits mTORC1‑mediated phosphorylation of TFEB/TFE3, thereby upregulating FAM134B and lysosomal genes and increasing calnexin‑FAM134B‑mediated ER‑phagy. 172

Through this layered circuitry—lectin‑assisted folding, reglucosylation surveillance, mannosidase‑triggered ERAD, and calnexin‑guided ER‑phagy—the calnexin/calreticulin system provides the ER with a versatile toolkit for shepherding glycoproteins toward productive folding or timely disposal.

Protein disulfide isomerases (PDIs)

The PDI family comprises 21 human paralogs that reside predominantly in the ER lumen, where the oxidizing environment favors disulfide‑bond formation (Fig. 2 ). 174 All share a modular architecture built from thioredoxin‑like domains: catalytically active modules carry the Cys‑X‑X‑Cys (CXXC) motif that toggles between oxidized and reduced states, whereas inactive modules act as scaffolds or substrate‑binding platforms. 174 This mix‑and‑match design underpins the family’s functional diversity, allowing individual PDIs to specialize in distinct client sets or quality‑control pathways.

During oxidative folding, an oxidized PDI donates a disulfide to a substrate cysteine, becoming reduced in the process; reduced PDI is then re‑oxidized by ER oxidoreductin 1 (ERO1) or related flavoproteins, closing the catalytic loop. 175 If mis‑paired bonds arise, the same enzyme—now in its reduced state—can break and reshuffle them until the native pattern is achieved. 176 By cycling between oxidation and isomerization, PDIs speed up correct disulfide acquisition and prevent nonproductive cross‑links.

In addition to disulfide bond formation, many PDIs double as holdase chaperones that suppress aggregation. 177 This redox‑independent activity broadens the scope of ER quality control, particularly for domains that fold slowly or remain partially reduced.

PDIs also interact with stress signaling. PDIA6 binds the luminal domains of IRE1α and PERK, attenuating their activity and preventing runaway UPR signaling; its loss prolongs XBP1 splicing and exacerbates RIDD activity. 178 – 180 In contrast, ERp18 regulates the third sensor, ATF6, by transiently holding ATF6 in the ER and reducing its disulfides to enable proper COPII packaging and Golgi processing during stress. 181 Through such sensor‑specific contacts, PDIs fine‑tune the amplitude and duration of each UPR branch, tipping the balance between adaptation and apoptosis. 181

In summary, ER-localized chaperones are essential for maintaining the integrity of the secretory pathway by ensuring that proteins are properly folded and functional before exiting the ER. Through a variety of mechanisms, ranging from ATP-driven conformational changes, lectin‒glycoprotein interactions, disulfide bond formation, etc., the cooperative action of these versatile proteins ensures that the ER can handle the vast amount of proteins it processes, maintaining cellular homeostasis and protein quality control.

HSP100/110 family: protein disaggregases

Protein aggregation, the clumping of misfolded proteins, disrupts cellular function and is implicated in disease. 182 Disaggregases, a specialized subset of molecular chaperones, reverse this process. Protein disaggregase function was first discovered in 1994, where yeast Hsp104, a member of the HSP100 family, was shown to resolubilize heat-inactivated luciferase from insoluble aggregates, highlighting its critical role in maintaining proteostasis. 183

HSP100 chaperones belong to the AAA+ (ATPases Associated with diverse cellular Activities) ATPase family and form hexameric rings with a central channel. 182 These chaperones use ATP hydrolysis to thread aggregated polypeptides through the channel, mechanically disentangling and refolding them. 184 , 185 This mechanism was confirmed by fusing bacterial ClpB (Caseinolytic peptidase B protein homolog; an HSP100 disaggregase) to ClpP (caseinolytic peptidase proteolytic subunit) peptidase. 186 Substrates threaded through the channel of ClpB were degraded by ClpP, confirming directional translocation.

HSP100 disaggregases rarely act alone. 184 , 187 In yeast and bacteria, they cooperate with HSP70 (e.g., Ssa1/DnaK) and HSP40 co-chaperones (e.g., Sis1/DnaJ). HSP70 targets HSP100 to aggregates via interactions with its middle domain. 182 , 188 Intriguingly, metazoans, including humans, lack canonical HSP100 disaggregases. 93 , 187 In the cytosol, instead, they rely on an HSP70-centric system: HSP70 (HSPA1A in humans), HSP110 (HSPH1 in humans, a nucleotide exchange factor/NEF), and J-proteins (DNAJA2, DNAJB1 in humans) collaborate to extract and refold aggregated proteins (Fig. 2 ). 93 , 187 , 189 This machinery uses the HSP70 ATPase cycle, which is enhanced by the NEF activity of HSP110, to generate mechanical force for disaggregation.

In this system, J proteins such as DNAJA2 and DNAJB1 target aggregated substrates and promote the recruitment of multiple HSP70 molecules onto the aggregate surface. 98 , 189 , 190 Dense arrays of HSP70 chaperones assemble cooperatively, and their ATP-driven binding and release cycles generate mechanical forces that progressively extract polypeptides from aggregates. HSP110 enhances this process by catalyzing nucleotide exchange in HSP70, accelerating chaperone turnover and promoting the formation of a thick HSP70 coating on aggregates. Together, these components transform the canonical HSP70 folding mechanism into a powerful, collective disaggregation machine capable of solubilizing even stable protein aggregates.

In the mitochondrial compartment, however, a dedicated HSP100 family disaggregase operates: CLPB (also known as SKD3). 191 , 192 Imported via the TOM/TIM pathway and cleaved by PARL to remove its targeting sequence, CLPB matures in the IMS with two AAA⁺ nucleotide-binding domains (NBD1/NBD2) and a unique N-terminal ankyrin-repeat (ANK) domain for client capture. 192

Under basal conditions, apo-CLPB assembles into a double-heptamer; upon ATP binding and substrate engagement, it remodels into a substrate-stabilized 12‑mer. 191 Coordinated ATP hydrolysis in NBD1 and NBD2 drives pore‑loop movements that translocate aggregated polypeptides through the central channel at 2 residues per ATP cycle. The ANK domain recognizes exposed hydrophobic motifs on nonnative IMS proteins, recruiting them to the ring entrance for efficient threading.

Recent functional studies further linked the disaggregase activity of CLPB to mitochondrial calcium signaling and dynamics: CLPB loss causes the regulators of the mitochondrial calcium uniporter complex (mtCU)—MICU1 and MICU2—to become insoluble, reducing mitochondrial Ca²⁺ uptake independently of cytosolic calcium levels and the membrane potential. 193 Moreover, CLPB directly interacts with the fusion mediator OPA1, preventing its aggregation; without CLPB, OPA1 insolubility increases, leading to mitochondrial fragmentation and a shift toward unstable kiss-and-run fusion events. 193 Together, these findings reveal that CLPB safeguards both mtCU complex integrity and OPA1 processing to coordinate mitochondrial calcium homeostasis and membrane dynamics.

In addition to HSP100 and HSP70, sHSPs also contribute significantly to the cellular defense against protein aggregation. 182 , 194 sHSPs, including HSPB1, HSPB5 (αB-crystallin), and HSPB8, act as ATP-independent “holdases” that bind to unfolded or misfolded proteins early during stress, preventing their irreversible aggregation. These chaperones recognize exposed hydrophobic regions on destabilized client proteins and stabilize them in a soluble, refolding-competent state. 195 Unlike HSP100 and HSP70, sHSPs do not actively refold substrates; instead, they maintain substrates in a non-aggregated form, effectively “buying time” until ATP-dependent chaperone systems (such as HSP70-HSP110) can initiate refolding or degradation. 196 Structurally, sHSPs assemble into dynamic oligomers whose size and composition adapt to cellular stress, and post-translational modifications such as phosphorylation (e.g., of HSPB1 at Ser15, Ser78, and Ser82) regulate their chaperone activity by altering oligomeric states.

Notably, specific sHSPs have evolved to partner with the HSP70 machinery directly. HSPB8, for example, forms a constitutive complex with the co-chaperone BAG3, which mediates the selective autophagy of misfolded proteins through the CASA (Chaperone-Assisted Selective Autophagy) pathway. 197 , 198 In the cytoskeleton and under mechanical strain, sHSPs such as HSPB1, HSPB5, and HSPB8 work together to stabilize unfolding-prone structures like intermediate filaments and Z-disc components, shielding them from aggregation until repair or turnover can occur. 199 , 200 Thus, while sHSPs do not perform mechanical disaggregation themselves, they form an essential frontline of proteostasis, buffering against proteotoxic stress and coordinating with ATP-dependent systems to maintain cellular protein homeostasis.

TCP1 ring complex (TRiC): a eukaryotic folding chamber

Group II chaperonins are located in the eukaryotic cytosol and are also found in archaea. Unlike Group I chaperonins, which require a separate co-chaperonin (such as HSP10 in mitochondria), Group II chaperonins possess an intrinsic lid mechanism that facilitates protein folding without the need for an external co-chaperonin. 129 This intrinsic lid is formed by helical protrusions that cover the central cavity upon ATP binding, creating an encapsulated environment for substrate proteins to fold correctly. In eukaryotes, the primary Group II chaperonin is CCT, also known as TRiC. 201 This complex is composed of two identical stacked rings, each containing eight similar, but nonidentical, subunits named CCT1 through CCT8 (Fig. 2 ). 202 Each subunit contributes to the formation of the central cavity and plays a role in substrate recognition and folding. The sequence divergence among the subunits allows TRiC to interact with a broader range of substrate proteins than the more homogeneous Group I chaperonins do. 202

TRiC assists in the folding of approximately 10% of the eukaryotic proteome, targeting a select set of substrates that are often essential for cellular function. 201 , 203 Notably, TRiC is central for the proper folding of cytoskeletal components such as actin and tubulin, as well as cell cycle regulators, including cyclin E, Cdc20, and the von Hippel–Lindau tumor suppressor (VHL). 201 Many of these substrates are characterized by WD40 repeats, which form propeller-like domains that struggle to fold without assistance. 204 Additionally, TRiC can fold substrates exceeding 100 kDa in size, which are too large for classical prokaryotic or eukaryotic chaperones to fold effectively. 202 , 205

One important feature of TRiC is its ability to bind co-translationally to nascent polypeptide chains as they emerge from the ribosome 202 (Fig. 2 ). This early engagement helps prevent aggregation and misfolding from the beginning of protein synthesis. While TRiC can independently facilitate the folding of its substrate proteins, it often collaborates with other chaperones to increase folding efficiency and prevent aggregation. 206 , 207 For example, prefoldin, a hexameric chaperone complex, binds to nascent polypeptide chains, stabilizing them in an unfolded state and delivering them to TRiC for proper folding. Despite differences in structure and encapsulation mechanisms, the ATP-driven reaction cycles of both Group I and Group II chaperonins are fundamentally similar. Both utilize ATP binding and hydrolysis to induce the conformational changes necessary for substrate encapsulation and release. 202 The equatorial domains of the chaperonins, which are responsible for ATP binding, are highly conserved across the two groups, highlighting a shared mechanism of energy transduction driving protein folding. 202 , 208

The sequence divergence among the TRiC subunits has expanded the range of possible substrate motifs recognized by the complex. 202 Unlike Group I chaperonins, which interact primarily with hydrophobic regions on unfolded proteins, TRiC subunits can recognize a variety of structural features. This diversity enables TRiC to assist in the folding of complex and multidomain proteins that are critical for eukaryotic cellular functions.

The folding continuum: accounting for flexibility and disorder in protein conformations

A discussion of protein folding inevitably refers to the “proper folding” and “native conformation” of proteins; this may lead to the misconception that proteins are limited to one distinct fold permissive of normal function, with deviations representing misfolding and dysfunction. Anfinsen’s thermodynamic hypothesis is frequently simplified to indicate that the amino acid sequence of a protein determines its conformation; if correct, there should not be variations in a protein’s fold. However, Anfinsen’s hypothesis also includes other factors that determine conformation, such as the minimization of Gibbs free energy and “the totality of interatomic interactions […] in a given environment”. 209 This suggests greater complexity than the simplified version and better mirrors the observed properties of proteins.

It is now well established that proteins differentially populate order and flexibility continua rather than adhering to a folded/unfolded dichotomy. 210 Instead of referring to a protein’s native conformation, it may be more appropriate to refer to its conformational space, which can be narrow or broad. For example, we currently recognize several classes of proteins that reversibly or irreversibly switch between multiple functional folds or that contain regions that never attain a fixed conformation in isolation. Importantly, the conformational space of such proteins is still sequence-specific (as opposed to random or governed exclusively by other factors). 211 Below, we discuss protein fold-switching and disorder and introduce different classes of proteins that exhibit fold multiplicity. The clinical importance of these protein classes is revisited later in the article.

Protein dynamics and disorder can be examined through a three-part taxonomy: monomorphic, metamorphic, and disordered proteins. Monomorphic and metamorphic proteins are also referred to as single-fold and fold-switching, respectively, and disordered proteins are best known under the name IDPs or as proteins with intrinsically disordered regions (IDRs), depending on the extent of the disorder. Whereas monomorphic proteins are characterized by a single well-defined conformation, metamorphic proteins may reversibly or irreversibly shift between two or more states. 212 While metamorphic proteins exhibit distinct conformations that they stably adhere to over time, disordered proteins have no well-defined native conformations, but dynamically sample any intermediate folds between the extremes that are permitted by their sequence and the environment. 212

There are nuances to these general statements. For example, monomorphic and metamorphic proteins, although generally stable, can still contain shorter flexible and dynamic regions, typically in extruding loops or in termini. They may also undergo more extensive conformational changes, such as with allosteric proteins, or exhibit larger-scale motion of folds relative to each other. For example, the nucleotide-free and nucleotide-bound structures of the bacterial ABC transporter MsbA (orthologous to human MDR1) are geometrically distinct owing to the pivoting and tilting of secondary structures or larger domains; nonetheless, they preserve the individual folds of these structures. 213 Although this example may appear as fold-switching, the lack of more fundamental rearrangements is consistent with a monomorphic protein. In contrast, the metamorphic chemokine XCL1 can interconvert between an α + β-fold and an all-β-fold, representing a more radical conformational change. 212 Another distinction is that IDPs, while essentially unfolded in isolation, can undergo induced folding upon certain interactions or environmental changes. 214 An example is α-synuclein, which can form α-helical multimers upon membrane interaction or stack in β-sheets to form cytosolic aggregates. 215

It is estimated that 0.5–4% of known protein structures may undergo fold-switching 216 and that 20–33% of eukaryotic proteins contain IDRs that are at least 30 residues long. 214 The DisProt database currently includes 1,270 human IDPs, of which 56 are annotated as 100% disordered. 217 IDRs contribute various properties to proteins that are integral to their function, most notably increasing their number of potential binding partners. 218 Many transcription factors contain IDRs that facilitate their regulation by a range of transcriptional coregulators or activators/inhibitors. A classic example is p53, which contains IDRs at both its N- and C-termini. The disorder at these regions allows interactions with many other proteins and contributes to the size of its nearly 1,000-protein interactome, each interaction with potentially differential effects on p53 conformation. 214 , 219

IDPs also have important functions as scaffolding proteins, where the multiplicity of regulatory mechanisms inherited from the IDR has important implications for the efficiency and coordination of intracellular signaling events. 218 In addition, a general feature of proteinaceous membrane-less organelles (PMLOs), such as Cajal bodies, nuclear speckles, and stress bodies, appears to be their large-scale inclusion of IDPs, which may contain properties favorable for PMLO biogenesis, including intrinsic flexibility and low-affinity interactions. 220 Moreover, the prominent role of IDPs such as α-synuclein, tau, and amyloid-β in neurodegenerative diseases featuring protein aggregation, as well as other IDPs implicated in different diseases, may suggest their general clinical relevance 214 (see below in Section “Causes and consequences of protein misfolding”).

Causes and consequences of protein misfolding

Protein folding is essential for maintaining a functional proteome and ensuring proper and healthy cellular function. 221 Failures in protein folding can have various consequences, including loss-of-function or toxic gain-of-function effects on individual proteins, the accumulation or aggregation of misfolded proteins, and the induction of downstream stress pathways. All of these factors may have systemic effects on cellular health, as well as on tissue or organ function, if larger cell populations are affected. This section will examine the factors that can interfere with proper protein folding and the possible ramifications of protein misfolding, including the cellular stress responses that are activated to mitigate folding errors.

Multiple errors, dysfunctions, or stresses can cause protein misfolding

The important factors that contribute to protein folding include its genetically encoded primary sequence, weak interactions both within the protein and between the protein and its solvent, and the molecular chaperones that aid in the folding process. Here, we outline how different disruptions to these factors may cause protein misfolding and their relevance in different diseases (Fig. 3 ). We also consider examples of how dysfunctional protein degradation may tip the balance toward an accumulation of misfolded protein species and evaluate the links between aging and protein misfolding. Finally, we consider some of the experimental techniques used to disrupt protein folding pathways in the study of general cellular responses to misfolding. Fig. 3 Causes and consequences of protein misfolding. Protein misfolding arises from various stressors, including genetic mutations, faulty synthesis, chaperone dysfunction, aberrant PTMs, heat shock, oxidative stress, nutrient deficiency, and dysfunctional degradation. These factors contribute to the pathogenesis of several neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), metabolic diseases (e.g., type 2 diabetes), and other proteinopathies

Errors in the protein synthesis pathway

Following the central dogma of molecular biology, every protein is encoded by a gene via its mRNA transcript. Neither the maintenance or replication of the genome nor the transcription and translation that leads to the synthesis of a protein product are mechanisms with perfect fidelity; thus, errors that can occur in any of these steps may result in protein misfolding. 222

The classical example of a DNA mutation-induced misfolding disease is cystic fibrosis (CF). CF is a rare autosomal recessive disease that most prominently manifests through an accumulation of mucus in the lungs, with subsequent difficulties in breathing, and chronic pulmonary bacterial infections, in addition to effects on the GI tract, pancreas, and reproductive system. 223 CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, a chloride channel with ~5,000 characterized mutations in the NCBI ClinVar database, of which ~1,600 are annotated as pathogenic or likely pathogenic. 224 On the basis of their effects on the CFTR protein, these mutations are classified into six categories (classes I–VI), of which class II includes mutations that cause CFTR misfolding. 225 This class includes the F508del mutation, which is the most frequent variant detected in CF and gives rise to a CFTR protein that exhibits defects in channel gating properties, 226 as well as increased retention in the ER followed by degradation by the ubiquitin–proteasome system (UPS). 227

In contrast to DNA mutations, transcriptional and translational errors are neither permanent nor typically as penetrant for protein folding. Nevertheless, investigations into the inverse correlation between the expression level and evolutionary rate of a protein indicate that eukaryotic cells are subject to selective pressures that favor the proper folding of proteins. 228 There is evidence that transcriptional errors sometimes underlie the generation of toxic protein products, e.g., amyloid β precursor protein (APP) and ubiquitin B (UBB), in AD and Down syndrome, respectively, and that these errors occur more frequently in aged cells. 229 , 230 In these cases, dinucleotide deletions of GA or GU near GAGAG motifs lead to +1 frameshifted mRNAs translated into C-terminally altered proteins that accumulate in amyloid plaques and neurofibrillary tangles. 230 It has also been hypothesized that +1 frameshifted UBB—through impaired function of the UPS—may contribute to impaired clearance of aggregating tau oligomers and impair the general contributions of the UPS to proteostasis in neurons. 230

At the transcript level, aberrant splicing is another cause of pathological protein products. In AD patients, decreased expression of the splicing regulator RBFOX1 has been observed, leading to upregulation of a specific isoform of APP, resulting in increased generation of the highly aggregation-prone amyloid-β peptide Aβ42. 231 Additionally, approximately one-third of the pathological mutations observed in the gene encoding tau (MAPT) have been reported to affect tau splicing and the ratio of tau isoforms containing three or four microtubule-binding domains (3R-tau to 4R-tau ratio)—a ratio whose imbalance is linked to impaired microtubule dynamics in tauopathies such as AD. 231

At the translational level, mutations that impair proofreading by alanyl-tRNA synthetase (AARS1), leading to mischarged tRNAs and amino acid misincorporation during translation, can lead to misfolded protein aggregation, ER stress, and Purkinje cell death in the pathogenesis of ataxia. 232 Estimates have suggested that ~15% of all proteins in a human cell contain at least one misincorporated amino acid, 233 with possible implications for protein folding. Recent research suggests that some hundred human proteins may exhibit frequent, or even preferential, substitutions of their genetically encoded amino acids at specific positions. 234 Among these proteins, some are associated with neurodegenerative diseases, such as APOE in AD and TDP-43 or FUS in ALS. 234 It remains to be explored whether these substitutions contribute to the etiology of folding-related diseases or whether they have other physiological functions that are not currently understood. In summary, imperfect or impaired fidelity in DNA replication or maintenance, transcription, or translation has the potential to cause protein misfolding linked to disease development.

Impairment of protein folding mechanisms: chaperonopathies

In Section “Molecular chaperones: Facilitators of protein folding dynamics”, we introduced molecular chaperones, enzymes that can regulate protein folding by interacting with and/or modifying unfolded proteins. Chaperones also fulfill other functions, including scaffolding activity between proteins or organelles, contributions to protein translocation across membranes, and the regulation of signaling pathways. Consequently, chaperone dysfunction can lead to many different pathologies, commonly termed chaperonopathies. The term has been used to describe not only specific diseases but also general states associated with chaperone insufficiency, e.g., aging. 235 For the purpose of this review, genes annotated as molecular chaperones or co-chaperones in the HUGO Gene Nomenclature Committee (HGNC) database were compared with a list of gene‒disease relationships in the NCBI ClinVar database. 224 Among the 179 genes annotated as molecular chaperones or co-chaperones in the HGNC database, 48 were associated with a total of 87 unique diseases in the ClinVar database. Among these diseases, some are directly related to dysfunctions in classical chaperone activity (protein folding), whereas others stem from events unrelated to protein folding (e.g., from signaling pathway dysregulation) or from an undetermined etiological mechanism. Below, we present some examples from the first category.

Crystallin alpha B (CRYAB) is an sHSP that contributes to the folding of both cytosolic and transmembrane proteins; in addition, it exhibits stress-dependent activation and protective effects against various amyloidoses. 236 , 237 Mutant CRYAB is implicated in the development of an autosomal dominant form of cataract (type 16; CTRCT16) as well as multiple types of myopathy. 224 , 237 Crystallins of the alpha, beta, and gamma classes (CRYA/-B/-G, of which only the CRYA proteins are sHSPs 237 ) are the major protein constituents of the vertebrate lens, and the CRYA class alone has been reported to make up ~30% of the water-soluble proteins of lens fibers. 238 Consequently, the structural and functional integrity of crystallins is important in maintaining lens function and vision. Among cataract-associated CRYAB mutations, the D140N variant results in an altered tertiary structure, increased surface hydrophobicity, and increased heat-induced aggregation, with a dominant negative effect on its wild-type counterpart. 239 In addition, while wild-type CRYAB exhibited intact chaperone activity by inhibiting dithiothreitol (DTT)-induced aggregation of insulin, the D140N variant promoted insulin aggregation at room temperature. 239 This finding suggests that both the aggregation of CRYAB itself and the negative effects of mutant CRYAB on the folding of other proteins (including wild-type crystallins) could contribute to the etiology of CTRCT16. CRYAB variants are also linked to diseases of muscle tissue, such as desmin-related myopathy (DRM; D109G, R120G) and dilated cardiomyopathy (DCM; D109G, R120G, R123W, G154S, R157H). 237 An in vivo study on cardiomyocyte-specific expression of the R120G variant further demonstrated how it may affect the brain in the context of ischemia‒reperfusion stress (mimicking ischemic stroke). R120G-mutant CRYAB undergoes amyloidogenic misfolding in the heart, disseminates to the brain via exosomal transport, and leads to increased neuroinflammation, increased infarct volume, and impaired functional recovery. 240 The protein has also attracted interest in neurodegenerative conditions, e.g., owing to its elevated concentration in AD brains, accumulation in amyloid plaques and a range of other aggregates or inclusion bodies, and potentially neurotoxic contributions in complex with the Aβ peptide. 241 , 242

Other diseases related to chaperone dysfunction include a cystic fibrosis-like disease with respiratory, gastrointestinal, hepatic, and cardiovascular symptoms that is linked to loss-of-function mutations in AGR2, encoding a PDI. 243 Mechanistically, AGR2 is involved in the production of the intestinal mucin MUC2, as well as the airway mucins MUC5AC and MUC5B 244 , 245 —these mucins are cysteine-rich proteins that depend on many disulfide bonds to attain their native conformation. Although this etiological mechanism has not been validated in patients, the symptoms of these AGR2-associated diseases are thus linked to the loss of PDI activity and the resulting mucin insufficiency, with presumptive effects on mucous barrier integrity in vital organs. In addition, four different chaperones are associated with the development of Charcot-Marie-Tooth (CMT) disease type 2 and distal hereditary motor neuropathy (dHMN): HSPB1, HSPB3, HSPB8, and DNAJB2. Approximately 30 different HSPB1 variants have been associated with CMT type 2 or dHMN—S135F being the most frequent and associated with both. 246 HSPB1 mutations have diverse effects, many of which affect microtubule binding and axonal transport in neurons, including the disruption of aggresome formation and the subsequent autophagic clearance of misfolded proteins by the S135F variant. 246 – 248 The effects of many HSPB1 variants on chaperone activity remain poorly understood, in part because current in vitro assays—such as aggregation suppression tests—typically assess function against a single model substrate. However, HSPB1 exhibits substrate-specific activity, and different variants may differentially affect the folding of distinct clients, complicating interpretation. 249 This limits our ability to draw generalizable conclusions about variant pathogenicity. Therefore, more comprehensive and physiologically relevant approaches are needed to elucidate how specific HSPB1 mutations contribute to the CMT type 2 and dHMN phenotypes.

Errors in co- or post-translational protein modifications

Various protein modifications that occur during or after protein synthesis (co- or post-translational), such as cofactor incorporation, glycosylation, lipidation, and other modifications, affect the folding and conformation of many proteins. In addition, some protein modifications are used by cellular quality control and degradation processes to prevent the accumulation of misfolded proteins. This section describes some of the protein modifications that play a role in protein folding, quality control, stability, and degradation and the effects of their disruption.

Phosphorylation

Phosphorylation is among the most common PTMs in the human proteome. It is estimated to affect the conformation, function, stability, localization, or interactions of ~30% of all human proteins and is regulated by ~500 protein kinases and ~200 protein phosphatases. 250 Given the widespread use of this PTM in maintaining cellular function, aberrant phosphorylation may have multiple disruptive effects, some of which are related to protein folding and aggregation. Although nine of the standard amino acids can be phosphorylated in principle, the phosphorylation of threonine, serine, and tyrosine are the most well studied and are likely the most abundant phosphorylation events in human cells. 251 Phosphorylation reversibly adds a dianionic (at physiological pH) phosphoryl group to an amino acid side chain, altering its bulk and charge and modifying its bonding capacities (e.g., facilitating hydrogen bonding, salt bridges, or metal ion coordination). Phosphorylation may thus directly induce conformational changes in a protein but also participate indirectly through the regulation of other PTMs, e.g., by tagging Ser/Thr-Pro motifs for proline isomerization. 252 In addition, phosphorylation may induce folding events in intrinsically disordered proteins, thereby regulating their activity. 253

Multiple neurodegenerative diseases are associated with abnormal phosphorylation of aggregation-prone proteins or peptides. A prototypical example of this is the hyperphosphorylation of tau in AD and other tauopathies, such as subtypes of frontotemporal dementia (specifically FTDP-17). Tau is an important regulator of microtubule dynamics, and the microtubule-binding properties of tau are directly regulated by its phosphorylation both within and outside of its microtubule-binding domains. 254 Early autopsy studies revealed that hyperphosphorylated tau is present in virtually all brain tissues from AD patients but is absent in non-AD controls. 255 Quantitatively, these studies indicated that abnormally phosphorylated tau in AD patients contained three to four times more phosphate groups ( ~ 7–9 mol PO 4 - per mol tau) than did normal tau ( ~ 2–3 mol PO 4 - per mol tau). 255 These clear trends are validated in more recent studies, where e.g., mass spectrometry has been used to show dramatic increases (approximately two orders of magnitude) in insoluble tau in AD brain tissue, as well as more extensive and frequent phosphorylation of tau in AD tissue than in control samples, in addition to other modifications, such as increased acetylation, ubiquitination, and methylation. 256

Abnormal tau phosphorylation is also observed in the tauopathies FTD, corticobasal degeneration, and progressive supranuclear palsy, although the tau isoforms and phosphorylation patterns show some variation between these diseases. 257 Tau hyperphosphorylation promotes its dissociation from microtubules, and while the prevailing view is that tau hyperphosphorylation promotes its aggregation, the direction of causality between tau phosphorylation and aggregation in disease, or the relative contributions of all tau PTMs, is not clear. 257 – 259 Combined with the observation that tau aggregation correlates with AD progression, it is assumed that tau aggregation in combination with Aβ pathology and other contextual features contributes to AD development. 257 , 259 Mechanistically, the identification of a relatively large number of protein kinases ( >20) 260 and phosphatases 261 that recognize tau as a substrate allows for multiple ways in which tau phosphorylation may be dysregulated. Notable tau kinases include GSK3α and -β—which act on the tau residues that are hyperphosphorylated in AD, and whose knockdown reduces tau phosphorylation and aggregation in a mouse model of AD—as well as CDK5, protein kinase A, MARK1/-2, casein kinase 2, and others. 257 , 259 , 260 Multiple mechanisms may act in concert to tip the balance in favor of tau hyperphosphorylation, such as oxidative stress, calcium dyshomeostasis, age-related alterations, or even Aβ-mediated modulation of cell surface receptors at synapses 262 ; more research is needed to assess this phenomenon. Other protein aggregates in different neurodegenerative diseases are also associated with abnormal phosphorylation; for example, hyperphosphorylation has been described for TDP-43 aggregates in amyotrophic lateral sclerosis (ALS) 263 and α-synuclein (SNCA) in Lewy bodies in PD and dementia with Lewy bodies. 264 Hypophosphorylation of huntingtin (HTT) at T3 has been associated with Huntington’s disease (HD), and HTT S13 phosphorylation has been shown to inhibit HTT aggregation and promote its autophagic clearance. 265

A pressing question for all of these observations is whether phosphorylation regulates the aggregation of these proteins, or vice versa, or a combination of the two. The phosphorylation of different residues may also have different effects (i.e., promoting vs. inhibiting aggregation); furthermore, it is possible that the hyperphosphorylation patterns observed in AD may not have effects similar to those of regular tau phosphorylation in regulating tau microtubule binding. In AD, tau phosphorylation has been reported to precede the formation of tau neurofibrillary tangles (NFTs), supporting a direction of causality from phosphorylation to aggregation 266 ; however, it is still possible that intermediate oligomeric forms of tau (preceding NFT formation) may promote some or all of the hyperphosphorylation. A study evaluating the microtubule-binding properties and polymerization kinetics of 16 different tau phosphomimetic mutants revealed that most mutants decreased the binding affinity of tau for tubulin, whereas their effects on tau polymerization, as well as the lag time and rate of polymerization, were more variable. 267 These in vitro studies may not perfectly recapitulate the effects of specific phosphorylation events in vivo but illustrate that there is no universal rule for all possible tau phosphorylation patterns and that tau polymerization or aggregation is not a necessary consequence of tau phosphorylation. Taken together, the phosphorylation of abnormal protein aggregates is a common trend in many neurodegenerative diseases, but protein- and disease-specific phosphorylation codes are currently not understood. A more detailed understanding of the causes and consequences of the phosphorylation of pathogenic misfolded proteins could have therapeutic implications depending on the respective proteins’ etiological contributions and druggability.

In addition to its direct effects on conformation, phosphorylation is also an important regulator of chaperone ATPase activity, as are their interactions with co-chaperones. 268 Specific C-terminal phosphorylations of the HSP70 and HSP90 family members HSPA1A and HSP90AA1 at T636 and T725/S726, respectively, which lead to their dissociation from the E3 ubiquitin ligase CHIP in favor of interaction with the co-chaperone HOP, were introduced previously. 104 The CHIP/HOP balance is relevant for neurodegenerative diseases, as STUB1 is an important contributor to tau degradation; moreover, tau phosphorylation at S416 is associated with decreased recognition by CHIP and increased tau aggregation. 269 Another previously discussed chaperone—CRYAB—is also phosphorylated under stress, resulting in a shift in its subcellular localization, purportedly increasing its activity. 237

Glycosylation

Protein glycosylation consists of the covalent linkage of carbohydrate oligomers or polymers (glycans) to proteins. The monosaccharide makeup, branching pattern, length, and chemical modifications of the glycans, as well as their attachment points on the target proteins, lead to a vast diversity of glycoconjugates that may confer various properties to their associated proteins, regulating, e.g., their conformation, localization, interactions, stability, solubility, etc. 270 It is estimated that up to 4% of the human genome encodes proteins involved in glycosylation, such as glycosyl- and oligosaccharyltransferases, glucosidases, epimerases, and nucleotide–sugar transporters. 270 Owing to the cell type and state-dependent expression and regulation of these enzymes, a cell’s glycoproteome is consequently context-dependent. 270

Glycosylation occurs primarily in the ER, where the co-translational N-linked glycosylation pathway and post-translational O-linked glycosylation pathways are initiated, and further processing occurs in the Golgi apparatus (as well as the initiation of several smaller glycosylation pathways). 270 While the cores of N- and O-linked glycans typically remain attached permanently, transient and dynamic O-GlcNAcylation is also carried out in the cytosol and nucleus to regulate processes such as transcription, translation, or cell cycle progression in response to stress- and nutrient-related cues. 270 Glycans may also be C-linked or C-terminally GPI-anchored (hybrid glycan/lipid modifications), but the focus of this review will be on N- and O-linked glycans and how they contribute to protein conformation, folding, and quality control.

In principle, there are numerous ways in which glycoconjugates may shape and stabilize the native conformation of a protein. Glycans are both bulky and primarily hydrophilic, 271 , 272 with the potential to participate in hydrogen bonding and van der Waals interactions with both the polypeptide backbone and side chains. They may sterically restrict certain conformations, contribute with allosteric effects to other regions of the protein, mediate intra- and intermolecular interactions that stabilize tertiary and quaternary conformations, or shield hydrophobic regions to restrict folding errors from the hydrophobic effect, aggregation, and increase a protein’s solubility. 271 – 273 Glycans can also influence protein folding through enthalpic and entropic effects on the unfolded or folded state of a protein. Folding is promoted by destabilization of the unfolded state (increased enthalpy or decreased entropy) or stabilization of the folded state (vice versa). 272 Entropic effects, particularly in the unfolded state, are suggested to be the major contributors, and potential enthalpic effects depend on the hydrophobicity of the specific glycan. 272

Interestingly, many glycoproteins can function normally when their glycan(s) are removed after folding, despite relying on the glycan for proper folding and exhibiting decreased stability in their folded state without glycans. 273 For example, the human ribonuclease RNASE1 can be N-glycosylated at three different sites (N34, N76, and N88); N34 glycosylation is the most prevalent one in vivo, as well as being the most evolutionary conserved glycosylation site. 274 While N-glycosylation (particularly at N34) enhances the thermostability of RNASE1 and resistance to proteolysis, a decrease in its in vitro enzymatic activity was observed for six of its seven glycoforms, of which only N34-monoglycosylated RNASE1 showed comparable activity to the aglycosylated enzyme. 274

Recombinant human erythropoietin (rhEPO) also has increased activity in vitro when it is aglycosylated, whereas the aglycosylated form has almost no activity in vivo. 275 rhEPO glycosylation decreases the rate of its metabolism both by the kidneys and liver and thereby greatly improves its half-life in circulation. Moreover, mutation of three of rhEPO’s four glycosylation sites (N36, N83, and S126, but not N24) has been shown to deplete secreted and intracellular soluble rhEPO from baby hamster kidney cells, leaving the only detectable rhEPO to be found in their insoluble fraction, suggesting that these aglycosylated states do not fold properly and are readily degraded. 276 This example of rhEPO is a reminder that in vivo properties may not adhere to patterns observed in vitro, which has implications for the potential translational impact of recombinant protein therapeutics.

Disrupted glycosylation may also characterize some CFTR variants associated with cystic fibrosis. CFTR is N-glycosylated at N894 and N900, and mutation of these residues can abolish CANX binding to CFTR in the ER; loss of these residues also impairs CFTR maturation and folding efficiency with both CANX-dependent and CANX-independent components. 277 ΔN900 mutants, in particular, are linked to the development of CF and appear to have substantially decreased stability compared with WT CFTR. 278

Perhaps the best characterized role of glycans in protein folding is that of N-glycosylation in ER protein folding and quality control, as described in Section “Molecular chaperones: Facilitators of protein folding dynamics”. Experimentally, one of the ways in which ER stress is commonly induced is by tunicamycin, an inhibitor of N-linked glycosylation. In addition to the central role of N-linked glycosylation in ER protein folding and quality control, studies have shown that O-linked glycosylation may also contribute in the case of certain substrates. Two ER-localized soluble fucosyltransferases—POFUT1 and POFUT2—have been reported to O-fucosylate proteins containing EGF repeats and thrombospondin type I repeats, respectively, in a discriminatory manner where they act only on properly folded substrates. 279 While this O-fucosylation is suggested to promote further folding, O-mannosylation catalyzed by ER-resident protein O-mannosyltransferases has been shown to label misfolding proteins for ERAD in yeast. 279 However, as this modification is prevalent on many proteins and is essential for the function of some (e.g., E-cadherin [CDH1]), it likely has pleiotropic functions. 280

In summary, while the folding contributions (or lack thereof) of various glycoconjugates remain uncharacterized for most proteins, there is evidence to support their impact on folding kinetics and protein stability. However, at present, there is not sufficient experimental evidence to unequivocally support or oppose this notion; thus, further research is needed in this area. Faulty or dysregulated glycosylation is implicated in multiple diseases. More than 170 congenital disorders of glycosylation (CDGs) have been identified, with roots in virtually any of the various glycosylation pathways in the cell and with clinical manifestations that range from mild to severe or even embryonic lethal. 281 On the basis of the available evidence, the extent to which the etiologies of these diseases are linked to specific kinds of disruption, such as aberrant folding of the affected glycoproteins, is unclear. Glycosylation has also been investigated in AD, where a dysregulated glycome and increased glycosylation of tau have been reported, and other proteins that may participate in AD etiology are also described to be under regulation by their glycosylation pattern, such as the activity of the BACE1 protease and possibly the processing of APP. 282 While there are currently few successful therapies for glycosylation-related diseases, further exploration of the glycobiology of AD and other diseases may help improve our understanding of their etiology, as well as the development of future diagnostic and therapeutic approaches.

Cofactor incorporation and metalation

Many proteins incorporate cofactors such as metal ions (Cu + , Fe 2+ , Mn 2+ ) or organic molecules (vitamin B 12 , NADPH, FMN, etc.) that contribute to their structure and are required for their function. Estimates suggest that more than one-third of the human proteome, and more than 40% of its enzymes, are metalloproteins. 283 , 284 Most metalloproteins directly accept their required metal ions into metal-binding sites (e.g., iron‒sulfur proteins), whereas some require that the metal ion is already incorporated into an organic molecule. 283 For example, iron must be incorporated into protoporphyrin IX by a ferrochelatase to form a heme molecule before it can be utilized by hemoproteins such as hemoglobin and cytochrome c . Similarly, molybdenum must be incorporated into molybdopterin to form the molybdenum cofactor (Moco) used by various oxidoreductases, such as xanthine dehydrogenase (XDH). 283

While some proteins accept their cofactors after folding into their native conformation, others incorporate their cofactors during the folding process and diverge in the folding kinetics, structure, and stability of their apo- and holoprotein forms. For example, it has been reported that the Cys 2 His 2 zinc finger motif—which, e.g., mediates DNA binding for numerous human transcriptional regulators—fails to adapt its functional ββα fold in the absence of zinc. 284 Research has also shown that depletion of riboflavin (vitamin B 2 ), which is essential for the formation of the FMN and FAD cofactors, leads to a general decrease in the levels of flavoproteins due to increased degradation of apoflavoproteins. 285 One of these flavoproteins, NQO1, is directed toward degradation by STUB1-mediated polyubiquitination upon riboflavin depletion; this degradation could be inhibited by truncation of NQO1’s C-terminal tail, which shows signs of unfolding in the absence of riboflavin. 285 Moreover, when B16 cells were treated with the Aβ42 peptide to seed protein aggregation, total protein aggregation was substantially greater in riboflavin-depleted cells. This may be explained by an increased propensity of flavoproteins to aggregate upon riboflavin depletion, as truncated apo-NQO1 coaggregated less with Aβ42 than did wild-type apo-NQO1. 285

Other examples of the impact of cofactor incorporation on protein structure include proteins implicated in neurodegenerative diseases. The prion protein (PrP), whose misfolding causes Creutzfeldt–Jakob disease in humans, attains a more rigid and misfolding-resistant conformation upon copper binding. 286 Frataxin (FXN), whose deficiency (mostly due to genetic GAA repeat expansions in the FXN gene, impairing its transcription) is causative for Friedreich’s ataxia (FRDA), and a putative iron chaperone that contributes to the assembly of iron–sulfur proteins. 287 Consequently, iron dyshomeostasis and deficient activity of iron‒sulfur enzymes are hallmarks of FRDA and may be major etiological components, perhaps together with increased ROS levels caused by mitochondrial iron accumulation. 287 In addition, FXN missense mutations that are observed in some cases of FRDA affect FXN’s iron binding capacity and stability; this finding suggests that mutant FXN may not be pathological only because of dysfunctional iron incorporation into other proteins but also because of impaired iron binding of FXN itself, with consequences for its stability and/or metallochaperone activity. 287

Finally, the demetalation of copper and zinc from SOD1 induces its misfolding and aggregation. 288 This finding has important implications for ALS, where >100 different SOD1 mutations are linked to a familial form of the disease. 288 Some of these mutations are associated with abrogating SOD1’s metal-binding sites, 288 whereas others may inhibit functional interactions between SOD1 and its copper chaperone CCS. 289 Notably, SOD1 aggregates are metal-deficient in a mouse model of familial ALS (while soluble SOD1 has a relatively high metal content), suggesting that SOD1 cofactor deficiency may have clinical relevance. 288 In contrast, neuronal accumulation of metal ions and their interaction with disease-associated protein aggregates is also a hypothesized etiological mechanism in multiple neurodegenerative diseases, implying that supplementation may not be the simple solution. 290 Together, these examples indicate that nutritional deficiencies or insufficient protein cofactor incorporation, e.g., due to loss of function in specific transporters, cofactor chaperones, or the cofactor-binding sites of proteins themselves, may lead to dysproteostasis through effects on protein folding and stability. Alternative upstream causes may include the inhibition of cofactor incorporation, or cofactor displacement, by certain toxins or heavy metals. While heavy metals disrupt protein folding, in most cases, it may not be clear whether this phenomenon is due to effects on protein cofactors or other mechanisms, such as the induction of oxidative stress. 291

Genotoxic or proteotoxic stresses and deficiencies

Heat shock

Heat promotes protein denaturation by increasing the rate at which weak noncovalent intramolecular bonds in proteins are broken (e.g., van der Waals interactions and hydrogen bonds). Although van der Waals interactions and hydrogen bonds have bond dissociation energies as low as ~4 and ~23 kJ/mol, respectively, and the average thermal energy for particles in an aqueous solution at 37 °C is ~38.6 kJ/mol, multiple factors (rapid bond recycling, the hydrophobic effect) maintain protein conformation at physiological temperatures. 292 An interesting question is whether the abnormal temperature increases experienced by humans in cases such as fever, hyperthermia, or even thermoablative/hyperthermic therapies increase the rate of bond dissociation sufficiently to challenge protein folding and proteostasis.

Fever and hyperthermia both refer to elevated basal body temperatures above the normal range of ~36.0 to ~37.5 °C. Previous work has shown that these temperatures have pleiotropic effects on cells, altering membrane properties, metabolism, anabolic processes, and cell morphology. 293 In vitro studies have shown appreciable cytotoxicity at temperatures ≥41 °C, with more dramatic effects at temperatures ≥42.5 °C, possibly with cell line-dependent variations. 294 Proteins differ in their thermolability, but evidence from differential scanning calorimetry (DSC) in human and mammalian cell lines suggests that signs of protein denaturation are detectable at 37–38 °C, are significant at 40–41 °C, and rise steeply with increasing temperature. 293 While the long-term consequences at these temperatures are less clear, they are likely limited by some level of thermotolerance, mediated, e.g., by activation of the HSR. Multiple studies in human and mouse cell lines, as well as in vivo experiments, have shown that febrile temperatures (38–39.5 °C) activate the HSR—as measured by HSF1 trimerization, HSF1 DNA-binding activity, and/or HSP70 family RNA and protein expression—in a dose-dependent manner, with minimal effects from temperatures at the lower end of the range or under brief heat exposure. 295 , 296

Fewer studies have examined other stress response pathways at physiologically relevant temperatures, and findings suggest that temperature effects are context dependent. In HeLa cells, all three arms of the UPR were activated after three hours at 43 °C but not at 40 °C. 297 In AD293 cells, 40 °C upregulated UPR markers (HSPA5, DNAJC3, GADD34, CHOP, and XBP1s), whereas 43 °C repressed them. 298 In this study, Hepa-1, HepG2, INS1 832/13 cells, and MEFs incubated at 40 °C presented limited and heterogeneous responses to some of the same UPR markers. A common trend was GADD34 induction, which was only accompanied by CHOP upregulation in INS1 832/13 cells, perhaps suggesting divergent regulation of the PERK arm of the UPR. 298 In contrast, HSPA1A was consistently upregulated upon mild heat shock in these cell lines, suggesting a more predictable induction of the HSR. 298

Comparisons of the HSR and UPR in MEFs and U2OS cells revealed differences in temperature sensitivity between both responses and cell lines. 299 HSF1 was upregulated at 39–44 °C in U2OS cells but not in MEFs. HSPA1A was strongly induced in both cell lines, whereas HSPB1 was slightly upregulated in U2OS cells and was primarily upregulated in MEFs at 42–43 °C. Mild heat shock had little effect on the UPR sensors: IRE1α and ATF6 were not transcriptionally induced, and PERK increased slightly at 40–41 °C in U2OS cells. The UPR effectors showed stronger responses in U2OS cells—XBP1s and CHOP increased at 40–44 °C and 39–42 °C, respectively—although XBP1s was only slightly upregulated in MEFs at 43–44 °C. Interestingly, ATF4 mRNA levels were downregulated in MEFs at 39–42 °C but remained unchanged in U2OS cells. While the evidence is limited, HSR activation downstream of mild heat shock appears to be less context-dependent than UPR activation. This may be due to differences between the ER and cytosolic proteomes, where those composed of transmembrane and secreted proteins in the ER may be more heat tolerant. 299

Inflammation and oxidative stress

Inflammation is a response to tissue injury or infection that normally promotes the elimination of foreign objects and self-repair. 300 An important component of inflammation is the generation of oxidative stress, which in turn may cause more proinflammatory signaling. 300 Key mediators of oxidative stress include reactive oxygen species (ROS) and reactive nitrogen species (RNS). ROS and RNS are not only generated in response to proinflammatory signaling but are also natural byproducts of multiple constitutively occurring cellular processes and, in some cases, are also utilized as secondary messengers. The ROS constitute molecules such as the hydroxyl radical ( • OH) generated from H 2 O 2 by the Fenton and Haber-Weiss reactions. 301 , 302 A second major ROS is the superoxide anion radical (O 2 •– ), which is produced by the reaction of O 2 with electron carriers of complexes I and III in the mitochondrial electron transport chain or by NADHP oxidases. 303 A third key ROS is hydrogen peroxide (H 2 O 2 ), which is produced by superoxide dismutase (SOD)-mediated conversion of O 2 •– and from ERO1A-mediated oxidation of protein disulfide isomerases during ER disulfide bond formation. 304 Among these three types of ROS, H 2 O 2 is a weaker oxidant and is associated with more selectively applied oxidative damage, whereas the strong oxidant HO • may cause extensive damage. 301 , 305 Moreover, different oxidants, particularly the less reactive ones, exhibit target selectivity, differing, e.g., in the amino acid side chains, they typically react with. 306 The RNS include nitric oxide (NO • ) and peroxynitrite anion (ONOO – ) — the latter generated in a reaction between O 2 •– and NO • 302 . NO • functions as a neurotransmitter or vasodilator when it is produced by NOS1 (nNOS) or NOS3 (eNOS), respectively, whereas NOS2 drives NO • production downstream of cytokine or PAMP signaling. 302 In addition to its oxidant effects, NO • may also exacerbate oxidative stress through the inhibition of glutamate-cysteine ligase (GCLC), leading to decreased synthesis of the abundant and important endogenous antioxidant glutathione (GSH). 307

Oxidative stress may disrupt proteostasis through multiple mechanisms. First, ROS and RNS are mutagenic substances that may react with DNA to produce different DNA lesions, such as 8-oxoG and 8-nitroG, which may cause G to T transversions or single-strand breaks by damaging the 2-deoxyribose backbone. 308 If unrepaired, these lesions may cause genetic entrenchment of aberrantly folded and/or functioning protein sequences. ROS and RNS may damage not only nucleic acids but also other macromolecules, including lipids, glycans, and proteins. 305 Proteins can be oxidized both at their backbone and at their sidechains, with possible consequences including fragmentation, crosslinking, cystine (or mixed disulfide dimer) formation, decarboxylation, deamination, tryptophane loss, and adduct formation, with implications for protein conformation, polarity, and interactions. 305 Moreover, sidechain radicals generated by oxidative damage can in turn oxidize other macromolecules, including other proteins, lipids, and DNA, potentially propagating oxidative damage. 305 Most side chain oxidation products are hydrophilic and may therefore be more disruptive to protein conformation when they occur at residues with higher side chain hydrophobicity. 305 Since these residues are typically buried within the protein, however, they are simultaneously less readily oxidized. 305 Common products from the oxidation of aliphatic side chains are alcohol, carbonyl, and hydroperoxide groups, whereas aromatic ring oxidation may introduce hydroxy adducts, electrophilic substituents (e.g., nitro-, chloro-, bromo-), ring crosslinking, or ring opening (e.g., tryptophan → kynurenine). 306 This notwithstanding, the oxidation of hydrophilic side chains can also lead to substantial impacts on the bulk, hydrophilicity, charge, and bonding propensities, such as aspartate or glutamate decarboxylation (removing a negative charge) or arginine oxidation to glutamic semialdehyde (losing the positively charged guanidinium group). 306 Importantly, in addition to the reduction of cystines and some other examples, proteins suffering oxidative damage are rarely repaired but are frequently subjected to proteolysis (albeit depending on the modification). 305

Inflammation and oxidative stress have been identified as contributing causes of multiple groups of diseases or degenerative processes, including obesity and metabolic conditions, cancer, neurodegenerative diseases, cardiovascular diseases, and aging. 309 , 310 A substantial body of research associates oxidative stress with neurodegenerative diseases. For example, aging brains exhibit metal dyshomeostasis, including iron and copper accumulation, of which copper has been linked to promoting Aβ and tau aggregation in AD; iron and copper may co-aggregate with Aβ, and these aggregates have oxidant activity, generating H 2 O 2 . 290 , 311 Age- and AD-related iron or copper accumulation may increase the rate of Fenton and Haber–Weiss reactions, which could contribute to the elevated oxidative stress markers observed in the aged and AD brains. 311 Similarly, a bidirectional link between zinc and oxidative stress, where oxidative stress can promote zinc accumulation and where zinc accumulation exerts prooxidant effects, has also been proposed for neurodegenerative diseases. 312 A pertinent question here is whether protein aggregation may introduce oxidative stress in some disease contexts. There is evidence that different species of protein aggregates associated with neurodegenerative diseases may act to promote ROS generation. 290 In addition to the oxidant activity of Aβ/copper aggregates, PD-associated α-synuclein oligomers are also oxidants and have been shown to increase cytosolic ROS production, as well as cause mitochondrial lipid and protein oxidation, leading to mitochondrial dysfunction. 313

Micro- and macronutrient deficiencies

The possible consequences of deficits or dysfunction in cofactor incorporation that were discussed previously relate to the larger-spanning topic of how micro- or macronutrient deficiencies may perturb protein folding and proteostasis. A recent estimate suggested that 99.3% of the world’s population may suffer from inadequate micronutrient intake. 314 In addition, nutrient deficiencies may also stem from diseases or genetic predispositions, adding to their prevalence and impact. For example, vitamin E, vitamin C, and selenium deficiencies are estimated to affect 67%, 53%, and 38% of the global population, respectively. 314 These three micronutrients are important antioxidants: selenium is a required cofactor for multiple antioxidant enzymes (including glutathione peroxidases and thioredoxin reductases), whereas vitamins C and E interact directly with ROS to reduce them, with vitamin C also contributing to the recycling of oxidized antioxidants (e.g., vitamin E). 315

With this background in mind and the posited effects of oxidative stress on protein folding as outlined in the previous section, the deficiencies mentioned above have clear implications for proteostasis. For example, severe vitamin C deficiency causes scurvy, which consists of connective tissue degeneration and is lethal when left untreated. 292 This is due to the essential role of vitamin C as a cofactor for the lysyl and prolyl hydroxylases that are involved in collagen biosynthesis and the integral role of hydroxylysine and hydroxyproline modifications in collagen conformation and crosslinking. 292 Without vitamin C, the lysines and prolines in collagen are not sufficiently hydroxylated, and the collagen monomers fail to fold and crosslink properly, leading to connective tissue pathology. 292

Another important antioxidant is the tripeptide glutathione (γ-glutamyl-cysteinyl-glycine [GSH]), whose biosynthesis depends on amino acid precursor availability and may be impaired by a protein-deficient diet (or certain diseases), specifically cysteine (and methionine), glutamate (and glutamine), or glycine deficiencies. 307 Amino acid deficiency may also disrupt proteostasis in a more direct manner. One example is tryptophan deficiency, which, e.g., is observed downstream of the upregulation of IDO1 (a tryptophan-catabolizing enzyme) in certain tumors. 316 Tryptophan deficiency leads to the misincorporation of phenylalanine at tryptophan codons by WARS1 (so-called W >F substitutions) and was observed to cause proteome-wide W >F enrichment, with suspected implications for protein folding and function (in many cases, due to the occurrence of highly conserved residues). 316 Notably, T-cell-mediated interferon-γ (IFNG) secretion (which may be generalized to inflammation) appears to be an upstream regulator of IDO1 expression. 316 These findings have therapeutic implications, as tryptophan-deficient tumors also display a greater number of neoantigens, promoting the immune recognition of tumor cells. 316 Tryptophan is also used in the biosynthesis of niacin (vitamin B3; which otherwise can be obtained through the diet), a precursor for nicotinamide adenine dinucleotide (NAD), which is an essential cofactor for several enzymes. 317 Among these enzymes is the sirtuin family of NAD-dependent protein deacetylases, 317 whose member SIRT1 supports the activity of HSF1 (the master regulator of the heat shock response), as well as other stress-inducible transcriptional regulators. 318 The disruptive effects of amino acid deficiency on proteostasis are also apparent from the induction of the integrated stress response (ISR) through GCN2 (EIF2AK4) under such conditions, leading to a global attenuation of protein synthesis and selective expression of certain genes, such as amino acid transporters and certain biosynthetic enzymes. 319

Dysfunctions in protein quality control and degradation machinery

Protein degradation is integral for removing both misfolded, damaged or outdated proteins from the cell and is continuously carried out via different pathways. Two of the main pathways involved in this process are the UPS and lysosomal proteolysis downstream, of e.g., autophagy or endocytosis. 320 Related to the UPS is the ERAD pathway, which specifically recognizes misfolded proteins within the ER and translocates them for UPS-mediated degradation in the cytosol 170 ; similarly, protein degradation processes are associated with other intracellular compartments, such as the nucleus 321 and mitochondria. 322 The major routes for protein degradation are discussed in more detail below, primarily in the context of stress responses, but it is important to note that they are also continuously active in unstressed cells.

The UPS mediates the degradation of ~15% of nascent polypeptides (co-translational ubiquitination), even in unperturbed cells; this degradation significantly increases when cells are subjected to signals that promote protein misfolding or translational stalling. 323 Accordingly, UPS dysfunction has been implicated in multiple diseases. In AD, both Αβ and Tau, the major pathological aggregating proteins, are UPS substrates. In addition, as mentioned in Section “Errors in the protein synthesis pathway”, the age- and AD-associated increases in +1-frameshifted ubiquitin B can block polyubiquitination and lead to an impairment in UPS function. 230 Intriguingly, it has been suggested that Aβ accumulation in AD may stem from decreased clearance rather than increased generation. 324 In PD, some familial variants are linked to mutations in PRKN , which encodes an E3 ubiquitin ligase, and PD-associated α-synuclein accumulation has also been shown to inhibit UPS activity (for a detailed discussion, see Lim & Tan (2007) 325 ). Moreover, a few additional genes encoding UPS components have been linked to other neurodegenerative disorders (including UBQLN2 and VCP2 in ALS) and other pathological protein aggregates (e.g., Tau, TDP-43, and polyQ proteins) that also exert inhibitory effects on the UPS. 326

While there is no strong evidence that UPS dysfunction is the primary etiological factor in these diseases, its integral role in maintaining proteostasis supports a contribution to their progression. For instance, pancreatic β cell-specific disruption of ERAD in mice leads to disrupted insulin maturation and hyperglycemia. 327 In myocardial ischemia, there is evidence that the UPS contributes to removing proteins damaged by oxidative stress and that ischemic conditions lead to oxidative damage to proteasome components themselves, with a corresponding accumulation of ubiquitinated proteins. 328 There is also evidence suggesting that oxidative damage to proteasome components may contribute to decreased proteasome activity in hypertrophic cardiomyopathy and heart failure. 329 Moreover, under proinflammatory conditions (e.g., exposure to IFNG or TNF), the catalytic components of the proteasome are exchanged, leading to the upregulation of an alternative form of the complex, called the immunoproteasome. 330 Notably, immunoproteasome upregulation has been associated with aging, and while it enhances the degradation of recombinant tau in the test tube, 331 an important question is to what extent it exhibits differential activity toward tau aggregates and other substrates in vivo and its significance in neurodegenerative diseases and whether it exhibits age-related declines in activity, as observed for the regular proteasome. 332

Other major protein degradation pathways converge on the lysosomes, downstream of either endocytosis of extracellular and cell surface proteins, or autophagy of cytoplasmic and organellar contents. 333 Dysfunction in lysosomal degradation, due to recessively inherited mutations in the genes encoding its enzymes, transporters, or biogenesis factors, results in a range of diseases collectively referred to as lysosomal storage diseases (LSDs), whose common pathology usually involves an accumulation of insufficiently degraded matter inside the lysosomes, and extensive lysosomal failure. 334 , 335 For LSDs, cell death or damage, chronic inflammation, and autoimmunity are common etiological components. 335 In addition, more than two-thirds of LSDs have neurological manifestations, suggesting a significant susceptibility of the nervous system to lysosomal dysfunction. 334 Since LSDs are rare and generally not comprehensively characterized, it is challenging to evaluate whether disrupted degradation of misfolded proteins specifically contributes to their etiology independently of the general accumulation of undegraded matter within lysosomes. There are several examples in which misfolded proteins may constitute an independent factor. 336 For example, neurons derived from the skin fibroblasts of a Gaucher’s disease patient demonstrated significant α-synuclein accumulation. This α-synuclein, in turn, disrupts lysosomal GLB1 activity, leading to elevated glucosylceramide levels, which subsequently further promote α-synuclein oligomerization. 337 This may, however, not be widespread, as it has been reported that ER stress and UPR activation are rarely reported in LSDs. Exceptions exist, such as in GM1 gangliosidosis resulting from beta-galactosidase (GLB1) dysfunction. 338 Conversely, consistent with the notion that many LSDs result from genetic mutations that disrupt the folding of the encoded protein, it has been observed in vitro that UPR or HSR activation (leading to the upregulation of molecular chaperones) can restore some enzyme activity, e.g., for Gaucher’s disease-associated β-glucocerebrosidase ( GBA1 ) mutations and Niemann–Pick disease, type C-associated NPC1 mutations. 339

Similar to the UPS, the autophagy–lysosome system also contributes to the degradation of protein aggregates linked to neurodegenerative disorders, such as tau aggregates linked to AD. 340 Mutations in the E3 ubiquitin ligase TRIAD3A, which facilitates the autophagic removal of tau, have been associated with neurodegenerative disorders such as HD and exacerbate tau aggregation and propagation in a mouse model. 341 Multiple AD-associated PSEN1 mutations disrupt the targeting of the vacuolar ATPase subunit (ATP6V0A1) to the lysosome, inhibiting lysosomal acidification and the activity of lysosomal proteases. 342 Notably, these results were linked to impaired ATP6V0A1 glycosylation, and similar effects were also observed when cells were treated with the N-glycosylation inhibitor tunicamycin, revealing how a commonly used experimental method to induce ER stress and UPR signaling may affect other components of the proteostasis network. 342 In summary, it is evident that the multiple proteolytic pathways of the cell are integral to maintaining proteostasis, and their dysfunction is intimately linked to various diseases.

Aging

While aging itself does not directly cause folding disorders or dysproteostasis via mechanisms that are distinct from those mentioned above, most of these mechanisms are associated with an age-correlated increase in frequency, prevalence, or extent. For example, strong links between constitutive inflammation and oxidative stress have been characterized in terms of “inflammaging” 343 and “free radical theory of aging”. 344 Moreover, age is a risk factor for proteinopathies such as neurodegenerative diseases, as discussed in Section “Diseases associated with protein folding defects”. Consequently, “loss of proteostasis” is considered one of the hallmarks of aging. 345

The expression of both autophagic and lysosomal components decreases with age, and disruption of autophagy and endocytosis causes neurodegeneration in mouse models, suggesting a possible explanation for the age dependency of this group of diseases. 345 – 347 The age-related declines in degradation activity that have been discussed for the UPS and autophagy–lysosome system are also shared by other proteolytic mechanisms, such as the mitochondrial Lon protease (LONP1), which degrades mitochondrial proteins with oxidative damage (not an infrequent occurrence due to significant ROS generation by the electron transport chain) and whose knockdown causes mitochondrial protein aggregation, leading to mitochondrial dysfunction and disruption. 348 Concurrent with decreased LONP1 activity in aged murine models, there is an increase in oxidized proteins in the mitochondria. 348

Another fundamental age-related change that may contribute to dysproteostasis is the accumulation of genetic mutations. Aging involves an ever-increasing cumulative load of DNA damage from replication error and mutagen exposure, coupled with deterioration in DNA repair capacity. 345 , 349 For example, human conditions of premature aging (progeroid syndromes) are characterized by loss of function of DNA repair components, such as the DNA helicase WRN, which is mutated in Werner syndrome. 349 As outlined previously, these mutations may either generate misfolded proteins or introduce loss-of-function mutations in the protein folding, modification, QC, or degradation machinery, with downstream consequences for cellular proteostasis.

Although transcription errors, translation errors, or protein damage are not permanent, such as DNA mutations, due to constant protein turnover by dilution and degradation, they may still accumulate over time. While the majority of proteins exhibit half-lives in the range of a few hours to a few days, others are long-lived and may persist from months to decades. 350 , 351 Examples of long-lived proteins include collagen (with a tissue-dependent half-life of ~100–200 years, 352 crystallins, nuclear pore complex components, histones, and others. 351 , 352 Errors in the transcription or translation of these proteins may result in significant accumulation of unfolded/misfolded moieties with potential pathological consequences. Moreover, during aging, proteins may undergo chemical modifications or aggregation that impede or prevent their degradation via the usual mechanisms. The deamidation of Asn and Gln into Asp and Glu, respectively, as well as the epimerization of amino acids from their L to D forms, are referred to as “molecular clocks”, as they accumulate over time in long-lived proteins. 352 Deamidation may alter the charge and structure of affected proteins and has been implicated in promoting the aggregation of the Aβ peptide, tau, and other proteins that accumulate in brain plaques. 353 – 355 Deamidation may also generate neoepitopes that incite autoimmunity, as exemplified by a handful of deamidated peptides that are presented on pancreatic β cells and targeted by T cells in patients with type 1 diabetes. 356 Similarly, amino acid epimerization may also accelerate protein aggregation: Asp epimerization in the Aβ peptide has been found to interfere with its lysosomal degradation. 357

Oxidative damage may also promote the accumulation of macromolecules. An example is lipofuscin, a conglomerate of oxidatively damaged lipids and proteins (as well as other constituents) that accumulate with both age and oxidative stress. 358 Moreover, S-nitrosylation of PDI inhibits its enzymatic activity, abrogates its cytoprotective effects upon proteostasis disruption and is enriched in brain tissue from AD and PD patients compared with control subjects. 359 As such, one aspect of the age-related decline in proteostasis is the accumulation of altered or damaged protein products. 345 This is accentuated both by age-associated increases in some of the stresses responsible for damage, as well as a progressive dysfunction in the quality control and degradation pathways that safeguard the proteome against damaged proteins. There are age-related changes in molecular chaperone induction and activity and a trend where basal expression levels of certain chaperones are increased in older animals, whereas the induction of other chaperones by heat shock is diminished (for a review, see 360 ). Age-related declines in the UPS, 332 , 345 the autophagy–lysosome pathway, 345 – 347 and other protein degradation mechanisms 348 may exacerbate the situation caused by increased protein damage and deficient protein folding. In addition, there is evidence that the capacity of stress response pathways such as the HSR also decreases with age. 361

Experimental perturbation of protein folding and proteostasis

To investigate the mechanisms of protein folding and the cellular response to misfolding, a wide range of chemical agents have been developed to perturb specific folding processes within the ER. These compounds interfere with different aspects of protein maturation, such as glycosylation, disulfide bond formation, calcium-dependent chaperone activity, or protein trafficking, thereby inducing the accumulation of misfolded proteins and triggering the UPR. While these tools provide essential experimental models to dissect folding stress pathways, their pleiotropic effects must be considered when experimental outcomes are interpreted.

As described above, N-linked glycosylation is one of the earliest and most essential modifications assisting protein folding in the ER. 362 The addition and processing of glycan moieties not only stabilize nascent polypeptides but also serve as molecular signals for quality control pathways. Among the most widely used compounds to perturb this process is tunicamycin, which blocks the first step of glycan precursor synthesis, preventing the addition of glycans to polypeptides. 362 This leads to the accumulation of unglycosylated, misfolded proteins within the ER lumen, activating all branches of the UPR.

Another frequently used compound, 2-deoxyglucose (2-DG), indirectly impairs glycosylation by inhibiting glycolysis, limiting the production of sugar nucleotides required for glycan synthesis. 363 Research also suggests that 2-DG-mediated inhibition of glycosylation may come from competition with mannose in the generation of dolichol-linked oligosaccharides and that exogenous mannose treatment is able to ameliorate 2-DG toxicity. 364 Another glycosylation inhibitor, kifunensine, targets mannosidase I, which leads to the accumulation of high-mannose glycoproteins. 365 Although kifunensine has been described as a suppressor of the UPR in several studies, it is more likely that it reduces the perceived level of ER stress by preventing misfolded glycoproteins from being recognized as defective, thereby limiting their degradation through the ERAD pathway.

As discussed in Section “HSP100/110 family: Protein disaggregases”, ER calcium stores are fundamental for protein folding and serve as cofactors for numerous folding enzymes and chaperones, including calreticulin and calnexin. Thapsigargin (Tg), a potent and specific inhibitor of the sarco/ER Ca²⁺-ATPase (SERCA), depletes ER calcium levels, severely impairing the folding environment. 366 Tg-induced calcium depletion rapidly triggers the UPR and downstream stress responses. However, beyond its effects on ER folding capacity, Tg elevates cytosolic calcium levels, activating calcium-dependent signaling pathways that influence apoptosis, gene expression, and mitochondrial function. 367 For example, Tg-evoked Ca²⁺ signals engage CaMKII, promoting pro-apoptotic JNK signaling and enhancing mitochondrial Ca²⁺ uptake that can precipitate Δψm loss and cytochrome-c release; altered ER–mitochondria Ca²⁺ transfer at contact sites (MAMs) further reshapes mitochondrial metabolism and dynamics. 368

Additional agents, such as cyclopiazonic acid, inhibit SERCA with lower potency and reversibility, resulting in different kinetic profiles of ER stress induction. 369 Calcium ionophores such as A23187 and ionomycin increase membrane permeability to calcium, disrupting gradients and contributing to folding stress via calcium imbalance. 370

Disulfide bond formation is essential for stabilizing the tertiary and quaternary structures of many secretory proteins. 371 DTT and β-mercaptoethanol are classic reducing agents used to experimentally cleave disulfide bonds, resulting in widespread protein unfolding and UPR activation. 372 These agents are often applied transiently to study folding stress recovery dynamics, as cells must rapidly reoxidize disulfide bonds upon removal of reductive stress. 373

Elevated levels of homocysteine, a metabolic intermediate, can also interfere with disulfide bond formation. 374 Homocysteine may form mixed disulfides with cysteine residues on nascent polypeptides or folding enzymes, leading to their misfolding. 374 These mechanisms are particularly relevant to disease states like cardiovascular pathology, where homocysteine accumulation is common. 375

Protein folding within the ER is tightly coupled to trafficking toward the Golgi and eventual secretion. 376 Interference with these processes can lead to indirect folding stress by causing protein accumulation in the ER. 376 Brefeldin A (BFA), a well-characterized inhibitor of ER-to-Golgi transport, blocks vesicle formation by targeting guanine nucleotide exchange factors (GEFs), leading to Golgi collapse and retention of cargo proteins within the ER. 372 , 376 Similarly, the ionophore monensin disrupts ion gradients within the Golgi, impairing PTMs and folding quality control. 377

Finally, the physical and chemical properties of the ER membrane itself are critical for maintaining folding homeostasis. 378 , 379 Alterations in lipid composition or cholesterol content can compromise the fluidity and structural integrity of the ER, affecting how transmembrane sensors such as IRE1, PERK, and ATF6 detect unfolded proteins. 379 Such membrane perturbations can alter the sensitivity of the UPR machinery, linking folding stress not only to protein-specific defects but also to metabolic and lipid-associated conditions such as nonalcoholic fatty liver disease. 379

Pathological consequences of protein misfolding

In addition to deleterious loss-of-function effects, protein misfolding may have lasting ramifications for cellular homeostasis through toxic gain-of-function. A prominent manifestation of this is when misfolded proteins acquire the ability to partake in extensive and nonproductive protein–protein interactions—that is, to aggregate. The accumulation of such aggregates is a correlative and/or causative feature of multiple disease types, including major neurodegenerative diseases and systemic amyloidoses. 380 There is also evidence, however, that some species of protein aggregates may have non-pathogenic physiological roles, which will be an interesting avenue for future research. 380

The formation of protein aggregates usually starts with disordered and homotypic peptide or protein monomers that can self-assemble into a variety of oligomeric structures. 380 Further aggregation consists of the association or addition of more oligomers or monomers that may lead to the formation of elongated protofibrils/protofilaments, which commonly twist around each other or associate laterally to form longer amyloid fibrils. 380 The proteins recognized to aggregate upon misfolding are heterogeneous in both sequence and structure. 380 Nevertheless, the regions that mediate the aggregation of these proteins have some common properties, such as increased hydrophobicity, amphipathic patterning (alternating between hydrophilic and phobic residues), and few charged residues. 380 Many of the initiating peptides or proteins are intrinsically disordered. 380

Typically, precursor species exhibit a high propensity for forming β-sheets, and the stacking of these β-sheets constitutes the predominant structural motif of higher-order amyloid fibrils. 380 These fibrils share a characteristic cross-β architecture, defined by β-strands oriented perpendicular to the fibril’s long axis. 381 The term “amyloid” itself is, in part, defined by the presence of a cross-β structure. Notably, cross-β fibrils can also arise from α-helical proteins that undergo conformational transitions into β-sheet-rich structures. 381 In rare cases, cross-α amyloid-like fibrils have been observed, consisting of α-helical segments stacked perpendicular to the fibril axis. 381 While the elongation of amyloid fibrils often involves conformational changes in the oligomers that initially form, other kinds of protein aggregates, such as amorphous/disordered and native-like aggregates, undergo less restructuring during their elongation. 380 , 381 Amyloid fibrils, together with nonamyloid amorphous aggregates and native-like assemblies, represent the three major categories of aggregation end products, all of which are linked to specific diseases. 380

To describe the kinetics of amyloid fibril formation, several models have been proposed, including nucleated polymerization, nucleated conformational conversion, and native-like aggregation. 382 A key distinction between the first two lies in whether the initial oligomers serve as elongation-competent nuclei or require further conformational changes to become so. 382 The last model describes circumstances where the aggregate-spawning monomers are not in a distinctively disordered or aggregation-prone conformation but rather in a native-like conformation where local unfolding or thermal fluctuations may initiate an aggregation cascade that causes downstream conformational changes and fibril elongation. 382 These different models are all representative of different aggregation processes observed for proteins implicated in conformational diseases. 382

Amyloid fibrils are structurally polymorphic and exhibit distinct pathological profiles. 383 Their deleterious effects arise from multiple mechanisms, including pro-inflammatory activity; disruption of cellular morphology; interference with organelle dynamics; sequestration of heterotypic interacting proteins involved in essential processes; and inhibition of proteasomal and autophagic pathways. 383 Moreover, the consequences of amyloidogenicity are not confined to the cell of origin—these fibrils can also propagate to neighboring cells, contributing to disease spread. 383 Notably, growing evidence suggests that intermediates along the aggregation pathway may be the primary cytotoxic species in conformational diseases. 380 Their smaller size and surface exposure of hydrophobic groups facilitate disruptive interactions with membranes and soluble biomolecules, including other proteins, RNA, and metabolites. 381

Multiple stress response pathways respond to protein misfolding

In previous sections, we explored the cellular dysfunctions and stressors that contribute to protein misfolding, along with its immediate consequences. Here, we expand the picture by examining key stress response pathways that detect and respond to protein misfolding or upstream stress signals. The proteostasis network, conceptualized as comprising over 1000 proteins, orchestrates protein folding, modification, quality control, and degradation. 384 Within this framework, the stress response pathways represent a regulatory layer outside the network itself. Specifically, we introduce the HSR, UPR, and mitochondrial UPR (UPR mt ). These pathways share molecular components that enable crosstalk, prompting us to consider both their specificity and functional overlap.

The heat shock response (HSR) senses and reacts to cytosolic dysproteostasis

It has been estimated that about half of the human proteome is translated on free ribosomes in the cytosol, although this is hard to determine and subject to cell line-specific differences. 385 A substantial portion of these proteins reside primarily in specific compartments, such as the nucleus or mitochondria, where they need to be translocated to their target compartments post-translationally. 93 , 386 During the cytosolic translation of these proteins, the nascent polypeptide chains that emerge from the ribosomes are rapidly bound by chaperones that prevent their aggregation with other unfolded proteins and mediate the next steps in their folding process. 93 An imbalance in the ratio of chaperones to unfolded proteins, or events that interfere with chaperone activity, may lead to an accumulation of unfolded proteins in the cytosol, which induces the HSR (Fig. 4 ). 387 Despite its name, the HSR responds to protein misfolding and dysproteostasis downstream of other stressors than heat shock, as well as to physiological cues that signal incipient stress on the proteostasis network, such as growth factor signaling. 387 – 390 Fig. 4 The canonical heat shock response orchestrated by HSF1. Under proteotoxic stress, such as heat shock, reactive oxygen/nitrogen species (ROS/RNS), or accumulation of misfolded proteins, HSF1 is activated through a multi-step process. In unstressed cells, HSF1 is maintained in a monomeric, inactive state through its association with molecular chaperones, particularly HSP90 and HSP70/HSP40. Upon stress, these chaperones are recruited to misfolded proteins, acting as a proteostasis rheostat: as misfolded proteins increase, more HSPs are titrated away from HSF1, allowing its dissociation. Freed HSF1 undergoes trimerization and is phosphorylated by upstream kinases which modulates its activity. The HSF1 trimer translocates to the nucleus, binds to heat shock elements (HSE) in target promoters, and drives transcription of a broad cohort of heat shock genes. As protein folding homeostasis is restored, the newly synthesized HSPs re-bind to HSF1, promoting its inactivation and disassembly—a negative feedback loop that fine-tunes the heat-shock response

The key actor in the human HSR is heat shock transcription factor 1 (HSF1), which mainly resides in the cytosol in a monomeric and inactive state under normal conditions. 361 The activation and inhibition of HSF1 involves a complex interplay of intra- and intermolecular interactions as well as PTMs; these interactions steer specific steps in HSF1 activation, such as its trimerization, nuclear translocation, DNA binding, association with transcriptional and epigenetic coregulators, and transcriptional activity. For example, the heptad repeat C (HR-C) region of HSF1 may interfere with HSF1 trimerization through intramolecular interactions with its HR-A/B region(s), which mediate intermolecular contacts in the trimer. 361 , 387 This autoinhibitory intramolecular interaction is directly regulated by heat-induced conformational changes in HSF1. 391 While PTMs of the HR-C domain have not been defined, S195 phosphorylation in the HR-A/B domain is associated with abolished autoinhibition by the HR-C domain, and multiple other phosphorylation, acetylation, and SUMOylation events in the other HSF1 domains are important regulators of its activity. 361 , 390 , 391 Moreover, both ROS and RNS, as well as endogenous oxidized or nitrated lipids, can activate HSF1. In the case of ROS, this effect appears to depend on the formation of a disulfide bridge that promotes HSF1 trimerization, whereas RNS-mediated activation may depend on the inhibition of HSP90 through S-nitrosylation. 390

In tandem with these events, the interaction of HSF1 with molecular chaperones is an important determinant of its activation. The HSP90 complex retains HSF1 in a monomeric state under normal conditions but may preferentially bind misfolded proteins under certain stress conditions, thereby releasing HSF1 from inhibition. HSF1–HSP90 interactions, which are promoted by HSF1 phosphorylation at S121, are also observed for trimeric activated HSF1, suggesting that they also contribute to attenuating the HSF1 response to stress. 361 , 390 In addition, HSP70/HSP40 complexes have been reported to negatively regulate DNA-bound HSF1 both by interfering with its ability to bind DNA and its ability to recruit transcriptional coactivators independent of DNA binding. This inhibition may be relieved by increasing the levels of unfolded proteins and reinstated as a negative feedback mechanism downstream of the HSF1 transcriptional response. 361 A 2018 study in S. cerevisiae provided insight into how different stressors may lead to HSR activation through different mechanisms, particularly with respect to whether HSR activation is driven by the absence of HSP90. 392 Active HSF1 trimers bind heat shock elements (HSEs) in the promoters of target genes and activate their transcription to support an adaptive response against dysproteostasis. HSF1-activated genes include those encoding cytosolic chaperones, such as HSP40 and -70 members (e.g., HSPA1A, HSPA6, HSPB1, DNAJB1, and DNAJB6), as well as regulators of chaperone activity (AHSA1 and STIP1), as well as some ~100 other targets. 388 , 393 Many of these latter target genes are related to additional HSF1 functions independent of the HSR, such as developmental processes (e.g., corticogenesis and spermatogenesis) and energy sensing. 389

Despite its central importance, HSF1 and its downstream target genes are not the only key components of the HSR; many sensors and signaling pathways that contribute to HSR regulation converge on HSF1 or its targets. In humans, two paralogs of HSF1 exist: HSF2 and HSF4. Tissue-specific HSF2 can activate both classical heat shock genes and other targets, either as homotrimers or as heterotrimers with HSF1. HSF4 is more ubiquitous and, apart from HSR, is best known for its role in development and lens physiology. 390 The importance of HSF2 for CRYAB expression in an HD mouse model, heterotrimerization of HSF1 and HSF2, and inhibition of HSR-related HSF2 activity by HSF4 suggest that both paralogs significantly contribute to maintaining proteostasis together with HSF1. 390 , 394 The HSF family also includes fewer characterized members, such as HSF5 and the more distantly related HSFX(1–4) and HSFY(1/2) proteins, which are encoded by genes on the X and Y chromosomes of humans, respectively. 394 , 395

As mentioned above, HSF1 is subject to numerous PTMs that govern its activation or inhibition at different levels, and the mediators of these PTMs themselves, or their upstream receptors or sensors, help integrate multiple different stimuli in the HSF1-mediated response. 361 , 390 Among the kinases recognized to phosphorylate and activate HSF1 are EEF2K (alias CaMKIII), mTORC1, MAP2K1/-2 (alias MEK1/-2), MAPK14 (p38 MAPK), and PLK1, suggesting that HSF1 activation may be regulated by calcium signaling, energy and nutrient availability, as well as growth factors, cytokines, and other extracellular signaling molecules, including possible coordination with the cell cycle. 390 For instance, nutrient availability affects HSF1 not only through mTORC1 activation but also via positive regulation by SIRT1 and negative regulation by AMPK. 389 Given the therapeutic relevance of protein kinases, targeting them with clinically approved inhibitors may offer a tractable strategy to modulate HSF1 indirectly. In cancer cells, for example, MEK inhibitors have been shown to induce cytotoxic amyloidogenesis through downstream suppression of HSF1 activity. 396

The HSR may play unique roles in various specific tissues. In humans and other animals, specific cell populations are equipped with temperature-sensing capabilities, namely, sensory neurons (thermoreceptors) of the peripheral nervous system that signal to neurons in the pons and, ultimately, the preoptic area of the hypothalamus, which in turn can elicit systemic responses. 397 While some of the notable responses sparked by such heat sensing are behavioral (e.g., seeking a cooler area) or largely supracellular (vasodilation, sweating, arrector pili relaxation), 397 evidence from model organisms indicates that HSF1 signaling may be upstream and/or downstream of noncell-autonomous regulation of the HSR in heterotypic tissues (i.e., signaling between different tissues). Most of this research is derived from C. elegans , where studies have shown that the overexpression of its HSF1 ortholog, both in neural and glial-like cells, enhances HSF1 signaling and the HSR in peripheral tissues. 398 , 399 Moreover, such signaling does not necessarily need to be unidirectional from neurons to peripheral cells, as C. elegans germ cells activate an HSF1-based transcriptional response to serotonin release from maternal neurons, 399 and stressed C. elegans embryos induce an HSF1-dependent response in maternal vulval tissue. 400 Interestingly, inter-tissue stress signaling in C. elegans may also occur through HSF1-independent mechanisms, as proteostatic disruption in muscle cells causes chaperone induction in multiple other tissues; furthermore, the overexpression of HSP90 in neural and intestinal tissues could in turn ameliorate dysproteostasis in muscle cells. 401 Similar organismal coordination of cellular HSF1 or chaperone activity in humans has not been described to date. Certain simplifying aspects of C. elegans as a model organism, such as the relative ease of signaling through gap junctions or the pseudocoelom compared with more complex analogous routes of intercellular or inter-tissue communication in humans, may render these mechanisms unique to smaller organisms such as nematodes. 402 However, owing to the appreciable extracellular input to multiple human stress response pathways, their possible regulation by systemic factors may be an exciting venue for future research.

UPR: An adaptive or apoptotic response to ER stress

The ER is a central hub for protein synthesis in eukaryotic cells. It serves as the primary site for the translation of secretory and transmembrane proteins—estimated to comprise one-third of the proteome—as well as many soluble proteins, including cytosolic ones. 385 , 386 Consequently, approximately half of the cellular proteome is estimated to be translated on the ER. 385 Beyond synthesis, the ER plays a critical role in protein folding, quality control (QC), and degradation, supported by a sophisticated array of resident chaperones, glycosyltransferases, oxidoreductases, and other folding machinery. While the ER is well-equipped to maintain proteostasis, excessive influx of nascent proteins or perturbations that impair its folding and QC capacity can lead to the accumulation of misfolded or unfolded proteins—a condition known as ER stress. This stress state activates a three-pronged adaptive response known as the UPR, which aims to restore ER homeostasis. 403 – 405

The metazoan UPR, including that of humans, is initiated by three transmembrane proteins that contribute to resolving ER stress through both distinct and shared mechanisms. 403 – 405 The three stress sensors are inositol-requiring enzyme 1 (IRE1α, also known as ERN1), PKR-like ER kinase (PERK, also known as EIF2AK3), and activating transcription factor 6 (ATF6) (Fig. 5 ). These stress sensors display a mode of activation similar to both each other and that of HSF1 in the HSR. Under ER proteostasis, the ER has sufficient protein-folding capacity to cover the influx of newly synthesized proteins, and there is an excess of the HSP70 family member BiP (alias HSPA5 or GRP78), which binds to the luminal domains of IRE1α, PERK, and ATF6, analogous to the HSP90-mediated inhibition of HSF1. BiP masks the regions involved in the activation of these sensors, rendering them inactive. 181 , 403 Upon ER stress, unfolded proteins accumulate in the ER, leading to gradual dissociation of BiP from IRE1α, PERK, and ATF6, which activates them. 403 Alternative models have also been posited and suggest, e.g., that additional factors may actively promote BiP dissociation under ER stress. 406 The levels of active BiP (capable of exerting chaperone activity or inhibiting the three UPR sensors) are also buffered by at least two mechanisms: (1) homo-oligomerization of BiP under low levels of unfolded proteins and (2) BiP AMPylation at T518 by the protein adenylyltransferase FICD. 403 This process and the downstream activation steps of the three stress sensors diverge in their mechanisms and are introduced individually below. Fig. 5 The three canonical UPR pathways signal ER stress to the nucleus. The UPR is a key signaling network that mitigates ER stress through three primary signaling pathways: IRE1α, PERK, and ATF6. Central to this response is HSP70 chaperone BiP (GRP78) that associates with these three proteins to keep them in an inactive state under normal conditions. However, during ER stress, BiP preferentially binds misfolded proteins, releasing and activating the three UPR sensors. Upon activation, IRE1α undergoes oligomerization and induces the unconventional cytosolic splicing of XBP1 mRNA, producing the transcription factor XBP1s, which translocates to the nucleus and upregulates genes involved in protein folding, ERAD, and glycosylation. In addition, activated IRE1 degrades specific RNAs through RIDD (Regulated IRE1 dependent decay). Furthermore, through its kinase function, IRE1α activates TRAF2, which in turn activates the NF-κB and JNK pathways. PERK activation leads to the phosphorylation of eIF2α, globally reducing protein synthesis to prevent further ER overload while selectively enhancing ATF4 translation, which regulates expression of genes associated with amino acid metabolism, oxidative stress response, autophagy, and apoptosis. Upon activation, ATF6 translocates to the Golgi where it is cleaved by S1P and S2P proteases, resulting in the active ATF6 transcription factor that translocates to the nucleus and upregulates expression of genes encoding ER chaperones, lipid biosynthesis enzymes, and ERAD components to increase ER folding capacity. Together, these pathways orchestrate a balance between adaptive stress responses and, if unresolved, apoptotic pathways, ensuring cellular proteostasis under ER stress conditions

The IRE1α pathway and its relationship with XBP1, RIDD, and JNK

IRE1α is an ER-resident type I transmembrane protein with a luminal stress-sensing domain and dual cytosolic effector domains: one domain confers protein serine/threonine (S/T) kinase activity, while the other domain provides endoribonuclease (RNase) activity. 407 Notably, outside of an observed in vitro phosphorylation of a heterologous peptide, the only recognized target of IRE1α protein kinase activity is IRE1α itself. Autophosphorylation of IRE1α is a prerequisite for the activation of its RNase activity. 408 The close paralog of IRE1α—IRE1β (ERN2), which is expressed predominantly or exclusively in epithelial cells of the gastrointestinal (GI) tract—exhibits similar but diverging RNase activities to IRE1α and can even antagonize IRE1α activity. 409

Historically, inactive IRE1α has been thought to exist as monomers bound and inhibited by BiP, with activation involving homodimerization and trans-autophosphorylation following BiP dissociation. 410 Beyond these homodimers, larger IRE1α oligomers—specifically back-to-back dimers—have also been identified. Subsequent studies suggested that these higher-order oligomers may be essential for full RNase activity, whereas the dimeric form may represent an inactive or less active state of the enzyme. 411 Previously, it has also been proposed that IRE1α dimers and oligomers may differentially contribute to XBP1 splicing and RIDD, with the former possibly being more dependent on higher-order IRE1α oligomerization. 412 Another model in which the direct binding of unfolded proteins to a luminal peptide-binding groove of IRE1α promotes its dimerization and activation has also been suggested. 410 This model was initially based on studies of yeast Ire1 and was suggested not to apply to human IRE1α owing to their structural differences. A later study, however, also revealed direct binding of the human IRE1α luminal domain to unfolded proteins, causing conformational changes and promoting its oligomerization and RNase activity. 410 Thus, the relative importance of the direct and indirect effects of unfolded proteins on IRE1α activation—through direct binding of unfolded proteins or BiP dissociation, respectively—is still not fully understood. 403 Independent of its luminal domain, IRE1α may also be activated by altered ER membrane lipid composition through its transmembrane domain. 413 In addition, other pathways may regulate IRE1α activity, such as TLR2- and TLR4-mediated activation, 414 , 415 AKT1-mediated inhibition, 414 , 415 or ERK1/-2 (MAPK3, MAPK1)- and AKT1-mediated stabilization. 416

IRE1α RNase activity mediates two distinct functions: unconventional (extranuclear) splicing of the XBP1 transcript and the cleavage of other cytosolic RNA species (e.g., mRNAs and miRNAs), with the latter termed regulated IRE1-dependent decay (RIDD). IRE1α RNase activity targets RNAs containing the CUGCAG consensus sequence in a stem loop (present, e.g., XBP1) but has also been found to cleave RNAs without this motif. 417 , 418 RIDD may therefore not exclusively target a specific subset of RNAs but could exhibit some nonspecific activity with more general effects on the cellular transcriptome. An in vitro cleavage assay in H929 cells upon ectopic expression of IRE1α and RNA sequencing (RNA-seq) identified 863 putative RIDD target mRNAs. 417 Among 32 selected mRNAs, 11 had the CUGCAG consensus sequence in a steam-loop motif at the observed cleavage site, and their expression was downregulated upon ectopic IRE1α expression. 417

The best characterized role of IRE1α is in the activation of the transcription factor XBP1s (Fig. 5 ). While the native XBP1 transcript is translated into a functional protein (XBP1u; u = unspliced), its cleavage at two sites by IRE1α excises a 26 nucleotide intron that leads to a frameshifted transcript encoding the functionally distinct XBP1s (s = spliced) protein, which is an active transcription factor. 404 After IRE1α-mediated cleavage of XBP1, the transcript is reconstituted to form XBP1s mRNA by the RNA ligase RTCB; this step may be regulated by RTCB phosphorylation. 419 As such, XBP1u is the dominant protein isoform in unstressed cells (albeit modestly expressed), whereas ER stress and UPR induction leads to XBP1 mRNA upregulation and increased XBP1s protein levels. This is followed by XBP1u protein upregulation, as elevated XBP1 mRNA levels persist while IRE1α activity diminishes. 420 The two XBP1 isoforms may be functionally antagonistic: XBP1u represses some XBP1s target genes (e.g., BiP), possibly through cytosolic sequestration and increased degradation of XBP1s. 420

XBP1s activates the transcription of genes that contain ER stress response elements (ERSE, ERSE-II) or UPR elements (UPREs) in their regulatory regions. 421 Among the genes activated by XBP1s are those that encode molecular chaperones (HSPA5, ERO1B, DNAJB9, DNAJC3, and PDIA6), ER quality control/ERAD components (EDEM1, UGGT1, and ERLEC1), and UPR signaling components themselves (XBP1 and ATF6). 422 , 423 Some of the XBP1s target genes are also under regulation by other UPR pathways; moreover, XBP1s can participate in transcriptional programs regarded as distinct from the UPR (e.g., plasma cell differentiation 424 or proinflammatory signaling in macrophages 414 ). A 2016 Perturb-seq study has helped elucidate the individual and joint transcriptional activities of the IRE1α, PERK, and ATF6 arms of the UPR under ER stress. 423 While XBP1s contributes to reinstating proteostasis by upregulating genes involved in ER protein import, folding, and quality control, it likely also exerts negative feedback on the IRE1α arm through its upregulation of DNAJB9, which promotes the inhibitory interaction of BiP with IRE1α. 148

In addition to instigating the XBP1s-mediated transcriptional response, activated IRE1α also serves as a scaffolding protein that facilitates the activation of other signaling pathways. In the best characterized example, the cytoplasmic domain of IRE1α recruits TRAF2 and ASK1 (alias MAP3K5), leading to downstream activation of JNK (MAPK8) under ER stress. 425 , 426 In mouse embryonic fibroblasts, IRE1α-mediated JNK activation under ER stress is dependent on tumor necrosis factor receptor 1 (TNFRSF1A). 427 In general, JNK activation is tightly linked to proapoptotic signaling through mechanisms such as phosphorylation and activation of the proapoptotic Bcl-2 family members BIM (BCL2L11), BMF, or BAD; in addition, it can activate apoptosis through the phosphorylation of the transcription factor JUN and the downstream upregulation of proapoptotic genes, including TNF, FASLG, and BAK1. 428 Consistent with this, IRE1α–JNK signaling is considered a contributing factor to apoptosis upon prolonged or excessive ER stress. 404 , 429 The IRE1α–XBP1s axis may also positively regulate c-JUN expression through downregulation of miR-216b. 430 However, a study on a liver-specific IRE1α knockout (KO) mouse model revealed c-JUN upregulation under ER stress only in IRE1α-KO livers but not in WT livers, suggesting that the positive regulation of c-JUN is not universal and may be context dependent. 431

IRE1α scaffolding activity may also lead to the activation of p38 MAPK (MAPK14), ERK1 (MAPK3), and NF-κB (NFKB) signaling, although these links have not been extensively studied and validated. 432 , 433 Different studies have pointed to the importance of IRE1α PTMs for its scaffolding activity. For example, a kinase-inactive IRE1α mutant has been shown to partially hinder JNK activation under ER stress. 425 Additionally, STUB1-mediated ubiquitination of IRE1α may be required for its phosphorylation and TRAF2 recruitment during ER stress 434 , while IRE1α sulfenylation appears necessary for TRAF2/ASK1/p38 activation (as well as being mutually exclusive with IRE1α phosphorylation and XBP1 splicing) under oxidative stress. 435 While further studies may be necessary to reconcile all these observations, collectively, they still allude to the importance of PTMs in regulating the activities of IRE1α. In addition to the interplay of IRE1α with JNK, its RIDD activity is also associated with proapoptotic effects, e.g., through the cleavage of miR-17 and other miRNAs to relieve the suppression of TXNIP and CASP2. 418 In summary, the activities of IRE1α under ER stress may have both adaptive and proapoptotic effects, depending on the external modulation of IRE1α itself or on the kinetics of the pathways it initiates.

The PERK pathway intersects with the integrated stress response (ISR) at eIF2α phosphorylation

PERK is a type I transmembrane ER protein containing a luminal domain similar to that of IRE1α and a cytosolic S/T protein kinase domain; this latter domain, unlike IRE1α, has multiple recognized targets, including both itself and other proteins, such as eIF2α and NRF2 (NFE2L2). 403 , 405 Moreover, PERK also has lipid kinase activity and may catalyze the conversion of diacylglycerol to phosphatidic acid. 436 Like IRE1α, PERK is normally inhibited by BiP binding, and its activation consists of BiP dissociation, homodimerization, and trans-autophosphorylation, allowing the recruitment and phosphorylation of other target proteins. 403 – 405 Furthermore, PERK may also share other modes of activation with IRE1α, such as direct binding to unfolded proteins 437 or an altered lipid composition of the ER membrane. 413

The best characterized pathway downstream of PERK activation involves PERK-mediated phosphorylation of eIF2α (EIF2S1) (eukaryotic translation initiation factor 2 subunit alpha) at S51 (Fig. 5 ). eIF2α must not be confused with EIF2A, which also participates in translation initiation, albeit only for specific mRNAs in a codon-dependent manner. 438 eIF2α, eIF2β (EIF2S2), and eIF2γ (EIF2S3) together form the EIF2 heterotrimer. 439 EIF2, in turn, is part of the 43S preinitiation complex (43 PIC), which consists of the 40S small ribosomal subunit, together with the initiation factors eIF1, eIF1A, eIF2, eIF3, eIF5. 439 The 43 PIC is recruited to the 5’-mG cap of mRNAs by the cap-binding EIF4E protein of the EIF4F complex. 439 , 440 GTP-bound EIF2 is responsible for the binding and delivery of Met-tRNAi Met to the 43 PIC, where this initiator tRNA base pairs with the mRNA start codon AUG and delivers methionine as the first amino acid of the nascent polypeptide chain. After Met-tRNAi Met dissociation, EIF5 hydrolyzes the GTP of EIF2 to GDP, and EIF2 dissociates from the 43 PIC. 439 , 441 Recycling of EIF2-GDP to allow its recruitment of a new Met-tRNAi Met and initiation of a new translation process requires the guanine nucleotide exchange factor (GEF) activity of the EIF2B α/β/δ/ε/γ heteropentamer. 441 EIF2B is not to be confused with eIF2β—the beta subunit of EIF2. For comprehensive reviews of eukaryotic translation initiation, see 439 and. 440

PERK is one of the four mammalian eIF2α (EIF2S1) kinases that interferes with translation initiation by phosphorylating eIF2α at S51; the others being HRI (EIF2AK1), PKR (EIF2AK2), and GCN2 (EIF2AK4), which are activated by distinct upstream stimuli. 319 , 440 This general mechanism of eIF2α S51 phosphorylation by an eIF2α kinase is referred to as the integrated stress response (ISR), as it can integrate many different upstream stimuli into a coordinated stress response. 319 However, due to each kinase having multiple downstream targets, the different contexts in which they may be activated and their effects on other cellular pathways, the ISR has different characteristics and outcomes depending on its mechanism of activation. 319

S51-phosphorylated eIF2α binds EIF2B with higher affinity, sequestering it and preventing it from catalyzing the recycling of the EIF2 ternary complex. 441 Therefore, the translation of mRNAs that require cap recognition by the EIF4F complex for translation initiation is inhibited, and the global rate of translation is reduced, decreasing the cellular load of nascent and unfolded proteins. In contrast, certain mRNAs (e.g., the ISR effector ATF4) contain short upstream open reading frames (uORFs) in their 5’ untranslated region (UTR), which promotes their translation under conditions of eIF2α phosphorylation. 442 In the absence of eIF2α phosphorylation, the ribosome translates these uORFs, as active EIF2B allows for EIF2 recycling before the ribosome reaches the next uORF. This prevents translation of the ATF4 coding sequence (CDS), as the last uORF extends multiple codons into the ATF4 CDS in a –1-frameshifted manner. 440 Consequently, the ribosome may not reinitiate translation of the ATF4 transcript from its bona fide start codon. However, when eIF2α is phosphorylated and EIF2B activity is decreased, EIF2 recycling proceeds more slowly, and for a substantial number of ribosomes, it occurs after the start site of the last uORF but before the ATF4 CDS, allowing translation of the full-length protein. 440 Therefore, ATF4 is upregulated upon ER stress or other stress conditions that activate the ISR. 319

ATF4 shares this mode of regulation with multiple other transcripts that are preferentially expressed under ER stress or the ISR, and many of these genes are also transcriptionally activated by ATF4, thereby requiring both ATF4 and eIF2α phosphorylation for their expression. Examples of this include GADD34 (PPP1R15A) 443 and CHOP. 444 GADD34 is a regulatory subunit of protein phosphatase 1 that promotes eIF2α dephosphorylation and thereby mediates negative feedback on PERK/ATF4 signaling. 403 While GADD34 may help attenuate the UPR before it progresses to an apoptotic phase, its reactivation of translation may also exacerbate ER stress to a cytotoxic effect under persistent dysproteostasis. 445 Consistent with this notion, pharmacological inhibition of eIF2α dephosphorylation with salubrinal is associated with increased survival of, e.g., rat PC12 cells under ER stress. 446

In addition to being a target gene, CHOP is one of the principal transcriptional coregulators of ATF4. A ChIP-seq study in mouse embryonic fibroblasts (MEFs) identified 321 CHOP-bound genes and 472 ATF4-bound genes, with 218 targets shared between the two. 447 Consistent with this overlap, RNA-seq analysis of ER-stressed MEFs lacking either ATF4 or CHOP revealed multiple regulatory patterns: some genes were similarly affected by both knockouts, while others were oppositely regulated or uniquely responsive to only one factor. 447 It revealed that both ATF4 and CHOP positively regulate genes involved in translation (e.g., initiation factors and aminoacyl-tRNA synthetases), in addition to more ATF4-specific contributions to amino acid biosynthesis (e.g., ASNS, PSAT1, and PHGDH) and transport (e.g., SLC7A11, SLC38A2, and SLC7A1). 447 Moreover, the study revealed mixed contributions of ATF4 and CHOP to ER protein folding and quality control processes through positive regulation of genes such as BiP, PIN1, SEL1L, PDIA4, SERPINH1, etc., as well as the other major UPR transcription factors XBP1 and ATF6. 447 , 448 These observations are in line with other studies, 448 including the targeted UPR perturb-seq study, which identified the PERK/ATF4 axis as having the largest unique regulon among the UPR arms (including its influence on amino acid homeostasis and translation) while also contributing to canonical UPR responses (bolstering protein folding and quality control) together with IRE1α/XBP1s and ATF6. 423 A notable feature of the ATF4 regulon is its inclusion of many ATF4 transcriptional coregulators, such as ATF3, CHOP, NRF2, and CEBPB/-D/-G, which may have implications for how the ATF4 transcriptional program is modulated over time. 448 Owing to its importance as a convergence point for the ISR, the range of influence of ATF4 also extends to the mitochondrial proteome and to genes involved in autophagy 448 — points that will be revisited in subsequent sections of this article.

Like the IRE1α/XBP1s axis, PERK/ATF4 signaling is also implicated in mediating the apoptotic response to persistent and excessive ER stress. 429 ATF4 increases the expression of the proapoptotic Bcl-2 family members PUMA (BBC3), NOXA (PMAIP1), and MCL1, 448 which are generally antiapoptotic unless alternatively spliced. 449 Moreover, downstream of ATF4 (and to some extent also downstream of XBP1s and ATF6 429 , 450 ), CHOP contributes to proapoptotic signaling through the activation of genes such as BIM (BCL2L11), DR5 (TNFRSF108), PUMA, BAX, CHAC1, and TRIB3, as well as the downregulation of antiapoptotic BCL2. 429 CHOP deletion has been shown to have cytoprotective effects in multiple mouse models of diseases characterized by constitutive ER stress and UPR activation, 445 , 450 suggesting that it may be an important transducer of proapoptotic UPR signaling in several contexts. This is further supported by observations that PERK/ATF4/CHOP activity, but not IRE1α or ATF6 activity, is sustained upon prolonged ER stress, leading to apoptosis, with PERK activation further impairing cell viability, whereas IRE1α activation improves it. 451 However, the extent to which proapoptotic UPR signaling is mediated primarily by individual genes or by the integrated output of entire signaling pathways, as well as how this process varies across different contexts, remains to be determined. For example, ATF4 and CHOP target TRIB3, which is another gene whose deletion decreases UPR-associated apoptosis, despite exerting negative feedback on ATF4 and CHOP signaling, 452 similar to the feedback from GADD34 and the effects of its inactivation. 445 Consequently, UPR activity appears to consist of delicately balanced adaptive and proapoptotic output. While this complicates efforts to delineate the UPR, it also suggests that the stress response may be sensitive to perturbations and a suitable target for therapeutic interventions.

Finally, we revisited the activities of PERK beyond eIF2α phosphorylation. The next best characterized substrate of PERK is NRF2, whose PERK-mediated phosphorylation prevents its binding to KEAP1, thereby relieving its cytosolic sequestration and allowing its nuclear translocation to transcriptionally regulate target genes as a key part of the antioxidant response. 453 Notably, similar to CHOP, NRF2 is also both a target gene and a transcriptional coregulator of ATF4, establishing it as an important effector of the PERK arm of the UPR. 448 Moreover, ATF4 and NRF2 may cooperate in other ISR pathways, such as under certain amino acid deficiencies, where GCN2 activates ATF4, and a lack of precursors for glutathione synthesis (glutamate, cystine) leads to NRF2 activation. 454 The principal targets of NRF2 mediate antioxidant activities and detoxification, such as glutathione biosynthesis enzymes (GCLC, GCLM), glutathione S-transferases (GSTs), redoxins (TXN, SRXN1), and UDP-glucuronosyltransferases (UGTs), and more. 455 While ATF4 and NRF2 share some target genes (SLC7A11, HMOX), their regulons appear to be mostly distinct from each other. 448 , 454 , 455 In fact, some of their transcriptional programs may be antagonistic, such as the induction of glutathione-cleaving CHAC1 by ATF4, which counteracts NRF2-driven expression of glutathione biosynthesis genes but may also serve to maintain NRF2 activation through this mechanism. 454 As such, NRF2 may perform functions downstream of PERK that the eIF2α/ATF4 axis alone is not capable of handling. In addition to NRF2, PERK may be involved in the activation of the pathways described above, such as p38 MAPK and NF-κB, which are also downstream of IRE1α scaffolding activity. 456 , 457

The ATF6 pathway

The third arm of the UPR is perhaps also the least complex, as only one protein—the transcription factor ATF6—takes on both the sensor and effector roles. ATF6 is an ER-resident type II transmembrane protein with a basic-leucine zipper (bZIP) domain in its N-terminal/cytoplasmic half. 405 Like IRE1α and PERK, its luminal region is bound by BiP, which dissociates upon ER stress to expose ATF6 Golgi localization signals, allowing the initiation of events that constitute its activation. 405 Following BiP dissociation, ATF6 is trafficked to the Golgi, where it undergoes sequential cleavage by Golgi-resident site 1 and site 2 proteases (S1P/MBTPS1 and S2P/MBTPS2, respectively), releasing a 50 kDa cleavage product that corresponds to the cytoplasmic half of ATF6 (referred to as ATF6p50 or ATF6-N [N = nuclear]), which subsequently translocates to the nucleus to mediate transcriptional regulation. 405

Evidence indicates that the reduction of ATF6 disulfide bridges by the ER oxidoreductase TXNDC12 (also known as ERp18) may facilitate ATF6 processing by S1P, as both S1P mutants and TXNDC12 knockout result in an additional 70 kDa ATF6 product and a diminished induction of ATF6 target genes 181 ; a similar role in ATF6 activation has also been proposed for the disulfide isomerase PDIA5. 458 Additional mechanisms have also been proposed to enhance ATF6 activation, such as ATF6 hypoglycosylation or interactions with members of the thrombospondin family of proteins. 405 Notably, the IRE1α and PERK arms may also contribute to ATF6 activation in multiple ways. For example, both ATF4 and XBP1s can activate ATF6 transcription, at least modestly. 405 Moreover, both ATF4 and XBP1s transcriptionally regulate multiple genes involved in ER-to-Golgi transport, which, albeit not being ATF6-specific, could help maintain the integrity of a central step in ATF6 activation. 459 , 460 Finally, p38 MAPK, whose induction under ER stress may be dependent on both IRE1α- and PERK, can contribute to regulating the nuclear translocation and activity of ATF6. 461

Like XBP1s, ATF6 binds ERSE and ERSE-II motifs in the regulatory elements of its target genes (and possibly also UPREs) and consequently exhibits an overlapping regulon with XBP1s; however, compared with XBP1s, ATF6 may be a more powerful inducer of ERSE-regulated genes but a less powerful inducer of ERSE-II-regulated genes. 421 In contrast to XBP1s, there is conflicting evidence regarding whether ATF6 binds UPREs. 421 , 462 ATF6 additionally recognizes cAMP response elements (CREs), which, together with their different coregulators and affinities for regulatory elements, help differentiate the contributions of XBP1s and ATF6 to the overall UPR transcriptional program. 421 Interestingly, the available evidence suggests that few UPR target genes are activated solely by ATF6, independent of contributions from XBP1s or ATF4. For example, an early microarray study indicated that ATF6 knockdown in MEFs had little impact on the expression of tunicamycin-inducible genes 422 ; the perturb-seq study mentioned above also supported the notion that many ATF6 target genes are under joint regulation by either XBP1s or ATF4, although ATF6 frequently exhibited the largest contributions to their expression. 423 Other findings emphasize that ATF6 deletion still impairs the net adaptive capacity of the UPR and is deleterious for stressed cells. 462 This finding corroborates the earlier point about the sensitivity of the UPR to perturbations, as apparently redundant mechanisms, when disrupted, have dramatic consequences for the cell. Among the ATF6 target genes, we find molecular chaperones (BiP, HSP90B1, and DNAJC3) and ER quality control components (CALR, EDEM1, and HERPUD1), which is consistent with the categories of genes induced by XBP1s and the general output of the UPR. 405 , 423 , 462 Interestingly, ATF6 has also been shown to regulate the expression of several oxidative stress-associated genes, including genes encoding the antioxidant proteins catalase (CAT), PRDX5, and SELENOS, which are not among the proteins traditionally linked to the antioxidant activities of the ER. 463 Moreover, like the IRE1α and PERK arms, ATF6 has also been implicated in the activation of NF-κB signaling (possibly through AKT1) upon treatment of cells with the subtilase cytotoxin. 464

The mitochondrial unfolded protein response (UPR mt ) and other mitochondrial stress responses

As noted above, the majority of mitochondrial proteins are synthesized in the cytosol and imported into mitochondria in an unfolded conformation. 465 Successful mitochondrial protein folding requires coordinated actions of mitochondrial-resident molecular chaperones, which mediate the unfolding and subsequent refolding of proteins during and after their translocation into mitochondria. 466 Additionally, mitochondrial proteases cleave presequences from matrix-targeted proteins, a process crucial for correct protein folding and maturation. 466 However, mitochondria present unique challenges to proteostasis, including oxidative damage caused by reactive oxygen species (ROS) from the respiratory chain and constant remodeling, fusion, and fission events according to metabolic demands. 303 , 466 Thus, mitochondrial proteostasis relies on dedicated constitutive and inducible processes collectively termed mitochondrial stress responses.

Mitochondrial protein folding stress arises predominantly from impaired protein import or intramitochondrial perturbations that disrupt protein folding, maturation, or stability. 467 Unlike ER stress pathways, mitochondrial stress responses are more diverse and are activated by distinct triggers rather than a single unified stimulus. These triggers commonly disrupt the mitochondrial membrane potential (ΔΨm) and electron transport chain integrity. 467 While extensively studied in model organisms (Fig. 6 , left), particularly yeast and C. elegans , the conservation and mechanisms of these pathways in human cells remain somewhat unresolved. Fig. 6 Mitochondrial UPR via the DELE1–HRI–eIF2α axis and downstream ATF4/ATF5 signaling. Left : In common model organisms, multiple processes that contribute to mitochondrial proteostasis have been characterized, a selection of which are illustrated here. Disrupted or stalled protein import, as well as protein misfolding, can perturb the mitochondrial membrane potential (ΔΨm), which exacerbates challenges to mitochondrial proteostasis. Misfolded and stalled mitochondrial proteins are subjected to proteasomal degradation through MAD and mitoTAD, respectively. A cytosolic accumulation of mitochondrial precursor proteins is termed mPOS and activates the mitoCPR and UPRam. mitoCPR is characterized by increased expression of molecular chaperones and other stress-responsive genes, as well as a multidrug resistance-like transcriptional program activated by PDR1 and PDR-3. mitoCPR also enhances the expression of CIS1, which may promote the degradation of mitochondrial precursors together with MSP1. The UPRam is associated with a general decrease in protein synthesis and increase in protein degradation, as well as a gene expression program resembling canonical ATF4 target genes. Other UPRam-mediated changes in gene expression may be linked to HSF1 or HAC1 activity. Since the figure represents pathways from multiple model organisms, human gene and protein nomenclature is used. Right: In human cells, a more unified model of the mitochondrial stress response (UPR mt ) has been characterized as relying on the ISR. A mitochondrial accumulation of misfolded proteins can activate the OMA1–DELE1–HRI axis, leading to a reduction in general translation, but an increase in the translation of uORF-regulated transcripts. These include the transcription factors ATF4 and ATF5, which activate the expression of molecular chaperones and other factors that can ameliorate mitochondrial dysproteostasis. ATF5 activation may also be enhanced by de-sequestration when its mitochondrial localization is disrupted by mitochondrial stress, putatively increasing its nuclear occupancy

In yeast, mitochondria-associated degradation (MAD)—analogous to ERAD—ensures proteostasis by extracting, ubiquitinating, and degrading misfolded mitochondrial proteins in the cytosol. 170 , 468 A specialized form called mitochondrial translocation-associated degradation (mitoTAD) specifically handles proteins stalled during import. 469 Excess accumulation of mitochondrial precursors due to import dysfunction results in mitochondrial precursor overaccumulation stress (mPOS). 470 This triggers at least two defined responses: UPRam (UPR activated by mistargeted proteins), which involves translational attenuation and increased proteasomal activity, and mitoCPR (mitochondrial Compromised Protein Response), which includes a multidrug resistance-like response governed by PDR3 and possibly PDR1—transcription factors with no clear human orthologs. 471 , 472

An intriguing question is why the HSR does not appear to be prominently involved in responding to mPOS. The original studies characterizing UPRam and mitoCPR included transcriptomic analyses that can be used to evaluate transcriptional signatures. Our unpublished reanalysis of these datasets (conducted for the purpose of this review) suggests potential contributions of HSF1 and HAC1 (the yeast ortholog of XBP1s) to the upregulated genes in the UPRam response. In contrast, mitoCPR exhibits a more diverse transcriptional profile, including upregulation of molecular chaperones and other stress-inducible genes responsive to heat shock, oxidative stress, and nutrient deprivation, alongside canonical PDR1/3 targets. Notably, only 18 transcripts were commonly upregulated across the two studies, underscoring the distinct nature of these stress responses.

Interestingly, a zebrafish study employing the same experimental perturbation as the yeast UPRam model—expression of mutant MIA40—did not reveal a direct overlap in upregulated transcripts. Instead, transcriptomic enrichment analyses highlighted pathways such as aminoacyl-tRNA synthetases, glutathione metabolism, molecular chaperones, one-carbon metabolism, and other canonical ATF4 targets. This divergence suggests that while mitochondrial import stress elicits a conserved cellular concern across species, the transcriptional programs mobilized in response may be highly context dependent.

A deeper understanding of how mitochondrial folding stress is sensed and transduced in human cells has been enabled by high-throughput approaches such as perturb-seq. A landmark study utilized single-cell RNA sequencing (scRNA-seq) to profile transcriptomic changes following genome-wide CRISPR interference (CRISPRi) in human K562 cells. 473 Among the 1,973 gene perturbations that induce strong transcriptional responses, those affecting the mitochondrial protein import machinery—including MIA40 (CHCHD4), TOMM22, TIMM23B, and components of the PAM and SAM complexes—elicited a distinct expression signature. 473 Notably, this signature clustered closely with perturbations of tRNA synthesis and components of the EIF2 complex, all of which activated canonical stress programs such as the integrated stress response (ISR), mTORC1 signaling, and nonsense-mediated decay pathways while concurrently suppressing oxidative phosphorylation and mitochondrial translocation-related gene expression. These findings were corroborated by an independent study in mice where disruption of the mitochondrial ribosomal subunit MRPS5 produced a similar transcriptional landscape, supporting a common response to disturbances in mitochondrial translation and import. 474

Strikingly, in the Perturb-seq study, perturbations of mitochondrial translation and translocation correlated more strongly with tRNA synthesis and EIF2 complex inhibition than with disruptions of cytosolic translation, despite the latter affecting a much broader portion of the proteome. 473 This correlation of tRNA synthesis/EIF2 perturbation and perturbation of mitochondrial translation or translocation may point to a particularly important role for the ISR in maintaining mitochondrial homeostasis, given that the ISR is a downstream event of both EIF2 insufficiency and ribosome stalling. 319 , 475

These features in the Perturb-seq data elegantly recapitulate the main findings of previous studies showing that the ISR also constitutes the backbone of a stress response to various mitochondrial insults in human cells, sometimes referred to as a mitochondrial unfolded protein response (mtUPR or UPR mt ). 476 , 477 While it was recognized already in 2002 that CHOP mediated a nuclear response to protein aggregation in the mitochondrial matrix, 478 recent findings established the canonical upstream regulator of CHOP, ATF4, as a major mediator of the UPR mt (Fig. 6 , right). Under mitochondrial stress caused by oligomycin-mediated respiratory chain inhibition, the OMA1 protease cleaves DELE1 at the inner membrane, followed by cytosolic accumulation of the DELE1 cleavage product and its interaction with HRI (EIF2AK1), enhancing the eIF2α kinase activity of HRI based on cell-free in vitro studies. 477 However, while DELE1 fragments were found to increase HRI activity and induce ATF4 expression under oligomycin treatment, OMA1 or DELE1 knockdown surprisingly enhanced eIF2α phosphorylation in oligomycin-treated HEK293T cells. This could indicate that DELE1 fragments also participate in negative feedback on eIF2α phosphorylation and/or directly affect ATF4 mRNA translation under stress conditions 477 ; regardless of the mechanism, this finding indicates an additional complexity in OMA1/DELE1/HRI-mediated UPR mt activation that is yet to be characterized.

ATF4 regulates several coregulators contributing to the human UPR mt , including CHOP and its paralog ATF5, which promote the expression of mitochondrial chaperones and the LONP1 protease under mitochondrial stress. 479 While overexpression of human ATF5 can rescue the UPR mt in C. elegans deficient in its ortholog ATFS-1—perhaps the principal regulator of the UPR mt in this model—its role in the mammalian UPR mt remains less clear, with evidence suggesting that ATF4 may act as the dominant effector under most mitochondrial stress conditions. 476 , 479 Nonetheless, ATF5 may play a role in an ATF4-independent, HSF1-mediated UPR mt that is induced by the mitochondrial HSP90 inhibitor GTPP or the LONP1 and HTRA2 protease inhibitors CDDO and Ucf-101, respectively. 480 Like C. elegans ATFS-1 (although weaker), human ATF5 also contains a mitochondrial localization signal, suggesting that the same mechanism, consisting of its mitochondrial sequestration under basal conditions and cytosolic and nuclear accumulation under mitochondrial stress, could play a role in human cells. 479 Additional signaling pathways, including those involving PKR (EIF2AK2), PERK (EIF2AK3), lysosomal acidification, and sirtuin-regulated antioxidant programs, have also been implicated in shaping the mitochondrial stress response. 477 , 481 – 483

In summary, mitochondrial protein folding stress may arise, e.g., from disrupted protein import, oxidative protein damage, protein misfolding, and perhaps more generally, perturbations to the inner membrane potential. The UPR mt integrates organelle-specific surveillance with cytosolic stress pathways—particularly the ISR—to restore mitochondrial proteostasis. While considerable mechanistic insight has been gained from model systems and high-throughput transcriptomic screens, further work is needed to resolve the cell type- and context-specific elements of this response in mammals and to clarify how folding-specific signals are distinguished from other mitochondrial insults.

Diseases associated with protein folding defects

It is now well established that protein misfolding and aggregation are the main or contributing etiological factors for a multitude of diseases (Fig. 3 ). 345 , 384 These diseases—particularly neurodegenerative diseases—are often referred to as proteinopathies or conformational diseases. A subset of proteinopathies is characterized by an accumulation of amyloid fibrils and is referred to as amyloidoses. In addition, protein misfolding may be exacerbated secondary to a preexisting disease condition and contribute to disease progression or additional pathology. Protein folding defects and dysproteostasis have also emerged as key factors in cancer. This section explores the links between protein misfolding and several major disease categories.

Neurodegenerative diseases

Neurodegenerative diseases (NDDs) are major global burdens of disease and are expected to continue to rise in incidence due to increasing life expectancy. In 2021, the global age-adjusted mortality of neurological disorders was estimated to be ~33/100,000, making it the seventh most prevalent cause of death among the major disease groups. 484 NDDs include diseases such as AD, PD, Huntington’s disease (HD), and ALS, which are characterized by a progressive dysfunction and loss of neurons in specific brain regions, leading to symptoms such as cognitive and motor deficits (e.g., dementia and tremors).

A hallmark of NDDs is the accumulation of toxic protein aggregates in the brain. These aggregates often arise from proteins that, due to mutation, post-translational modification, or aberrant processing, adopt aggregation-prone conformations and gradually accumulate. 326 In some NDDs, such as traumatic brain injury or spinal cord injury, protein aggregates—like tau—are considered secondary to the disease but may nonetheless contribute to its persistence or progression. 326 A small subset of NDDs, such as hereditary PD attributed to LRRK2 mutation, are not associated with toxic protein aggregation. 326 Nevertheless, protein aggregation is considered a primary contributor to disease development in most NDDs, including major classes such as AD and PD, which are covered in more detail in the following sections. In addition, dysproteostasis in a wider sense, including disruption of protein degradation pathways such as the UPS and the autophagy‒lysosome system, has been considered a separate hallmark of NDDs. 326

Alzheimer’s disease

AD is the most prevalent NDD and the leading contributor to dementia, accounting for two-thirds of dementia cases. 485 AD has highly age-dependent incidence rates, is far more common in older populations, and is also more prevalent in women than in men. 485 Due to the risk conferred by advanced age and global increases in life expectancy, the incidence of AD is estimated to triple by the year 2050. 485 AD risk is also increased by certain genetic predispositions, including at least 29 multigene loci, 486 and both genetic and nongenetic factors contribute to the estimated 60–80% heritability of AD. 485 AD is characterized by progressive cognitive impairment over its course, typically culminating in severe memory deficits, mood and behavioral changes, aphasia, and motor deficits. 487

AD is characterized by dysproteostasis at many different levels, most notably through the well-characterized presence of abnormal protein aggregates in AD brains. This is exemplified by recent guidelines on AD research, which have promoted a framework in which the disease is defined exclusively on the basis of biomarkers, such as the ATN system, wherein (A)myloid-β plaques, (T)au neurofibrillary tangles, and (N)eurodegeneration constitute the three classes of biomarkers. 485 , 488 In this framework, the use of clinical symptoms or signs in AD diagnosis is de-emphasized or discontinued altogether. This is motivated, for instance, by the observations that 10–30% of patients diagnosed with AD dementia do not exhibit the biomarkers by which AD is defined and, conversely, that these biomarkers are present upon biopsy in a large fraction (30–40%) of asymptomatic (cognitively unimpaired) elderly individuals. 488 As such, a shift to the biomarker-based ATN framework in AD research may position future studies to more precisely identify AD-specific etiological factors. Measuring the levels of the ATN biomarkers in patients, however, requires a small battery of invasive or costly tests, such as cerebrospinal fluid (CSF) sampling, positron emission tomography (PET) scans with amyloid or tau ligands, and magnetic resonance imaging (MRI) to evaluate neurodegeneration, and is currently not a feasible approach for the everyday clinical diagnosis of AD. 488 In the clinic, cognitive tests and patient/carer history remain the mainstay methods for identifying AD signs and symptoms (amnesia, disorientation, mood changes, etc.), and additional laboratory tests (full blood count, metabolic panel, etc.) are used to rule out differential diagnoses (e.g., metabolic causes of dementia), often with radiological imaging (MRI/PET) to assess neurodegeneration and rule out vascular dementia. 487

Protein aggregates in AD primarily come in two flavors: the abovementioned amyloid-β (Aβ) peptides and tau neurofibrillary tangles (NFTs). Aggregation-prone Aβ peptides are derived from amyloid-beta precursor protein (APP) when cleaved by β-secretase and γ-secretase complexes (the amyloidogenic pathway); the latter complex releases a 37–49-residue-long region of the APP transmembrane domain. 489 The length of the Aβ peptide determines its physicochemical properties and propensity for aggregation. Aβ40 (where 40 describes the peptide’s length) predominates in healthy individuals and does not aggregate readily, whereas Aβ42 includes two extra hydrophobic residues (I41 and A42) and is the main contributor to Aβ aggregation in AD. 489 Notably, mutations in PSEN1 or PSEN2 (constituting alternative catalytic components of the γ-secretase complex), which lead to increased production of Aβ42, are responsible for large fractions of hereditary AD cases, and APP mutations that influence the interaction of the APP protein with secretase complexes to increase the generation of aggregation-prone Aβ peptides, are also risk-conferring for AD. 489 The Aβ aggregates themselves form extracellularly after the secretion of Aβ peptides. 489

As outlined in Section “Errors in co- or post-translational protein modifications”, tau NFT generation may be prefaced by tau hyperphosphorylation, leading to the adoption of an aberrant conformation and dissociation of tau from microtubules and conferring resistance to proteasomal and autophagic degradation. 257 – 259 Consequently, tau proteins form beta-sheet-rich paired helical filaments (PHFs) that aggregate into NFTs and accumulate intracellularly. NFT (neurofibrillary tangle) is a term based on the early identification of extensive cytoskeletal polymers (microtubules, intermediate filaments/neurofilaments) in neurons by microscopy, at a time when they cannot be further discerned and are collectively referred to as neurofibrils. 490 Subsequently, tau aggregates were identified as abnormal “neurofibrils” with a tangled appearance, 491 and the NFT term has stuck with these tau aggregates till present day. A definitive diagnosis of AD requires the detection of both Aβ aggregates and tau NFTs and is corroborated by coincident neurodegeneration. 488 Abnormal levels of amyloidogenic Aβ peptides or hyperphosphorylated tau may be detected via positron emission tomography (PET) scans in tandem with radiotracer labeling of the corresponding proteins or through sampling of cerebrospinal fluid (CSF), whereas neurodegeneration is more readily visualized via magnetic resonance imaging (MRI). 326 , 488

According to the amyloid hypothesis, AD pathogenesis is initiated by Aβ aggregation, which promotes subsequent progressive tau hyperphosphorylation and tau NFT generation; the latter correlates more strongly with clinical manifestations (e.g., cognitive decline) than does the former. 258 , 485 On the basis of these findings, multiple putative etiological mechanisms, such as the indirect or direct modulation of a two-digit number of neuronal cell surface receptors by extracellular Aβ, have been proposed as effects of Aβ and tau buildups. 258 , 489 The activation of PRRs on microglia and astroglia by misfolded proteins may promote extensive neuroinflammation and contribute to AD progression. 492 Yet other mechanisms may contribute to the generation of Aβ and tau pathology or act in parallel. Above, we have introduced several examples, such as metal dyshomeostasis mediated oxidative stress, 290 , 311 oxidative stress due to mitochondrial dysfunction, 493 deficiencies in proteasome- or lysosome-mediated protein degradation, 324 , 342 and aging-associated protein deamidation or amino acid epimerization. 353 – 355 , 357 Aβ and tau pathology has also been implicated in the facilitation of neuronal hyperexcitability, possibly contributing to the cognitive dysfunction observed in AD, together with other mechanisms such as calcium dyshomeostasis and dysregulated glutamatergic or GABAergic signaling. 494 Taken together, evidence suggests that errors at multiple levels of the proteostasis network, many of which may act additively or synergistically, may contribute to AD pathogenesis, highlighting the potential for further research in this field to possibly advance the management of AD and other NDDs.

Parkinson’s disease

PD is the second most frequently diagnosed neurodegenerative disorder, and, like AD, its incidence increases with increasing age. 495 Consequently, PD is also expected to increase in prevalence owing to global trends of increasing life expectancy, but a significant portion of its observed increase in incidence—suggested to be the most rapid among neurodegenerative disorders—cannot be explained by aging population structures. 496 Other factors, such as increased environmental pollution, have been proposed to provide additional explanations for the observed rise in PD diagnoses. 496 PD is a progressive disease whose symptoms often present a decade prior to diagnosis and commonly features motor dysfunction (tremors, bradykinesia, instability, rigidity), depression, fatigue, cognitive problems, constipation, and other symptoms. 496 Motor symptoms are the primary signs employed as diagnostic criteria and, on their own, constitute parkinsonism (also referred to as Parkinson’s syndrome). 497 A certain PD diagnosis requires post-mortem identification of α-synuclein protein aggregates in intracellular Lewy bodies (which also include some ~300 other protein species) and Lewy neurites in the brain, particularly in the substantia nigra, accompanied by a loss of dopaminergic neurons, which explains the observed motor symptoms. 496 , 498 While α-synuclein aggregates in the substantia nigra provide the most compelling link to the disease’s motor manifestations, they first develop in other brain regions (e.g., the olfactory bulb) and gradually develop more extensively throughout the brain. 498 Notably, evidence suggests that α-synuclein aggregates may spread to other brain regions through exocytosis and endocytosis of proteins in tandem with a prion-like process in which misfolded conformers catalyze the misfolding of normal conformers. 496 , 499 The presence of α-synuclein aggregates makes PD a synucleinopathy, along with dementia with Lewy bodies and multiple system atrophy, which are characterized as atypical cases of parkinsonism. 496

The hallmark presence of α-synuclein aggregates in PD, similar to that of Aβ and tau in AD, implicates dysproteostasis in its etiology, and central questions include how the aggregates form and to what extent they are causative for the disease. Multiple genetic variants of varying penetrance have been linked to PD and are predominantly represented among early-onset (age <50–60 years) cases of the disease. These include mutations in SNCA itself, in PRKN and PINK1 (discussed in the context of mitophagy) in early-onset PD, and in LRRK2 and DNAJC13 in classic PD. 500 Many of the genes or loci whose mutations are linked to PD converge on some common pathways, such as vesicular trafficking ( SNCA , VAMP4 , RAB29 ), mitochondrial function ( ALAS1 , PINK1 , MCCC1 ), lysosomal function ( GBA1 , ATP6V01 , GALC ), and the proteostasis network ( BAG3 , DNAJ6 , PRKN ), possibly pointing toward different routes to similar states of cellular dysfunction. 500 α-Synuclein aggregates themselves are associated with disruption of ER-to-Golgi trafficking as well as mitochondrial and lysosomal functions, and accordingly, the overall landscape of possible etiological processes in PD includes many theoretical feedback mechanisms in which the different dysfunctional pathways magnify each other’s dysfunction. 500 For example, lysosomal function depends on vesicular trafficking for the delivery of its enzymes and mitochondrial respiration for ATP to drive transport, acidification, and catabolic processes. PD-linked mutations may interfere with any of these pathways, leading, e.g., to decreased lysosomal degradation of α-synuclein aggregates or increased aggregation of α-synuclein due to oxidative damage downstream of ROS release from defective mitochondria. As such, different kinds of mutations, environmental insults, or age-related alterations in the activity of these central processes may be connected in an ever-regressing circle. 500

Metabolic disorders

Metabolic disorder is a broad term that subsumes conditions and diseases characterized by complications or pathology that, in part, or completely, is caused by sustained imbalances in macronutrient intake and/or metabolism or by physiological responses to such sustained imbalances. For instance, obesity is a metabolic disorder characterized by excess body fat due to the maintenance of a prolonged positive energy balance and often has disadvantageous effects on metrics such as blood lipid and blood sugar levels, inflammation, and hormonal signaling. 501 Type 2 diabetes mellitus (T2D) is another metabolic disorder characterized by insufficient pancreatic insulin production due to a loss of pancreatic β-cells and the consequent dysregulation of glucose and lipid metabolism—a hallmark of persistently elevated blood glucose levels. 502 Finally, the etiology of the majority of cardiovascular diseases (CVDs)—the largest cause of death globally as of 2021 495 —are intimately linked to multiple other conditions regarded as metabolic disorders (e.g., obesity, T2D, hyperlipidemia), 503 underscoring their impact on global health. In this section, we explore the alterations and disruptions to proteostasis observed in these disorders, as well as the secondary contributions of stress response pathways to their pathophysiology.

Type 2 diabetes

T2D is a condition in which peripheral tissue insulin resistance combined with decreased pancreatic β-cell mass and/or function leads to chronic hyperglycemia. 502 Multiple other mechanisms—recently referred to as “the deleterious dozen”—have also been characterized as contributing to the development of hyperglycemia. 502 The associated glucotoxicity, oxidative stress, and other stresses, together with contributions from common comorbidities such as obesity and hypertension, act upon multiple tissues and organs to accelerate metabolic aging, frailty, physical dysfunction, and disability. 504 Closely following the global progression toward more sedentary lifestyles and unhealthy diets, the incidence of T2D is increasing and poses a formidable challenge to public health. 502

As with other secretory cell types, proteostasis in β-cells is under constant pressure due to their high rates of protein synthesis and secretion. Specifically, upon elevated blood glucose, β-cells synthesize proinsulin, which is proteolytically processed and secreted as insulin. Studies suggest that insulin production may constitute 10–50% of total β-cell protein synthesis, depending on the level of stimulation. 505 Proinsulin is inherently prone to misfolding, with an estimated misfolding rate of 20% for the wild-type protein—increasing with certain INS gene variants, perturbations to parameters such as pH and Ca 2+ levels in the ER, or inadequate function in pathways that maintain or restore ER function, including the UPR. 505 For instance, Perk -knockout mice progressively develop a T2D-like phenotype, and in humans, PERK loss-of-function mutations are causative for Wolcott‒Rallison syndrome, which involves the onset of diabetes during infancy. 506 Mice with pancreatic Ire1 deletion display defects in the glucose-induced expression of genes involved in insulin biosynthesis, leading to decreased insulin secretion and elevated blood glucose. 507 However, hyperactive IRE1α signaling is also associated with β-cell deficits, and ATF4 and CHOP deletion may have protective effects against β-cell dysfunction or T2D, suggesting that the UPR may also mediate apoptotic signaling in stressed β-cells. 404 , 508 Attempts at expressing 35 S-labeled proinsulin in non-β-cell lines have shown that it excessively aggregates and is subject to large-scale degradation, indicating that β-cells rely on specialized adaptations and a fine-tuned ER environment to handle the requirements for insulin expression and secretion. 509 Consequently, genetic predispositions or other insults that exacerbate proinsulin aggregation have been proposed as common upstream contributors to the development of T2D. 505 In line with this, treatments that putatively enhance the protein folding capacity of the ER, such as the chemical chaperones 4-PBA and TUDCA (tauroursodeoxycholic acid), have shown promise in alleviating hyperglycemia and insulin insensitivity in obese and diabetic mice. 510 In one example, ER stress and β-cell death in the Akita mouse model of diabetes, which carries an INS mutation that promotes its misfolding, has been alleviated through autophagy activation via rapamycin-mediated mTOR inhibition. 511

T2D is also associated with pancreatic aggregation of the islet amyloid polypeptide (IAPP), which is processed by the same proteases as insulin and cosecreted with insulin by β-cells. 512 Pancreatic IAPP aggregates exhibit β-cell toxicity and correlate with β-cell loss in humans. 512 This intuitively seems contradictory, as β-cell loss in T2D patients should decrease IAPP production and secretion, possibly suggesting that IAPP aggregates may form at an earlier stage of the disease, where insulin resistance causes still highly functional β-cells to upregulate their secretory activities. Research indicates that IAPP aggregates are amenable to clearance by autophagy and that mice with β-cell-specific Atg7 knockout are more susceptible to β-cell toxicity and the development of diabetes when they express human IAPP (hIAPP), 513 whereas hIAPP-expressing mice treated with trehalose exhibit enhanced autophagic activity and improved glucose tolerance. 514 Other studies have demonstrated that β-cell-specific autophagy deficiency is cytotoxic to mice, suggesting more general contributions to β-cell viability. 515 Despite the observed significance of an intact autophagy pathway in vitro for human β-cell lines and in vivo for rodent β-cells, autophagy deficiency has not been explicitly established as a contributing etiological factor in T2D itself. 502

Nonalcoholic fatty liver disease

Another metabolic disorder closely linked to obesity is nonalcoholic fatty liver disease (NAFLD), an umbrella term for liver conditions of different severities, ranging from the generally nonprogressive NAFL to progressive and more severe nonalcoholic steatohepatitis (NASH). 516 NAFLD involves hepatic triglyceride accumulation (steatosis) accompanied by inflammation and liver degeneration and may progress to both more severe liver conditions (cirrhosis, hepatocellular carcinoma) as well as to extrahepatic disease (T2D, cardiovascular disease). 516 Both the total number of cases of NAFLD, as well as the proportion of severe cases, are increasing in prevalence; a 2016 meta-analysis estimated the global NAFLD prevalence to be ~25%. 517 Despite this, therapeutic opportunities are currently scarce, although candidates may be emerging in clinical trials. 516 , 518

Owing to its role in lipid synthesis, the ER has been at the center of attention in NAFLD, and studies have indicated ways in which pathways regulating ER function (e.g., the UPR) may contribute to NAFLD pathogenesis, as well as characterized disruptions to the proteostasis network that are commonly observed in NAFLD. For instance, ER stress markers are upregulated in the livers of obese subjects but decrease after gastric bypass surgery, correlating with a decrease in liver steatosis 519 ; moreover, indicators of increased ER stress are detected in liver biopsies from NAFLD patients. 520 Steatosis may, e.g., induce ER stress through alterations in ER membrane composition, which has been shown to disrupt the SERCA channel and trigger Ca 2+ dyshomeostasis. 521 The hepatic deletion of either Ire1α or Xbp1 in mice leads to dysregulated lipid homeostasis, but in diverging ways, increasing or decreasing liver steatosis, respectively; this could perhaps be due to observations that IRE1 RIDD activity toward certain miRNAs has been characterized as protective against steatosis. 522 The contributions of the other UPR arms to lipid homeostasis have also been described, including protective effects of both the PERK/eIF2α and ATF6 branches against hepatosteatosis in ER-stressed mice and an ATF6-mediated upregulation of fatty acid oxidation and downregulation of lipogenesis in hepatocytes. 522 , 523 Taken together, the dual roles of the ER and UPR in both lipid and protein homeostasis likely enables some level of crosstalk between the two. However, persistent ER stress has also been implicated in driving NAFLD progression through UPR-mediated activation of pro-inflammatory (NF-κB, JNK, and the NLRP3 inflammasome) and apoptotic pathways. 522 , 523

In addition to the UPR, the HSR may also contribute to protection against NAFLD progression. A progressive downregulation of HSF1 has been reported under NASH pathogenesis, where HSF1 activation by SYSU-3d was observed to decrease NASH pathology in mice, in part through alleviation of oxidative stress. 524 This gradual decline in HSF1 and downstream chaperone activity during NAFLD progression, inversely correlated with plasma markers of oxidative stress, has also been demonstrated in obese patients, 525 and a study applying heat shock and mild electrical stimulation to putatively activate the HSR has shown promise in decreasing NAFLD markers in patients with metabolic syndrome or T2D. 526

Due to the role of autophagy in lipid metabolism and the regulation of intracellular lipid stores—termed lipophagy—as well as its function in the removal of damaged macromolecules and organelles, studies have also examined the potential involvement of autophagy in NAFLD. Other reviews have described how the overexpression of specific autophagy genes, or their upstream transcriptional regulators, can alleviate steatosis in mouse models of obesity or hyperinsulinemia that exhibit autophagy deficiency. 527 Conversely, perturbation of autophagy in hepatocytes may exacerbate oxidative damage and proapoptotic signaling. 527 Liver biopsies from NAFLD patients show signs of impaired autophagic flux, 520 indicating that observations from cell lines and animal models may also hold up in human patients. In vitro experiments highlight the mTOR pathway as one of the possible mechanisms that may mediate autophagy suppression in hepatocytes upon fatty acid accumulation. 520 Taken together, there is evidence for the dysregulation of several central proteostasis pathways in NAFLD. Given the promising effects of their manipulation in preclinical models, some of these pathways may represent candidate targets for future therapies aimed at these liver pathologies.

Cancer

Cancer encompasses diseases characterized by uncontrolled clonal cell proliferation driven by genetic alterations that enable rapid growth and high mutability. 528 As tumors evolve in harsh environments, they experience significant proteotoxic stress that challenges their protein-folding machinery. 529 Oncogenic mutations often result in unstable or misfolded proteins, whereas chromosomal abnormalities such as aneuploidy produce imbalances in protein complex subunits, leading to the accumulation of unpaired polypeptides. In this context, increased protein synthesis, especially in cancers driven by oncogenes such as MYC, floods the cell with nascent polypeptides requiring proper folding. 529

These internal stressors are further intensified by the tumor microenvironment (TME). Dysregulated metabolism, oxidative stress, hypoxia, and nutrient deprivation not only promote protein damage and misfolding but also exacerbate the burden on folding systems. 529 Collectively, these conditions create a state of chronic proteotoxic stress in cancer cells.

To survive these challenges, cancer cells activate stress response pathways—including the UPR, autophagy, and the HSR—which together increase folding capacity, reduce protein load, and sustain cell viability. 529 , 530 These pathways are not merely protective; their successful engagement supports continued proliferation, apoptosis evasion, immune escape, and therapy resistance. 529 In contrast, failure to maintain proteostasis results in growth arrest or cell death. This divergence presents potential therapeutic vulnerability, as it may allow the selective targeting of cancer cells by disrupting their reliance on proteostasis mechanisms.

Central to this adaptive machinery are molecular chaperones, particularly HSPs, which are markedly upregulated in many tumor types and frequently correlate with poor prognosis and resistance to therapy. 531 Among them, HSP90 is especially critical, stabilizing a broad range of oncogenic clients—including kinases, transcription factors, and ubiquitin ligases. 107 Critical oncogenic signaling proteins such as EGFR, HER2, AKT, and BCR-ABL rely on HSP90 for stability and function. 107 , 109 , 532 Additionally, mutant TP53 proteins, which frequently exhibit dominant-negative or gain-of-function mutations, are safeguarded by HSP90, preventing proteasomal degradation and sustaining tumor progression. 107

In addition to stabilizing oncoproteins, molecular chaperones also actively suppress apoptosis. For example, HSP70 sequesters key proapoptotic factors such as APAF-1 and AIF, thereby increasing the threshold for apoptosis induction. 533 – 535 Other chaperones, such as HSP27 and associated co-chaperones further enhance cell survival, and disrupting these interactions can restore the sensitivity of cancer cells to apoptosis. 535

A major site of proteostasis disruption in cancer is the ER, where high translational activity and secretory demands can easily overwhelm folding capacity. Oncogenes such as MYC, RAS, BRAF, and HER2 stimulate excessive protein synthesis, quickly saturating the folding capacity of the ER. 529 , 536 For example, c-MYC overexpression in MEFs activates UPR signaling, which can be reversed by treatment with chemical chaperones such as 4-phenylbutyric acid. 537 In the Eμ-Myc mouse model, the UPR is activated in lymphocytes and is dependent on elevated protein synthesis, as reducing the translational load (e.g., via L24 haploinsufficiency) prevents UPR induction.

Cancers with high secretory activity—such as multiple myeloma, which produces high levels of immunoglobulins, or mucin-secreting lung, breast, and colon tumors—place continuous folding demands on the ER, potentially increasing their reliance on the UPR. 530 The TME further induces ER stress. As tumors outgrow their blood supply, they develop hypoxic and nutrient-deprived regions. 530 , 538 Hypoxia impairs oxidative protein folding due to limited oxygen availability for disulfide bond formation, 539 whereas glucose deprivation impairs glycosylation and calcium homeostasis, which are essential for ER function. 538 , 540 These stressors exacerbate protein misfolding, activating UPR signaling, particularly in hypoxic tumor regions. 541

To adapt, cancer cells exploit three branches of the UPR—IRE1, PERK, and ATF6—which collectively reduce the ER burden, increase folding and degradation capacity, and sustain survival under stress. 538 However, in cancer, these pathways often hijack to support not only proteostasis but also oncogenic growth, metabolic reprogramming, immune evasion, and drug resistance. 530 , 542 Below, we examine how each arm of the UPR is rewired in cancer to reinforce malignant progression.

PERK signaling in cancer

The PERK–ATF4 arm of the UPR plays a critical role in maintaining protein homeostasis in cancer cells under proteotoxic stress. 530 , 537 , 543 – 546 By balancing global protein synthesis and coordinating adaptive transcriptional programs, PERK signaling supports cell survival, metabolic adaptation, and resistance to stress.

Recent studies have indicated that ATF4 and the oncoprotein MYC co-occupy the promoter regions of more than 30 MYC target genes to regulate metabolic pathways and protein synthesis, establishing the cellular homeostasis necessary for rapid cell growth. 543 Among these proteins is 4E-binding protein 1 (4E-BP1), a negative regulator of translation that buffers the proteome against MYC-induced misfolding. Experimental ablation of PERK or eIF2α phosphorylation in MYC-expressing cells triggers apoptosis and abrogates tumorigenesis in vivo, 537 highlighting the role of PERK as a gatekeeper of proteostasis in rapidly proliferating cancer cells.

PERK–ATF4 signaling also promotes metabolic rewiring, notably through the upregulation of MTHFD2, a key enzyme in mitochondrial one-carbon metabolism. 544 MTHFD2 levels are significantly increased in many cancer types, and its silencing significantly impairs prostate cancer (PCa) tumor development in preclinical models, which is consistent with its overexpression in human PCa. 544 Under stress conditions, when MYC levels are downregulated due to the inhibition of protein translation, ATF4 compensates by inducing MTHFD2 expression, ensuring continued support for the m1C cycle and maintaining cellular metabolic homeostasis. Additionally, PERK promotes autophagy, both as a mechanism for ER quality control and as a source of metabolic substrates. 537 , 547 ATF4 and its downstream target CHOP promote the expression of autophagy genes such as ATG5, ATG12, and BECN1, facilitating the clearance of unfolded proteins when the proteasome is overwhelmed. 548 Pharmacological autophagy inhibition sensitizes tumors to hypoxia and irradiation, whereas PERK–ATF4-mediated autophagy promotes resistance to anoikis in invasive cancer cells by limiting ROS accumulation. 545 – 547 This was suggested as a mechanism of reduced lung metastasis of fibrosarcoma cells upon ATF4 knockdown. 545

PERK signaling supports antioxidant defense mechanisms by activating NRF2 through phosphorylation, leading to its release from KEAP1 and nuclear translocation to induce the expression of ROS-detoxifying genes, aiding cancer cell survival under oxidative stress. 453 , 542 Nrf2-knockout MEF cells display significantly increased sensitivity to tunicamycin. 453 PERK also promotes antioxidant defense via ATF4, which induces NRF2 and genes for GSH synthesis, thereby reducing ROS levels. Paradoxically, a recent study reported that ATF4 also upregulates the expression of CHAC1, a GSH-degrading enzyme that reduces GSH levels. 454 CHAC1 knockdown led to a strong increase in GSH levels and fully prevented NRF2 stabilization upon ATF4 induction. Measurement of intracellular or extracellular GSH, cystine and glutamate levels indicated that cells deplete GSH to increase cysteine availability. This raises the question as to why cells need extra cysteine under stress conditions. Upon ATF4 induction, the increased expression of the xCT antiporter system, which imports extracellular cystine in exchange for intracellular glutamate, is considered a cellular mechanism to induce GSH synthesis to detoxify ROS. However, the reduced levels of GSH may indicate that cells may need cysteine for another purpose.

ATF4-mediated induction of the cysteine-rich protein CRELD2 may help explain the increased cysteine demand observed during stress. 549 While cysteine is one of the least abundant amino acids—comprising less than 2% of residues in most proteins—CRELD2, which localizes to the ER and Golgi, is exceptionally enriched in cysteine (10.8%) and contributes to ER homeostasis by interacting with chaperones and stress-related enzymes. 549 In skeletal cells, CRELD2 functions as a chaperone for the LRP1 protein and has also been reported to regulate ER calcium release. 549 According to the genome-wide Perturb-seq data analyzed by GeneSetR (our unpublished data), CRELD2 expression is markedly upregulated upon the knockdown of BiP, or DHDDS, an enzyme essential for N-linked protein glycosylation. 550 Studies in CRELD2-deficient mice further suggest that the protein enhances ER stress tolerance and protein folding capacity. 551 Together, these findings support the idea that PERK/ATF4-driven cysteine accumulation may promote the synthesis of CRELD2, a critical ER chaperone, under stress conditions.

In addition to its role in proteostasis, CRELD2 has been implicated in cancer metastasis and immunomodulation. It is linked to tumor progression in several cancers and enhances endothelial cell invasiveness. 552 – 554 By facilitating proper protein folding during ER stress, PERK/ATF4 signaling may indirectly support CRELD2-driven metastatic potential. Additionally, CRELD2 plays a key role in reprogramming the TME by promoting the transformation of fibroblasts into cancer-associated fibroblasts (CAFs), thereby fostering a tumor-supportive stroma. 553 , 554 In breast and cutaneous squamous cell carcinoma, ROCK signaling induces CRELD2 expression and secretion via the PERK/ATF4 axis. Conditioned medium from ROCK-activated tumor cells elevates CRELD2 levels, which in turn enhances fibroblast motility and transforms their phenotype to a tumor-promoting state. In contrast, fibroblasts exposed to media lacking CRELD2 exhibit reduced motility, whereas recombinant CRELD2 restores motility, highlighting its role as a paracrine driver of CAF activity. In vivo coengrafting of ROCK-educated fibroblasts with tumor cells accelerates tumor growth, demonstrating that CRELD2 is both necessary and sufficient to drive a tumor-supportive fibroblast phenotype. Thus, ATF4/CRELD2 signaling not only supports cancer cell survival under stress but also reprograms the surrounding stroma to foster tumor growth and progression.

PERK/ATF4 signaling promotes cancer metastasis through multiple mechanisms, particularly by supporting epithelial-to-mesenchymal transition (EMT), a process that enhances cancer cell invasion and motility. 555 In cells that have undergone EMT, PERK/ATF4 signaling is constitutively activated, likely to manage the increased secretory load resulting from elevated ECM production, which promotes cell motility and invasion. 555 Primary breast cancer (BCa) cells with EMT markers exhibit increased PERK levels, increased eIF2α phosphorylation, and ATF4 gene signatures correlated with EMT programs across various tumors. 555 PERK inhibition reduces invasion and tumorsphere formation, highlighting its role in metastasis. 555 Additionally, ATF4 promotes EMT by upregulating the expression of transcription factors such as Slug and enhancing angiogenesis via VEGF. 556 , 557

In addition to its direct role in cancer cells, PERK/ATF4 signaling contributes to tumor progression through immunomodulation. In myeloid-derived suppressor cells (MDSCs), ATF4 activation promotes an immunosuppressive phenotype. 558 PERK deletion impairs NRF2-dependent antioxidant defense, disrupts mitochondrial homeostasis, and activates STING-dependent type I interferon signaling, reducing MDSC-mediated T-cell suppression and slowing tumor growth. In vitro, PERK deletion in MDSCs significantly reduced their ability to suppress CD8 + T-cell proliferation, whereas in vivo, it markedly delayed tumor growth, highlighting the critical role of ATF4 in maintaining immunosuppressive MDSCs. Additionally, ATF4-mediated CHOP expression in MDSCs enhances immune suppression by driving interleukin-6 (IL-6) production through CCAAT/enhancer-binding protein-β (C/EBPβ) signaling. 559

PERK-ATF4-C/EBPβ signaling is also critical for reprogramming hematopoietic stem/progenitor cells (HSPCs) into MDSC precursors in the spleen. 560 Given the toxicity of systemic PERK inhibition, targeted delivery of PERK inhibitors to the spleen was tested in hepatoma and lung carcinoma models. Splenic administration of PERK inhibitors (GSK2606414, AMG PERK 44) reduces tumor growth more effectively than direct tumor targeting does, suggesting that localized PERK inhibition may enhance antitumor immunity while minimizing toxicity. 560 , 561

PERK/ATF4 signaling also regulates macrophage polarization within the TME. In bone marrow-derived macrophages, PERK activity increases during differentiation into the immunosuppressive M2 phenotype, supporting mitochondrial function through serine biosynthesis and α-ketoglutarate production. 562 Macrophages from Psat1-deficient mice (an Atf4 target gene) show reduced M2 polarization and impaired T-cell suppression. In vivo, Psat1 deletion in myeloid cells reduces melanoma tumor growth, highlighting a role for ATF4/PSAT1 signaling in the immunosuppressive functions of M2 macrophages. 562

PERK inhibition may also enhance antitumor immunity by inducing immunogenic cell death (ICD). In melanoma models, PERK deletion or pharmacological inhibition triggers SEC61β-mediated paraptosis in ER-stressed cancer cells, leading to ICD and the activation of type I interferon responses in dendritic cells (DCs). 563 These activated DCs promote T-cell recruitment and activation, driving robust antitumor immunity. PERK inhibition delays tumor growth in a T-cell-dependent manner and enhances the efficacy of immune checkpoint blockade therapies such as anti-PD-1. 563

Additionally, PERK/ATF4 signaling modulates CD8 + T-cell survival and function. 564 , 565 Under stress, PERK-ATF4-CHOP-Bim activation induces CD8 + T-cell death, which can be rescued by PERK inhibition. 564 Taurine deficiency in CD + T cells also triggers exhaustion through PERK/ATF4 signaling, a process exacerbated in the TME, where tumor cells outcompete T cells for taurine uptake. 565 Therefore, targeting PERK may enhance CD8 + T-cell viability and antitumor function.

Collectively, these findings highlight the multifaceted role of PERK/ATF4 signaling in affecting proteostasis in cancer metastasis and immune regulation. By controlling factors such as CRELD2 and modulating immune cell function, PERK/ATF4 drives tumor progression through both cancer cell-intrinsic and microenvironmental mechanisms. Targeting this pathway offers promising therapeutic strategies to limit metastasis and improve immunotherapy outcomes.

IRE1α signaling in cancer

The IRE1α-XBP1 signaling axis is increasingly recognized as a critical regulator of tumor progression and immune modulation across multiple cancer types, including triple-negative breast cancer (TNBC), PCa, and non-small cell lung cancer (NSCLC). Elevated IRE1α activity has been observed in these malignancies, and its inhibition—either genetically or pharmacologically—has been shown to suppress tumor growth in preclinical models. 566 – 568 For example, shRNA-mediated knockdown of XBP1 in fibrosarcoma cells or expression of dominant-negative IRE1α in glioma cells significantly inhibited tumor growth and angiogenesis. Notably, the overexpression of XBP1s in fibrosarcoma cells with dominant-negative IRE1α expression rescued these effects, confirming the functional importance of this pathway in tumor biology. 569 , 570

In addition to its role in supporting tumor cell growth, IRE1α signaling profoundly influences the tumor immune microenvironment. 566 In PCa, androgen receptor signaling activates IRE1α-XBP1s to promote c-MYC-driven progression. 567 , 571 In syngeneic mouse models, IRE1α loss impaired tumor growth in an XBP1s-dependent manner and remodeled the TME by reducing the number of immunosuppressive TAMs and Tregs while increasing the number of effector T and NK cells. 566 Mechanistically, IRE1α inhibition enhances interferon-γ signaling and downregulates tumor-promoting pathways such as mTORC1 and glycolysis. Consistently, the IRE1α RNase inhibitor MKC8866 sensitized PCa tumors to anti-PD-1 therapy. Similar effects were observed in NSCLC, where IRE1α loss delayed tumor growth and boosted effector T-cell infiltration while reducing Tregs. This effect was reversed by XBP1s overexpression. Tumor-derived prostaglandin E2 (PGE2), which is reduced upon IRE1α loss, was identified as a key modulator of immune suppression. 572

In ovarian cancer, tumor-derived factors activate IRE1α-XBP1 in T cells, impairing mitochondrial function and IFN-γ production. 573 Patient T cells showed increased XBP1 splicing, which was correlated with reduced infiltration and antitumor activity. XBP1-deficient T cells in mice enhance antitumor immunity, suggesting their therapeutic potential in targeting this pathway.

The IRE1α-XBP1s signaling pathway is also important for NK cell proliferation and immune responses against viral infections and tumors. 574 NK cells lacking IRE1α or XBP1 exhibited significantly compromised proliferation and expansion. Pharmacological blockade of IRE1α resulted in reduced oxidative phosphorylation and mitochondrial respiration, which are critical for NK cell function. 574 Moreover, similar to findings in PCa cells, c-MYC was identified as a direct target of XBP1s, which contributes to NK cell proliferation. 567 This mechanism was further validated in vivo via an intravenous B16 melanoma model, in which IRE1α-deficient NK cells failed to control lung tumor colonization, resulting in fewer infiltrating NK cells in the lungs and reduced expression of c-MYC and the proliferation marker Ki-67. 574

Another recent study explored how tumor-derived lipids promote protumorigenic polarization in macrophages through the activation of the IRE1-XBP1s pathway. 575 Conditioned medium (CM) from melanoma cells significantly increased lipid accumulation and the expression of protumorigenic markers, such as arginase 1 (ARG1) and mannose receptor C-type I (MRC1), in bone marrow-derived macrophages (BMDMs). Interestingly, CM treatment induced the splicing of XBP1 without significantly activating the PERK pathway or stimulating the expression of ATF6 targets. STF083010, an IRE1α inhibitor, suppressed these protumorigenic changes. 575 In vivo, myeloid-specific XBP1 deletion reduced melanoma tumor growth and TAM numbers. The macrophage-inducible calcium-dependent lectin receptor (MINCLE) is induced by lipid signals from tumor cells, which facilitate the activation of the IRE1-XBP1s pathway in macrophages. 575 CM from tumor cells stimulated MINCLE expression, and its blockade impaired CM-induced protumorigenic responses in BMDMs. Notably, the lipid β-glucosylceramide was identified as a key bioactive component driving these effects. Genetic and pharmacological approaches have confirmed that targeting IRE1-XBP1s signaling and lipid metabolism could effectively diminish the protumorigenic polarization of TAMs and inhibit tumor progression, presenting promising therapeutic strategies for cancer treatment. 575

XBP1 is also overexpressed in basal-like TNBC cell lines compared with luminal subtypes. 576 In orthotopic xenografts, inducible XBP1 knockdown in MDA-MB-231 cells reduced tumor growth, metastasis, angiogenesis, and the CD44⁺CD24⁻ cancer stem-like population. Doxorubicin combined with XBP1 knockdown fully suppressed tumor growth and stemness. Patient-derived CD44 high /CD24 low cells also presented increased XBP1 splicing and UPR marker expression. This study also revealed a significant correlation between XBP1s binding and HIF1α motifs, indicating that XBP1s may play a role in hypoxia adaptation and stem cell maintenance.

Together with these findings on the basis of activation of the XBP1s pathway, a recent study suggested that IRE1α plays a significant role in modulating the immune response to taxane chemotherapy in TNBC through the regulated IRE1α-dependent decay (RIDD) pathway. 577 RIDD degrades double-stranded RNA (dsRNA) generated by docetaxel, limiting inflammasome activation. MKC8866 plus docetaxel triggered dsRNA accumulation, NLRP3 activation, and pyroptotic cell death, with major changes in the TME. While docetaxel alone resulted in minimal TIL and CD8 + T-cell infiltration, combination treatment led to substantial increases in these immune populations in tumors. Global gene expression analyses revealed that IRE1α target genes were negatively correlated with cytotoxic T lymphocyte signatures in BCa patients treated with neoadjuvant taxane-based therapy. 577 scRNA-seq analysis indicated that combination therapy altered the TME by significantly increasing the number of MHC-II-positive macrophages and dendritic cells, which participate in T-cell priming. Furthermore, the data showed that the therapy not only enhanced cytotoxic T-cell activation but also successfully upregulated PD-L1 expression in tumors, increasing their responsiveness to PD-1 inhibitors. Importantly, restoring the IRE1α pathway through genetic means successfully prevented the immunostimulatory effects of docetaxel, indicating its critical role in immune modulation. Overall, these findings suggest that targeting IRE1α could be a viable strategy to overcome immune evasion in immune-cold tumors and enhance the efficacy of chemotherapy in TNBC.

In addition to these significant effects on the TME, the inhibition of IRE1α signaling also suppresses TNBC cell growth. 578 MKC8866 reduces the proliferation and secretion of protumorigenic cytokines (IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2) and enhances paclitaxel efficacy in mouse models. 578 Notably, the combination of MKC8866 with paclitaxel resulted in significantly enhanced tumor growth suppression and increased survival in mouse models while also reducing mammosphere formation post-chemotherapy, a surrogate marker for cancer stem cell properties, suggesting that the maintenance of IRE1α inhibition could prevent tumor reemergence after chemotherapy cessation. Consistently, high IRE1α activity is correlated with inflammation and poor prognosis in basal-like TNBC. 578

IRE1α activity has also been shown to modulate antigen presentation in dendritic cells (DCs), thereby influencing CD8⁺ T-cell responses. 579 In DCs, antigen-derived hydrophobic peptides activate IRE1α, which triggers RIDD-mediated degradation of MHC class I heavy chains, reducing their capacity to present antigens to T cells. Interestingly, knockout of IRE1α in CT26 colon cancer cells had a minimal effect on tumor growth in syngeneic mice, whereas systemic pharmacological inhibition of IRE1α significantly suppressed tumor progression. Treated animals presented elevated surface MHC-I on DCs and increased infiltration of cytotoxic CD8⁺ T cells in the TME. In contrast, IRE1α knockout in 4T1 TNBC cells reduced tumor size by ~50%, whereas systemic IRE1α inhibition led to an ~80% reduction. 579 scRNA-seq analysis confirmed the increased abundance of both DCs and CD8⁺ T effector cells in treated tumors. In the orthotopic EMT6 TNBC model, IRE1α deletion alone had little impact on tumor growth, mirroring the CT26 model. However, combining IRE1α inhibition with anti-PD-L1 treatment resulted in strong tumor suppression. These findings suggest that targeting IRE1α can enhance DC-mediated T-cell priming and recruitment, ultimately strengthening antitumor immunity. In contrast, another study reported that IRE1α overexpression in CT26 colorectal and Lewis lung carcinoma cells limited tumor growth. 580 IRE1α overexpression induced XBP1 splicing and RIDD activation. In immunocompetent, but not immunodeficient, mice, tumor growth was reduced, accompanied by increased CD3⁺, CD4⁺, and CD8⁺ T cells. Further studies in different model systems are warranted to evaluate the effects of IRE1α overexpression on tumor growth.

Collectively, these findings reveal that IRE1α acts as a potent modulator of both biology of the cancer cell and immune cell dynamics within the TME. Thus, targeting IRE1α and its associated pathways may represent a therapeutic strategy to reprogram the TME, enhancing the effectiveness of existing immunotherapies. Future efforts should be directed toward elucidating the specific immune mechanisms by which IRE1α influences TME composition and function, with the potential to inform novel therapeutic interventions in cancer treatment.

ATF6 signaling in cancer

The ATF6 arm is the least characterized among the canonical ER stress pathways in terms of cancer; nevertheless, several studies have suggested that it also contributes to various aspects of tumor progression, chemoresistance, and prognosis. Similar to the other two arms of the UPR, ATF6 transcriptional activity is also elevated across various cancer types, including colorectal cancer, lung cancer, PCa, and BCa, albeit to different degrees. 581 , 582 In colon cancer, ATF6 directly upregulates the expression of CIP2A, an oncogene associated with poor prognosis. 581 Another study in colon cancer explored the role of ATF6 in protecting cells from DNA damage by inducing BRCA1 through mTOR signaling. 583 A very recent study reported that ATF6 facilitates colorectal cancer growth by promoting a cancer stem cell-like phenotype through Wnt signaling. 584 Genetic or biochemical inhibition of ATF6 activity significantly halted the cell cycle and decreased the viability of colorectal cancer cell lines. Moreover, Dox-induced ATF6 knockdown in Colo201 tumor xenografts resulted in an over 70% reduction in tumor volume.

ATF6 signaling was also suggested to be a link between alcohol consumption and the progression of PCa. 585 Golgi fragmentation in PCa patient tumors was positively correlated with the rate of alcohol consumption; in addition, ethanol (EtOH) induced Golgi fragmentation, which led to the translocation of S1P and S2P proteases from the Golgi to the ER, leading to the activation of ATF6 signaling. ATF6 knockdown suppressed EtOH-induced increases in colony formation and trans-well migration. The growth of xenografted LNCaP tumors was enhanced in EtOH-fed animals, and Golgi fragmentation and ATF6 translocation to the nucleus were detected in these tumors. 585

In melanoma, ATF6 is upregulated upon PTEN deletion; this upregulation is linked to ENTPD5 expression, which has been suggested to play an important role in promoting melanoma cell proliferation, motility, and metastasis through IGF1R signaling. 586 Finally, in gastrointestinal stromal tumors (GISTs), ATF6 expression was observed in 67% of patient samples and was correlated with shorter relapse-free survival. 587 GISTs are often characterized by mutations in the KIT protein, resulting in the production of a mutant form (MT-KIT) that accumulates in the Golgi complex. It has been reported that ATF6 contributes to GIST development by mediating HSP90 expression, which enhances the folding and stability of MT-KIT. In addition, pharmacological or genetic inhibition of ATF6 reduced GIST cell viability both in vitro and in vivo, irrespective of imatinib resistance. In summary, these data suggest that ATF6 signaling may be involved in promoting different cancer types.

Other diseases

Beyond the aforementioned diseases, several other disorders arise directly from protein misfolding, highlighting the centrality of proteostasis to human health. Lysosomal storage disorders such as Fabry disease, Gaucher disease, and Niemann–Pick type C (NPC) exemplify how misfolding disrupts critical degradation pathways. In Fabry disease, mutations in the GLA gene destabilize α-galactosidase A, leading to misfolding, ER retention, and degradation via ER-associated pathways, thereby preventing lysosomal trafficking and resulting in glycosphingolipid accumulation and multiorgan dysfunction. 588 In Gaucher disease, mutations impair the folding of glucocerebrosidase, similarly triggering ER-associated degradation and accumulation of glucosylceramide within macrophages. 589 NPC, which is caused predominantly by mutations in the NPC1 protein, results in destabilization and degradation of a lysosomal cholesterol transporter, culminating in lipid accumulation and secondary neuronal dysfunction. 590 These examples illustrate how protein misfolding within the secretory pathway compromises lysosomal function, organelle homeostasis, and cellular viability, as previously described for membrane proteins such as CFTR in cystic fibrosis (see Section “Errors in the protein synthesis pathway”).

Other systemic protein misfolding disorders, such as transthyretin (TTR) amyloidosis, further demonstrate how destabilization of otherwise soluble proteins can lead to pathogenic aggregation. 591 , 592 In TTR amyloidosis, tetramer destabilization facilitates monomer dissociation and partial unfolding, triggering the formation of β-sheet–rich amyloid fibrils, which are deposited extracellularly and disrupt tissue architecture. 591 , 592 Interestingly, the pathological shift arises not from loss of native function but from a toxic gain of function through aggregation, illustrating that even minor perturbations in protein stability can drive systemic disease.

Prion diseases, including sporadic and familial forms of Creutzfeldt–Jakob disease, provide a striking example of pathogenic protein misfolding propagation. 593 In these disorders, the normal cellular prion protein (PrP C ), which is rich in α-helices, misfolds into a β-sheet–rich pathogenic isoform (PrP Sc ), which acts as a seed to induce misfolding of additional PrP molecules. This autocatalytic mechanism, which is unique among human diseases, results in widespread neurodegeneration, spongiform changes, and rapid clinical deterioration, underscoring how protein misfolding can drive both cellular dysfunction and protein-only infectious transmission.

Frontotemporal dementia (FTD) and multiple system atrophy (MSA) are additional misfolding-related diseases. In FTD, abnormal aggregation of tau or TDP-43 disrupts microtubule dynamics or RNA processing, respectively, leading to neuronal vulnerability and degeneration. 594 In MSA, aberrant accumulation of α-synuclein in oligodendrocytes, rather than neurons, underscores the diversity of misfolding targets and cellular contexts, with glial dysfunction contributing to multisystem neurodegeneration. 595

Collectively, these disorders demonstrate that protein misfolding is central in a wide range of diseases, from single-enzyme deficiencies to systemic fibrillopathies and progressive neurodegenerative syndromes. Despite variations in the identity of the misfolded proteins, the affected cell types, and the clinical manifestations, a unifying principle emerges: disruption of proteostasis through misfolding and aggregation is a fundamental driver of pathology across diverse cell types and tissues.

Therapeutic strategies and progress in protein misfolding and dysproteostasis-related diseases

As described above, complex challenges are posed by protein folding disorders and dysproteostasis-related diseases. A variety of strategies have emerged to restore protein folding and homeostasis and mitigate disease progression (Fig. 7 ). Here we explore these therapeutic approaches, focusing first on strategies that directly influence protein folding and aggregation. We discuss methods that enhance molecular chaperone function, promote protein disaggregation or inhibit aggregation, and modulate PTMs to stabilize proteins. Subsequently, we examine interventions targeting cellular stress responses, including the modulation of the HSR, UPR, ISR, and the enhancement of autophagy and the UPS. By addressing both the molecular and the cellular aspects of proteostasis, these strategies offer promising avenues for the treatment of disorders associated with protein folding and dysproteostasis. Fig. 7 Therapeutic strategies against protein folding and abnormalities in proteostasis. Different therapeutic strategies are aimed at correcting protein folding defects and restoring cellular proteostasis. Small molecules, such as chemical chaperones and molecular chaperone modulators, assist in refolding misfolded proteins, preventing aggregation. Osmolytes and gene therapy can support proper protein conformation and cellular function. Misfolded proteins that fail to refold are targeted for degradation through the proteasome, autophagy, and lysosomal pathways, whose functions may be enhanced or restored by various means, including both pharmacological and lifestyle interventions. Stress response pathways represent another category of therapeutic targets. UPR inhibitors modulate the UPR, while ISR inhibitors target eIF2α phosphorylation. Additionally, HSF1 activators enhance the HSR to boost chaperone function. Metabolic regulators such as mTOR inhibitors and AMPK activators influence protein homeostasis by modulating translation and degradation pathways. In cancer, targeting protein homeostasis is also a therapeutic strategy, where HSP90 and IRE1α inhibitors are being explored alongside immune checkpoint inhibitors. Collectively, these pharmacological approaches aim to restore proteostasis and mitigate diseases associated with protein misfolding and aggregation

Strategies targeting protein folding and aggregation

Molecular chaperone enhancement

Pharmacological strategies targeting protein folding pathways represent promising therapeutic approaches to alleviate the toxic consequences of protein misfolding and aggregation across a range of diseases. Small molecules known as chemical chaperones have attracted increasing attention in this context. 596 These compounds promote proper folding, prevent aggregation, and stabilize protein conformations through diverse mechanisms, operating independently of the ATP-dependent cycles characteristic of molecular chaperones such as HSPs.

Chemical chaperones can be broadly categorized into two mechanistic classes: osmolytes and hydrophobic compounds. 596 Osmolytes, such as trimethylamine N-oxide (TMAO), trehalose, betaine, and glycerol, are naturally occurring small molecules that promote protein stability by modifying solvent properties and shifting the folding equilibrium toward the native state. 597 , 598 These compounds are widely utilized by extremophiles and stress-adapted organisms to maintain protein function under harsh environmental conditions and have shown potential in therapeutic and biotechnological applications.

In contrast, hydrophobic chemical chaperones act by transiently shielding exposed hydrophobic patches on misfolded or partially folded proteins, thereby reducing aggregation and facilitating proper folding or trafficking, particularly within the ER. 596 One of the best-characterized hydrophobic chemical chaperones is 4-phenylbutyrate (4-PBA), which helps stabilize protein conformation and improves the folding capacity of the ER, thereby reducing the accumulation of misfolded proteins in the ER. 510 Administration of PBA led to significant improvements in proteostasis in aged mice, resulting in consolidated sleep patterns and enhanced cognitive performance. 599 Specifically, PBA treatment reduced the expression of markers of ER stress in the cortex and hippocampus, such as phosphorylated PERK and ATF4, while increasing the expression of the molecular chaperone GRP78. Additionally, PBA enhanced CREB activation, a transcription factor associated with memory formation and synaptic plasticity, thereby improving learning outcomes in hippocampus-dependent tasks.

In addition to its effects on aging, PBA has been found to be effective in many disease contexts characterized by protein misfolding and ER stress. 600 Despite the large number of studies on its potential, translating these effects into robust clinical outcomes has proven challenging. Although it is an FDA-approved drug for the treatment of urea cycle disorders and has a well-known safety profile, only a few clinical trials have been conducted to investigate its potential for treating neurodegenerative diseases. 601

TUDCA has been well studied in the context of several protein folding-associated diseases. 602 Multiple preclinical studies indicate that it exerts neuroprotective effects in animal models of neurodegenerative diseases such as AD, PD, HD, and ALS. 602 The combination of PBA and TUDCA has been investigated for the treatment of ALS. In the phase II CENTAUR trial, this combination significantly slowed functional decline in patients. 601 , 603 These promising results led to the conditional approval of the PBA-TUDCA combination for the treatment of ALS. 604 However, recent developments have tempered this initial optimism. 605 A subsequent phase III clinical trial, the PHOENIX trial, failed to demonstrate a significant difference between the treatment and placebo groups, leading to the withdrawal of the combination from the market. 605 This outcome underscores the challenges associated with translating promising preclinical and early clinical findings into effective treatments for complex neurodegenerative diseases such as ALS.

Migalastat is another FDA-approved chemical chaperone that exemplifies the therapeutic potential of pharmacological chaperones. 606 Specifically, approved for Fabry disease, migalastat functions by selectively binding to and stabilizing certain mutant forms of α-galactosidase A (α-Gal A) that retain residual activity. 607 Fabry disease is a lysosomal storage disorder resulting from mutations in the GLA gene, leading to deficient α-Gal A activity and subsequent accumulation of globotriaosylceramide (Gb3) in various organs. 607 By acting as a chemical chaperone, migalastat promotes the proper folding of these mutant enzymes, facilitates their trafficking to the lysosome, and restores enzymatic activity, thereby reducing substrate accumulation and ameliorating disease symptoms. 607

The combination therapy of elexacaftor , tezacaftor , and ivacaftor (Trikafta) represents another highly successful chemical chaperone-based approach approved for the treatment of cystic fibrosis (CF). As described previously in Section “Errors in the protein synthesis pathway”, CF is caused by mutations in the CFTR gene, leading to the degradation of misfolded CFTR proteins before they reach the cell surface. Elexacaftor and tezacaftor function as folding correctors, enhancing the proper folding and trafficking of the CFTR protein, whereas ivacaftor potentiates channel opening. 608 By combining these agents, Trikafta addresses both the folding defect and the gating dysfunction of CFTR, leading to markedly enhanced lung function, reduced pulmonary exacerbations, and improved quality of life in patients with at least one F508del mutation, accounting for the majority of CF cases. Indeed, after its approval, this drug combination led to over 80% decrease in lung transplantation in CF patients. 609

Ambroxol is another chemical chaperone with demonstrated efficacy in lysosomal storage disorders such as Gaucher disease, where it stabilizes β-glucocerebrosidase (GCase), enhancing enzymatic activity and lysosomal trafficking. 610 , 611 Ambroxol has garnered interest for its potential therapeutic role in PD. 610 , 611 The ability of ambroxol to increase GCase activity in neuronal cells reduces α-synuclein aggregation, thereby exerting neuroprotective effects. 612 Clinical trials are currently underway to evaluate the safety and efficacy of ambroxol in patients with PD and Lewy body dementia. 613 Current findings suggest that ambroxol is well tolerated and can cross the blood‒brain barrier, leading to increased GCase activity in the central nervous system. 611

Tafamidis is another pharmacological chaperone that has gained approval for clinical use, specifically in the treatment of TTR amyloidosis. 591 , 592 Tafamidis works by binding selectively to the thyroxine-binding sites of the TTR tetramer, stabilizing it and preventing its dissociation into monomers—the critical first step in amyloid formation. 614 By maintaining the stability of the TTR tetramer, tafamidis reduces amyloid deposition, thereby slowing the progression of the disease and improving clinical outcomes in patients with familial amyloid polyneuropathy and cardiomyopathy. 592

Another promising development in the field of molecular chaperones is the design of specific compounds that stabilize normal protein conformations to prevent misfolding. A notable example is a rationally designed molecular chaperone known as MC (N,N’-([cyclohexylmethylene]di-4,1-phenylene)bis(2-[1-pyrrolidinyl]acetamide)). 615 This compound was engineered through docking simulations, molecular dynamics, and quantum chemical calculations to specifically bind and stabilize PrP C . In the context of transmissible spongiform encephalopathies (TSEs), fatal neurodegenerative diseases caused by prion proteins, MC has demonstrated significant therapeutic potential.

In vitro studies have shown that MC not only stabilizes PrP C but also eradicates prions in infected cells, prevents the formation of drug-resistant prion strains, and inhibits the interaction between prions and abnormal aggregates. 615 In vivo, weekly administration of MC in prion-infected mice prolonged survival, and intravenous administration in macaques infected with bovine TSE slowed disease progression and reduced disease-associated biomarkers in the cerebrospinal fluid. Very recently, MC has been designated as an orphan drug for the treatment of prion disease. These findings highlight the potential of de novo-designed chaperone compounds like MC as therapeutic agents for TSEs and possibly other protein misfolding disorders. As discussed in Section “Computational and theoretical approaches: Simulating folding processes”, with the advent of advanced AI-based tools such as AlphaFold and AlphaProteo, the rational design of molecular chaperones such as MC may become increasingly feasible. As our understanding of protein folding and misfolding mechanisms deepens and as computational methods continue to evolve, the development of new molecular chaperones tailored to prevent or correct misfolding in various diseases holds great promise for the future.

In addition to chemical chaperones that stabilize proteins through direct physicochemical mechanisms, considerable effort has been dedicated to developing pharmacological strategies that enhance the expression or function of endogenous molecular chaperones. One of the most advanced compounds in this category is arimoclomol, a pharmacological coinducer of HSPs. Arimoclomol enhances HSF1 activation, thereby amplifying the HSR under conditions of cellular stress. 616 This results in increased chaperone expression, which improves protein folding, reduces aggregation, and enhances the clearance of misfolded proteins.

Arimoclomol has shown therapeutic potential in diseases associated with protein misfolding and very recently was approved by the FDA for treating Niemann-Pick type C disease, a lysosomal storage disorder characterized by severe neurological and systemic symptoms. 617 This marked a significant milestone in the development of HSP-based therapies. Niemann‒Pick type C disease has limited treatment options, making arimoclomol a vital addition to the therapeutic arsenal. By amplifying the HSR and enhancing HSP70 expression, arimoclomol facilitates the proper folding and activity of enzymes critical for lysosomal function, thereby reducing substrate accumulation and mitigating disease progression. 616

In addition to its efficacy in treating lysosomal storage disorders, arimoclomol has demonstrated neuroprotective effects in preclinical models of neurodegenerative diseases such as ALS. 618 , 619 In transgenic mouse models of ALS, arimoclomol delayed disease onset, improved motor neuron survival, and extended lifespan. 619 These effects are attributed to its ability to reduce protein aggregation, support protein homeostasis, and enhance cellular stress resilience. Despite promising preclinical outcomes, recently published phase III clinical trial data suggest that compared with placebo, arimoclomol does not significantly improve efficacy outcomes in patients with ALS. 620 In the ORARIALS-01 trial, which assessed the safety and efficacy of arimoclomol in 239 participants over 76 weeks, no statistically significant differences were observed in the primary outcome, the Combined Assessment of Function and Survival (CAFS) rank score, and mortality between the arimoclomol and placebo groups.

While these results underscore the inherent challenges of translating chaperone-based therapies into clinical success, arimoclomol exemplifies the potential of harnessing the cell’s endogenous proteostasis machinery for therapeutic benefit. Continued advancements in molecular chaperone modulation, patient selection, and combinatorial treatment strategies will likely define the next frontier in targeting protein misfolding diseases.

Inhibiting protein aggregation or promoting aggregation

Efforts to modulate protein aggregation have led to a range of candidate compounds aimed at inhibiting oligomerization or facilitating the disaggregation of existing aggregates. While many such agents remain in preclinical development, several have progressed to clinical evaluation, offering potential disease-modifying benefits. This subsection highlights some of the most advanced and promising compounds.

Anle138b (emrusolmin) is a particularly promising small-molecule aggregation inhibitor identified through a high-throughput screen targeting α-synuclein and prion protein oligomerization. 621 Orally available and brain penetrant, anle138b binds to cavities within fibrils, stabilizing polar interactions and thereby preventing the formation of toxic oligomers. Notably, it is not limited to α-synuclein; preclinical studies indicate that anle138b can also reduce tau and amyloid-β aggregates. 622 , 623 In rodent models of PD and MSA, anle138b reduced α-synuclein deposits, preserved dopaminergic neurons, and improved motor function—even when treatment began after symptom onset. 624 – 626 Similarly, in tauopathy and amyloid-β models, the compound reduced the aggregate load and improved neuronal survival and cognition. 622 , 623 Following encouraging safety data in a phase I trial, anle138b is now poised for phase II efficacy studies in MSA, highlighting its potential as a disease-modifying therapy ( NCT04685265 ; NCT06568237 ).

Valiltramiprosate (ALZ-801; tramiprosate) is another small-molecule drug that adopts a different strategy for treating amyloid pathology. As an oral agent that is highly penetrant through the blood‒brain barrier, valiltramiprosate binds and stabilizes soluble Aβ monomers, preventing their conversion into toxic oligomers. 627 , 628 In a two-year, open-label phase II trial involving APOE4 carriers with early AD, treatment with valiltramiprosate reduced plasma p-tau181 levels, slowed hippocampal atrophy, and maintained cognitive performance. 629 Owing to its favorable safety profile, this compound is now under evaluation in a phase III trial targeting APOE4 homozygotes, a population with a particularly high amyloid burden. 630

While valiltramiprosate targets soluble Aβ, CLR01 represents a distinct class of aggregation inhibitors, described as “molecular tweezers” (for a recent review, see 631 , 632 ). The unique mechanism of the compound stems from its ability to bind to lysine residues on misfolded proteins via noncovalent, shape‒complementary interactions. By anchoring to these positively charged side chains, CLR01 disrupts the electrostatic and hydrophobic contacts necessary for oligomer and fibril formation.

Unlike traditional aggregation inhibitors that may target a single protein species, the broad specificity of CLR01 for lysine-rich regions confers the ability to interfere with multiple amyloidogenic proteins, including α-synuclein and tau. 633 – 635 Studies have demonstrated that CLR01 not only prevents the initial formation of amyloid fibrils but also remodels existing fibrils into nontoxic, off-pathway oligomers. 636 CLR01 inhibited Aβ fibrillization, reduced oligomer-associated toxicity, and preserved synaptic function in primary neuronal cultures. 637 Similarly, in a zebrafish model of PD, CLR01 mitigated α-synuclein-induced neurotoxicity and rescued dopaminergic neurons from degenerative changes. 633 Moreover, in transgenic mouse models overexpressing human α-synuclein, CLR01 administered at 12 months of age improved motor deficits and reduced the oligomeric α-synuclein burden. When α-synuclein aggregates were injected directly into the striatum or substantia nigra, CLR01 similarly curtailed the pathology. 638 These findings indicate that CLR01 can confer neuroprotection by directly interfering with pathogenic protein structures.

The final example of a small molecule drug effective against protein aggregation is squalene (ENT-01), which prevents the initial nucleation step of α-synuclein aggregation by competitively binding to negatively charged phospholipids on vesicular membranes. 639 , 640 The high affinity of squalamine for these membranes effectively displaces α-synuclein, reducing the local concentration of the protein at the membrane interface and preventing it from adopting aggregation-prone conformations. In biochemical assays, squalamine markedly reduced the formation of α-synuclein fibrils and oligomers, and in cultured human neuroblastoma cells, it substantially diminished oligomer-induced cytotoxicity. 639 , 641 Experiments in C. elegans expressing human α-synuclein demonstrated that the compound not only decreased aggregation levels but also almost completely reversed the accompanying muscle paralysis. These findings confirm that targeting the early, membrane-dependent nucleation events of α-synuclein aggregation can mitigate the downstream toxicity and functional impairments associated with synucleinopathies. ENT-01, an orally administered formulation of squalamine, has advanced into clinical trials for PD. 642 Another clinical trial was initiated to explore the ability of the compound to address PD-related dementia; however, this trial was recently withdrawn for unknown reasons ( NCT03938922 ).

Antibodies targeting protein aggregates

Owing to the central role and putative etiological contributions of protein aggregates in NDDs—including Aβ and tau aggregates in AD, α-synuclein in PD, and others—there is substantial interest in treatments that directly target these aggregates to promote their clearance or slow their spread. In addition to the small molecule aggregation inhibitors or stabilizers mentioned above, recent developments in this strategy have leveraged monoclonal antibodies (mAbs) that selectively target aggregates. As reviewed extensively elsewhere, the binding of mAbs, to e.g., Aβ, can promote clearance through various mechanisms. 643 These include direct recognition of the FC region of the antibody by microglia or indirect recognition mediated by the complement system, which leads to subsequent phagocytosis of the resulting complexes. 643 Lecanemab and donanemab are FDA-approved mAbs that target Aβ in distinct ways, both showing moderate benefits in clinical trials in slowing the rate of cognitive decline versus placebo, as evaluated by CDR-SB and iADRS scores, respectively. 644 , 645 Two phase III trials (EMERGE and ENGAGE) on another anti-Aβ mAb, aducanumab, were stopped due to meeting prespecified futility criteria, although it was later recognized that some assumptions of the analysis were violated and inaccurately predicted the final outcomes. 646 Nevertheless, in the final analysis, EMERGE, but not ENGAGE, met its primary endpoint (and three secondary endpoints), with aducanumab showing beneficial effects on a reduced decline in cognition and function (per CDR-SB). 646 In addition, both trials reported significant decreases in the amyloid PET and plasma p-tau indices, which is consistent with the findings of previous studies. 646 Aducanumab is FDA-approved for milder stages of cognitive impairment or AD. 647

Not all drugs designed after these principles exhibit equally promising results, examples including the first-generation anti-Aβ mAbs solanezumab, 648 crenazumab, 649 and bapinuezemab. 650 Another drug, the α-synuclein-targeting mAb prasinezumab, showed a lack of benefit for PD patients in a phase 2 trial reported in 2022, 651 although a post hoc analysis suggested a reduced rate of progression of motor symptoms in a subset of patients. 652 Prasinezumab is currently being evaluated in another trial. 653 Evidence of research misconduct in work that may have influenced the approval for testing of prasinezumab by a central investigator in this field serves as a wake-up call and reminder of the rigor and scrutiny needed when conducting or reviewing research. 653

Strategies targeting cellular stress responses

Modulation of the heat shock response

One therapeutic strategy against protein–misfolding disorders is the use of small molecules that increase chaperone expression or activity, thereby bolstering cellular proteostasis. A promising candidate in this context is LA1011, a dihydropyridine derivative identified as an Hsp90 coinducer. 654 In wild‑type mice, LA1011 improves spatial learning and memory, whereas in APPxPS1 AD models, it reduces neurodegeneration, preserves neuronal populations, increases dendritic spine density, mitigates tau pathology, and decreases the amyloid plaque burden. 654 , 655 Structural studies have revealed that LA1011 interacts with the C-terminal domain of Hsp90, potentially disrupting the binding of FKBP51, a co-chaperone implicated in tau hyperphosphorylation. 656 The precise mechanism of the neuroprotective effects of LA1011, including its impact on Hsp90 client proteins and other co-chaperones, requires further elucidation.

Sulforaphane, a phytochemical found in cruciferous vegetables, also harnesses the heat shock response by upregulating the co-chaperone CHIP. 657 , 658 In a triple transgenic mouse model of AD (3 × Tg-AD), oral administration of sulforaphane reduced Aβ and tau levels, including phosphorylated tau, and improved cognitive performance. 657 In another model involving intracerebroventricular injection of amyloid, 6 days of sulforaphane treatment enhanced cognition without affecting amyloid accumulation. 659 In another study in which amyloid aggregation was induced by aluminum and galactose treatment, long-term sulforaphane treatment decreased amyloid plaques, preserved cholinergic neurons and enhanced cognitive function. 660 , 661 Although not conclusive, these effects were attributed to the upregulation of CHIP and HSP70, leading to enhanced clearance of Aβ and tau. 657

An alternative strategy to enhance chaperone expression is to release HSF1 from its inhibitory complex with HSP90. 662 In various neurodegenerative disease models, this approach reduces misfolded protein aggregates, including pathological tau species. 662 – 664 Recent studies revealed that HSP90 can subtly reshape the conformation of Tau, shifting it toward an open state that favors the formation of small oligomers while simultaneously inhibiting fibrillization. 665 Although this approach might help in preventing large insoluble aggregates, it paradoxically supports a dynamic pool of toxic oligomers that evade normal clearance mechanisms. Moreover, the Hsp70/Hsp90 multichaperone complex can bind and hold pathologically phosphorylated Tau species, maintaining them in a soluble but misfolded state that may accumulate over time, potentially contributing to disease progression. 666

Despite these insights, the clinical translation of early-generation HSP90 inhibitors has been hampered by systemic toxicity and insufficient CNS penetration. 662 While some of these compounds reduce tau aggregation and improve neuronal viability in short-term applications, achieving long-term safety and efficacy is challenging. 667 To address these limitations, recent research has focused on more refined strategies. One promising approach involves the use of nanoparticles to deliver HSP90 inhibitors. 668 In parallel, the development of OS47720, a CNS-permeable and comparatively safe HSP90 inhibitor, has expanded the therapeutic horizon. 663 Prolonged (months-long) administration of OS47720 in AD-like mouse models not only induces a beneficial heat shock response but also preserves synaptic structure and function, offering a more viable and enduring therapeutic route for combating tauopathy-driven neurodegeneration.

Beyond direct pharmacological modulators, the development of HSP-inspired nanochaperones represents a next-generation concept. 669 , 670 Inspired by natural chaperones, these synthetic nanoassemblies provide a platform to selectively bind misfolded proteins, suppress their aggregation, and facilitate clearance by promoting their uptake by microglia. 669 Although still at an early stage, such nanochaperones have shown efficacy in preclinical models of AD by reducing Aβ aggregates and improving cognitive function. These systems represent a versatile strategy, potentially customizable to target specific aggregate types while minimally impacting protein homeostasis.

A recent study introduced a novel nanochaperone-mediated autophagy (NCMA) strategy aimed at selectively targeting and eliminating pathogenic tau and its aggregates. 671 This approach utilizes a customized nanochaperone, Beclin1-VQIINK-nChap (BVNC), which is composed of a micelle with hydrophobic microdomains, tau-binding VQIINK peptides, and Beclin 1 peptides that activate autophagy. BVNC specifically targets and binds pathogenic tau, stabilizing microtubules and maintaining tau homeostasis. The Beclin 1 peptides induce autophagy, forming autophagosomes around the bound tau. These autophagosomes then fuse with lysosomes, enhancing autophagic flux and promoting tau degradation. This innovative NCMA-based approach has been shown to be effective in preclinical AD models by reducing the tau burden and significantly improving cognitive function, representing a promising therapeutic strategy for neurodegenerative diseases.

The translational potential of nanochaperone-based therapies will depend on careful optimization of their size, surface chemistry, biodistribution, and safety profiles. 670 Questions surrounding long-term biocompatibility, brain penetration, and immunogenicity must be addressed before clinical applications. Nevertheless, the rational design principles underpinning nanochaperones—modularity, specificity, and biocompatibility—mark an exciting frontier in the pharmacological manipulation of cellular stress responses.

Targeting the unfolded protein response

Chronic UPR activation is also a hallmark of neurodegenerative disorders, causing proteostasis imbalance and neuronal loss, and targeting UPR pathways is a potential therapeutic strategy. Here, we highlight recent advancements in UPR modulation for the treatment of neurodegenerative diseases.

As summarized above, the PERK‒eIF2α axis of the UPR plays a central role in translational control during ER stress. 672 In many neurodegenerative diseases, including AD, PD, and ALS, increased phosphorylation of PERK and eIF2α is consistently observed in the brains of patients. 673 Prolonged PERK activation suppresses global protein synthesis, leading to synaptic failure and neuronal death 674 These disruptions are central to the pathology of neurodegeneration, as demonstrated in animal models. 673

Experimental approaches have highlighted the therapeutic potential of modulating PERK signaling. Genetic interventions have successfully mitigated synaptic failure and neuronal loss in AD and prion-diseased mice, with notable survival improvements in certain cases. 674 – 676 Similarly, pharmacological inhibitors of PERK, such as GSK2606414, restored protein synthesis and prevented neuronal degeneration in preclinical models of prion disease, tauopathy, PD, ALS, and FTD. 677 – 680 Despite these encouraging results, systemic inhibition of PERK is associated with significant on-target pancreatic toxicity, thus presenting a major challenge for clinical translation. 681

To address this limitation, alternative inhibition strategies have been investigated. 681 , 682 The small molecule ISRIB (Integrated Stress Response Inhibitor) binds eIF2B and enhances translation downstream of eIF2α phosphorylation without altering PERK activity. 682 , 683 In wild-type mice, ISRIB administration improved memory performance in behavioral tests. 682 In animal models of neurodegeneration, ISRIB has shown significant neuroprotective effects. 673 , 684 Particularly in prion-infected mice, the administration of ISRIB led to a complete absence (0/12) of clinical signs of prion disease, in contrast with the vehicle-treated control group, in which all the mice (9/9) developed confirmatory signs. 673 In this study, ISRIB not only prevented neuronal loss in the hippocampus but also reduced typical spongiform pathology associated with prion diseases, demonstrating its potential efficacy in mitigating neurodegeneration. ISRIB significantly prolonged the survival of prion-infected mice without causing pancreatic toxicity; however, the authors noted that ISRIB-treated animals were sacrificed because they lost 20% of their body weight despite a lack of clinical or neurodegenerative signs of prion disease, potentially due to the off-target effects of ISRIB.

On the basis of this unfavorable pharmacodynamic profile of ISRIB, the same group performed a compound library screen and identified trazodone, an antidepressant, and dibenzoylmethane (DBM), a naturally occurring compound known for its anti-inflammatory and anticancer properties, as two promising inhibitors of eIF2α phosphorylation (eIF2α-P). 685 In prion-diseased mice, treatment with either trazodone or DBM effectively restored memory function, prevented the progression of neurological symptoms, and reduced neurodegeneration, significantly extending survival. Similarly, in tauopathy-frontotemporal dementia models, both compounds showed neuroprotective effects, reversing memory impairments and reducing hippocampal atrophy. Additionally, trazodone lowered phosphorylated Tau levels, further highlighting its therapeutic potential. In a recent study in which noncanonical amino acid tagging was used, only two weeks of trazodone treatment restored the hippocampal translatome to a profile comparable to that of healthy mice, with significant recovery of synaptic and mitochondrial protein levels. 686 This recovery was paralleled by the restoration of synaptic and mitochondrial function, as well as a reversal of their disease-associated decline.

Despite these promising findings, the efficacy of trazodone in clinical settings has raised concerns. 687 Previous trials investigating the use of trazodone to treat sleep disturbances in Alzheimer’s patients reported no significant benefits, which could be due to its low dose (50 mg) and short treatment duration. 688 , 689 Furthermore, the sedative effects of trazodone may not overlap with its ability to modulate the UPR, complicating the interpretation of these results. These trials primarily involved patients with moderate to severe AD, a stage that may be less responsive to such treatments; thus, there may still be potential for trazodone to benefit early or prodromal stages of neurodegeneration, which should be tested by dose optimization and patient stratification in future clinical trials. 689

Since eIF2α phosphorylation is a central event in the ISR, which is regulated not only by PERK but also by other stress-sensing kinases, therapeutic targeting of eIF2α-P could unintentionally disrupt multiple essential cellular processes. SC79, an AKT activator, was proposed to lower eIF2α-P levels without imposing broad ISR inhibition. 681 Activated AKT enhances the phosphorylation of Thr799 within the kinase insert loop of PERK and subsequently reduces its ability to bind and phosphorylate eIF2α. In prion-diseased mice, SC79 effectively reduced eIF2α-P levels, providing significant neuroprotection and extending survival. In the 5xFAD mouse model, oral SC79 treatment enhanced memory retention and reduced anxiety without affecting amyloid-β levels. 690 While SC79 itself may not be suitable for clinical use owing to its own limitations, as a proof-of-principle tool, it highlights the potential of selectively modulating PERK activity as a therapeutic strategy.

In addition to PERK signaling, the IRE1α–XBP1 axis has emerged as a critical player in neurodegenerative diseases, displaying both protective and detrimental effects depending on the context. 691 The overexpression of spliced XBP1s through AAV-based gene delivery has demonstrated substantial neuroprotection in rodent models of AD, HD, and PD. 692 – 695 In these settings, enhancing XBP1s expression appears to alleviate ER stress, restore proteostasis, and preserve neuronal integrity. For example, in mouse models of PD, XBP1s expression in the substantia nigra protects dopaminergic neurons against neurotoxin-induced degeneration, while in HD models, it reduces protein aggregation in the striatum. 692 – 694 Similarly, in mouse and C. elegans models, XBP1s mitigates amyloid-β or tau toxicity. 696 , 697 Moreover, evidence also suggests that XBP1s expression during brain aging preserves synaptic plasticity, prevents cognitive decline, and normalizes proteomic alterations associated with neurodegenerative pathology. 698 Taken together, several lines of evidence suggest that enhancing IRE1α-XBP1s signaling promotes adaptive responses that can mitigate neurodegenerative pathology.

However, this protective paradigm is complicated by findings that reducing IRE1α–XBP1 signaling can unexpectedly confer neuroprotection in certain contexts. For example, conditional genetic deletion of Xbp1 in mouse models of ALS and HD produced beneficial effects. 699 , 700 Instead of exacerbating disease, the loss of Xbp1 enhanced autophagy, facilitating the clearance of misfolded proteins such as mutant SOD1 aggregates in ALS and mutant huntingtin aggregates in HD. Similarly, in models of AD, targeting IRE1 improved cognitive outcomes. 701 Recently, mesencephalic astrocyte-derived neurotrophic factor (MANF)-mediated inhibition of IREα signaling was reported to protect neurons in an animal model of PD from ER stress-induced death. 702 These results emphasize the complex interplay between UPR branches and cellular degradative pathways, suggesting that the therapeutic manipulation of IRE1α–XBP1s signaling may need to be finely tuned. In some disease states, blunting IRE1α–XBP1s activity appears to shift the cell toward alternative protective responses, such as autophagy, that can more effectively handle the buildup of toxic aggregates.

While preclinical findings suggest that the IRE1α–XBP1s axis can act as a double-edged sword in neurodegenerative diseases, translating these insights into clinical applications remains challenging. Despite encouraging data, only a few inhibitors of the IRE1α–XBP1s pathway have been tested in vivo. For example, only one study from nearly a decade ago reported a modest but significant neuroprotective effect of KIRA6, an allosteric IRE1α inhibitor, in retinal degeneration models. 703 Moreover, the long-term consequences of altering UPR pathways in chronic neurodegenerative disorders are still unknown; thus, the possibility of off-target effects must be carefully weighed, given the wide-ranging physiological roles of UPR signaling. Nonetheless, the growing arsenal of small molecules and gene therapy strategies offers hope for selectively targeting IRE1α–XBP1s to mitigate neurodegeneration without disrupting essential cellular homeostasis.

Targeting autophagy and the ubiquitin‒proteasome system

As reviewed above, when protein folding issues occur in the cell, leading to the formation of various types of aggregates, one pathway for recovery is autophagy. There is compelling evidence for the importance of autophagy in major diseases such as cancer, neurodegenerative and cardiovascular diseases, as well as aging; thus, autophagy has received substantial attention as a possible therapeutic target or point of intervention. 704 , 705

Owing to the many molecular components constituting the autophagy–lysosome pathway and the large number of pathways and mechanisms that regulate autophagy, multiple therapeutic strategies have been explored, some of them making it to clinical trials. Moreover, while increased autophagy is generally regarded as beneficial in the prevention of, e.g., age-related tissue dyshomeostasis and neurodegenerative diseases, the reverse is often true in cancer. Across different tumor types, autophagy supports sustained metabolism, growth, and resistance to therapy in cancer cells. 706 As such, there is a need to target autophagy in different ways depending on the context; here, we focus on therapeutic strategies that aim to activate autophagy to ameliorate dysproteostasis. There are other recent reviews on autophagy-inhibiting strategies in cancer (e.g. 706 ). This section will present some of the different autophagy-targeting strategies in general terms, along with specific emerging and established interventions that may show promise.

Interventions targeting the central autophagy machinery

The central autophagy machinery consists of autophagy receptors and proteins involved in autophagosome formation, as well as upstream kinases and ubiquitin ligases that mark cargo for degradation. In vivo studies have demonstrated that targeting individual genes within this machinery can significantly influence autophagic flux, tissue homeostasis, and overall organismal health. 707 For instance, the overexpression of Atg5, a key protein for autophagosome formation, enhances autophagy, reduces obesity, improves insulin sensitivity, and extends lifespan in mice. 708 In a mouse model of AD, lentiviral expression of Becn1, a core component of the autophagy initiation complex, reduced both intracellular and extracellular Aβ accumulation. 709 Moreover, a specific Becn1 mutation that reduces its sequestration by Bcl2 has been shown to enhance autophagic flux, mitigate age-related phenotypes, and prolong lifespan in mice. 710 These findings suggest that gene therapies could be viable options, especially in disease cases linked to variants of central autophagy genes. 711

In addition to the BECN1/BCL2 example, BECN1 sequestration may also be relieved by small-molecule BCL2 inhibitors that selectively target the BECN1 interaction over those of BCL2 with proapoptotic proteins. 712 Other small pharmaceutical molecules acting at the autophagy machinery include autophagy-targeting chimeras (AUTACs), which can be designed to target specific proteins via guanine-based degradation tags. 713 AUTACs employ principles similar to those of proteolysis-targeting chimeras (PROTACs), although the latter leverages the proteasome rather than autophagy to mediate targeted protein degradation. 713

Therapeutically targeting lysosomal function

Downstream of the recognition, capture, and lysosomal transfer of cargo by the central autophagy machinery, a range of lysosomal proteins that facilitate or mediate the degradation of this cargo are also potential targets in autophagy-manipulating therapeutics. LSDs, whose common pathophysiological aspects include lysosomal dysfunction due to the loss of function of lysosomal enzymes, provide good examples of diverse therapeutic strategies aimed at restoring lysosomal function downstream of different defects. LSD treatments may involve hematopoietic stem cell transplantation (HSCT) to replenish active enzymes, small molecule-based substrate reduction therapies (SRTs) to decrease the production of accumulating substrates, pharmacological chaperone therapies that stabilize mutated enzymes, enzyme replacement therapies (ERTs), and gene therapy. 714 , 715 For example, as an SRT, miglustat has been used to inhibit glucosylceramide synthase to reduce the lysosomal sphingolipid load and is an approved treatment for Niemann–Pick type C 716 ; moreover, miglustat acts as a chaperone for glucocerebrosidase (GBA1), 714 an enzyme whose loss-of-function variants are linked to both Gaucher disease and PD risk. 613 In mouse models of PD, GBA1 loss leads to α-synuclein accumulation, and GBA1 overexpression reduces the α-synuclein load. 613 GBA1 activity can also be restored by the pharmacological chaperone ambroxol, which is currently being tested for its safety and efficacy in PD dementia (PDD) in a phase II trial. 613

In Hunter syndrome, iduronate-2-sulfatase (IDS) deficiency leads to lysosomal glycosaminoglycan accumulation. For this disease, multiple ERTs, including infusions of recombinant idursulfase beta 717 and, more recently, pabinafusp alfa, which displays improved blood–brain barrier permeability, 718 have been evaluated in clinical trials. Although these treatments require weekly infusions and are not curative, they show promise for increasing quality of life and extending life expectancy. Gene therapy may represent an opportunity to further alleviate developmental defects and extend the time to disease onset in LSDs; currently, multiple gene therapies are in clinical trials for different LSDs (for a review, see. 715 Experimentally, lysosomal function in GBA1 mutant cells, or other disease models, has also been improved through the restoration of lysosomal pH. 719 Mutations in the lysosomal polyamine exporter ATP13A2—linked to Kufor-Rakeb syndrome, a juvenile-onset form of PDD—can cause lysosomal alkalinization and decreased autophagosome clearance. 719 Lysosome-targeted acidic nanoparticles have been shown to restore lysosomal pH and enhance autophagosome clearance in ATP13A2-mutant fibroblasts. 719 Another review discussed the potential application of therapies that increase the intracellular concentration of cAMP or zinc for lysosomal reacidification. 720

Intervening with autophagy-regulating pathways

Among the multiple signaling pathways implicated in regulating autophagy, the mTOR pathway has received the most attention as a possible therapeutic target. Across multiple model organisms, the longevity-increasing effects of TOR inhibition—either through genetic, pharmacological, or dietary interventions 721 —have been well established and shown to act in concert with the consequent stimulation of autophagy. 704 Notably, the beneficial effects of TOR inhibition are also attributed to decreased protein synthesis. 704 Moreover, autophagy has been shown to mediate the beneficial reductions of polyQ-expanded protein aggregates in mouse and fly models of Huntington disease downstream of TOR inhibition. 722 mTOR inhibitors are clinically approved in different settings, e.g., for immunosuppressive and anticancer purposes. 723 These inhibitors include rapamycin and its derivatives (e.g., everolimus and temsirolimus), as well as multiple second-generation mTOR inhibitors, which have been reviewed extensively elsewhere. 723 , 724 As such, several mTOR-inhibiting drugs that may be leveraged for their autophagy-inducing potential already exist. Autophagy is also successfully activated in vivo through inhibition of the acetyltransferase EP300, abolishing its acetylation of the Raptor (RPTOR) subunit of mTORC1 and thereby inhibiting TOR activity. Among the compounds that exhibit inhibitory effects on EP300 are nordihydroguaiaretic acid (NDGA), C646, and the acetylsalicylate (aspirin) derivative salicylate, although the actions of the latter appear to also be mediated by non-EP300-mediated mechanisms. 725

An important mediator of the autophagy-enhancing effects of mTOR inhibition is the activation of TFEB, a transcriptional regulator recruited to lysosomes and phosphorylated by mTORC1, leading to its sequestration by 14-3-3 proteins. 704 In addition, autophagy can be stimulated through the activation of AMPK, which acts antagonistically to mTOR. AMPK activation and downstream autophagy induction may be achieved by metformin or trehalose 726 ; the latter also stimulates protein folding as an osmolyte. 727 Resveratrol, a natural compound found in plants, induces autophagy and may do so through promiscuous effects on multiple targets, 728 including direct inhibition of mTOR. 729 While we cannot cover all possible approaches here, there are recent reviews that provide an in-depth overview of additional mTOR-dependent and -independent approaches to target autophagy through its upstream regulatory pathways. 345 , 711 , 726

Lifestyle interventions that leverage autophagy

It has long been known that dietary interventions such as caloric restriction may promote human health and longevity; this has recently received increasing attention, with scientific studies documenting tangible effects and characterizing the underlying mechanisms, leading to increased interest by the public at large. In 1934, McCay & Crowell referred to the notion that slower growth increases longevity as an “ancient theory” and recapitulated some of the current literature on the topic, showing, for instance, the inverse correlation between growth rate and longevity in rats—data that have since been corroborated. 730 Notably, caloric restriction and other diets that aim at mimicking its effects (e.g., intermittent or periodic fasting, ketogenic diets) have been shown to consistently restore or enhance autophagy. 705 , 730 Upon caloric restriction, mechanisms that contribute to the activation of autophagy may include increased sirtuin expression and activity, coupled with decreased insulin/IGF1 signaling leading to, e.g., decreased mTORC1 activity. 730 In general, autophagy may contribute to increasing longevity or slowing age-related health declines through preventing or alleviating cytotoxicity and subsequent tissue/organ degeneration stemming from the accumulation of damaged or dysfunctional molecules and organelles within cells. 731 For example, autophagy has been described as central for stem cell metabolism and in preventing stem cell senescence, thereby supporting the regenerative mechanisms of certain tissues. 732

Dietary interventions may also include various modes of supplementation. Among the dietary compounds that are experimentally associated with autophagy induction are spermidine, 733 EGCG, 734 resveratrol 735 and trehalose. 726 In addition, nicotinamide adenine dinucleotide (NAD) augmentation by, e.g., oral nicotinamide riboside (NR) intake, has been shown to increase the transcription of both proteasomal and lysosomal components and decrease serum and CSF inflammatory cytokine levels in PD patients, 736 suggesting that it may be explored whether the targeting of age-associated declines in NAD synthesis could ameliorate age-related decreases in protein degradation pathways as well as inflammaging. We have also discussed above how micro- and macronutrient deficiencies may disrupt proteostasis, which may similarly be ameliorated through dietary modifications (Section “Genotoxic or proteotoxic stresses and deficiencies”). While dietary supplements are widely used and may provide opportunities in bolstering public health through their relative availability, affordability, and noninvasive nature, drawbacks include their potentially promiscuous or poorly characterized effects, issues in isolating and determining the causality of their effects, or their potential under- or overconsumption outside a regulated setting. 737 Although the links between some of the mentioned dietary interventions, autophagy, and health have been explored in vitro and in model organisms, controlled trials that establish their efficacy in humans are currently lacking. Additional research may lead to a more integral role for these interventions in future efforts to prevent common degenerative diseases associated with lifestyle or aging.

Protein misfolding, proteostasis and immunotherapy

The last two decades have seen the emergence of immunotherapy as a transformative new avenue for treating diseases; it involves harnessing or modifying the immune system rather than specifically targeting diseased tissue. Immunotherapy approaches have been particularly successful for certain cancers (for reviews, see 738 , 739 ). Nevertheless, challenges exist, such as limited response in some patients owing to tumor heterogeneity and immune evasion mechanisms, development of resistance (primary or acquired), immune-related adverse effects (such as cytokine release syndrome), high cost and the need for sophisticated infrastructure (for a review, see 740 ).

Major types of immunotherapies include immune checkpoint inhibitors (ICIs), which block immune checkpoints to reactivate T-cell responses against tumors; CAR-T-cell therapy, in which patient T cells are engineered to express chimeric antigen receptors (CARs) that target, e.g., specific cancer cells; cancer vaccines and cytokines that boost immune responses to eliminate disease; and monoclonal antibodies that target specific antigens to trigger immune-mediated destruction. In the previous sections, we provided examples of monoclonal antibodies that are used in different settings to combat dysproteostasis. Below, we use ICI as an example to show how proteostasis and immunotherapy approaches could be linked and how this could be actionable, with a focus on cancer therapies.

We have observed in the previous sections that protein folding and proteostasis are significantly disrupted in cancer, which often hijacks normal cellular proteostasis mechanisms for survival. Accordingly, a number of approaches that target proteostasis mechanisms are being developed as a means to destabilize tumors. In principle, immune approaches can also target the proteostasis machinery, which can assist in this quest. In addition, dysproteostasis in tumors can generate neoantigens that can facilitate the recognition of cancer cells by the immune system and their destruction.

In the context of cancer, dendritic cells (DCs), which are one type of antigen-presenting cells, and cytotoxic T lymphocytes (CTLs) are two of the most central immune cells involved in antitumor immunity. In response to changes in the TME, such as inflammation, DCs are attracted to tumor sites as part of the innate immune response; they then take up fragments of dead cancer cells or the material excreted from them, digest them into small fragments, and load them onto major histocompatibility complexes I and II. These are then presented at the surface of DCs to CTLs or T helper cells in the lymph nodes. Antitumor responses to particular antigens in tumors are then activated by CTLs.

Cancer cells present neoantigens on their cell surface through MHC-I complexes, and the ability of CTLs to recognize these foreign peptides is, in the context of ICI, evaluated to be directly proportional to the tumor mutational burden. 741 Since loss of MHC-I complexes increases the vulnerability of cancer cells to depletion by NK cells, tumors evolve ways to evade immune detection and inhibit immune function in the TME. The prime example of this is alteration in the expression of checkpoint inhibitor proteins, such as programmed death ligand 1 (PD-L1) and Cytotoxic T Lymphocyte-Associated protein 4 (CTLA-4) (for a review, see 742 ). PD-L1 is a transmembrane protein normally expressed on the surface of some macrophages, DCs, and activated T and B cells. It binds to another transmembrane cell surface protein, programmed death 1 (PD-1), which is specifically expressed on CTLs. The interactions between PD-L1 and PD-1 normally help prevent immune-mediated tissue damage upon activation. On the other hand, CTLA-4 is normally expressed on regulatory T cells, contributing to their inhibitory function, and its expression increases in T cells upon activation. CTLA-4 is homologous to the T-cell costimulatory protein CD28, both of which bind to B7 on antigen-presenting cells. Whereas the binding of CD28 to B7 is costimulatory, the binding of CTLA-4, which is more avid than that of CD28, is coinhibitory.

Tumor cells express PD-L1 to engage PD-1 to inhibit CTL function. Thus, monoclonal antibodies have been developed to inhibit this interaction, targeting either PD-1 (e.g., nivolumab, pembrolizumab) or PD-L1 (e.g., avelumab, atezolizumab) to restore CTL function and antitumor immunity. Similarly, since CTLA-4 directly inhibits CTL function, antagonistic antibodies against CTLA-4 have been developed to inhibit its interaction with B7 to activate antitumor immunity (e.g., ipilimumab). In the last two decades, these checkpoint inhibitors have transformed cancer therapy for some cancer types (for reviews, see 742 ). New checkpoints have also been identified and are now being explored for ICI. However, as noted above, significant hurdles exist, and currently, only approximately 13% of cancer patients benefit from ICI therapies. 743

Recent studies have shown that different aspects of protein folding and the proteostasis network significantly influence the expression of the checkpoint proteins PD-L1 and CTLA-4. For example, BiP is necessary for the stability and trafficking of PD-L1. 744 In fact, increased BiP expression through UPR activation is one way by which tumors increase the surface accumulation of PD-L1. Other chaperones, such as HSP90, may also be involved in PD-L1 expression in tumor cells. 745 An HSP90 inhibitor, AUY-922, induces HSPA8 expression, which competes with CMTM6 for binding to PD-L1 and facilitates its lysosomal degradation to inhibit tumor growth and enhance the antitumor efficacy of anti-PD-L1 and anti-CTLA-4 treatment in BCa. 746 HSP90 appears to play additional roles in maintaining an immunosuppressive phenotype, as a low level of HSP90 inhibition, which is not sufficient to inhibit the HSR or UPR, or affect PD-L1 expression or localization, increases MHC-I presentation at the cell surface. 747 Consistent with its role in activating the immune response, this low level of HSP90 inhibition resulted in a lower tumor burden in animal models. These findings suggest that the protein folding machinery and the chaperone system may play important roles in shaping the immunopeptidome and thus the overall immune response.

ER stress and chronic UPR activation can also upregulate PD-L1 expression in immunosuppressive aspects of the TME. For example, upon Kaposi’s sarcoma-associated herpesvirus ( KSHV ) infection of macrophages, the IRE1α-XBP1 pathway is activated and increases the expression of PD-L1, potentially impairing the immune response. 748 Similarly, in melanoma, activation of the IRE1α‒XBP1 pathway increases macrophage PD-L1 expression and promotes tumor immune evasion. 749 In addition, ER stress may stimulate the exosomal release of miR-23a by liver cancer cells, leading to the downstream upregulation of PD-L1 expression in macrophages through the miR-23a–PTEN–AKT pathway, thereby promoting tumor progression. 750 These studies show that ER stress-mediated PD-L1 expression in macrophages can inhibit T-cell function and promote tumor cell escape from antitumor immunity.

Recent studies have provided examples of how targeting key proteostasis regulators can sensitize tumors to ICIs in cancer types that are known not to respond to them (i.e., “cold” tumors, such as cancers of the prostate, ovary, and pancreas). For example, as noted above (Section 4.3.2), we have recently shown that genetic or small-molecule inhibition of IRE1α in syngeneic and orthotopic mouse models of PCa decreased tumor growth, accompanied by potentiation of interferon responses and activation of immune system-related pathways in the TME. 566 The small-molecule IRE1α inhibitor MKC8866, which is currently in clinical trials, reprogrammed the TME and enhanced anti-PD-1 therapy. These results show that IRE1α signaling, a key player in the overall proteostasis network, interferes with antitumor immunity in the TME, making it a promising target for improving anti-PD-1 immunotherapy in PCa. Interestingly, recent work has shown that targeting IRE1α signaling can increase ICI efficacy in ovarian, breast, and colon cancer models as well, suggesting that it may have broad utility as a combination therapy with ICIs. 579 , 751 , 752 However, the molecular mechanisms by which IRE1α co-targeting with ICIs affects different cancer types vary, and further work is needed to understand the basis of these differences.

Another area of functional intersection of protein folding, proteostasis and ICI resistance is the established link between HSPA1A and HSPA1B expression in CD4 + /CD8 + T cells and ICI resistance across various cancers. 753 In this interesting work, a single-cell atlas of T cells from 308,048 transcriptomes across 16 cancer types was established, resulting in the identification of a previously undescribed T-cell type, T Stress Response (TSTR) cells, with a unique stress response state. HSPA1A and HSPA1B expression in TSTR cells in the TME significantly increased following ICI treatment, especially in nonresponsive tumors; these findings suggest that TSTR cells and HSP expression may promote resistance to immunotherapy. Interestingly, in our data on IRE1α inhibition in conjunction with ICI treatment described above, MKC8866 + anti-PD-1 therapy reduced HSPA1A and HSPA1B expression in CD8 + T cells and increased the expression of T-cell activation markers. 566 In another study, the immune landscape of tumors from metastatic castration-resistant PCa by scRNA-Seq revealed that resistance to ICIs was associated with an increase in the HSP90 - steroid hormone receptor pathway and HSF1 activation. 754

In summary, these findings suggest that protein folding and the proteostasis state of the cell/tissue may have a major influence on the potential efficacy of ICIs; thus, combining ICIs with proteostasis-targeting therapies may have translational impacts in the clinic. Further work is needed to test this possibility.

Conclusion and future perspectives

Proteins are central actors in cell biology across the tree of life, each with remarkable versatility and efficiency arising from their intricately folded structures. For over two centuries, a primary goal in protein research has been to understand how a linear polypeptide adopts its native 3D conformation, how folding can be measured experimentally, and how accurately this process can be predicted from sequence alone. Not only this is a key question in basic molecular biology, but also important clinically since protein folding defects and dysproteostasis are linked to many major diseases. As detailed in Sections “Historical perspective and milestone events in protein folding” and “Causes and consequences of protein misfolding” of this Review, complementary experimental and computational approaches have provided major insights into folding mechanics and proteostasis under normal physiology. Leveraging this knowledge, a number of targeted therapies have been established, and many more are in development (Sections “Diseases associated with protein folding defects” and “Therapeutic strategies and progress in protein misfolding and dysproteostasis-related diseases”). However, complex folding and homeostasis networks still pose substantial challenges for developing novel therapies. Recent breakthroughs in computational biology and AI, biophysics, biochemistry, molecular and cell biology, and medicine hold great promise for unprecedented advancements in fundamental science as well as translational applications in the future.

In mammalian cells, protein synthesis is among the most energy-demanding processes. Remarkably, approximately one-third of all newly synthesized proteins are rapidly degraded, often due to folding issues, errors, redundancy, and delays that are intrinsic to protein synthesis regulation. Proteins are also continuously and dynamically modified and transported across cellular compartments in response to changing physiological conditions and intra- or extracellular stresses. As detailed in Sections 3 and 5, without rigorous quality control by molecular chaperones, disaggregases, and degradation machinery, these processes may give rise to a state of dysproteostasis that can either result in cell death or disease. Perturbations causing dysfunction may arise from genetic mutations, environmental stresses, aging, errors in protein synthesis or post-translational modifications, or impairment of the cellular quality control pathways themselves. In response, interconnected stress‒response pathways, including the cytosolic HSR, the UPR, and the UPRmt, act collectively to restore proteostasis.

Looking ahead, several promising approaches are emerging. Advances in deep learning and AI-driven protein structure prediction are expected to further expand our understanding of dynamic folding processes, improve simulations that incorporate PTMs, and aid in predicting multiprotein complexes and interactions. These advances will impact not only fundamental science but also translational efforts, including the rational design of small molecules and therapeutic antibodies and even the engineering of synthetic proteins with customized folding properties.

Here, we have highlighted diseases where protein misfolding and dysproteostasis is involved; in the future, a major focus will be on defining disease-specific mechanisms of protein misfolding that constitute the basis for novel therapies. For example, AD, PD, HD, and ALS all involve the accumulation of misfolded proteins in the nervous system. With the knowledge base and novel tools that are becoming available, rather than focusing on late-stage disease protein aggregates, future therapies will instead focus on preventing early misfolding events and stabilizing native conformations, as well as developing early diagnostic tools. Conversely, in cancer, novel approaches will be developed to inhibit protein folding and increase dysproteostasis by targeting different key pathways for folding, the proteasome, autophagy, the UPR, etc. In metabolic and rare diseases where protein misfolding is the culprit, small molecules that can restore native folding or gene editing approaches are being developed to correct mutations that generate misfolding.

Protein folding and proteostasis research has entered a transformative era driven by technological advances and computational breakthroughs. However, critical controversies and knowledge gaps remain—ranging from incomplete mechanistic models to the complexity of stress responses across compartments. Many of these arise from the gap between in vitro systems and the complex cellular environments in which folding occurs, as well as from assumptions embedded in current computational and mechanistic models. For example, the folding intermediates remain elusive in structural studies. While energy landscape theory and the concept of foldons provide a conceptual framework, direct observation of these transient states is technically challenging. Misfolded and partially folded intermediates are thought to be central to aggregation diseases (e.g., in AD and PD), yet their precise structures, lifespans, and fates are unclear. Moreover, there is debate over the universality of folding pathways. Some proteins appear to follow highly reproducible paths; others fold via multiple routes. Whether the pathway is encoded in sequence, modulated by context, or inherently stochastic remains an open question.

Another area of incomplete knowledge involves molecular chaperones which are essential for maintaining proteostasis. For example, their substrate specificity and functional interplay remain poorly understood. Many client proteins are shared between HSP70, HSP90, and chaperonins, often in sequential or overlapping networks. Interestingly, knockout or depletion of individual chaperones frequently results in partial compensation, raising questions about functional redundancy and backup mechanisms. Moreover, while some chaperones facilitate folding, others perform distinct or additional roles—such as acting as disaggregases or triage factors for degradation. Defining the precise boundaries and switching mechanisms among these roles remains an unresolved challenge.

There are also challenges in the translational route to fundamental discoveries in protein folding and proteostasis research. Pharmacological targeting of proteostasis regulators—such as HSP90 inhibitors, IRE1α inhibitors, or chemical chaperones—has shown promise in preclinical models. However, their clinical efficacy remains limited, and off-target effects are a concern. The problem lies in the pleiotropic nature of these pathways: chaperones and stress regulators are involved in numerous cellular processes beyond protein folding. In addition, the context dependency of these pathways complicates therapeutic design. For example, enhancing HSR may protect against neurodegeneration but could support tumor growth. Conversely, inhibiting the UPR may sensitize cancer cells but induce toxicity in normal secretory tissues. A nuanced understanding of cell type specificity, stress duration, and feedback regulation is essential for refining these strategies.

Addressing these open questions is crucial not only for advancing our understanding of fundamental biology but also for translating insights into effective therapies for diseases characterized by protein misfolding, aggregation, and stress dysregulation. A key direction for future research will be to better define the crosstalk among the diverse pathways governing protein folding and proteostasis. While individual components—such as the UPR in the ER and mitochondria, the HSR in the cytosol, and compartment-specific quality control mechanisms—have been extensively studied, their interconnections remain incompletely understood. Notably, interactions between ER stress signaling and mitochondrial pathways, as well as cross-regulation between the ER UPR and cytosolic HSR, warrant deeper investigation. A more integrated understanding of these networks will not only enrich basic biological knowledge but also lay the groundwork for targeted therapeutic strategies aimed at correcting dysproteostasis.

In summary, substantial progress has been made in elucidating the complex landscape of protein folding and proteostasis; however, continued technological innovation and interdisciplinary collaboration are essential to overcome current limitations. These efforts hold promise for the development of precise diagnostic tools and transformative therapies—whether to preserve protein function in degenerative diseases or to exploit proteostasis vulnerabilities in conditions such as cancer.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Omer Faruk Kuzu, Lars Jørgen Tvenge Granerud

Acknowledgements

This work was funded by the Norwegian Research Council (303353), the Norwegian Cancer Society (247110), Helse Sør-Øst (2021022, 2022041, 2023078) and Anders Jahre fund (102583101, 10,000). Figures 2 – 7 were created via BioRender ( http://biorender.com/ ). During the writing of this article, generative large language models were used to obtain information on specific topics and to help identify relevant literature. None of the writing was produced by these models, and only manually reviewed references were included.

Author contributions

OFK, LJTG, and FS conceived and conceptualized the work, wrote the manuscript, prepared the figures, and edited the work. All authors have reviewed and approved the manuscript.

Competing interests

The authors declare no competing interests.

References

1. Hartley, H. Origin of the word 'protein'. Nature 168 , 244 (1951). 10.1038/168244a0 14875059

2. Fruton JS Contrasts in scientific style. Emil Fischer and Franz Hofmeister: Their research groups and their theory of protein structure Proc. Am. Philos. Soc. 1985 129 313 370 11621201 Fruton, J. S. Contrasts in scientific style. Emil Fischer and Franz Hofmeister: Their research groups and their theory of protein structure. Proc. Am. Philos. Soc. 129 , 313–370 (1985). 11621201

3. Chick H On the “heat coagulation” of proteins J. Physiol. 1910 40 404 430 10.1113/jphysiol.1910.sp001378 16993016 PMC1533708 Chick, H. On the “heat coagulation” of proteins. J. Physiol. 40 , 404–430 (1910). 16993016 10.1113/jphysiol.1910.sp001378 PMC1533708

4. Anson ML Mirsky AE On some general properties of proteins J. Gen. Physiol. 1925 9 169 179 10.1085/jgp.9.2.169 19872240 PMC2140798 Anson, M. L. & Mirsky, A. E. On some general properties of proteins. J. Gen. Physiol. 9 , 169–179 (1925). 19872240 10.1085/jgp.9.2.169 PMC2140798

5. Wu H Studies on denaturation of proteins. XIII. A theory of denaturation. 1931 Adv. Protein Chem. 1995 46 6 26 10.1016/S0065-3233(08)60330-7 7771324 Wu, H. Studies on denaturation of proteins. XIII. A theory of denaturation. 1931. Adv. Protein Chem. 46 , 6–26 (1995). discussion 21-25. 7771324

6. Pauling L Corey RB Branson HR The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain Proc. Natl. Acad. Sci. USA 1951 37 205 211 10.1073/pnas.37.4.205 14816373 PMC1063337 Pauling, L., Corey, R. B. & Branson, H. R. The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain. Proc. Natl. Acad. Sci. USA 37 , 205–211 (1951). 14816373 10.1073/pnas.37.4.205 PMC1063337

7. Sanger F Thompson EO The amino-acid sequence in the glycyl chain of insulin. I. The identification of lower peptides from partial hydrolysates Biochem J. 1953 53 353 366 10.1042/bj0530353 13032078 PMC1198157 Sanger, F. & Thompson, E. O. The amino-acid sequence in the glycyl chain of insulin. I. The identification of lower peptides from partial hydrolysates. Biochem J. 53 , 353–366 (1953). 13032078 10.1042/bj0530353 PMC1198157

8. Kendrew JC A three-dimensional model of the myoglobin molecule obtained by x-ray analysis Nature 1958 181 662 666 10.1038/181662a0 13517261 Kendrew, J. C. et al. A three-dimensional model of the myoglobin molecule obtained by x-ray analysis. Nature 181 , 662–666 (1958). 13517261 10.1038/181662a0

9. Perutz MF Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by X-ray analysis Nature 1960 185 416 422 10.1038/185416a0 18990801 Perutz, M. F. et al. Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by X-ray analysis. Nature 185 , 416–422 (1960). 18990801 10.1038/185416a0

10. Anfinsen CB Haber E Sela M White FH Jr The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain Proc. Natl. Acad. Sci. USA 1961 47 1309 1314 10.1073/pnas.47.9.1309 13683522 PMC223141 Anfinsen, C. B., Haber, E., Sela, M. & White, F. H. Jr The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain. Proc. Natl. Acad. Sci. USA 47 , 1309–1314 (1961). 13683522 10.1073/pnas.47.9.1309 PMC223141

11. Levinthal C How to fold graciously Mossbauer Spectrosc. Biol. Syst. 1969 67 22 24 Levinthal, C. How to fold graciously. Mossbauer Spectrosc. Biol. Syst. 67 , 22–24 (1969).

12. Ptitsyn OB Stages in the mechanism of self-organization of protein molecules Dokl. Akad. Nauk SSSR 1973 210 1213 1215 4721708 Ptitsyn, O. B. Stages in the mechanism of self-organization of protein molecules. Dokl. Akad. Nauk SSSR 210 , 1213–1215 (1973). 4721708

13. Lee SY Karplus M Bashford D Weaver D Brownian dynamics simulation of protein folding: a study of the diffusion-collision model Biopolymers 1987 26 481 506 10.1002/bip.360260404 3567323 Lee, S. Y., Karplus, M., Bashford, D. & Weaver, D. Brownian dynamics simulation of protein folding: a study of the diffusion-collision model. Biopolymers 26 , 481–506 (1987). 3567323 10.1002/bip.360260404

14. Karplus M Weaver DL Protein folding dynamics: the diffusion-collision model and experimental data Protein Sci. 1994 3 650 668 10.1002/pro.5560030413 8003983 PMC2142854 Karplus, M. & Weaver, D. L. Protein folding dynamics: the diffusion-collision model and experimental data. Protein Sci. 3 , 650–668 (1994). 8003983 10.1002/pro.5560030413 PMC2142854

15. Wuthrich K NMR - this other method for protein and nucleic acid structure determination Acta Crystallogr D. Biol. Crystallogr 1995 51 249 270 10.1107/S0907444994010188 15299291 Wuthrich, K. NMR - this other method for protein and nucleic acid structure determination. Acta Crystallogr D. Biol. Crystallogr 51 , 249–270 (1995). 15299291 10.1107/S0907444994010188

16. Fersht AR Optimization of rates of protein folding: the nucleation-condensation mechanism and its implications Proc. Natl. Acad. Sci. USA 1995 92 10869 10873 10.1073/pnas.92.24.10869 7479900 PMC40532 Fersht, A. R. Optimization of rates of protein folding: the nucleation-condensation mechanism and its implications. Proc. Natl. Acad. Sci. USA 92 , 10869–10873 (1995). 7479900 10.1073/pnas.92.24.10869 PMC40532

17. Itzhaki LS Otzen DE Fersht AR The structure of the transition state for folding of chymotrypsin inhibitor 2 analysed by protein engineering methods: evidence for a nucleation-condensation mechanism for protein folding J. Mol. Biol. 1995 254 260 288 10.1006/jmbi.1995.0616 7490748 Itzhaki, L. S., Otzen, D. E. & Fersht, A. R. The structure of the transition state for folding of chymotrypsin inhibitor 2 analysed by protein engineering methods: evidence for a nucleation-condensation mechanism for protein folding. J. Mol. Biol. 254 , 260–288 (1995). 7490748 10.1006/jmbi.1995.0616

18. Bryngelson JD Onuchic JN Socci ND Wolynes PG Funnels, pathways, and the energy landscape of protein folding: A synthesis Proteins 1995 21 167 195 10.1002/prot.340210302 7784423 Bryngelson, J. D., Onuchic, J. N., Socci, N. D. & Wolynes, P. G. Funnels, pathways, and the energy landscape of protein folding: A synthesis. Proteins 21 , 167–195 (1995). 7784423 10.1002/prot.340210302

19. Onuchic JN Luthey-Schulten Z Wolynes PG Theory of protein folding: The energy landscape perspective Annu Rev. Phys. Chem. 1997 48 545 600 10.1146/annurev.physchem.48.1.545 9348663 Onuchic, J. N., Luthey-Schulten, Z. & Wolynes, P. G. Theory of protein folding: The energy landscape perspective. Annu Rev. Phys. Chem. 48 , 545–600 (1997). 9348663 10.1146/annurev.physchem.48.1.545

20. Rollins GC Dill KA General mechanism of two-state protein folding kinetics J. Am. Chem. Soc. 2014 136 11420 11427 10.1021/ja5049434 25056406 PMC5104671 Rollins, G. C. & Dill, K. A. General mechanism of two-state protein folding kinetics. J. Am. Chem. Soc. 136 , 11420–11427 (2014). 25056406 10.1021/ja5049434 PMC5104671

21. Maity H Protein folding: the stepwise assembly of foldon units Proc. Natl. Acad. Sci. USA 2005 102 4741 4746 10.1073/pnas.0501043102 15774579 PMC555724 Maity, H. et al. Protein folding: the stepwise assembly of foldon units. Proc. Natl. Acad. Sci. USA 102 , 4741–4746 (2005). 15774579 10.1073/pnas.0501043102 PMC555724

22. Fink AL Chaperone-mediated protein folding Physiol. Rev. 1999 79 425 449 10.1152/physrev.1999.79.2.425 10221986 Fink, A. L. Chaperone-mediated protein folding. Physiol. Rev. 79 , 425–449 (1999). 10221986 10.1152/physrev.1999.79.2.425

23. Ritossa F A new puffing pattern induced by temperature shock and DNP in Drosophila Experientia 1962 18 571 573 10.1007/BF02172188 Ritossa, F. A new puffing pattern induced by temperature shock and DNP in Drosophila. Experientia 18 , 571–573 (1962).

24. Georgopoulos CP Hendrix RW Casjens SR Kaiser AD Host participation in bacteriophage lambda head assembly J. Mol. Biol. 1973 76 45 60 10.1016/0022-2836(73)90080-6 4578100 Georgopoulos, C. P., Hendrix, R. W., Casjens, S. R. & Kaiser, A. D. Host participation in bacteriophage lambda head assembly. J. Mol. Biol. 76 , 45–60 (1973). 4578100 10.1016/0022-2836(73)90080-6

25. Barraclough R Ellis RJ Protein synthesis in chloroplasts. IX. Assembly of newly-synthesized large subunits into ribulose bisphosphate carboxylase in isolated intact pea chloroplasts Biochim Biophys. Acta 1980 608 19 31 10.1016/0005-2787(80)90129-X 7388030 Barraclough, R. & Ellis, R. J. Protein synthesis in chloroplasts. IX. Assembly of newly-synthesized large subunits into ribulose bisphosphate carboxylase in isolated intact pea chloroplasts. Biochim Biophys. Acta 608 , 19–31 (1980). 7388030 10.1016/0005-2787(80)90129-x

26. Laskey RA Honda BM Mills AD Finch JT Nucleosomes are assembled by an acidic protein which binds histones and transfers them to DNA Nature 1978 275 416 420 10.1038/275416a0 692721 Laskey, R. A., Honda, B. M., Mills, A. D. & Finch, J. T. Nucleosomes are assembled by an acidic protein which binds histones and transfers them to DNA. Nature 275 , 416–420 (1978). 692721 10.1038/275416a0

27. Ellis J Proteins as molecular chaperones Nature 1987 328 378 379 10.1038/328378a0 3112578 Ellis, J. Proteins as molecular chaperones. Nature 328 , 378–379 (1987). 3112578 10.1038/328378a0

28. Goloubinoff P Christeller JT Gatenby AA Lorimer GH Reconstitution of active dimeric ribulose bisphosphate carboxylase from an unfoleded state depends on two chaperonin proteins and Mg-ATP Nature 1989 342 884 889 10.1038/342884a0 10532860 Goloubinoff, P., Christeller, J. T., Gatenby, A. A. & Lorimer, G. H. Reconstitution of active dimeric ribulose bisphosphate carboxylase from an unfoleded state depends on two chaperonin proteins and Mg-ATP. Nature 342 , 884–889 (1989). 10532860 10.1038/342884a0

29. Schwalbe H The future of integrated structural biology Structure 2024 32 1563 1580 10.1016/j.str.2024.08.014 39293444 Schwalbe, H. et al. The future of integrated structural biology. Structure 32 , 1563–1580 (2024). 39293444 10.1016/j.str.2024.08.014

30. Chen YH Yang JT Martinez HM Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion Biochemistry 1972 11 4120 4131 10.1021/bi00772a015 4343790 Chen, Y. H., Yang, J. T. & Martinez, H. M. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry 11 , 4120–4131 (1972). 4343790 10.1021/bi00772a015

31. Miles AJ Wallace BA Circular dichroism spectroscopy of membrane proteins Chem. Soc. Rev. 2016 45 4859 4872 10.1039/C5CS00084J 27347568 Miles, A. J. & Wallace, B. A. Circular dichroism spectroscopy of membrane proteins. Chem. Soc. Rev. 45 , 4859–4872 (2016). 27347568 10.1039/c5cs00084j

32. Kuwajima K Rapid formation of secondary structure framework in protein folding studied by stopped-flow circular dichroism FEBS Lett. 1987 221 115 118 10.1016/0014-5793(87)80363-0 3040467 Kuwajima, K. et al. Rapid formation of secondary structure framework in protein folding studied by stopped-flow circular dichroism. FEBS Lett. 221 , 115–118 (1987). 3040467 10.1016/0014-5793(87)80363-0

33. Lerner, E. et al. Toward dynamic structural biology: Two decades of single-molecule Forster resonance energy transfer. Science 359 , eaan1133 (2018). 10.1126/science.aan1133 PMC6200918 29348210

34. Stryer L Haugland RP Energy transfer: a spectroscopic ruler Proc. Natl. Acad. Sci. USA 1967 58 719 726 10.1073/pnas.58.2.719 5233469 PMC335693 Stryer, L. & Haugland, R. P. Energy transfer: a spectroscopic ruler. Proc. Natl. Acad. Sci. USA 58 , 719–726 (1967). 5233469 10.1073/pnas.58.2.719 PMC335693

35. Nagayama K Two-dimensional NMR spectroscopy: An application to the study of flexibility of protein molecules Adv. Biophys. 1981 14 139 204 7015809 Nagayama, K. Two-dimensional NMR spectroscopy: An application to the study of flexibility of protein molecules. Adv. Biophys. 14 , 139–204 (1981). 7015809

36. Camacho-Zarco AR NMR provides unique insight into the functional dynamics and interactions of intrinsically disordered proteins Chem. Rev. 2022 122 9331 9356 10.1021/acs.chemrev.1c01023 35446534 PMC9136928 Camacho-Zarco, A. R. et al. NMR provides unique insight into the functional dynamics and interactions of intrinsically disordered proteins. Chem. Rev. 122 , 9331–9356 (2022). 35446534 10.1021/acs.chemrev.1c01023 PMC9136928

37. Phillips JC Wlodawer A Yevitz MM Hodgson KO Applications of synchrotron radiation to protein crystallography: Preliminary results Proc. Natl. Acad. Sci. USA 1976 73 128 132 10.1073/pnas.73.1.128 1061106 PMC335853 Phillips, J. C., Wlodawer, A., Yevitz, M. M. & Hodgson, K. O. Applications of synchrotron radiation to protein crystallography: Preliminary results. Proc. Natl. Acad. Sci. USA 73 , 128–132 (1976). 1061106 10.1073/pnas.73.1.128 PMC335853

38. Chen S Location of a folding protein and shape changes in GroEL-GroES complexes imaged by cryo-electron microscopy Nature 1994 371 261 264 10.1038/371261a0 7915827 Chen, S. et al. Location of a folding protein and shape changes in GroEL-GroES complexes imaged by cryo-electron microscopy. Nature 371 , 261–264 (1994). 7915827 10.1038/371261a0

39. Bustamante C Alexander L Maciuba K Kaiser CM Single-molecule studies of protein folding with optical tweezers Annu Rev. Biochem 2020 89 443 470 10.1146/annurev-biochem-013118-111442 32569525 PMC7487275 Bustamante, C., Alexander, L., Maciuba, K. & Kaiser, C. M. Single-molecule studies of protein folding with optical tweezers. Annu Rev. Biochem 89 , 443–470 (2020). 32569525 10.1146/annurev-biochem-013118-111442 PMC7487275

40. Hope H Cryocrystallography of biological macromolecules: A generally applicable method Acta Crystallogr B 1988 44 22 26 10.1107/S0108768187008632 3271102 Hope, H. Cryocrystallography of biological macromolecules: A generally applicable method. Acta Crystallogr B 44 , 22–26 (1988). 3271102 10.1107/s0108768187008632

41. Ha T Probing the interaction between two single molecules: Fluorescence resonance energy transfer between a single donor and a single acceptor Proc. Natl. Acad. Sci. USA 1996 93 6264 6268 10.1073/pnas.93.13.6264 8692803 PMC39010 Ha, T. et al. Probing the interaction between two single molecules: Fluorescence resonance energy transfer between a single donor and a single acceptor. Proc. Natl. Acad. Sci. USA 93 , 6264–6268 (1996). 8692803 10.1073/pnas.93.13.6264 PMC39010

42. Talaga DS Dynamics and folding of single two-stranded coiled-coil peptides studied by fluorescent energy transfer confocal microscopy Proc. Natl. Acad. Sci. USA 2000 97 13021 13026 10.1073/pnas.97.24.13021 11087856 PMC27171 Talaga, D. S. et al. Dynamics and folding of single two-stranded coiled-coil peptides studied by fluorescent energy transfer confocal microscopy. Proc. Natl. Acad. Sci. USA 97 , 13021–13026 (2000). 11087856 10.1073/pnas.97.24.13021 PMC27171

43. Pervushin K Riek R Wider G Wuthrich K Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution Proc. Natl. Acad. Sci. USA 1997 94 12366 12371 10.1073/pnas.94.23.12366 9356455 PMC24947 Pervushin, K., Riek, R., Wider, G. & Wuthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA 94 , 12366–12371 (1997). 9356455 10.1073/pnas.94.23.12366 PMC24947

44. Sherman E Using fluorescence correlation spectroscopy to study conformational changes in denatured proteins Biophys. J. 2008 94 4819 4827 10.1529/biophysj.107.120220 18326651 PMC2397356 Sherman, E. et al. Using fluorescence correlation spectroscopy to study conformational changes in denatured proteins. Biophys. J. 94 , 4819–4827 (2008). 18326651 10.1529/biophysj.107.120220 PMC2397356

45. Lenne PF States and transitions during forced unfolding of a single spectrin repeat FEBS Lett. 2000 476 124 128 10.1016/S0014-5793(00)01704-X 10913598 Lenne, P. F. et al. States and transitions during forced unfolding of a single spectrin repeat. FEBS Lett. 476 , 124–128 (2000). 10913598 10.1016/s0014-5793(00)01704-x

46. Yang G Solid-state synthesis and mechanical unfolding of polymers of T4 lysozyme Proc. Natl. Acad. Sci. USA 2000 97 139 144 10.1073/pnas.97.1.139 10618384 PMC26629 Yang, G. et al. Solid-state synthesis and mechanical unfolding of polymers of T4 lysozyme. Proc. Natl. Acad. Sci. USA 97 , 139–144 (2000). 10618384 10.1073/pnas.97.1.139 PMC26629

47. Konermann L Pan J Liu YH Hydrogen exchange mass spectrometry for studying protein structure and dynamics Chem. Soc. Rev. 2011 40 1224 1234 10.1039/C0CS00113A 21173980 Konermann, L., Pan, J. & Liu, Y. H. Hydrogen exchange mass spectrometry for studying protein structure and dynamics. Chem. Soc. Rev. 40 , 1224–1234 (2011). 21173980 10.1039/c0cs00113a

48. Nogales E Scheres SH Cryo-EM: A Unique Tool for the Visualization of Macromolecular Complexity Mol. Cell 2015 58 677 689 10.1016/j.molcel.2015.02.019 26000851 PMC4441764 Nogales, E. & Scheres, S. H. Cryo-EM: A Unique Tool for the Visualization of Macromolecular Complexity. Mol. Cell 58 , 677–689 (2015). 26000851 10.1016/j.molcel.2015.02.019 PMC4441764

49. Kuhlbrandt W Biochemistry. The resolution revolution Science 2014 343 1443 1444 10.1126/science.1251652 24675944 Kuhlbrandt, W. Biochemistry. The resolution revolution. Science 343 , 1443–1444 (2014). 24675944 10.1126/science.1251652

50. Spence JCH XFELs for structure and dynamics in biology IUCrJ 2017 4 322 339 10.1107/S2052252517005760 28875020 PMC5571796 Spence, J. C. H. XFELs for structure and dynamics in biology. IUCrJ 4 , 322–339 (2017). 28875020 10.1107/S2052252517005760 PMC5571796

51. Pinter G Real-time nuclear magnetic resonance spectroscopy in the study of biomolecular kinetics and dynamics Magn. Reson (Gott.) 2021 2 291 320 10.5194/mr-2-291-2021 37904763 PMC10539803 Pinter, G. et al. Real-time nuclear magnetic resonance spectroscopy in the study of biomolecular kinetics and dynamics. Magn. Reson (Gott.) 2 , 291–320 (2021). 37904763 10.5194/mr-2-291-2021 PMC10539803

52. Fowler DM High-resolution mapping of protein sequence-function relationships Nat. Methods 2010 7 741 746 10.1038/nmeth.1492 20711194 PMC2938879 Fowler, D. M. et al. High-resolution mapping of protein sequence-function relationships. Nat. Methods 7 , 741–746 (2010). 20711194 10.1038/nmeth.1492 PMC2938879

53. Fowler DM Fields S Deep mutational scanning: a new style of protein science Nat. Methods 2014 11 801 807 10.1038/nmeth.3027 25075907 PMC4410700 Fowler, D. M. & Fields, S. Deep mutational scanning: a new style of protein science. Nat. Methods 11 , 801–807 (2014). 25075907 10.1038/nmeth.3027 PMC4410700

54. Jermutus L Ryabova LA Pluckthun A Recent advances in producing and selecting functional proteins by using cell-free translation Curr. Opin. Biotechnol. 1998 9 534 548 10.1016/S0958-1669(98)80042-6 9821285 Jermutus, L., Ryabova, L. A. & Pluckthun, A. Recent advances in producing and selecting functional proteins by using cell-free translation. Curr. Opin. Biotechnol. 9 , 534–548 (1998). 9821285 10.1016/s0958-1669(98)80042-6

55. Tsuboyama K Mega-scale experimental analysis of protein folding stability in biology and design Nature 2023 620 434 444 10.1038/s41586-023-06328-6 37468638 PMC10412457 Tsuboyama, K. et al. Mega-scale experimental analysis of protein folding stability in biology and design. Nature 620 , 434–444 (2023). 37468638 10.1038/s41586-023-06328-6 PMC10412457

56. Biancalana M Koide S Molecular mechanism of Thioflavin-T binding to amyloid fibrils Biochim Biophys. Acta 2010 1804 1405 1412 10.1016/j.bbapap.2010.04.001 20399286 PMC2880406 Biancalana, M. & Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys. Acta 1804 , 1405–1412 (2010). 20399286 10.1016/j.bbapap.2010.04.001 PMC2880406

57. Teoh CL Chemical fluorescent probe for detection of abeta oligomers J. Am. Chem. Soc. 2015 137 13503 13509 10.1021/jacs.5b06190 26218347 PMC4756585 Teoh, C. L. et al. Chemical fluorescent probe for detection of abeta oligomers. J. Am. Chem. Soc. 137 , 13503–13509 (2015). 26218347 10.1021/jacs.5b06190 PMC4756585

58. Wu C Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations J. Am. Chem. Soc. 2007 129 1225 1232 10.1021/ja0662772 17263405 Wu, C. et al. Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations. J. Am. Chem. Soc. 129 , 1225–1232 (2007). 17263405 10.1021/ja0662772

59. Cox SJ High-throughput screening at the membrane interface reveals inhibitors of amyloid-beta Biochem. 2020 59 2249 2258 10.1021/acs.biochem.0c00328 32469202 PMC10323872 Cox, S. J. et al. High-throughput screening at the membrane interface reveals inhibitors of amyloid-beta. Biochem. 59 , 2249–2258 (2020). 32469202 10.1021/acs.biochem.0c00328 PMC10323872

60. Aslund A Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses ACS Chem. Biol. 2009 4 673 684 10.1021/cb900112v 19624097 PMC2886514 Aslund, A. et al. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem. Biol. 4 , 673–684 (2009). 19624097 10.1021/cb900112v PMC2886514

61. Simon RA Pentameric thiophene-based ligands that spectrally discriminate amyloid-beta and tau aggregates display distinct solvatochromism and viscosity-induced spectral shifts Chemistry 2014 20 12537 12543 10.1002/chem.201402890 25111601 PMC4221846 Simon, R. A. et al. Pentameric thiophene-based ligands that spectrally discriminate amyloid-beta and tau aggregates display distinct solvatochromism and viscosity-induced spectral shifts. Chemistry 20 , 12537–12543 (2014). 25111601 10.1002/chem.201402890 PMC4221846

62. Shirani H Synthesis of thiophene-based optical ligands that selectively detect tau pathology in Alzheimer’s disease Chemistry 2017 23 17127 17135 10.1002/chem.201703846 28926133 PMC5928317 Shirani, H. et al. Synthesis of thiophene-based optical ligands that selectively detect tau pathology in Alzheimer’s disease. Chemistry 23 , 17127–17135 (2017). 28926133 10.1002/chem.201703846 PMC5928317

63. Zhao Y A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein Chem. Sci. 2020 11 4773 4778 10.1039/C9SC05620C 34122933 PMC8159431 Zhao, Y. et al. A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein. Chem. Sci. 11 , 4773–4778 (2020). 34122933 10.1039/c9sc05620c PMC8159431

64. Fang D Engineering of donor-acceptor-donor curcumin analogues as near-infrared fluorescent probes for in vivo imaging of amyloid-beta species Theranostics 2022 12 3178 3195 10.7150/thno.68679 35547754 PMC9065200 Fang, D. et al. Engineering of donor-acceptor-donor curcumin analogues as near-infrared fluorescent probes for in vivo imaging of amyloid-beta species. Theranostics 12 , 3178–3195 (2022). 35547754 10.7150/thno.68679 PMC9065200

65. Leng H Dual-emission GFP chromophore-based derivative for imaging and discriminating abeta oligomers and aggregates Anal. Chem. 2022 94 1999 2006 10.1021/acs.analchem.1c03452 35041386 Leng, H. et al. Dual-emission GFP chromophore-based derivative for imaging and discriminating abeta oligomers and aggregates. Anal. Chem. 94 , 1999–2006 (2022). 35041386 10.1021/acs.analchem.1c03452

66. Klunk WE Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann. Neurol. 2004 55 306 319 10.1002/ana.20009 14991808 Klunk, W. E. et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55 , 306–319 (2004). 14991808 10.1002/ana.20009

67. Yang L Rieves D Ganley C Brain amyloid imaging–FDA approval of florbetapir F18 injection N. Engl. J. Med 2012 367 885 887 10.1056/NEJMp1208061 22931256 Yang, L., Rieves, D. & Ganley, C. Brain amyloid imaging–FDA approval of florbetapir F18 injection. N. Engl. J. Med 367 , 885–887 (2012). 22931256 10.1056/NEJMp1208061

68. Barthel H Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study Lancet Neurol. 2011 10 424 435 10.1016/S1474-4422(11)70077-1 21481640 Barthel, H. et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol. 10 , 424–435 (2011). 21481640 10.1016/S1474-4422(11)70077-1

69. Thal DR Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid beta-protein deposition Acta Neuropathol. 2018 136 557 567 10.1007/s00401-018-1897-9 30123935 PMC6132944 Thal, D. R. et al. Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid beta-protein deposition. Acta Neuropathol. 136 , 557–567 (2018). 30123935 10.1007/s00401-018-1897-9 PMC6132944

70. Bao W PET neuroimaging of Alzheimer’s disease: Radiotracers and their utility in clinical research Front Aging Neurosci. 2021 13 624330 10.3389/fnagi.2021.624330 34025386 PMC8134674 Bao, W. et al. PET neuroimaging of Alzheimer’s disease: Radiotracers and their utility in clinical research. Front Aging Neurosci. 13 , 624330 (2021). 34025386 10.3389/fnagi.2021.624330 PMC8134674

71. Leuzy A Tau PET imaging in neurodegenerative tauopathies-still a challenge Mol. Psychiatry 2019 24 1112 1134 10.1038/s41380-018-0342-8 30635637 PMC6756230 Leuzy, A. et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol. Psychiatry 24 , 1112–1134 (2019). 30635637 10.1038/s41380-018-0342-8 PMC6756230

72. Harada R Preclinical characterization of the Tau PET Tracer [(18)F]SNFT-1: comparison of Tau PET tracers J. Nucl. Med. 2023 64 1495 1501 10.2967/jnumed.123.265593 37321821 Harada, R. et al. Preclinical characterization of the Tau PET Tracer [(18)F]SNFT-1: comparison of Tau PET tracers. J. Nucl. Med. 64 , 1495–1501 (2023). 37321821 10.2967/jnumed.123.265593

73. Yue K A test of lattice protein folding algorithms Proc. Natl. Acad. Sci. USA 1995 92 325 329 10.1073/pnas.92.1.325 7816842 PMC42871 Yue, K. et al. A test of lattice protein folding algorithms. Proc. Natl. Acad. Sci. USA 92 , 325–329 (1995). 7816842 10.1073/pnas.92.1.325 PMC42871

74. Scheraga HA Khalili M Liwo A Protein-folding dynamics: overview of molecular simulation techniques Annu Rev. Phys. Chem. 2007 58 57 83 10.1146/annurev.physchem.58.032806.104614 17034338 Scheraga, H. A., Khalili, M. & Liwo, A. Protein-folding dynamics: overview of molecular simulation techniques. Annu Rev. Phys. Chem. 58 , 57–83 (2007). 17034338 10.1146/annurev.physchem.58.032806.104614

75. Weiner SJ Kollman PA Nguyen DT Case DA An all atom force field for simulations of proteins and nucleic acids J. Comput Chem. 1986 7 230 252 10.1002/jcc.540070216 29160584 Weiner, S. J., Kollman, P. A., Nguyen, D. T. & Case, D. A. An all atom force field for simulations of proteins and nucleic acids. J. Comput Chem. 7 , 230–252 (1986). 29160584 10.1002/jcc.540070216

76. Voelz VA Pande VS Bowman GR Folding@home: Achievements from over 20 years of citizen science herald the exascale era Biophys. J. 2023 122 2852 2863 10.1016/j.bpj.2023.03.028 36945779 PMC10398258 Voelz, V. A., Pande, V. S. & Bowman, G. R. Folding@home: Achievements from over 20 years of citizen science herald the exascale era. Biophys. J. 122 , 2852–2863 (2023). 36945779 10.1016/j.bpj.2023.03.028 PMC10398258

77. Clementi C Coarse-grained models of protein folding: Toy models or predictive tools? Curr. Opin. Struct. Biol. 2008 18 10 15 10.1016/j.sbi.2007.10.005 18160277 Clementi, C. Coarse-grained models of protein folding: Toy models or predictive tools?. Curr. Opin. Struct. Biol. 18 , 10–15 (2008). 18160277 10.1016/j.sbi.2007.10.005

78. Levine BG Micellization studied by GPU-accelerated coarse-grained molecular dynamics J. Chem. Theory Comput 2011 7 4135 4145 10.1021/ct2005193 26598358 Levine, B. G. et al. Micellization studied by GPU-accelerated coarse-grained molecular dynamics. J. Chem. Theory Comput 7 , 4135–4145 (2011). 26598358 10.1021/ct2005193

79. Tan AC Gilbert D Deville Y Multi-class protein fold classification using a new ensemble machine learning approach Genome Inf. 2003 14 206 217 15706535 Tan, A. C., Gilbert, D. & Deville, Y. Multi-class protein fold classification using a new ensemble machine learning approach. Genome Inf. 14 , 206–217 (2003). 15706535

80. Peto M Kloczkowski A Honavar V Jernigan RL Use of machine learning algorithms to classify binary protein sequences as highly-designable or poorly-designable BMC Bioinforma. 2008 9 487 10.1186/1471-2105-9-487 PMC2655094 19014713 Peto, M., Kloczkowski, A., Honavar, V. & Jernigan, R. L. Use of machine learning algorithms to classify binary protein sequences as highly-designable or poorly-designable. BMC Bioinforma. 9 , 487 (2008). 10.1186/1471-2105-9-487 PMC2655094 19014713

81. He J Rule generation for protein secondary structure prediction with support vector machines and decision tree IEEE Trans. Nanobiosci. 2006 5 46 53 10.1109/TNB.2005.864021 16570873 He, J. et al. Rule generation for protein secondary structure prediction with support vector machines and decision tree. IEEE Trans. Nanobiosci. 5 , 46–53 (2006). 10.1109/tnb.2005.864021 16570873

82. Jumper J Highly accurate protein structure prediction with AlphaFold Nature 2021 596 583 589 10.1038/s41586-021-03819-2 34265844 PMC8371605 Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596 , 583–589 (2021). 34265844 10.1038/s41586-021-03819-2 PMC8371605

83. Varadi M AlphaFold Protein Structure Database in 2024: Providing structure coverage for over 214 million protein sequences Nucleic Acids Res 2024 52 D368 D375 10.1093/nar/gkad1011 37933859 PMC10767828 Varadi, M. et al. AlphaFold Protein Structure Database in 2024: Providing structure coverage for over 214 million protein sequences. Nucleic Acids Res . 52 , D368–D375 (2024). 37933859 10.1093/nar/gkad1011 PMC10767828

84. Baek M Accurate prediction of protein structures and interactions using a three-track neural network Science 2021 373 871 876 10.1126/science.abj8754 34282049 PMC7612213 Baek, M. et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science 373 , 871–876 (2021). 34282049 10.1126/science.abj8754 PMC7612213

85. Krishna R Generalized biomolecular modeling and design with RoseTTAFold All-Atom Science 2024 384 eadl2528 10.1126/science.adl2528 38452047 Krishna, R. et al. Generalized biomolecular modeling and design with RoseTTAFold All-Atom. Science 384 , eadl2528 (2024). 38452047 10.1126/science.adl2528

86. Du Z The trRosetta server for fast and accurate protein structure prediction Nat. Protoc. 2021 16 5634 5651 10.1038/s41596-021-00628-9 34759384 Du, Z. et al. The trRosetta server for fast and accurate protein structure prediction. Nat. Protoc. 16 , 5634–5651 (2021). 34759384 10.1038/s41596-021-00628-9

87. Omidi A AlphaFold-Multimer accurately captures interactions and dynamics of intrinsically disordered protein regions Proc. Natl. Acad. Sci. USA 2024 121 e2406407121 10.1073/pnas.2406407121 39446390 PMC11536093 Omidi, A. et al. AlphaFold-Multimer accurately captures interactions and dynamics of intrinsically disordered protein regions. Proc. Natl. Acad. Sci. USA 121 , e2406407121 (2024). 39446390 10.1073/pnas.2406407121 PMC11536093

88. Liu J Enhancing alphafold-multimer-based protein complex structure prediction with MULTICOM in CASP15 Commun. Biol. 2023 6 1140 10.1038/s42003-023-05525-3 37949999 PMC10638423 Liu, J. et al. Enhancing alphafold-multimer-based protein complex structure prediction with MULTICOM in CASP15. Commun. Biol. 6 , 1140 (2023). 37949999 10.1038/s42003-023-05525-3 PMC10638423

89. Abramson J Accurate structure prediction of biomolecular interactions with AlphaFold 3 Nature 2024 630 493 500 10.1038/s41586-024-07487-w 38718835 PMC11168924 Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630 , 493–500 (2024). 38718835 10.1038/s41586-024-07487-w PMC11168924

90. Ooka K Arai M Accurate prediction of protein folding mechanisms by simple structure-based statistical mechanical models Nat. Commun. 2023 14 6338 10.1038/s41467-023-41664-1 37857633 PMC10587348 Ooka, K. & Arai, M. Accurate prediction of protein folding mechanisms by simple structure-based statistical mechanical models. Nat. Commun. 14 , 6338 (2023). 37857633 10.1038/s41467-023-41664-1 PMC10587348

91. Ooka, K., Liu, R. & Arai, M. The Wako-Saito-Munoz-Eaton model for predicting protein folding and dynamics. Molecules 27 , 4460 (2022). 10.3390/molecules27144460 PMC9319528 35889332

92. Zambaldi, V. et al. De novo design of high-affinity protein binders with AlphaProteo. arXiv preprint arXiv:2409.08022 , (2024).

93. Rosenzweig R Nillegoda NB Mayer MP Bukau B The Hsp70 chaperone network Nat. Rev. Mol. Cell Biol. 2019 20 665 680 10.1038/s41580-019-0133-3 31253954 Rosenzweig, R., Nillegoda, N. B., Mayer, M. P. & Bukau, B. The Hsp70 chaperone network. Nat. Rev. Mol. Cell Biol. 20 , 665–680 (2019). 31253954 10.1038/s41580-019-0133-3

94. Bukau B Horwich AL The Hsp70 and Hsp60 chaperone machines Cell 1998 92 351 366 10.1016/S0092-8674(00)80928-9 9476895 Bukau, B. & Horwich, A. L. The Hsp70 and Hsp60 chaperone machines. Cell 92 , 351–366 (1998). 9476895 10.1016/s0092-8674(00)80928-9

95. Finka A Goloubinoff P Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis Cell Stress Chaperones 2013 18 591 605 10.1007/s12192-013-0413-3 23430704 PMC3745260 Finka, A. & Goloubinoff, P. Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis. Cell Stress Chaperones 18 , 591–605 (2013). 23430704 10.1007/s12192-013-0413-3 PMC3745260

96. Zhuravleva A Gierasch LM Substrate-binding domain conformational dynamics mediate Hsp70 allostery Proc. Natl. Acad. Sci. USA 2015 112 E2865 E2873 10.1073/pnas.1506692112 26038563 PMC4460500 Zhuravleva, A. & Gierasch, L. M. Substrate-binding domain conformational dynamics mediate Hsp70 allostery. Proc. Natl. Acad. Sci. USA 112 , E2865–E2873 (2015). 26038563 10.1073/pnas.1506692112 PMC4460500

97. Zhuravleva A Clerico EM Gierasch LM An interdomain energetic tug-of-war creates the allosterically active state in Hsp70 molecular chaperones Cell 2012 151 1296 1307 10.1016/j.cell.2012.11.002 23217711 PMC3521165 Zhuravleva, A., Clerico, E. M. & Gierasch, L. M. An interdomain energetic tug-of-war creates the allosterically active state in Hsp70 molecular chaperones. Cell 151 , 1296–1307 (2012). 23217711 10.1016/j.cell.2012.11.002 PMC3521165

98. Kampinga HH Craig EA The HSP70 chaperone machinery: J proteins as drivers of functional specificity Nat. Rev. Mol. Cell Biol. 2010 11 579 592 10.1038/nrm2941 20651708 PMC3003299 Kampinga, H. H. & Craig, E. A. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat. Rev. Mol. Cell Biol. 11 , 579–592 (2010). 20651708 10.1038/nrm2941 PMC3003299

99. Stankiewicz M Nikolay R Rybin V Mayer MP CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates FEBS J. 2010 277 3353 3367 10.1111/j.1742-4658.2010.07737.x 20618441 Stankiewicz, M., Nikolay, R., Rybin, V. & Mayer, M. P. CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates. FEBS J. 277 , 3353–3367 (2010). 20618441 10.1111/j.1742-4658.2010.07737.x

100. Qian SB CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70 Nature 2006 440 551 555 10.1038/nature04600 16554822 PMC4112096 Qian, S. B. et al. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 440 , 551–555 (2006). 16554822 10.1038/nature04600 PMC4112096

101. Hohfeld J Cyr DM Patterson C From the cradle to the grave: molecular chaperones that may choose between folding and degradation EMBO Rep. 2001 2 885 890 10.1093/embo-reports/kve206 11600451 PMC1084084 Hohfeld, J., Cyr, D. M. & Patterson, C. From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep. 2 , 885–890 (2001). 11600451 10.1093/embo-reports/kve206 PMC1084084

102. Scheufler C Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine Cell 2000 101 199 210 10.1016/S0092-8674(00)80830-2 10786835 Scheufler, C. et al. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 101 , 199–210 (2000). 10786835 10.1016/S0092-8674(00)80830-2

103. Nitika Porter CM Truman AW Truttmann MC Post-translational modifications of Hsp70 family proteins: Expanding the chaperone code J. Biol. Chem. 2020 295 10689 10708 10.1074/jbc.REV120.011666 32518165 PMC7397107 Nitika, Porter, C. M., Truman, A. W. & Truttmann, M. C. Post-translational modifications of Hsp70 family proteins: Expanding the chaperone code. J. Biol. Chem. 295 , 10689–10708 (2020). 32518165 10.1074/jbc.REV120.011666 PMC7397107

104. Muller P C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances Oncogene 2013 32 3101 3110 10.1038/onc.2012.314 22824801 Muller, P. et al. C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene 32 , 3101–3110 (2013). 22824801 10.1038/onc.2012.314

105. Preissler S AMPylation matches BiP activity to client protein load in the endoplasmic reticulum Elife 2015 4 e12621 10.7554/eLife.12621 26673894 PMC4739761 Preissler, S. et al. AMPylation matches BiP activity to client protein load in the endoplasmic reticulum. Elife 4 , e12621 (2015). 26673894 10.7554/eLife.12621 PMC4739761

106. Perera LA Structures of a deAMPylation complex rationalise the switch between antagonistic catalytic activities of FICD Nat. Commun. 2021 12 5004 10.1038/s41467-021-25076-7 34408154 PMC8373988 Perera, L. A. et al. Structures of a deAMPylation complex rationalise the switch between antagonistic catalytic activities of FICD. Nat. Commun. 12 , 5004 (2021). 34408154 10.1038/s41467-021-25076-7 PMC8373988

107. Schopf FH Biebl MM Buchner J The HSP90 chaperone machinery Nat. Rev. Mol. Cell Biol. 2017 18 345 360 10.1038/nrm.2017.20 28429788 Schopf, F. H., Biebl, M. M. & Buchner, J. The HSP90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 18 , 345–360 (2017). 28429788 10.1038/nrm.2017.20

108. Qu X Structural basis for the dynamic chaperoning of disordered clients by Hsp90 Nat. Struct. Mol. Biol. 2024 31 1482 1491 10.1038/s41594-024-01337-z 38890550 Qu, X. et al. Structural basis for the dynamic chaperoning of disordered clients by Hsp90. Nat. Struct. Mol. Biol. 31 , 1482–1491 (2024). 38890550 10.1038/s41594-024-01337-z

109. Chiosis G Digwal CS Trepel JB Neckers L Structural and functional complexity of HSP90 in cellular homeostasis and disease Nat. Rev. Mol. Cell Biol. 2023 24 797 815 10.1038/s41580-023-00640-9 37524848 PMC10592246 Chiosis, G., Digwal, C. S., Trepel, J. B. & Neckers, L. Structural and functional complexity of HSP90 in cellular homeostasis and disease. Nat. Rev. Mol. Cell Biol. 24 , 797–815 (2023). 37524848 10.1038/s41580-023-00640-9 PMC10592246

110. Genest O Wickner S Doyle SM Hsp90 and Hsp70 chaperones: Collaborators in protein remodeling J. Biol. Chem. 2019 294 2109 2120 10.1074/jbc.REV118.002806 30401745 PMC6369297 Genest, O., Wickner, S. & Doyle, S. M. Hsp90 and Hsp70 chaperones: Collaborators in protein remodeling. J. Biol. Chem. 294 , 2109–2120 (2019). 30401745 10.1074/jbc.REV118.002806 PMC6369297

111. Silbermann, L. M., Vermeer, B., Schmid, S. & Tych, K. The known unknowns of the Hsp90 chaperone. Elife . 13 , e102666 (2024). 10.7554/eLife.102666 PMC11687934 39737863

112. Bhattacharya K The Hsp70-Hsp90 co-chaperone Hop/Stip1 shifts the proteostatic balance from folding towards degradation Nat. Commun. 2020 11 5975 10.1038/s41467-020-19783-w 33239621 PMC7688965 Bhattacharya, K. et al. The Hsp70-Hsp90 co-chaperone Hop/Stip1 shifts the proteostatic balance from folding towards degradation. Nat. Commun. 11 , 5975 (2020). 33239621 10.1038/s41467-020-19783-w PMC7688965

113. Wang X Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis Cell 2006 127 803 815 10.1016/j.cell.2006.09.043 17110338 Wang, X. et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127 , 803–815 (2006). 17110338 10.1016/j.cell.2006.09.043

114. Roe SM The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37) Cell 2004 116 87 98 10.1016/S0092-8674(03)01027-4 14718169 Roe, S. M. et al. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116 , 87–98 (2004). 14718169 10.1016/s0092-8674(03)01027-4

115. Shin CS LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding Nat. Commun. 2021 12 265 10.1038/s41467-020-20597-z 33431889 PMC7801493 Shin, C. S. et al. LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding. Nat. Commun. 12 , 265 (2021). 33431889 10.1038/s41467-020-20597-z PMC7801493

116. Schulz C Rehling P Remodelling of the active presequence translocase drives motor-dependent mitochondrial protein translocation Nat. Commun. 2014 5 4349 10.1038/ncomms5349 25008211 Schulz, C. & Rehling, P. Remodelling of the active presequence translocase drives motor-dependent mitochondrial protein translocation. Nat. Commun. 5 , 4349 (2014). 25008211 10.1038/ncomms5349

117. Liu Q Regulated cycling of mitochondrial Hsp70 at the protein import channel Science 2003 300 139 141 10.1126/science.1083379 12677068 Liu, Q. et al. Regulated cycling of mitochondrial Hsp70 at the protein import channel. Science 300 , 139–141 (2003). 12677068 10.1126/science.1083379

118. Young JC Hoogenraad NJ Hartl FU Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70 Cell 2003 112 41 50 10.1016/S0092-8674(02)01250-3 12526792 Young, J. C., Hoogenraad, N. J. & Hartl, F. U. Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell 112 , 41–50 (2003). 12526792 10.1016/s0092-8674(02)01250-3

119. Havalova, H. et al. Mitochondrial HSP70 chaperone system-the influence of post-translational modifications and involvement in human diseases. Int. J. Mol. Sci . 22 , 8077 (2021). 10.3390/ijms22158077 PMC8347752 34360841

120. Sichting M Maintenance of structure and function of mitochondrial Hsp70 chaperones requires the chaperone Hep1 EMBO J. 2005 24 1046 1056 10.1038/sj.emboj.7600580 15719019 PMC554129 Sichting, M. et al. Maintenance of structure and function of mitochondrial Hsp70 chaperones requires the chaperone Hep1. EMBO J. 24 , 1046–1056 (2005). 15719019 10.1038/sj.emboj.7600580 PMC554129

121. Srivastava S Regulation of mitochondrial protein import by the nucleotide exchange factors GrpEL1 and GrpEL2 in human cells J. Biol. Chem. 2017 292 18075 18090 10.1074/jbc.M117.788463 28848044 PMC5672033 Srivastava, S. et al. Regulation of mitochondrial protein import by the nucleotide exchange factors GrpEL1 and GrpEL2 in human cells. J. Biol. Chem. 292 , 18075–18090 (2017). 28848044 10.1074/jbc.M117.788463 PMC5672033

122. Jores T Cytosolic Hsp70 and Hsp40 chaperones enable the biogenesis of mitochondrial beta-barrel proteins J. Cell Biol. 2018 217 3091 3108 10.1083/jcb.201712029 29930205 PMC6122992 Jores, T. et al. Cytosolic Hsp70 and Hsp40 chaperones enable the biogenesis of mitochondrial beta-barrel proteins. J. Cell Biol. 217 , 3091–3108 (2018). 29930205 10.1083/jcb.201712029 PMC6122992

123. Bhangoo MK Multiple 40-kDa heat-shock protein chaperones function in Tom70-dependent mitochondrial import Mol. Biol. Cell 2007 18 3414 3428 10.1091/mbc.e07-01-0088 17596514 PMC1951752 Bhangoo, M. K. et al. Multiple 40-kDa heat-shock protein chaperones function in Tom70-dependent mitochondrial import. Mol. Biol. Cell 18 , 3414–3428 (2007). 17596514 10.1091/mbc.E07-01-0088 PMC1951752

124. Koch C The ER-SURF pathway uses ER-mitochondria contact sites for protein targeting to mitochondria EMBO Rep. 2024 25 2071 2096 10.1038/s44319-024-00113-w 38565738 PMC11014988 Koch, C. et al. The ER-SURF pathway uses ER-mitochondria contact sites for protein targeting to mitochondria. EMBO Rep. 25 , 2071–2096 (2024). 38565738 10.1038/s44319-024-00113-w PMC11014988

125. Radford SE GroEL: More than Just a folding cage Cell 2006 125 831 833 10.1016/j.cell.2006.05.021 16751091 Radford, S. E. GroEL: More than Just a folding cage. Cell 125 , 831–833 (2006). 16751091 10.1016/j.cell.2006.05.021

126. Gupta AJ Active cage mechanism of chaperonin-assisted protein folding demonstrated at single-molecule level J. Mol. Biol. 2014 426 2739 2754 10.1016/j.jmb.2014.04.018 24816391 Gupta, A. J. et al. Active cage mechanism of chaperonin-assisted protein folding demonstrated at single-molecule level. J. Mol. Biol. 426 , 2739–2754 (2014). 24816391 10.1016/j.jmb.2014.04.018

127. Caruso Bavisotto C Hsp60 post-translational modifications: Functional and pathological consequences Front Mol. Biosci. 2020 7 95 10.3389/fmolb.2020.00095 32582761 PMC7289027 Caruso Bavisotto, C. et al. Hsp60 post-translational modifications: Functional and pathological consequences. Front Mol. Biosci. 7 , 95 (2020). 32582761 10.3389/fmolb.2020.00095 PMC7289027

128. Felipe Perez R Mochi G Khan A Woodford M Mitochondrial chaperone code: Just warming up Cell Stress Chaperones 2024 29 483 496 10.1016/j.cstres.2024.05.002 38763405 PMC11153887 Felipe Perez, R., Mochi, G., Khan, A. & Woodford, M. Mitochondrial chaperone code: Just warming up. Cell Stress Chaperones 29 , 483–496 (2024). 38763405 10.1016/j.cstres.2024.05.002 PMC11153887

129. Singh, M. K. et al. Molecular chaperonin HSP60: Current understanding and future prospects. Int. J. Mol. Sci . 25 , 5483 (2024). 10.3390/ijms25105483 PMC11121636 38791521

130. Chandra D Choy G Tang DG Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3 J. Biol. Chem. 2007 282 31289 31301 10.1074/jbc.M702777200 17823127 Chandra, D., Choy, G. & Tang, D. G. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J. Biol. Chem. 282 , 31289–31301 (2007). 17823127 10.1074/jbc.M702777200

131. Soltys BJ Gupta RS Immunoelectron microscopic localization of the 60-kDa heat shock chaperonin protein (Hsp60) in mammalian cells Exp. Cell Res. 1996 222 16 27 10.1006/excr.1996.0003 8549659 Soltys, B. J. & Gupta, R. S. Immunoelectron microscopic localization of the 60-kDa heat shock chaperonin protein (Hsp60) in mammalian cells. Exp. Cell Res. 222 , 16–27 (1996). 8549659 10.1006/excr.1996.0003

132. Caruso Bavisotto C Exosomal HSP60: A potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment Expert Rev. Mol. Diagn. 2017 17 815 822 10.1080/14737159.2017.1356230 28718351 Caruso Bavisotto, C. et al. Exosomal HSP60: A potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment. Expert Rev. Mol. Diagn. 17 , 815–822 (2017). 28718351 10.1080/14737159.2017.1356230

133. Min S Heat shock protein 60 couples an oxidative stress-responsive p38/MK2 signaling and NF-kappaB survival machinery in cancer cells Redox Biol. 2022 51 102293 10.1016/j.redox.2022.102293 35316673 PMC8943299 Min, S. et al. Heat shock protein 60 couples an oxidative stress-responsive p38/MK2 signaling and NF-kappaB survival machinery in cancer cells. Redox Biol. 51 , 102293 (2022). 35316673 10.1016/j.redox.2022.102293 PMC8943299

134. Albakova Z Mangasarova Y The HSP immune network in cancer Front Immunol. 2021 12 796493 10.3389/fimmu.2021.796493 34917098 PMC8669653 Albakova, Z. & Mangasarova, Y. The HSP immune network in cancer. Front Immunol. 12 , 796493 (2021). 34917098 10.3389/fimmu.2021.796493 PMC8669653

135. Zhu H An efficient delivery of DAMPs on the cell surface by the unconventional secretion pathway Biochem Biophys. Res Commun. 2011 404 790 795 10.1016/j.bbrc.2010.12.061 21168385 Zhu, H. et al. An efficient delivery of DAMPs on the cell surface by the unconventional secretion pathway. Biochem Biophys. Res Commun. 404 , 790–795 (2011). 21168385 10.1016/j.bbrc.2010.12.061

136. Ellgaard L Helenius A Quality control in the endoplasmic reticulum Nat. Rev. Mol. Cell Biol. 2003 4 181 191 10.1038/nrm1052 12612637 Ellgaard, L. & Helenius, A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4 , 181–191 (2003). 12612637 10.1038/nrm1052

137. Anelli T Sitia R Protein quality control in the early secretory pathway EMBO J. 2008 27 315 327 10.1038/sj.emboj.7601974 18216874 PMC2234347 Anelli, T. & Sitia, R. Protein quality control in the early secretory pathway. EMBO J. 27 , 315–327 (2008). 18216874 10.1038/sj.emboj.7601974 PMC2234347

138. Sicari D A guide to assessing endoplasmic reticulum homeostasis and stress in mammalian systems FEBS J. 2020 287 27 42 10.1111/febs.15107 31647176 Sicari, D. et al. A guide to assessing endoplasmic reticulum homeostasis and stress in mammalian systems. FEBS J. 287 , 27–42 (2020). 31647176 10.1111/febs.15107

139. Braakman I Hebert DN Protein folding in the endoplasmic reticulum Cold Spring Harb. Perspect. Biol. 2013 5 a013201 10.1101/cshperspect.a013201 23637286 PMC3632058 Braakman, I. & Hebert, D. N. Protein folding in the endoplasmic reticulum. Cold Spring Harb. Perspect. Biol. 5 , a013201 (2013). 23637286 10.1101/cshperspect.a013201 PMC3632058

140. Haas IG BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum Experientia 1994 50 1012 1020 10.1007/BF01923455 7988659 Haas, I. G. BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum. Experientia 50 , 1012–1020 (1994). 7988659 10.1007/BF01923455

141. Adams BM Canniff NP Guay KP Hebert DN The role of endoplasmic reticulum chaperones in protein folding and quality control Prog. Mol. Subcell. Biol. 2021 59 27 50 10.1007/978-3-030-67696-4_3 34050861 PMC9185992 Adams, B. M., Canniff, N. P., Guay, K. P. & Hebert, D. N. The role of endoplasmic reticulum chaperones in protein folding and quality control. Prog. Mol. Subcell. Biol. 59 , 27–50 (2021). 34050861 10.1007/978-3-030-67696-4_3 PMC9185992

142. Lee AS The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress Methods 2005 35 373 381 10.1016/j.ymeth.2004.10.010 15804610 Lee, A. S. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 35 , 373–381 (2005). 15804610 10.1016/j.ymeth.2004.10.010

143. Bertolotti A Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response Nat. Cell Biol. 2000 2 326 332 10.1038/35014014 10854322 Bertolotti, A. et al. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2 , 326–332 (2000). 10854322 10.1038/35014014

144. Blau M ERj1p uses a universal ribosomal adaptor site to coordinate the 80S ribosome at the membrane Nat. Struct. Mol. Biol. 2005 12 1015 1016 10.1038/nsmb998 16244660 Blau, M. et al. ERj1p uses a universal ribosomal adaptor site to coordinate the 80S ribosome at the membrane. Nat. Struct. Mol. Biol. 12 , 1015–1016 (2005). 16244660 10.1038/nsmb998

145. Pobre KFR Poet GJ Hendershot LM The endoplasmic reticulum (ER) chaperone BiP is a master regulator of ER functions: Getting by with a little help from ERdj friends J. Biol. Chem. 2019 294 2098 2108 10.1074/jbc.REV118.002804 30563838 PMC6369273 Pobre, K. F. R., Poet, G. J. & Hendershot, L. M. The endoplasmic reticulum (ER) chaperone BiP is a master regulator of ER functions: Getting by with a little help from ERdj friends. J. Biol. Chem. 294 , 2098–2108 (2019). 30563838 10.1074/jbc.REV118.002804 PMC6369273

146. Shen Y Hendershot LM ERdj3, a stress-inducible endoplasmic reticulum DnaJ homologue, serves as a cofactor for BiP’s interactions with unfolded substrates Mol. Biol. Cell 2005 16 40 50 10.1091/mbc.e04-05-0434 15525676 PMC539150 Shen, Y. & Hendershot, L. M. ERdj3, a stress-inducible endoplasmic reticulum DnaJ homologue, serves as a cofactor for BiP’s interactions with unfolded substrates. Mol. Biol. Cell 16 , 40–50 (2005). 15525676 10.1091/mbc.E04-05-0434 PMC539150

147. Lai CW Otero JH Hendershot LM Snapp E ERdj4 protein is a soluble endoplasmic reticulum (ER) DnaJ family protein that interacts with ER-associated degradation machinery J. Biol. Chem. 2012 287 7969 7978 10.1074/jbc.M111.311290 22267725 PMC3318715 Lai, C. W., Otero, J. H., Hendershot, L. M. & Snapp, E. ERdj4 protein is a soluble endoplasmic reticulum (ER) DnaJ family protein that interacts with ER-associated degradation machinery. J. Biol. Chem. 287 , 7969–7978 (2012). 22267725 10.1074/jbc.M111.311290 PMC3318715

148. Amin-Wetzel N A J-protein co-chaperone recruits BiP to monomerize IRE1 and repress the unfolded protein response Cell 2017 171 1625 1637 e1613 10.1016/j.cell.2017.10.040 29198525 PMC5733394 Amin-Wetzel, N. et al. A J-protein co-chaperone recruits BiP to monomerize IRE1 and repress the unfolded protein response. Cell 171 , 1625–1637 e1613 (2017). 29198525 10.1016/j.cell.2017.10.040 PMC5733394

149. Ushioda R ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER Science 2008 321 569 572 10.1126/science.1159293 18653895 Ushioda, R. et al. ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER. Science 321 , 569–572 (2008). 18653895 10.1126/science.1159293

150. Rutkowski DT The role of p58IPK in protecting the stressed endoplasmic reticulum Mol. Biol. Cell 2007 18 3681 3691 10.1091/mbc.e07-03-0272 17567950 PMC1951758 Rutkowski, D. T. et al. The role of p58IPK in protecting the stressed endoplasmic reticulum. Mol. Biol. Cell 18 , 3681–3691 (2007). 17567950 10.1091/mbc.E07-03-0272 PMC1951758

151. Petrova K Oyadomari S Hendershot LM Ron D Regulated association of misfolded endoplasmic reticulum lumenal proteins with P58/DNAJc3 EMBO J. 2008 27 2862 2872 10.1038/emboj.2008.199 18923430 PMC2580781 Petrova, K., Oyadomari, S., Hendershot, L. M. & Ron, D. Regulated association of misfolded endoplasmic reticulum lumenal proteins with P58/DNAJc3. EMBO J. 27 , 2862–2872 (2008). 18923430 10.1038/emboj.2008.199 PMC2580781

152. Lee TG The 58,000-dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins Mol. Cell Biol. 1994 14 2331 2342 7511204 10.1128/mcb.14.4.2331-2342.1994 PMC358600 Lee, T. G. et al. The 58,000-dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins. Mol. Cell Biol. 14 , 2331–2342 (1994). 7511204 10.1128/mcb.14.4.2331-2342.1994 PMC358600

153. Roobol A p58IPK is an inhibitor of the eIF2alpha kinase GCN2 and its localization and expression underpin protein synthesis and ER processing capacity Biochem J. 2015 465 213 225 10.1042/BJ20140852 25329545 Roobol, A. et al. p58IPK is an inhibitor of the eIF2alpha kinase GCN2 and its localization and expression underpin protein synthesis and ER processing capacity. Biochem J. 465 , 213–225 (2015). 25329545 10.1042/BJ20140852

154. Yan W Control of PERK eIF2alpha kinase activity by the endoplasmic reticulum stress-induced molecular chaperone P58IPK Proc. Natl. Acad. Sci. USA 2002 99 15920 15925 10.1073/pnas.252341799 12446838 PMC138540 Yan, W. et al. Control of PERK eIF2alpha kinase activity by the endoplasmic reticulum stress-induced molecular chaperone P58IPK. Proc. Natl. Acad. Sci. USA 99 , 15920–15925 (2002). 12446838 10.1073/pnas.252341799 PMC138540

155. Pugh KW Alnaed M Brackett CM Blagg BSJ The biology and inhibition of glucose-regulated protein 94/gp96 Med Res Rev. 2022 42 2007 2024 10.1002/med.21915 35861260 PMC10003671 Pugh, K. W., Alnaed, M., Brackett, C. M. & Blagg, B. S. J. The biology and inhibition of glucose-regulated protein 94/gp96. Med Res Rev. 42 , 2007–2024 (2022). 35861260 10.1002/med.21915 PMC10003671

156. Amankwah YS Structural transitions modulate the chaperone activities of Grp94 Proc. Natl. Acad. Sci. USA 2024 121 e2309326121 10.1073/pnas.2309326121 38483986 PMC10962938 Amankwah, Y. S. et al. Structural transitions modulate the chaperone activities of Grp94. Proc. Natl. Acad. Sci. USA 121 , e2309326121 (2024). 38483986 10.1073/pnas.2309326121 PMC10962938

157. Huck JD Structural and Functional Analysis of GRP94 in the Closed State Reveals an Essential Role for the Pre-N Domain and a Potential Client-Binding Site Cell Rep. 2017 20 2800 2809 10.1016/j.celrep.2017.08.079 28930677 PMC5608278 Huck, J. D. et al. Structural and Functional Analysis of GRP94 in the Closed State Reveals an Essential Role for the Pre-N Domain and a Potential Client-Binding Site. Cell Rep. 20 , 2800–2809 (2017). 28930677 10.1016/j.celrep.2017.08.079 PMC5608278

158. Sun, S. et al. Visualization of conformational transition of GRP94 in solution. Life Sci. Alliance 7 , e202302051 (2024). 10.26508/lsa.202302051 PMC10638095 37949474

159. Huang, B. et al. The endoplasmic reticulum chaperone BiP is a closure-accelerating cochaperone of Grp94. Proc. Natl. Acad. Sci. USA 119 , e2118793119 (2022). 10.1073/pnas.2118793119 PMC8812556 35078937

160. Brenner, J. C. et al. Conformational plasticity of a BiP-GRP94 chaperone complex. bioRxiv , 2024.2002.2001.578445, (2024). 10.1038/s41594-025-01619-0 PMC12527940 40659993

161. Amankwah YS Grp94 works upstream of BiP in protein remodeling under heat stress J. Mol. Biol. 2022 434 167762 10.1016/j.jmb.2022.167762 35905823 Amankwah, Y. S. et al. Grp94 works upstream of BiP in protein remodeling under heat stress. J. Mol. Biol. 434 , 167762 (2022). 35905823 10.1016/j.jmb.2022.167762

162. Alao JP Insight into the nucleotide based modulation of the Grp94 molecular chaperone using multiscale dynamics J. Phys. Chem. B 2023 127 5389 5409 10.1021/acs.jpcb.3c00260 37294929 PMC10292203 Alao, J. P. et al. Insight into the nucleotide based modulation of the Grp94 molecular chaperone using multiscale dynamics. J. Phys. Chem. B 127 , 5389–5409 (2023). 37294929 10.1021/acs.jpcb.3c00260 PMC10292203

163. Azam TP Mechanism of client loading from BiP to Grp94 and its disruption by select inhibitors Nat. Commun. 2025 16 3575 10.1038/s41467-025-58658-w 40234402 PMC12000397 Azam, T. P. et al. Mechanism of client loading from BiP to Grp94 and its disruption by select inhibitors. Nat. Commun. 16 , 3575 (2025). 40234402 10.1038/s41467-025-58658-w PMC12000397

164. Hebert DN Lamriben L Powers ET Kelly JW The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis Nat. Chem. Biol. 2014 10 902 910 10.1038/nchembio.1651 25325701 PMC4232232 Hebert, D. N., Lamriben, L., Powers, E. T. & Kelly, J. W. The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis. Nat. Chem. Biol. 10 , 902–910 (2014). 25325701 10.1038/nchembio.1651 PMC4232232

165. Kapoor M Interactions of substrate with calreticulin, an endoplasmic reticulum chaperone J. Biol. Chem. 2003 278 6194 6200 10.1074/jbc.M209132200 12464625 Kapoor, M. et al. Interactions of substrate with calreticulin, an endoplasmic reticulum chaperone. J. Biol. Chem. 278 , 6194–6200 (2003). 12464625 10.1074/jbc.M209132200

166. Kozlov G Gehring K Calnexin cycle - structural features of the ER chaperone system FEBS J. 2020 287 4322 4340 10.1111/febs.15330 32285592 PMC7687155 Kozlov, G. & Gehring, K. Calnexin cycle - structural features of the ER chaperone system. FEBS J. 287 , 4322–4340 (2020). 32285592 10.1111/febs.15330 PMC7687155

167. Ninagawa S George G Mori K Mechanisms of productive folding and endoplasmic reticulum-associated degradation of glycoproteins and non-glycoproteins Biochim Biophys. Acta Gen. Subj. 2021 1865 129812 10.1016/j.bbagen.2020.129812 33316349 Ninagawa, S., George, G. & Mori, K. Mechanisms of productive folding and endoplasmic reticulum-associated degradation of glycoproteins and non-glycoproteins. Biochim Biophys. Acta Gen. Subj. 1865 , 129812 (2021). 33316349 10.1016/j.bbagen.2020.129812

168. Tannous A Pisoni GB Hebert DN Molinari M N-linked sugar-regulated protein folding and quality control in the ER Semin Cell Dev. Biol. 2015 41 79 89 10.1016/j.semcdb.2014.12.001 25534658 PMC4474783 Tannous, A., Pisoni, G. B., Hebert, D. N. & Molinari, M. N-linked sugar-regulated protein folding and quality control in the ER. Semin Cell Dev. Biol. 41 , 79–89 (2015). 25534658 10.1016/j.semcdb.2014.12.001 PMC4474783

169. Hebert DN Foellmer B Helenius A Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum Cell 1995 81 425 433 10.1016/0092-8674(95)90395-X 7736594 Hebert, D. N., Foellmer, B. & Helenius, A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell 81 , 425–433 (1995). 7736594 10.1016/0092-8674(95)90395-x

170. Fregno I Molinari M Proteasomal and lysosomal clearance of faulty secretory proteins: ER-associated degradation (ERAD) and ER-to-lysosome-associated degradation (ERLAD) pathways Crit. Rev. Biochem Mol. Biol. 2019 54 153 163 10.1080/10409238.2019.1610351 31084437 Fregno, I. & Molinari, M. Proteasomal and lysosomal clearance of faulty secretory proteins: ER-associated degradation (ERAD) and ER-to-lysosome-associated degradation (ERLAD) pathways. Crit. Rev. Biochem Mol. Biol. 54 , 153–163 (2019). 31084437 10.1080/10409238.2019.1610351

171. Bloemeke N Intramembrane client recognition potentiates the chaperone functions of calnexin EMBO J. 2022 41 e110959 10.15252/embj.2022110959 36314723 PMC9753464 Bloemeke, N. et al. Intramembrane client recognition potentiates the chaperone functions of calnexin. EMBO J. 41 , e110959 (2022). 36314723 10.15252/embj.2022110959 PMC9753464

172. De Leonibus C Sestrin2 drives ER-phagy in response to protein misfolding Dev. Cell 2024 59 2035 2052.e2010 10.1016/j.devcel.2024.07.004 39094564 PMC11338521 De Leonibus, C. et al. Sestrin2 drives ER-phagy in response to protein misfolding. Dev. Cell 59 , 2035–2052.e2010 (2024). 39094564 10.1016/j.devcel.2024.07.004 PMC11338521

173. Kim DY A selective ER-phagy exerts neuroprotective effects via modulation of alpha-synuclein clearance in parkinsonian models Proc. Natl. Acad. Sci. USA 2023 120 e2221929120 10.1073/pnas.2221929120 37669380 PMC10500278 Kim, D. Y. et al. A selective ER-phagy exerts neuroprotective effects via modulation of alpha-synuclein clearance in parkinsonian models. Proc. Natl. Acad. Sci. USA 120 , e2221929120 (2023). 37669380 10.1073/pnas.2221929120 PMC10500278

174. Matsusaki M The Protein Disulfide Isomerase Family: From proteostasis to pathogenesis Biochim Biophys. Acta Gen. Subj. 2020 1864 129338 10.1016/j.bbagen.2019.04.003 30986509 Matsusaki, M. et al. The Protein Disulfide Isomerase Family: From proteostasis to pathogenesis. Biochim Biophys. Acta Gen. Subj. 1864 , 129338 (2020). 30986509 10.1016/j.bbagen.2019.04.003

175. Zito E ERO1: A protein disulfide oxidase and H2O2 producer Free Radic. Biol. Med 2015 83 299 304 10.1016/j.freeradbiomed.2015.01.011 25651816 Zito, E. ERO1: A protein disulfide oxidase and H2O2 producer. Free Radic. Biol. Med 83 , 299–304 (2015). 25651816 10.1016/j.freeradbiomed.2015.01.011

176. Rahman NSA Functions and mechanisms of protein disulfide isomerase family in cancer emergence Cell Biosci. 2022 12 129 10.1186/s13578-022-00868-6 35965326 PMC9375924 Rahman, N. S. A. et al. Functions and mechanisms of protein disulfide isomerase family in cancer emergence. Cell Biosci. 12 , 129 (2022). 35965326 10.1186/s13578-022-00868-6 PMC9375924

177. Cai H Wang CC Tsou CL Chaperone-like activity of protein disulfide isomerase in the refolding of a protein with no disulfide bonds J. Biol. Chem. 1994 269 24550 24552 10.1016/S0021-9258(17)31426-6 7929125 Cai, H., Wang, C. C. & Tsou, C. L. Chaperone-like activity of protein disulfide isomerase in the refolding of a protein with no disulfide bonds. J. Biol. Chem. 269 , 24550–24552 (1994). 7929125

178. Eletto D Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling via disulfide-dependent association Mol. Cell 2014 53 562 576 10.1016/j.molcel.2014.01.004 24508390 PMC3977204 Eletto, D. et al. Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling via disulfide-dependent association. Mol. Cell 53 , 562–576 (2014). 24508390 10.1016/j.molcel.2014.01.004 PMC3977204

179. Eletto D Eletto D Boyle S Argon Y PDIA6 regulates insulin secretion by selectively inhibiting the RIDD activity of IRE1 FASEB J. 2016 30 653 665 10.1096/fj.15-275883 26487694 PMC4714551 Eletto, D., Eletto, D., Boyle, S. & Argon, Y. PDIA6 regulates insulin secretion by selectively inhibiting the RIDD activity of IRE1. FASEB J. 30 , 653–665 (2016). 26487694 10.1096/fj.15-275883 PMC4714551

180. Yu J Phosphorylation switches protein disulfide isomerase activity to maintain proteostasis and attenuate ER stress EMBO J. 2020 39 e103841 10.15252/embj.2019103841 32149426 PMC7232009 Yu, J. et al. Phosphorylation switches protein disulfide isomerase activity to maintain proteostasis and attenuate ER stress. EMBO J. 39 , e103841 (2020). 32149426 10.15252/embj.2019103841 PMC7232009

181. Oka OB ERp18 regulates activation of ATF6alpha during unfolded protein response EMBO J. 2019 38 e100990 10.15252/embj.2018100990 31368601 PMC6670016 Oka, O. B. et al. ERp18 regulates activation of ATF6alpha during unfolded protein response. EMBO J. 38 , e100990 (2019). 31368601 10.15252/embj.2018100990 PMC6670016

182. Mogk A Bukau B Kampinga HH Cellular handling of protein aggregates by disaggregation machines Mol. Cell 2018 69 214 226 10.1016/j.molcel.2018.01.004 29351843 Mogk, A., Bukau, B. & Kampinga, H. H. Cellular handling of protein aggregates by disaggregation machines. Mol. Cell 69 , 214–226 (2018). 29351843 10.1016/j.molcel.2018.01.004

183. Parsell DA Kowal AS Singer MA Lindquist S Protein disaggregation mediated by heat-shock protein Hsp104 Nature 1994 372 475 478 10.1038/372475a0 7984243 Parsell, D. A., Kowal, A. S., Singer, M. A. & Lindquist, S. Protein disaggregation mediated by heat-shock protein Hsp104. Nature 372 , 475–478 (1994). 7984243 10.1038/372475a0

184. Seyffer F Hsp70 proteins bind Hsp100 regulatory M domains to activate AAA+ disaggregase at aggregate surfaces Nat. Struct. Mol. Biol. 2012 19 1347 1355 10.1038/nsmb.2442 23160352 Seyffer, F. et al. Hsp70 proteins bind Hsp100 regulatory M domains to activate AAA+ disaggregase at aggregate surfaces. Nat. Struct. Mol. Biol. 19 , 1347–1355 (2012). 23160352 10.1038/nsmb.2442

185. Avellaneda MJ Processive extrusion of polypeptide loops by a Hsp100 disaggregase Nature 2020 578 317 320 10.1038/s41586-020-1964-y 31996849 Avellaneda, M. J. et al. Processive extrusion of polypeptide loops by a Hsp100 disaggregase. Nature 578 , 317–320 (2020). 31996849 10.1038/s41586-020-1964-y

186. Weibezahn J Thermotolerance requires refolding of aggregated proteins by substrate translocation through the central pore of ClpB Cell 2004 119 653 665 10.1016/j.cell.2004.11.027 15550247 Weibezahn, J. et al. Thermotolerance requires refolding of aggregated proteins by substrate translocation through the central pore of ClpB. Cell 119 , 653–665 (2004). 15550247 10.1016/j.cell.2004.11.027

187. Rampelt H Metazoan Hsp70 machines use Hsp110 to power protein disaggregation EMBO J. 2012 31 4221 4235 10.1038/emboj.2012.264 22990239 PMC3492728 Rampelt, H. et al. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J. 31 , 4221–4235 (2012). 22990239 10.1038/emboj.2012.264 PMC3492728

188. Winkler J Tyedmers J Bukau B Mogk A Hsp70 targets Hsp100 chaperones to substrates for protein disaggregation and prion fragmentation J. Cell Biol. 2012 198 387 404 10.1083/jcb.201201074 22869599 PMC3413357 Winkler, J., Tyedmers, J., Bukau, B. & Mogk, A. Hsp70 targets Hsp100 chaperones to substrates for protein disaggregation and prion fragmentation. J. Cell Biol. 198 , 387–404 (2012). 22869599 10.1083/jcb.201201074 PMC3413357

189. Sztangierska, W. et al. Early steps of protein disaggregation by Hsp70 chaperone and class B J-domain proteins are shaped by Hsp110. Elife . 13 , RP94795 (2024). 10.7554/eLife.94795 PMC11479587 39404743

190. Wentink AS Molecular dissection of amyloid disaggregation by human HSP70 Nature 2020 587 483 488 10.1038/s41586-020-2904-6 33177717 Wentink, A. S. et al. Molecular dissection of amyloid disaggregation by human HSP70. Nature 587 , 483–488 (2020). 33177717 10.1038/s41586-020-2904-6

191. Wu D Comprehensive structural characterization of the human AAA+ disaggregase CLPB in the apo- and substrate-bound states reveals a unique mode of action driven by oligomerization PLoS Biol. 2023 21 e3001987 10.1371/journal.pbio.3001987 36745679 PMC9934407 Wu, D. et al. Comprehensive structural characterization of the human AAA+ disaggregase CLPB in the apo- and substrate-bound states reveals a unique mode of action driven by oligomerization. PLoS Biol. 21 , e3001987 (2023). 36745679 10.1371/journal.pbio.3001987 PMC9934407

192. Gupta A Dodecamer assembly of a metazoan AAA(+) chaperone couples substrate extraction to refolding Sci. Adv. 2023 9 eadf5336 10.1126/sciadv.adf5336 37163603 PMC10171807 Gupta, A. et al. Dodecamer assembly of a metazoan AAA(+) chaperone couples substrate extraction to refolding. Sci. Adv. 9 , eadf5336 (2023). 37163603 10.1126/sciadv.adf5336 PMC10171807

193. D’Angelo D Dependence of mitochondrial calcium signalling and dynamics on the disaggregase, CLPB Nat. Commun. 2025 16 2810 10.1038/s41467-025-57641-9 40118824 PMC11928477 D’Angelo, D. et al. Dependence of mitochondrial calcium signalling and dynamics on the disaggregase, CLPB. Nat. Commun. 16 , 2810 (2025). 40118824 10.1038/s41467-025-57641-9 PMC11928477

194. Janowska, M. K., Baughman, H. E. R., Woods, C. N. & Klevit, R. E. Mechanisms of small heat shock proteins. Cold Spring Harb. Perspect Biol . 11 , a034025 (2019). 10.1101/cshperspect.a034025 PMC6771367 30833458

195. Haslbeck M Vierling E A first line of stress defense: small heat shock proteins and their function in protein homeostasis J. Mol. Biol. 2015 427 1537 1548 10.1016/j.jmb.2015.02.002 25681016 PMC4360138 Haslbeck, M. & Vierling, E. A first line of stress defense: small heat shock proteins and their function in protein homeostasis. J. Mol. Biol. 427 , 1537–1548 (2015). 25681016 10.1016/j.jmb.2015.02.002 PMC4360138

196. Zwirowski S Hsp70 displaces small heat shock proteins from aggregates to initiate protein refolding EMBO J. 2017 36 783 796 10.15252/embj.201593378 28219929 PMC5350560 Zwirowski, S. et al. Hsp70 displaces small heat shock proteins from aggregates to initiate protein refolding. EMBO J. 36 , 783–796 (2017). 28219929 10.15252/embj.201593378 PMC5350560

197. Carra S Seguin SJ Landry J HspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagy Autophagy 2008 4 237 239 10.4161/auto.5407 18094623 Carra, S., Seguin, S. J. & Landry, J. HspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagy. Autophagy 4 , 237–239 (2008). 18094623 10.4161/auto.5407

198. Ganassi M A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism Mol. Cell 2016 63 796 810 10.1016/j.molcel.2016.07.021 27570075 Ganassi, M. et al. A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Mol. Cell 63 , 796–810 (2016). 27570075 10.1016/j.molcel.2016.07.021

199. Dubinska-Magiera M Contribution of small heat shock proteins to muscle development and function FEBS Lett. 2014 588 517 530 10.1016/j.febslet.2014.01.005 24440355 Dubinska-Magiera, M. et al. Contribution of small heat shock proteins to muscle development and function. FEBS Lett. 588 , 517–530 (2014). 24440355 10.1016/j.febslet.2014.01.005

200. Arrigo AP Gibert B Protein interactomes of three stress inducible small heat shock proteins: HspB1, HspB5 and HspB8 Int J. Hyperth. 2013 29 409 422 10.3109/02656736.2013.792956 23697380 Arrigo, A. P. & Gibert, B. Protein interactomes of three stress inducible small heat shock proteins: HspB1, HspB5 and HspB8. Int J. Hyperth. 29 , 409–422 (2013). 10.3109/02656736.2013.792956 23697380

201. Zeng C Revisiting the chaperonin T-complex protein-1 ring complex in human health and disease: A proteostasis modulator and beyond Clin. Transl. Med 2024 14 e1592 10.1002/ctm2.1592 38363102 PMC10870801 Zeng, C. et al. Revisiting the chaperonin T-complex protein-1 ring complex in human health and disease: A proteostasis modulator and beyond. Clin. Transl. Med 14 , e1592 (2024). 38363102 10.1002/ctm2.1592 PMC10870801

202. Spiess C Meyer AS Reissmann S Frydman J Mechanism of the eukaryotic chaperonin: Protein folding in the chamber of secrets Trends Cell Biol. 2004 14 598 604 10.1016/j.tcb.2004.09.015 15519848 PMC2812437 Spiess, C., Meyer, A. S., Reissmann, S. & Frydman, J. Mechanism of the eukaryotic chaperonin: Protein folding in the chamber of secrets. Trends Cell Biol. 14 , 598–604 (2004). 15519848 10.1016/j.tcb.2004.09.015 PMC2812437

203. Smith TM Willardson BM Mechanistic insights into protein folding by the eukaryotic chaperonin complex CCT Biochem Soc. Trans. 2022 50 1403 1414 10.1042/BST20220591 36196890 PMC9704529 Smith, T. M. & Willardson, B. M. Mechanistic insights into protein folding by the eukaryotic chaperonin complex CCT. Biochem Soc. Trans. 50 , 1403–1414 (2022). 36196890 10.1042/BST20220591 PMC9704529

204. Valpuesta JM Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT FEBS Lett. 2002 529 11 16 10.1016/S0014-5793(02)03180-0 12354605 Valpuesta, J. M. et al. Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT. FEBS Lett. 529 , 11–16 (2002). 12354605 10.1016/s0014-5793(02)03180-0

205. Russmann F Folding of large multidomain proteins by partial encapsulation in the chaperonin TRiC/CCT Proc. Natl. Acad. Sci. USA 2012 109 21208 21215 10.1073/pnas.1218836109 23197838 PMC3535605 Russmann, F. et al. Folding of large multidomain proteins by partial encapsulation in the chaperonin TRiC/CCT. Proc. Natl. Acad. Sci. USA 109 , 21208–21215 (2012). 23197838 10.1073/pnas.1218836109 PMC3535605

206. Gestaut, D. et al. The chaperonin TRiC/CCT associates with prefoldin through a conserved electrostatic interface essential for cellular proteostasis. Cell 177 , 751–765.e715 (2019). 10.1016/j.cell.2019.03.012 PMC6629582 30955883

207. Melville MW The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex Mol. Cell Biol. 2003 23 3141 3151 10.1128/MCB.23.9.3141-3151.2003 12697815 PMC153194 Melville, M. W. et al. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol. Cell Biol. 23 , 3141–3151 (2003). 12697815 10.1128/MCB.23.9.3141-3151.2003 PMC153194

208. Kim S Willison KR Horwich AL Cystosolic chaperonin subunits have a conserved ATPase domain but diverged polypeptide-binding domains Trends Biochem Sci. 1994 19 543 548 10.1016/0968-0004(94)90058-2 7846767 Kim, S., Willison, K. R. & Horwich, A. L. Cystosolic chaperonin subunits have a conserved ATPase domain but diverged polypeptide-binding domains. Trends Biochem Sci. 19 , 543–548 (1994). 7846767 10.1016/0968-0004(94)90058-2

209. Anfinsen CB Principles that govern the folding of protein chains Science 1973 181 223 230 10.1126/science.181.4096.223 4124164 Anfinsen, C. B. Principles that govern the folding of protein chains. Science 181 , 223–230 (1973). 4124164 10.1126/science.181.4096.223

210. Marsh JA Buried and accessible surface area control intrinsic protein flexibility J. Mol. Biol. 2013 425 3250 3263 10.1016/j.jmb.2013.06.019 23811058 Marsh, J. A. Buried and accessible surface area control intrinsic protein flexibility. J. Mol. Biol. 425 , 3250–3263 (2013). 23811058 10.1016/j.jmb.2013.06.019

211. Ruff KM Pappu RV AlphaFold and implications for intrinsically disordered proteins J. Mol. Biol. 2021 433 167208 10.1016/j.jmb.2021.167208 34418423 Ruff, K. M. & Pappu, R. V. AlphaFold and implications for intrinsically disordered proteins. J. Mol. Biol. 433 , 167208 (2021). 34418423 10.1016/j.jmb.2021.167208

212. Chakravarty D Schafer JW Porter LL Distinguishing features of fold-switching proteins Protein Sci. 2023 32 e4596 10.1002/pro.4596 36782353 PMC9951197 Chakravarty, D., Schafer, J. W. & Porter, L. L. Distinguishing features of fold-switching proteins. Protein Sci. 32 , e4596 (2023). 36782353 10.1002/pro.4596 PMC9951197

213. Ward A Flexibility in the ABC transporter MsbA: Alternating access with a twist Proc. Natl. Acad. Sci. USA 2007 104 19005 19010 10.1073/pnas.0709388104 18024585 PMC2141898 Ward, A. et al. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc. Natl. Acad. Sci. USA 104 , 19005–19010 (2007). 18024585 10.1073/pnas.0709388104 PMC2141898

214. Trivedi, R. & Nagarajaram, H. A. Intrinsically disordered proteins: An overview. Int. J. Mol. Sci . 23 , 14050 (2022). 10.3390/ijms232214050 PMC9693201 36430530

215. Waxman EA Giasson BI Molecular mechanisms of alpha-synuclein neurodegeneration Biochim Biophys. Acta 2009 1792 616 624 10.1016/j.bbadis.2008.09.013 18955133 PMC2756732 Waxman, E. A. & Giasson, B. I. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys. Acta 1792 , 616–624 (2009). 18955133 10.1016/j.bbadis.2008.09.013 PMC2756732

216. Porter LL Looger LL Extant fold-switching proteins are widespread Proc. Natl. Acad. Sci. USA 2018 115 5968 5973 10.1073/pnas.1800168115 29784778 PMC6003340 Porter, L. L. & Looger, L. L. Extant fold-switching proteins are widespread. Proc. Natl. Acad. Sci. USA 115 , 5968–5973 (2018). 29784778 10.1073/pnas.1800168115 PMC6003340

217. Aspromonte MC DisProt in 2024: improving function annotation of intrinsically disordered proteins Nucleic Acids Res 2024 52 D434 D441 10.1093/nar/gkad928 37904585 PMC10767923 Aspromonte, M. C. et al. DisProt in 2024: improving function annotation of intrinsically disordered proteins. Nucleic Acids Res 52 , D434–D441 (2024). 37904585 10.1093/nar/gkad928 PMC10767923

218. Cortese MS Uversky VN Dunker AK Intrinsic disorder in scaffold proteins: getting more from less Prog. Biophys. Mol. Biol. 2008 98 85 106 10.1016/j.pbiomolbio.2008.05.007 18619997 PMC2671330 Cortese, M. S., Uversky, V. N. & Dunker, A. K. Intrinsic disorder in scaffold proteins: getting more from less. Prog. Biophys. Mol. Biol. 98 , 85–106 (2008). 18619997 10.1016/j.pbiomolbio.2008.05.007 PMC2671330

219. Uversky, V. N. p53 Proteoforms and intrinsic disorder: An illustration of the protein structure-function continuum concept. Int. J. Mol. Sci . 17 , 1874 (2016). 10.3390/ijms17111874 PMC5133874 27834926

220. Darling AL Liu Y Oldfield CJ Uversky VN Intrinsically disordered proteome of human membrane-less organelles Proteomics 2018 18 e1700193 10.1002/pmic.201700193 29068531 Darling, A. L., Liu, Y., Oldfield, C. J. & Uversky, V. N. Intrinsically disordered proteome of human membrane-less organelles. Proteomics 18 , e1700193 (2018). 29068531 10.1002/pmic.201700193

221. Gidalevitz T Kikis EA Morimoto RI A cellular perspective on conformational disease: The role of genetic background and proteostasis networks Curr. Opin. Struct. Biol. 2010 20 23 32 10.1016/j.sbi.2009.11.001 20053547 PMC3050498 Gidalevitz, T., Kikis, E. A. & Morimoto, R. I. A cellular perspective on conformational disease: The role of genetic background and proteostasis networks. Curr. Opin. Struct. Biol. 20 , 23–32 (2010). 20053547 10.1016/j.sbi.2009.11.001 PMC3050498

222. Garofalo R Broad range of missense error frequencies in cellular proteins Nucleic Acids Res 2019 47 2932 2945 10.1093/nar/gky1319 30649420 PMC6451103 Garofalo, R. et al. Broad range of missense error frequencies in cellular proteins. Nucleic Acids Res 47 , 2932–2945 (2019). 30649420 10.1093/nar/gky1319 PMC6451103

223. Sharma J Keeling KM Rowe SM Pharmacological approaches for targeting cystic fibrosis nonsense mutations Eur. J. Med Chem. 2020 200 112436 10.1016/j.ejmech.2020.112436 32512483 PMC7384597 Sharma, J., Keeling, K. M. & Rowe, S. M. Pharmacological approaches for targeting cystic fibrosis nonsense mutations. Eur. J. Med Chem. 200 , 112436 (2020). 32512483 10.1016/j.ejmech.2020.112436 PMC7384597

224. Landrum MJ ClinVar: Public archive of relationships among sequence variation and human phenotype Nucleic Acids Res 2014 42 D980 D985 10.1093/nar/gkt1113 24234437 PMC3965032 Landrum, M. J. et al. ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42 , D980–D985 (2014). 24234437 10.1093/nar/gkt1113 PMC3965032

225. Ferec C Cutting GR Assessing the disease-liability of mutations in CFTR Cold Spring Harb. Perspect. Med 2012 2 a009480 10.1101/cshperspect.a009480 23209179 PMC3543074 Ferec, C. & Cutting, G. R. Assessing the disease-liability of mutations in CFTR. Cold Spring Harb. Perspect. Med 2 , a009480 (2012). 23209179 10.1101/cshperspect.a009480 PMC3543074

226. Cai ZW Liu J Li HY Sheppard DN Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis Acta Pharm. Sin. 2011 32 693 701 10.1038/aps.2011.71 PMC4009972 21642944 Cai, Z. W., Liu, J., Li, H. Y. & Sheppard, D. N. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis. Acta Pharm. Sin. 32 , 693–701 (2011). 10.1038/aps.2011.71 PMC4009972 21642944

227. Lukacs GL Verkman AS CFTR: Folding, misfolding and correcting the DeltaF508 conformational defect Trends Mol. Med. 2012 18 81 91 10.1016/j.molmed.2011.10.003 22138491 PMC3643519 Lukacs, G. L. & Verkman, A. S. CFTR: Folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol. Med. 18 , 81–91 (2012). 22138491 10.1016/j.molmed.2011.10.003 PMC3643519

228. Yang JR Zhuang SM Zhang J Impact of translational error-induced and error-free misfolding on the rate of protein evolution Mol. Syst. Biol. 2010 6 421 10.1038/msb.2010.78 20959819 PMC2990641 Yang, J. R., Zhuang, S. M. & Zhang, J. Impact of translational error-induced and error-free misfolding on the rate of protein evolution. Mol. Syst. Biol. 6 , 421 (2010). 20959819 10.1038/msb.2010.78 PMC2990641

229. Vermulst M Transcription errors induce proteotoxic stress and shorten cellular lifespan Nat. Commun. 2015 6 8065 10.1038/ncomms9065 26304740 PMC4684168 Vermulst, M. et al. Transcription errors induce proteotoxic stress and shorten cellular lifespan. Nat. Commun. 6 , 8065 (2015). 26304740 10.1038/ncomms9065 PMC4684168

230. van Leeuwen FW Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients Science 1998 279 242 247 10.1126/science.279.5348.242 9422699 van Leeuwen, F. W. et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients. Science 279 , 242–247 (1998). 9422699 10.1126/science.279.5348.242

231. Nikom D Zheng S Alternative splicing in neurodegenerative disease and the promise of RNA therapies Nat. Rev. Neurosci. 2023 24 457 473 10.1038/s41583-023-00717-6 37336982 Nikom, D. & Zheng, S. Alternative splicing in neurodegenerative disease and the promise of RNA therapies. Nat. Rev. Neurosci. 24 , 457–473 (2023). 37336982 10.1038/s41583-023-00717-6

232. Lee JW Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration Nature 2006 443 50 55 10.1038/nature05096 16906134 Lee, J. W. et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature 443 , 50–55 (2006). 16906134 10.1038/nature05096

233. Drummond DA Wilke CO The evolutionary consequences of erroneous protein synthesis Nat. Rev. Genet 2009 10 715 724 10.1038/nrg2662 19763154 PMC2764353 Drummond, D. A. & Wilke, C. O. The evolutionary consequences of erroneous protein synthesis. Nat. Rev. Genet 10 , 715–724 (2009). 19763154 10.1038/nrg2662 PMC2764353

234. Tsour, S. et al. Alternate RNA decoding results in stable and abundant proteins in mammals. bioRxiv , (2024). 10.1038/s41586-026-10678-2 PMC13384240 42343131

235. Macario AJ Conway de Macario E Sick chaperones, cellular stress, and disease N. Engl. J. Med 2005 353 1489 1501 10.1056/NEJMra050111 16207851 Macario, A. J. & Conway de Macario, E. Sick chaperones, cellular stress, and disease. N. Engl. J. Med 353 , 1489–1501 (2005). 16207851 10.1056/NEJMra050111

236. D’Agostino M The cytosolic chaperone alpha-crystallin B rescues folding and compartmentalization of misfolded multispan transmembrane proteins J. Cell Sci. 2013 126 4160 4172 23843626 10.1242/jcs.125443 D’Agostino, M. et al. The cytosolic chaperone alpha-crystallin B rescues folding and compartmentalization of misfolded multispan transmembrane proteins. J. Cell Sci. 126 , 4160–4172 (2013). 23843626 10.1242/jcs.125443

237. Thorkelsson, A. & Chin, M. T. Role of the ALpha-B-crystallin protein in cardiomyopathic disease. Int. J. Mol. Sci . 25 , 2826 (2024). 10.3390/ijms25052826 PMC10932246 38474073

238. Graw J Genetics of crystallins: cataract and beyond Exp. Eye Res. 2009 88 173 189 10.1016/j.exer.2008.10.011 19007775 Graw, J. Genetics of crystallins: cataract and beyond. Exp. Eye Res. 88 , 173–189 (2009). 19007775 10.1016/j.exer.2008.10.011

239. Liu Y A novel alphaB-crystallin mutation associated with autosomal dominant congenital lamellar cataract Invest Ophthalmol. Vis. Sci. 2006 47 1069 1075 10.1167/iovs.05-1004 16505043 PMC2078606 Liu, Y. et al. A novel alphaB-crystallin mutation associated with autosomal dominant congenital lamellar cataract. Invest Ophthalmol. Vis. Sci. 47 , 1069–1075 (2006). 16505043 10.1167/iovs.05-1004 PMC2078606

240. Liu Y Peripherally misfolded proteins exacerbate ischemic stroke-induced neuroinflammation and brain injury J. Neuroinflamm. 2021 18 29 10.1186/s12974-021-02081-7 PMC7818745 33472658 Liu, Y. et al. Peripherally misfolded proteins exacerbate ischemic stroke-induced neuroinflammation and brain injury. J. Neuroinflamm. 18 , 29 (2021). 10.1186/s12974-021-02081-7 PMC7818745 33472658

241. Dabir DV Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology Am. J. Pathol. 2004 164 155 166 10.1016/S0002-9440(10)63106-9 14695329 PMC1602238 Dabir, D. V. et al. Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. Am. J. Pathol. 164 , 155–166 (2004). 14695329 10.1016/s0002-9440(10)63106-9 PMC1602238

242. Yoo BC Deranged expression of molecular chaperones in brains of patients with Alzheimer’s disease Biochem Biophys. Res Commun. 2001 280 249 258 10.1006/bbrc.2000.4109 11162507 Yoo, B. C. et al. Deranged expression of molecular chaperones in brains of patients with Alzheimer’s disease. Biochem Biophys. Res Commun. 280 , 249–258 (2001). 11162507 10.1006/bbrc.2000.4109

243. Bertoli-Avella A A disorder clinically resembling cystic fibrosis caused by biallelic variants in the AGR2 gene J. Med Genet 2022 59 993 1001 10.1136/jmedgenet-2021-108150 34952832 PMC9554030 Bertoli-Avella, A. et al. A disorder clinically resembling cystic fibrosis caused by biallelic variants in the AGR2 gene. J. Med Genet 59 , 993–1001 (2022). 34952832 10.1136/jmedgenet-2021-108150 PMC9554030

244. Park SW The protein disulfide isomerase AGR2 is essential for production of intestinal mucus Proc. Natl. Acad. Sci. USA 2009 106 6950 6955 10.1073/pnas.0808722106 19359471 PMC2678445 Park, S. W. et al. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc. Natl. Acad. Sci. USA 106 , 6950–6955 (2009). 19359471 10.1073/pnas.0808722106 PMC2678445

245. Schroeder BW AGR2 is induced in asthma and promotes allergen-induced mucin overproduction Am. J. Respir. Cell Mol. Biol. 2012 47 178 185 10.1165/rcmb.2011-0421OC 22403803 PMC3423459 Schroeder, B. W. et al. AGR2 is induced in asthma and promotes allergen-induced mucin overproduction. Am. J. Respir. Cell Mol. Biol. 47 , 178–185 (2012). 22403803 10.1165/rcmb.2011-0421OC PMC3423459

246. Muranova LK Sudnitsyna MV Strelkov SV Gusev NB Mutations in HspB1 and hereditary neuropathies Cell Stress Chaperones 2020 25 655 665 10.1007/s12192-020-01099-9 32301006 PMC7332652 Muranova, L. K., Sudnitsyna, M. V., Strelkov, S. V. & Gusev, N. B. Mutations in HspB1 and hereditary neuropathies. Cell Stress Chaperones 25 , 655–665 (2020). 32301006 10.1007/s12192-020-01099-9 PMC7332652

247. Holmgren A Charcot-Marie-Tooth causing HSPB1 mutations increase Cdk5-mediated phosphorylation of neurofilaments Acta Neuropathol. 2013 126 93 108 10.1007/s00401-013-1133-6 23728742 PMC3963106 Holmgren, A. et al. Charcot-Marie-Tooth causing HSPB1 mutations increase Cdk5-mediated phosphorylation of neurofilaments. Acta Neuropathol. 126 , 93–108 (2013). 23728742 10.1007/s00401-013-1133-6 PMC3963106

248. Haidar M Neuropathy-causing mutations in HSPB1 impair autophagy by disturbing the formation of SQSTM1/p62 bodies Autophagy 2019 15 1051 1068 10.1080/15548627.2019.1569930 30669930 PMC6526868 Haidar, M. et al. Neuropathy-causing mutations in HSPB1 impair autophagy by disturbing the formation of SQSTM1/p62 bodies. Autophagy 15 , 1051–1068 (2019). 30669930 10.1080/15548627.2019.1569930 PMC6526868

249. Mymrikov, E. V. et al. The chaperone activity and substrate spectrum of human small heat shock proteins. J. Biol. Chem. 292 , 672–684 (2017). 10.1074/jbc.M116.760413 PMC5241741 27909051

250. Sacco F Perfetto L Castagnoli L Cesareni G The human phosphatase interactome: An intricate family portrait FEBS Lett. 2012 586 2732 2739 10.1016/j.febslet.2012.05.008 22626554 PMC3437441 Sacco, F., Perfetto, L., Castagnoli, L. & Cesareni, G. The human phosphatase interactome: An intricate family portrait. FEBS Lett. 586 , 2732–2739 (2012). 22626554 10.1016/j.febslet.2012.05.008 PMC3437441

251. Hunter T A journey from phosphotyrosine to phosphohistidine and beyond Mol. Cell 2022 82 2190 2200 10.1016/j.molcel.2022.05.007 35654043 PMC9219344 Hunter, T. A journey from phosphotyrosine to phosphohistidine and beyond. Mol. Cell 82 , 2190–2200 (2022). 35654043 10.1016/j.molcel.2022.05.007 PMC9219344

252. Nishi H Shaytan A Panchenko AR Physicochemical mechanisms of protein regulation by phosphorylation Front Genet 2014 5 270 10.3389/fgene.2014.00270 25147561 PMC4124799 Nishi, H., Shaytan, A. & Panchenko, A. R. Physicochemical mechanisms of protein regulation by phosphorylation. Front Genet 5 , 270 (2014). 25147561 10.3389/fgene.2014.00270 PMC4124799

253. Bah A Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch Nature 2015 519 106 109 10.1038/nature13999 25533957 Bah, A. et al. Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch. Nature 519 , 106–109 (2015). 25533957 10.1038/nature13999

254. Hanger DP Anderton BH Noble W Tau phosphorylation: The therapeutic challenge for neurodegenerative disease Trends Mol. Med 2009 15 112 119 10.1016/j.molmed.2009.01.003 19246243 Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med 15 , 112–119 (2009). 19246243 10.1016/j.molmed.2009.01.003

255. Kopke E Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease J. Biol. Chem. 1993 268 24374 24384 10.1016/S0021-9258(20)80536-5 8226987 Kopke, E. et al. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268 , 24374–24384 (1993). 8226987

256. Wesseling H Tau PTM profiles identify patient heterogeneity and stages of alzheimer’s disease Cell 2020 183 1699 1713.e1613 10.1016/j.cell.2020.10.029 33188775 PMC8168922 Wesseling, H. et al. Tau PTM profiles identify patient heterogeneity and stages of alzheimer’s disease. Cell 183 , 1699–1713.e1613 (2020). 33188775 10.1016/j.cell.2020.10.029 PMC8168922

257. Buee L Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res. Brain Res. Rev. 2000 33 95 130 10.1016/S0165-0173(00)00019-9 10967355 Buee, L. et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 , 95–130 (2000). 10967355 10.1016/s0165-0173(00)00019-9

258. De Strooper B Karran E The cellular phase of Alzheimer’s disease Cell 2016 164 603 615 10.1016/j.cell.2015.12.056 26871627 De Strooper, B. & Karran, E. The cellular phase of Alzheimer’s disease. Cell 164 , 603–615 (2016). 26871627 10.1016/j.cell.2015.12.056

259. Lim S Cell-based models to investigate tau aggregation Comput Struct. Biotechnol. J. 2014 12 7 13 10.1016/j.csbj.2014.09.011 25505502 PMC4262059 Lim, S. et al. Cell-based models to investigate tau aggregation. Comput Struct. Biotechnol. J. 12 , 7–13 (2014). 25505502 10.1016/j.csbj.2014.09.011 PMC4262059

260. Rawat, P. et al. Phosphorylated tau in alzheimer’s disease and other tauopathies. Int. J. Mol. Sci . 23 , 12841 (2022). 10.3390/ijms232112841 PMC9654278 36361631

261. Liu F Grundke-Iqbal I Iqbal K Gong CX Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation Eur. J. Neurosci. 2005 22 1942 1950 10.1111/j.1460-9568.2005.04391.x 16262633 Liu, F., Grundke-Iqbal, I., Iqbal, K. & Gong, C. X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22 , 1942–1950 (2005). 16262633 10.1111/j.1460-9568.2005.04391.x

262. Benilova I Karran E De Strooper B The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes Nat. Neurosci. 2012 15 349 357 10.1038/nn.3028 22286176 Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat. Neurosci. 15 , 349–357 (2012). 22286176 10.1038/nn.3028

263. Prasad A Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis Front Mol. Neurosci. 2019 12 25 10.3389/fnmol.2019.00025 30837838 PMC6382748 Prasad, A. et al. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front Mol. Neurosci. 12 , 25 (2019). 30837838 10.3389/fnmol.2019.00025 PMC6382748

264. Kawahata, I., Finkelstein, D. I. & Fukunaga, K. Pathogenic Impact of alpha-Synuclein Phosphorylation and Its Kinases in alpha-Synucleinopathies. Int. J. Mol. Sci . 23 , 6216 (2022). 10.3390/ijms23116216 PMC9181156 35682892

265. Hegde RN TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington’s disease models EMBO J. 2020 39 e104671 10.15252/embj.2020104671 32757223 PMC7459410 Hegde, R. N. et al. TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington’s disease models. EMBO J. 39 , e104671 (2020). 32757223 10.15252/embj.2020104671 PMC7459410

266. Bancher C Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease Brain Res 1989 477 90 99 10.1016/0006-8993(89)91396-6 2495152 Bancher, C. et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res . 477 , 90–99 (1989). 2495152 10.1016/0006-8993(89)91396-6

267. Sun Q Gamblin TC Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization Biochemistry 2009 48 6002 6011 10.1021/bi900602h 19459590 PMC2739831 Sun, Q. & Gamblin, T. C. Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Biochemistry 48 , 6002–6011 (2009). 19459590 10.1021/bi900602h PMC2739831

268. Velasco, L., Dublang, L., Moro, F. & Muga, A. The complex phosphorylation patterns that regulate the activity of Hsp70 and its cochaperones. Int. J .Mol. Sci . 20 , 4122 (2019). 10.3390/ijms20174122 PMC6747476 31450862

269. Nadel CM Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP Nat. Commun. 2024 15 7972 10.1038/s41467-024-52075-1 39266525 PMC11393453 Nadel, C. M. et al. Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP. Nat. Commun. 15 , 7972 (2024). 39266525 10.1038/s41467-024-52075-1 PMC11393453

270. Schjoldager KT Narimatsu Y Joshi HJ Clausen H Global view of human protein glycosylation pathways and functions Nat. Rev. Mol. Cell Biol. 2020 21 729 749 10.1038/s41580-020-00294-x 33087899 Schjoldager, K. T., Narimatsu, Y., Joshi, H. J. & Clausen, H. Global view of human protein glycosylation pathways and functions. Nat. Rev. Mol. Cell Biol. 21 , 729–749 (2020). 33087899 10.1038/s41580-020-00294-x

271. Shental-Bechor D Levy Y Folding of glycoproteins: toward understanding the biophysics of the glycosylation code Curr. Opin. Struct. Biol. 2009 19 524 533 10.1016/j.sbi.2009.07.002 19647993 Shental-Bechor, D. & Levy, Y. Folding of glycoproteins: toward understanding the biophysics of the glycosylation code. Curr. Opin. Struct. Biol. 19 , 524–533 (2009). 19647993 10.1016/j.sbi.2009.07.002

272. Lu D Yang C Liu Z How hydrophobicity and the glycosylation site of glycans affect protein folding and stability: A molecular dynamics simulation J. Phys. Chem. B 2012 116 390 400 10.1021/jp203926r 22118044 Lu, D., Yang, C. & Liu, Z. How hydrophobicity and the glycosylation site of glycans affect protein folding and stability: A molecular dynamics simulation. J. Phys. Chem. B 116 , 390–400 (2012). 22118044 10.1021/jp203926r

273. Mitra N Sinha S Ramya TN Surolia A N-linked oligosaccharides as outfitters for glycoprotein folding, form and function Trends Biochem Sci. 2006 31 156 163 10.1016/j.tibs.2006.01.003 16473013 Mitra, N., Sinha, S., Ramya, T. N. & Surolia, A. N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends Biochem Sci. 31 , 156–163 (2006). 16473013 10.1016/j.tibs.2006.01.003

274. Ressler VT Raines RT Consequences of the endogenous N-glycosylation of human ribonuclease 1 Biochemistry 2019 58 987 996 10.1021/acs.biochem.8b01246 30633504 PMC6380942 Ressler, V. T. & Raines, R. T. Consequences of the endogenous N-glycosylation of human ribonuclease 1. Biochemistry 58 , 987–996 (2019). 30633504 10.1021/acs.biochem.8b01246 PMC6380942

275. Delorme E Role of glycosylation on the secretion and biological activity of erythropoietin Biochemistry 1992 31 9871 9876 10.1021/bi00156a003 1390770 Delorme, E. et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31 , 9871–9876 (1992). 1390770 10.1021/bi00156a003

276. Dube S Fisher JW Powell JS Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function J. Biol. Chem. 1988 263 17516 17521 10.1016/S0021-9258(19)77865-X 3182860 Dube, S., Fisher, J. W. & Powell, J. S. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J. Biol. Chem. 263 , 17516–17521 (1988). 3182860

277. Glozman R N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic J. Cell Biol. 2009 184 847 862 10.1083/jcb.200808124 19307599 PMC2699153 Glozman, R. et al. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J. Cell Biol. 184 , 847–862 (2009). 19307599 10.1083/jcb.200808124 PMC2699153

278. Chang XB Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator J. Cell Sci. 2008 121 2814 2823 10.1242/jcs.028951 18682497 PMC2677381 Chang, X. B. et al. Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator. J. Cell Sci. 121 , 2814–2823 (2008). 18682497 10.1242/jcs.028951 PMC2677381

279. Vasudevan D Haltiwanger RS Novel roles for O-linked glycans in protein folding Glycoconj. J. 2014 31 417 426 10.1007/s10719-014-9556-4 25186198 PMC4214879 Vasudevan, D. & Haltiwanger, R. S. Novel roles for O-linked glycans in protein folding. Glycoconj. J. 31 , 417–426 (2014). 25186198 10.1007/s10719-014-9556-4 PMC4214879

280. Lommel M Protein O-mannosylation is crucial for E-cadherin-mediated cell adhesion Proc. Natl. Acad. Sci. USA 2013 110 21024 21029 10.1073/pnas.1316753110 24297939 PMC3876218 Lommel, M. et al. Protein O-mannosylation is crucial for E-cadherin-mediated cell adhesion. Proc. Natl. Acad. Sci. USA 110 , 21024–21029 (2013). 24297939 10.1073/pnas.1316753110 PMC3876218

281. Stanley P Genetics of glycosylation in mammalian development and disease Nat. Rev. Genet 2024 25 715 729 38724711 10.1038/s41576-024-00725-x Stanley, P. Genetics of glycosylation in mammalian development and disease. Nat. Rev. Genet 25 , 715–729 (2024). 38724711 10.1038/s41576-024-00725-x

282. Kang Y Zhang Q Xu S Yu Y The alteration and role of glycoconjugates in Alzheimer’s disease Front Aging Neurosci. 2024 16 1398641 10.3389/fnagi.2024.1398641 38946780 PMC11212478 Kang, Y., Zhang, Q., Xu, S. & Yu, Y. The alteration and role of glycoconjugates in Alzheimer’s disease. Front Aging Neurosci. 16 , 1398641 (2024). 38946780 10.3389/fnagi.2024.1398641 PMC11212478

283. Zhang, Y. & Zheng, J. Bioinformatics of metalloproteins and metalloproteomes. Molecules 25 , 3366 (2020). 10.3390/molecules25153366 PMC7435645 32722260

284. Wilson CJ Apiyo D Wittung-Stafshede P Role of cofactors in metalloprotein folding Q Rev. Biophys. 2004 37 285 314 10.1017/S003358350500404X 16194296 Wilson, C. J., Apiyo, D. & Wittung-Stafshede, P. Role of cofactors in metalloprotein folding. Q Rev. Biophys. 37 , 285–314 (2004). 16194296 10.1017/S003358350500404X

285. Martinez-Limon A Recognition of enzymes lacking bound cofactor by protein quality control Proc. Natl. Acad. Sci. USA 2016 113 12156 12161 10.1073/pnas.1611994113 27733512 PMC5087029 Martinez-Limon, A. et al. Recognition of enzymes lacking bound cofactor by protein quality control. Proc. Natl. Acad. Sci. USA 113 , 12156–12161 (2016). 27733512 10.1073/pnas.1611994113 PMC5087029

286. Hodak M Chisnell R Lu W Bernholc J Functional implications of multistage copper binding to the prion protein Proc. Natl. Acad. Sci. USA 2009 106 11576 11581 10.1073/pnas.0903807106 19561303 PMC2710693 Hodak, M., Chisnell, R., Lu, W. & Bernholc, J. Functional implications of multistage copper binding to the prion protein. Proc. Natl. Acad. Sci. USA 106 , 11576–11581 (2009). 19561303 10.1073/pnas.0903807106 PMC2710693

287. Correia AR Dynamics, stability and iron-binding activity of frataxin clinical mutants FEBS J. 2008 275 3680 3690 10.1111/j.1742-4658.2008.06512.x 18537827 Correia, A. R. et al. Dynamics, stability and iron-binding activity of frataxin clinical mutants. FEBS J. 275 , 3680–3690 (2008). 18537827 10.1111/j.1742-4658.2008.06512.x

288. Sirangelo, I. & Iannuzzi, C. The Role of Metal Binding in the Amyotrophic Lateral Sclerosis-Related Aggregation of Copper-Zinc Superoxide Dismutase. Molecules 22 , 1429 (2017). 10.3390/molecules22091429 PMC6151412 28850080

289. Seetharaman SV Immature copper-zinc superoxide dismutase and familial amyotrophic lateral sclerosis Exp. Biol. Med. (Maywood) 2009 234 1140 1154 10.3181/0903-MR-104 19596823 PMC2850267 Seetharaman, S. V. et al. Immature copper-zinc superoxide dismutase and familial amyotrophic lateral sclerosis. Exp. Biol. Med. (Maywood) 234 , 1140–1154 (2009). 19596823 10.3181/0903-MR-104 PMC2850267

290. Barnham KJ Masters CL Bush AI Neurodegenerative diseases and oxidative stress Nat. Rev. Drug Discov. 2004 3 205 214 10.1038/nrd1330 15031734 Barnham, K. J., Masters, C. L. & Bush, A. I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3 , 205–214 (2004). 15031734 10.1038/nrd1330

291. Tamas MJ Heavy metals and metalloids as a cause for protein misfolding and aggregation Biomolecules 2014 4 252 267 10.3390/biom4010252 24970215 PMC4030994 Tamas, M. J. et al. Heavy metals and metalloids as a cause for protein misfolding and aggregation. Biomolecules 4 , 252–267 (2014). 24970215 10.3390/biom4010252 PMC4030994

292. Lehninger, A. L. Lehninger Principles of Biochemistry: David L. Nelson, Michael M. Cox . 7 edn, (W. H. Freeman, 2017).

293. Lepock JR Protein denaturation during heat shock Adv. Mol. Cell Biol. 1997 19 223 259 10.1016/S1569-2558(08)60079-X Lepock, J. R. Protein denaturation during heat shock. Adv. Mol. Cell Biol. 19 , 223–259 (1997).

294. Henle KJ Dethlefsen LA Time-temperature relationships for heat-induced killing of mammalian cells Ann. NY Acad. Sci. 1980 335 234 253 10.1111/j.1749-6632.1980.tb50752.x 6931521 Henle, K. J. & Dethlefsen, L. A. Time-temperature relationships for heat-induced killing of mammalian cells. Ann. NY Acad. Sci. 335 , 234–253 (1980). 6931521 10.1111/j.1749-6632.1980.tb50752.x

295. Singh IS Hasday JD Fever, hyperthermia and the heat shock response Int J. Hyperth. 2013 29 423 435 10.3109/02656736.2013.808766 23863046 Singh, I. S. & Hasday, J. D. Fever, hyperthermia and the heat shock response. Int J. Hyperth. 29 , 423–435 (2013). 10.3109/02656736.2013.808766 23863046

296. Evans SS Repasky EA Fisher DT Fever and the thermal regulation of immunity: the immune system feels the heat Nat. Rev. Immunol. 2015 15 335 349 10.1038/nri3843 25976513 PMC4786079 Evans, S. S., Repasky, E. A. & Fisher, D. T. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat. Rev. Immunol. 15 , 335–349 (2015). 25976513 10.1038/nri3843 PMC4786079

297. Homma T Fujii J Heat stress promotes the down-regulation of IRE1alpha in cells: An atypical modulation of the UPR pathway Exp. Cell Res 2016 349 128 138 10.1016/j.yexcr.2016.10.006 27743894 Homma, T. & Fujii, J. Heat stress promotes the down-regulation of IRE1alpha in cells: An atypical modulation of the UPR pathway. Exp. Cell Res 349 , 128–138 (2016). 27743894 10.1016/j.yexcr.2016.10.006

298. Xu X Hyperthermia induces the ER stress pathway PLoS One 2011 6 e23740 10.1371/journal.pone.0023740 21876766 PMC3158104 Xu, X. et al. Hyperthermia induces the ER stress pathway. PLoS One 6 , e23740 (2011). 21876766 10.1371/journal.pone.0023740 PMC3158104

299. Dukic, B. et al. Mild hyperthermia-induced thermogenesis in the endoplasmic reticulum defines stress response mechanisms. Cells . 13 , 1141 (2024). 10.3390/cells13131141 PMC11240596 38994992

300. Lugrin J Rosenblatt-Velin N Parapanov R Liaudet L The role of oxidative stress during inflammatory processes Biol. Chem. 2014 395 203 230 10.1515/hsz-2013-0241 24127541 Lugrin, J., Rosenblatt-Velin, N., Parapanov, R. & Liaudet, L. The role of oxidative stress during inflammatory processes. Biol. Chem. 395 , 203–230 (2014). 24127541 10.1515/hsz-2013-0241

301. Hayes JD Dinkova-Kostova AT Tew KD Oxidative stress in cancer Cancer Cell 2020 38 167 197 10.1016/j.ccell.2020.06.001 32649885 PMC7439808 Hayes, J. D., Dinkova-Kostova, A. T. & Tew, K. D. Oxidative stress in cancer. Cancer Cell 38 , 167–197 (2020). 32649885 10.1016/j.ccell.2020.06.001 PMC7439808

302. Moldogazieva NT Mokhosoev IM Feldman NB Lutsenko SV ROS and RNS signalling: adaptive redox switches through oxidative/nitrosative protein modifications Free Radic. Res 2018 52 507 543 10.1080/10715762.2018.1457217 29589770 Moldogazieva, N. T., Mokhosoev, I. M., Feldman, N. B. & Lutsenko, S. V. ROS and RNS signalling: adaptive redox switches through oxidative/nitrosative protein modifications. Free Radic. Res 52 , 507–543 (2018). 29589770 10.1080/10715762.2018.1457217

303. Murphy MP How mitochondria produce reactive oxygen species Biochem J. 2009 417 1 13 10.1042/BJ20081386 19061483 PMC2605959 Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem J. 417 , 1–13 (2009). 19061483 10.1042/BJ20081386 PMC2605959

304. Sies H Berndt C Jones DP Oxidative stress Annu Rev. Biochem 2017 86 715 748 10.1146/annurev-biochem-061516-045037 28441057 Sies, H., Berndt, C. & Jones, D. P. Oxidative stress. Annu Rev. Biochem 86 , 715–748 (2017). 28441057 10.1146/annurev-biochem-061516-045037

305. Davies MJ The oxidative environment and protein damage Biochim Biophys. Acta 2005 1703 93 109 10.1016/j.bbapap.2004.08.007 15680218 Davies, M. J. The oxidative environment and protein damage. Biochim Biophys. Acta 1703 , 93–109 (2005). 15680218 10.1016/j.bbapap.2004.08.007

306. Hawkins CL Davies MJ Detection, identification, and quantification of oxidative protein modifications J. Biol. Chem. 2019 294 19683 19708 10.1074/jbc.REV119.006217 31672919 PMC6926449 Hawkins, C. L. & Davies, M. J. Detection, identification, and quantification of oxidative protein modifications. J. Biol. Chem. 294 , 19683–19708 (2019). 31672919 10.1074/jbc.REV119.006217 PMC6926449

307. Wu G Glutathione metabolism and its implications for health J. Nutr. 2004 134 489 492 10.1093/jn/134.3.489 14988435 Wu, G. et al. Glutathione metabolism and its implications for health. J. Nutr. 134 , 489–492 (2004). 14988435 10.1093/jn/134.3.489

308. Nikitaki Z Hellweg CE Georgakilas AG Ravanat JL Stress-induced DNA damage biomarkers: applications and limitations Front Chem. 2015 3 35 10.3389/fchem.2015.00035 26082923 PMC4451417 Nikitaki, Z., Hellweg, C. E., Georgakilas, A. G. & Ravanat, J. L. Stress-induced DNA damage biomarkers: applications and limitations. Front Chem. 3 , 35 (2015). 26082923 10.3389/fchem.2015.00035 PMC4451417

309. Furman D Chronic inflammation in the etiology of disease across the life span Nat. Med 2019 25 1822 1832 10.1038/s41591-019-0675-0 31806905 PMC7147972 Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med 25 , 1822–1832 (2019). 31806905 10.1038/s41591-019-0675-0 PMC7147972

310. Forman HJ Zhang H Targeting oxidative stress in disease: promise and limitations of antioxidant therapy Nat. Rev. Drug Discov. 2021 20 689 709 10.1038/s41573-021-00233-1 34194012 PMC8243062 Forman, H. J. & Zhang, H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat. Rev. Drug Discov. 20 , 689–709 (2021). 34194012 10.1038/s41573-021-00233-1 PMC8243062

311. Hung YH Bush AI Cherny RA Copper in the brain and Alzheimer’s disease J. Biol. Inorg. Chem. 2010 15 61 76 10.1007/s00775-009-0600-y 19862561 Hung, Y. H., Bush, A. I. & Cherny, R. A. Copper in the brain and Alzheimer’s disease. J. Biol. Inorg. Chem. 15 , 61–76 (2010). 19862561 10.1007/s00775-009-0600-y

312. Frazzini V Rockabrand E Mocchegiani E Sensi SL Oxidative stress and brain aging: is zinc the link? Biogerontology 2006 7 307 314 10.1007/s10522-006-9045-7 17028932 Frazzini, V., Rockabrand, E., Mocchegiani, E. & Sensi, S. L. Oxidative stress and brain aging: is zinc the link?. Biogerontology 7 , 307–314 (2006). 17028932 10.1007/s10522-006-9045-7

313. Ludtmann MHR alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease Nat. Commun. 2018 9 2293 10.1038/s41467-018-04422-2 29895861 PMC5997668 Ludtmann, M. H. R. et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease. Nat. Commun. 9 , 2293 (2018). 29895861 10.1038/s41467-018-04422-2 PMC5997668

314. Passarelli S Global estimation of dietary micronutrient inadequacies: a modelling analysis Lancet Glob. Health 2024 12 e1590 e1599 10.1016/S2214-109X(24)00276-6 39218000 PMC11426101 Passarelli, S. et al. Global estimation of dietary micronutrient inadequacies: a modelling analysis. Lancet Glob. Health 12 , e1590–e1599 (2024). 39218000 10.1016/S2214-109X(24)00276-6 PMC11426101

315. Halliwell B Understanding mechanisms of antioxidant action in health and disease Nat. Rev. Mol. Cell Biol. 2024 25 13 33 10.1038/s41580-023-00645-4 37714962 Halliwell, B. Understanding mechanisms of antioxidant action in health and disease. Nat. Rev. Mol. Cell Biol. 25 , 13–33 (2024). 37714962 10.1038/s41580-023-00645-4

316. Pataskar A Tryptophan depletion results in tryptophan-to-phenylalanine substitutants Nature 2022 603 721 727 10.1038/s41586-022-04499-2 35264796 PMC8942854 Pataskar, A. et al. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature 603 , 721–727 (2022). 35264796 10.1038/s41586-022-04499-2 PMC8942854

317. Denu JM Vitamin B3 and sirtuin function Trends Biochem. Sci. 2005 30 479 483 10.1016/j.tibs.2005.07.004 16039130 Denu, J. M. Vitamin B3 and sirtuin function. Trends Biochem. Sci. 30 , 479–483 (2005). 16039130 10.1016/j.tibs.2005.07.004

318. Westerheide SD Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1 Science 2009 323 1063 1066 10.1126/science.1165946 19229036 PMC3429349 Westerheide, S. D. et al. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323 , 1063–1066 (2009). 19229036 10.1126/science.1165946 PMC3429349

319. Pakos-Zebrucka K The integrated stress response EMBO Rep. 2016 17 1374 1395 10.15252/embr.201642195 27629041 PMC5048378 Pakos-Zebrucka, K. et al. The integrated stress response. EMBO Rep. 17 , 1374–1395 (2016). 27629041 10.15252/embr.201642195 PMC5048378

320. Sun-Wang JL Ivanova S Zorzano A The dialogue between the ubiquitin-proteasome system and autophagy: Implications in ageing Ageing Res Rev. 2020 64 101203 10.1016/j.arr.2020.101203 33130248 Sun-Wang, J. L., Ivanova, S. & Zorzano, A. The dialogue between the ubiquitin-proteasome system and autophagy: Implications in ageing. Ageing Res Rev. 64 , 101203 (2020). 33130248 10.1016/j.arr.2020.101203

321. Enam C Geffen Y Ravid T Gardner RG Protein Quality Control Degradation in the Nucleus Annu Rev. Biochem 2018 87 725 749 10.1146/annurev-biochem-062917-012730 29925261 Enam, C., Geffen, Y., Ravid, T. & Gardner, R. G. Protein Quality Control Degradation in the Nucleus. Annu Rev. Biochem 87 , 725–749 (2018). 29925261 10.1146/annurev-biochem-062917-012730

322. Koppen M Langer T Protein degradation within mitochondria: Versatile activities of AAA proteases and other peptidases Crit. Rev. Biochem Mol. Biol. 2007 42 221 242 10.1080/10409230701380452 17562452 Koppen, M. & Langer, T. Protein degradation within mitochondria: Versatile activities of AAA proteases and other peptidases. Crit. Rev. Biochem Mol. Biol. 42 , 221–242 (2007). 17562452 10.1080/10409230701380452

323. Wang F Durfee LA Huibregtse JM A cotranslational ubiquitination pathway for quality control of misfolded proteins Mol. Cell 2013 50 368 378 10.1016/j.molcel.2013.03.009 23583076 PMC3654026 Wang, F., Durfee, L. A. & Huibregtse, J. M. A cotranslational ubiquitination pathway for quality control of misfolded proteins. Mol. Cell 50 , 368–378 (2013). 23583076 10.1016/j.molcel.2013.03.009 PMC3654026

324. Mawuenyega KG Decreased clearance of CNS beta-amyloid in Alzheimer’s disease Science 2010 330 1774 10.1126/science.1197623 21148344 PMC3073454 Mawuenyega, K. G. et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330 , 1774 (2010). 21148344 10.1126/science.1197623 PMC3073454

325. Lim KL Tan JM Role of the ubiquitin proteasome system in Parkinson’s disease BMC Biochem 2007 8 S13 10.1186/1471-2091-8-S1-S13 18047737 PMC2106364 Lim, K. L. & Tan, J. M. Role of the ubiquitin proteasome system in Parkinson’s disease. BMC Biochem 8 , S13 (2007). 18047737 10.1186/1471-2091-8-S1-S13 PMC2106364

326. Wilson DM Hallmarks of neurodegenerative diseases Cell 2023 186 693 714 10.1016/j.cell.2022.12.032 36803602 Wilson, D. M. et al. Hallmarks of neurodegenerative diseases. Cell 186 , 693–714 (2023). 36803602 10.1016/j.cell.2022.12.032

327. Hu Y Endoplasmic reticulum-associated degradation (ERAD) has a critical role in supporting glucose-stimulated insulin secretion in pancreatic beta-cells Diabetes 2019 68 733 746 10.2337/db18-0624 30626610 Hu, Y. et al. Endoplasmic reticulum-associated degradation (ERAD) has a critical role in supporting glucose-stimulated insulin secretion in pancreatic beta-cells. Diabetes 68 , 733–746 (2019). 30626610 10.2337/db18-0624

328. Mearini G Schlossarek S Willis MS Carrier L The ubiquitin-proteasome system in cardiac dysfunction Biochim Biophys. Acta 2008 1782 749 763 10.1016/j.bbadis.2008.06.009 18634872 Mearini, G., Schlossarek, S., Willis, M. S. & Carrier, L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys. Acta 1782 , 749–763 (2008). 18634872 10.1016/j.bbadis.2008.06.009

329. Predmore JM Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies Circulation 2010 121 997 1004 10.1161/CIRCULATIONAHA.109.904557 20159828 PMC2857348 Predmore, J. M. et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 121 , 997–1004 (2010). 20159828 10.1161/CIRCULATIONAHA.109.904557 PMC2857348

330. Mishto M Immunoproteasome and LMP2 polymorphism in aged and Alzheimer’s disease brains Neurobiol. Aging 2006 27 54 66 10.1016/j.neurobiolaging.2004.12.004 16298241 Mishto, M. et al. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer’s disease brains. Neurobiol. Aging 27 , 54–66 (2006). 16298241 10.1016/j.neurobiolaging.2004.12.004

331. Cardozo C Michaud C Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway Arch. Biochem Biophys. 2002 408 103 110 10.1016/S0003-9861(02)00493-9 12485608 Cardozo, C. & Michaud, C. Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway. Arch. Biochem Biophys. 408 , 103–110 (2002). 12485608 10.1016/s0003-9861(02)00493-9

332. Li XJ Li S Proteasomal dysfunction in aging and Huntington disease Neurobiol. Dis. 2011 43 4 8 10.1016/j.nbd.2010.11.018 21145396 PMC3090713 Li, X. J. & Li, S. Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 43 , 4–8 (2011). 21145396 10.1016/j.nbd.2010.11.018 PMC3090713

333. Xu H Ren D Lysosomal physiology Annu Rev. Physiol. 2015 77 57 80 10.1146/annurev-physiol-021014-071649 25668017 PMC4524569 Xu, H. & Ren, D. Lysosomal physiology. Annu Rev. Physiol. 77 , 57–80 (2015). 25668017 10.1146/annurev-physiol-021014-071649 PMC4524569

334. Schultz ML Tecedor L Chang M Davidson BL Clarifying lysosomal storage diseases Trends Neurosci. 2011 34 401 410 10.1016/j.tins.2011.05.006 21723623 PMC3153126 Schultz, M. L., Tecedor, L., Chang, M. & Davidson, B. L. Clarifying lysosomal storage diseases. Trends Neurosci. 34 , 401–410 (2011). 21723623 10.1016/j.tins.2011.05.006 PMC3153126

335. Platt FM Lysosomal storage diseases Nat. Rev. Dis. Prim. 2018 4 27 10.1038/s41572-018-0025-4 30275469 Platt, F. M. et al. Lysosomal storage diseases. Nat. Rev. Dis. Prim. 4 , 27 (2018). 30275469 10.1038/s41572-018-0025-4

336. Monaco A Fraldi A Protein aggregation and dysfunction of autophagy-lysosomal pathway: A vicious cycle in lysosomal storage diseases Front Mol. Neurosci. 2020 13 37 10.3389/fnmol.2020.00037 32218723 PMC7079699 Monaco, A. & Fraldi, A. Protein aggregation and dysfunction of autophagy-lysosomal pathway: A vicious cycle in lysosomal storage diseases. Front Mol. Neurosci. 13 , 37 (2020). 32218723 10.3389/fnmol.2020.00037 PMC7079699

337. Mazzulli JR Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies Cell 2011 146 37 52 10.1016/j.cell.2011.06.001 21700325 PMC3132082 Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 , 37–52 (2011). 21700325 10.1016/j.cell.2011.06.001 PMC3132082

338. Platt FM Boland B van der Spoel AC The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction J. Cell Biol. 2012 199 723 734 10.1083/jcb.201208152 23185029 PMC3514785 Platt, F. M., Boland, B. & van der Spoel, A. C. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J. Cell Biol. 199 , 723–734 (2012). 23185029 10.1083/jcb.201208152 PMC3514785

339. Ingemann L Kirkegaard T Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities J. Lipid Res 2014 55 2198 2210 10.1194/jlr.R048090 24837749 PMC4617124 Ingemann, L. & Kirkegaard, T. Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities. J. Lipid Res 55 , 2198–2210 (2014). 24837749 10.1194/jlr.R048090 PMC4617124

340. Lee MJ Lee JH Rubinsztein DC Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system Prog. Neurobiol. 2013 105 49 59 10.1016/j.pneurobio.2013.03.001 23528736 Lee, M. J., Lee, J. H. & Rubinsztein, D. C. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog. Neurobiol. 105 , 49–59 (2013). 23528736 10.1016/j.pneurobio.2013.03.001

341. Zhou J The autophagy adaptor TRIAD3A promotes tau fibrillation by nested phase separation Nat. Cell Biol. 2024 26 1274 1286 10.1038/s41556-024-01461-4 39009640 PMC11921440 Zhou, J. et al. The autophagy adaptor TRIAD3A promotes tau fibrillation by nested phase separation. Nat. Cell Biol. 26 , 1274–1286 (2024). 39009640 10.1038/s41556-024-01461-4 PMC11921440

342. Lee JH Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations Cell 2010 141 1146 1158 10.1016/j.cell.2010.05.008 20541250 PMC3647462 Lee, J. H. et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141 , 1146–1158 (2010). 20541250 10.1016/j.cell.2010.05.008 PMC3647462

343. Franceschi C Inflammaging: a new immune-metabolic viewpoint for age-related diseases Nat. Rev. Endocrinol. 2018 14 576 590 10.1038/s41574-018-0059-4 30046148 Franceschi, C. et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14 , 576–590 (2018). 30046148 10.1038/s41574-018-0059-4

344. Beckman KB Ames BN The free radical theory of aging matures Physiol. Rev. 1998 78 547 581 10.1152/physrev.1998.78.2.547 9562038 Beckman, K. B. & Ames, B. N. The free radical theory of aging matures. Physiol. Rev. 78 , 547–581 (1998). 9562038 10.1152/physrev.1998.78.2.547

345. Lopez-Otin C Hallmarks of aging: An expanding universe Cell 2023 186 243 278 10.1016/j.cell.2022.11.001 36599349 Lopez-Otin, C. et al. Hallmarks of aging: An expanding universe. Cell 186 , 243–278 (2023). 36599349 10.1016/j.cell.2022.11.001

346. Zhou X Deletion of PIK3C3/Vps34 in sensory neurons causes rapid neurodegeneration by disrupting the endosomal but not the autophagic pathway Proc. Natl. Acad. Sci. USA 2010 107 9424 9429 10.1073/pnas.0914725107 20439739 PMC2889054 Zhou, X. et al. Deletion of PIK3C3/Vps34 in sensory neurons causes rapid neurodegeneration by disrupting the endosomal but not the autophagic pathway. Proc. Natl. Acad. Sci. USA 107 , 9424–9429 (2010). 20439739 10.1073/pnas.0914725107 PMC2889054

347. Hara T Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice Nature 2006 441 885 889 10.1038/nature04724 16625204 Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441 , 885–889 (2006). 16625204 10.1038/nature04724

348. Ugarte N Petropoulos I Friguet B Oxidized mitochondrial protein degradation and repair in aging and oxidative stress Antioxid. Redox Signal 2010 13 539 549 10.1089/ars.2009.2998 19958171 Ugarte, N., Petropoulos, I. & Friguet, B. Oxidized mitochondrial protein degradation and repair in aging and oxidative stress. Antioxid. Redox Signal 13 , 539–549 (2010). 19958171 10.1089/ars.2009.2998

349. Maynard, S. et al. DNA Damage, DNA repair, aging, and neurodegeneration. Cold Spring Harb. Perspect Med . 5, a025130 (2015). 10.1101/cshperspect.a025130 PMC4588127 26385091

350. Toyama BH Identification of long-lived proteins reveals exceptional stability of essential cellular structures Cell 2013 154 971 982 10.1016/j.cell.2013.07.037 23993091 PMC3788602 Toyama, B. H. et al. Identification of long-lived proteins reveals exceptional stability of essential cellular structures. Cell 154 , 971–982 (2013). 23993091 10.1016/j.cell.2013.07.037 PMC3788602

351. Heo S Identification of long-lived synaptic proteins by proteomic analysis of synaptosome protein turnover Proc. Natl. Acad. Sci. USA 2018 115 E3827 E3836 10.1073/pnas.1720956115 29610302 PMC5910858 Heo, S. et al. Identification of long-lived synaptic proteins by proteomic analysis of synaptosome protein turnover. Proc. Natl. Acad. Sci. USA 115 , E3827–E3836 (2018). 29610302 10.1073/pnas.1720956115 PMC5910858

352. Truscott RJW Schey KL Friedrich MG Old proteins in man: A field in its infancy Trends Biochem Sci. 2016 41 654 664 10.1016/j.tibs.2016.06.004 27426990 PMC5500981 Truscott, R. J. W., Schey, K. L. & Friedrich, M. G. Old proteins in man: A field in its infancy. Trends Biochem Sci. 41 , 654–664 (2016). 27426990 10.1016/j.tibs.2016.06.004 PMC5500981

353. Adav SS Dementia-linked amyloidosis is associated with brain protein deamidation as revealed by proteomic profiling of human brain tissues Mol. Brain 2016 9 20 10.1186/s13041-016-0200-z 26892330 PMC4759965 Adav, S. S. et al. Dementia-linked amyloidosis is associated with brain protein deamidation as revealed by proteomic profiling of human brain tissues. Mol. Brain 9 , 20 (2016). 26892330 10.1186/s13041-016-0200-z PMC4759965

354. Dunkelberger EB Deamidation accelerates amyloid formation and alters amylin fiber structure J. Am. Chem. Soc. 2012 134 12658 12667 10.1021/ja3039486 22734583 PMC3410046 Dunkelberger, E. B. et al. Deamidation accelerates amyloid formation and alters amylin fiber structure. J. Am. Chem. Soc. 134 , 12658–12667 (2012). 22734583 10.1021/ja3039486 PMC3410046

355. Dan A Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer’s disease brain Acta Neuropathol. Commun. 2013 1 54 10.1186/2051-5960-1-54 24252707 PMC3893535 Dan, A. et al. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer’s disease brain. Acta Neuropathol. Commun. 1 , 54 (2013). 24252707 10.1186/2051-5960-1-54 PMC3893535

356. James, E. A., Pietropaolo, M. & Mamula, M. J. Immune recognition of beta-cells: Neoepitopes as key players in the loss of tolerance. Diabetes 67 , 1035–1042 (2018). 10.2337/dbi17-0030 PMC5961411 29784651

357. Lambeth TR Spontaneous isomerization of long-lived proteins provides a molecular mechanism for the lysosomal failure observed in Alzheimer’s disease ACS Cent. Sci. 2019 5 1387 1395 10.1021/acscentsci.9b00369 31482121 PMC6716341 Lambeth, T. R. et al. Spontaneous isomerization of long-lived proteins provides a molecular mechanism for the lysosomal failure observed in Alzheimer’s disease. ACS Cent. Sci. 5 , 1387–1395 (2019). 31482121 10.1021/acscentsci.9b00369 PMC6716341

358. Brunk UT Terman A Lipofuscin: Mechanisms of age-related accumulation and influence on cell function Free Radic. Biol. Med 2002 33 611 619 10.1016/S0891-5849(02)00959-0 12208347 Brunk, U. T. & Terman, A. Lipofuscin: Mechanisms of age-related accumulation and influence on cell function. Free Radic. Biol. Med . 33 , 611–619 (2002). 12208347 10.1016/s0891-5849(02)00959-0

359. Uehara T S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration Nature 2006 441 513 517 10.1038/nature04782 16724068 Uehara, T. et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441 , 513–517 (2006). 16724068 10.1038/nature04782

360. Sharma A Molecular chaperones as therapeutic target: Hallmark of neurodegenerative disorders Mol. Neurobiol. 2024 61 4750 4767 10.1007/s12035-023-03846-2 38127187 Sharma, A. et al. Molecular chaperones as therapeutic target: Hallmark of neurodegenerative disorders. Mol. Neurobiol. 61 , 4750–4767 (2024). 38127187 10.1007/s12035-023-03846-2

361. Anckar J Sistonen L Regulation of HSF1 function in the heat stress response: implications in aging and disease Annu Rev. Biochem 2011 80 1089 1115 10.1146/annurev-biochem-060809-095203 21417720 Anckar, J. & Sistonen, L. Regulation of HSF1 function in the heat stress response: implications in aging and disease. Annu Rev. Biochem 80 , 1089–1115 (2011). 21417720 10.1146/annurev-biochem-060809-095203

362. Yoo J GlcNAc-1-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation Nat. Struct. Mol. Biol. 2018 25 217 224 10.1038/s41594-018-0031-y 29459785 PMC5840018 Yoo, J. et al. GlcNAc-1-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation. Nat. Struct. Mol. Biol. 25 , 217–224 (2018). 29459785 10.1038/s41594-018-0031-y PMC5840018

363. Yu SM Kim SJ Endoplasmic reticulum stress (ER-stress) by 2-deoxy-D-glucose (2DG) reduces cyclooxygenase-2 (COX-2) expression and N-glycosylation and induces a loss of COX-2 activity via a Src kinase-dependent pathway in rabbit articular chondrocytes Exp. Mol. Med 2010 42 777 786 10.3858/emm.2010.42.11.079 20926918 PMC2992857 Yu, S. M. & Kim, S. J. Endoplasmic reticulum stress (ER-stress) by 2-deoxy-D-glucose (2DG) reduces cyclooxygenase-2 (COX-2) expression and N-glycosylation and induces a loss of COX-2 activity via a Src kinase-dependent pathway in rabbit articular chondrocytes. Exp. Mol. Med 42 , 777–786 (2010). 20926918 10.3858/emm.2010.42.11.079 PMC2992857

364. Pajak, B. et al. 2-Deoxy-d-Glucose and its analogs: From diagnostic to therapeutic agents. Int. J. Mol. Sci . 21 , 234 (2019). 10.3390/ijms21010234 PMC6982256 31905745

365. Elbein AD Tropea JE Mitchell M Kaushal GP Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I J. Biol. Chem. 1990 265 15599 15605 10.1016/S0021-9258(18)55439-9 2144287 Elbein, A. D., Tropea, J. E., Mitchell, M. & Kaushal, G. P. Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J. Biol. Chem. 265 , 15599–15605 (1990). 2144287

366. Sehgal P Inhibition of the sarco/endoplasmic reticulum (ER) Ca(2+)-ATPase by thapsigargin analogs induces cell death via ER Ca(2+) depletion and the unfolded protein response J. Biol. Chem. 2017 292 19656 19673 10.1074/jbc.M117.796920 28972171 PMC5712609 Sehgal, P. et al. Inhibition of the sarco/endoplasmic reticulum (ER) Ca(2+)-ATPase by thapsigargin analogs induces cell death via ER Ca(2+) depletion and the unfolded protein response. J. Biol. Chem. 292 , 19656–19673 (2017). 28972171 10.1074/jbc.M117.796920 PMC5712609

367. Tombal B Weeraratna AT Denmeade SR Isaacs JT Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells Prostate 2000 43 303 317 10.1002/1097-0045(20000601)43:4<303::AID-PROS10>3.0.CO;2-V 10861750 Tombal, B., Weeraratna, A. T., Denmeade, S. R. & Isaacs, J. T. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 43 , 303–317 (2000). 10861750 10.1002/1097-0045(20000601)43:4<303::aid-pros10>3.0.co;2-v

368. Timmins JM Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways J. Clin. Invest 2009 119 2925 2941 10.1172/JCI38857 19741297 PMC2752072 Timmins, J. M. et al. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J. Clin. Invest 119 , 2925–2941 (2009). 19741297 10.1172/JCI38857 PMC2752072

369. Harriman JF Endoplasmic reticulum Ca(2+) signaling and calpains mediate renal cell death Cell Death Differ. 2002 9 734 741 10.1038/sj.cdd.4401029 12058278 Harriman, J. F. et al. Endoplasmic reticulum Ca(2+) signaling and calpains mediate renal cell death. Cell Death Differ. 9 , 734–741 (2002). 12058278 10.1038/sj.cdd.4401029

370. Engedal N Modulation of intracellular calcium homeostasis blocks autophagosome formation Autophagy 2013 9 1475 1490 10.4161/auto.25900 23970164 Engedal, N. et al. Modulation of intracellular calcium homeostasis blocks autophagosome formation. Autophagy 9 , 1475–1490 (2013). 23970164 10.4161/auto.25900

371. Frand AR Cuozzo JW Kaiser CA Pathways for protein disulphide bond formation Trends Cell Biol. 2000 10 203 210 10.1016/S0962-8924(00)01745-1 10754564 Frand, A. R., Cuozzo, J. W. & Kaiser, C. A. Pathways for protein disulphide bond formation. Trends Cell Biol. 10 , 203–210 (2000). 10754564 10.1016/s0962-8924(00)01745-1

372. Oslowski CM Urano F Measuring ER stress and the unfolded protein response using mammalian tissue culture system Methods Enzymol. 2011 490 71 92 10.1016/B978-0-12-385114-7.00004-0 21266244 PMC3701721 Oslowski, C. M. & Urano, F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol. 490 , 71–92 (2011). 21266244 10.1016/B978-0-12-385114-7.00004-0 PMC3701721

373. Avezov E Lifetime imaging of a fluorescent protein sensor reveals surprising stability of ER thiol redox J. Cell Biol. 2013 201 337 349 10.1083/jcb.201211155 23589496 PMC3628511 Avezov, E. et al. Lifetime imaging of a fluorescent protein sensor reveals surprising stability of ER thiol redox. J. Cell Biol. 201 , 337–349 (2013). 23589496 10.1083/jcb.201211155 PMC3628511

374. Glushchenko AV Jacobsen DW Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease Antioxid. Redox Signal 2007 9 1883 1898 10.1089/ars.2007.1809 17760510 PMC2855132 Glushchenko, A. V. & Jacobsen, D. W. Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease. Antioxid. Redox Signal 9 , 1883–1898 (2007). 17760510 10.1089/ars.2007.1809 PMC2855132

375. Austin RC Lentz SR Werstuck GH Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease Cell Death Differ. 2004 11 S56 S64 10.1038/sj.cdd.4401451 15243582 Austin, R. C., Lentz, S. R. & Werstuck, G. H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 11 , S56–S64 (2004). 15243582 10.1038/sj.cdd.4401451

376. Citterio C Unfolded protein response and cell death after depletion of brefeldin A-inhibited guanine nucleotide-exchange protein GBF1 Proc. Natl. Acad. Sci. USA 2008 105 2877 2882 10.1073/pnas.0712224105 18287014 PMC2268553 Citterio, C. et al. Unfolded protein response and cell death after depletion of brefeldin A-inhibited guanine nucleotide-exchange protein GBF1. Proc. Natl. Acad. Sci. USA 105 , 2877–2882 (2008). 18287014 10.1073/pnas.0712224105 PMC2268553

377. Mollenhauer HH Morre DJ Rowe LD Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity Biochim Biophys. Acta 1990 1031 225 246 10.1016/0304-4157(90)90008-Z 2160275 PMC7148783 Mollenhauer, H. H., Morre, D. J. & Rowe, L. D. Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys. Acta 1031 , 225–246 (1990). 2160275 10.1016/0304-4157(90)90008-Z PMC7148783

378. Halbleib K Activation of the Unfolded Protein Response by Lipid Bilayer Stress Mol. Cell 2017 67 673 684.e678 10.1016/j.molcel.2017.06.012 28689662 Halbleib, K. et al. Activation of the Unfolded Protein Response by Lipid Bilayer Stress. Mol. Cell 67 , 673–684.e678 (2017). 28689662 10.1016/j.molcel.2017.06.012

379. Koh, J. H., Wang, L., Beaudoin-Chabot, C. & Thibault, G. Lipid bilayer stress-activated IRE-1 modulates autophagy during endoplasmic reticulum stress. J. Cell Sci . 131 , jcs217992 (2018). 10.1242/jcs.217992 30333136

380. Chiti F Dobson CM Protein misfolding, functional amyloid, and human disease Annu Rev. Biochem 2006 75 333 366 10.1146/annurev.biochem.75.101304.123901 16756495 Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu Rev. Biochem 75 , 333–366 (2006). 16756495 10.1146/annurev.biochem.75.101304.123901

381. Almeida, Z. L. & Brito, R. M. M. Structure and aggregation mechanisms in amyloids. Molecules 25 , 1195 (2020). 10.3390/molecules25051195 PMC7179426 32155822

382. Chiti F Dobson CM Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade Annu Rev. Biochem 2017 86 27 68 10.1146/annurev-biochem-061516-045115 28498720 Chiti, F. & Dobson, C. M. Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annu Rev. Biochem 86 , 27–68 (2017). 28498720 10.1146/annurev-biochem-061516-045115

383. Li D Liu C Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases Nat. Rev. Neurosci. 2022 23 523 534 10.1038/s41583-022-00603-7 35637417 Li, D. & Liu, C. Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. Nat. Rev. Neurosci. 23 , 523–534 (2022). 35637417 10.1038/s41583-022-00603-7

384. Powers ET Biological and chemical approaches to diseases of proteostasis deficiency Annu Rev. Biochem 2009 78 959 991 10.1146/annurev.biochem.052308.114844 19298183 Powers, E. T. et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev. Biochem 78 , 959–991 (2009). 19298183 10.1146/annurev.biochem.052308.114844

385. Reid DW Nicchitta CV Diversity and selectivity in mRNA translation on the endoplasmic reticulum Nat. Rev. Mol. Cell Biol. 2015 16 221 231 10.1038/nrm3958 25735911 PMC4494666 Reid, D. W. & Nicchitta, C. V. Diversity and selectivity in mRNA translation on the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 16 , 221–231 (2015). 25735911 10.1038/nrm3958 PMC4494666

386. Uhlen M Proteomics. Tissue-based map of the human proteome Science 2015 347 1260419 10.1126/science.1260419 25613900 Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347 , 1260419 (2015). 25613900 10.1126/science.1260419

387. Morimoto RI The heat shock response: systems biology of proteotoxic stress in aging and disease Cold Spring Harb. Symp. Quant. Biol. 2011 76 91 99 10.1101/sqb.2012.76.010637 22371371 Morimoto, R. I. The heat shock response: systems biology of proteotoxic stress in aging and disease. Cold Spring Harb. Symp. Quant. Biol. 76 , 91–99 (2011). 22371371 10.1101/sqb.2012.76.010637

388. Richter K Haslbeck M Buchner J The heat shock response: life on the verge of death Mol. Cell 2010 40 253 266 10.1016/j.molcel.2010.10.006 20965420 Richter, K., Haslbeck, M. & Buchner, J. The heat shock response: life on the verge of death. Mol. Cell 40 , 253–266 (2010). 20965420 10.1016/j.molcel.2010.10.006

389. Li J Labbadia J Morimoto RI Rethinking HSF1 in stress, development, and organismal health Trends Cell Biol. 2017 27 895 905 10.1016/j.tcb.2017.08.002 28890254 PMC5696061 Li, J., Labbadia, J. & Morimoto, R. I. Rethinking HSF1 in stress, development, and organismal health. Trends Cell Biol. 27 , 895–905 (2017). 28890254 10.1016/j.tcb.2017.08.002 PMC5696061

390. Dayalan Naidu S Dinkova-Kostova AT Regulation of the mammalian heat shock factor 1 FEBS J. 2017 284 1606 1627 10.1111/febs.13999 28052564 Dayalan Naidu, S. & Dinkova-Kostova, A. T. Regulation of the mammalian heat shock factor 1. FEBS J. 284 , 1606–1627 (2017). 28052564 10.1111/febs.13999

391. Gomez-Pastor R Burchfiel ET Thiele DJ Regulation of heat shock transcription factors and their roles in physiology and disease Nat. Rev. Mol. Cell Biol. 2018 19 4 19 10.1038/nrm.2017.73 28852220 PMC5794010 Gomez-Pastor, R., Burchfiel, E. T. & Thiele, D. J. Regulation of heat shock transcription factors and their roles in physiology and disease. Nat. Rev. Mol. Cell Biol. 19 , 4–19 (2018). 28852220 10.1038/nrm.2017.73 PMC5794010

392. Alford BD Brandman O Quantification of Hsp90 availability reveals differential coupling to the heat shock response J. Cell Biol. 2018 217 3809 3816 10.1083/jcb.201803127 30131327 PMC6219726 Alford, B. D. & Brandman, O. Quantification of Hsp90 availability reveals differential coupling to the heat shock response. J. Cell Biol. 217 , 3809–3816 (2018). 30131327 10.1083/jcb.201803127 PMC6219726

393. Humburg P Characterisation of the global transcriptional response to heat shock and the impact of individual genetic variation Genome Med 2016 8 87 10.1186/s13073-016-0345-5 27553423 PMC4995779 Humburg, P. et al. Characterisation of the global transcriptional response to heat shock and the impact of individual genetic variation. Genome Med 8 , 87 (2016). 27553423 10.1186/s13073-016-0345-5 PMC4995779

394. Akerfelt M Morimoto RI Sistonen L Heat shock factors: integrators of cell stress, development and lifespan Nat. Rev. Mol. Cell Biol. 2010 11 545 555 10.1038/nrm2938 20628411 PMC3402356 Akerfelt, M., Morimoto, R. I. & Sistonen, L. Heat shock factors: integrators of cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 11 , 545–555 (2010). 20628411 10.1038/nrm2938 PMC3402356

395. Joutsen, J. & Sistonen, L. Tailoring of proteostasis networks with heat shock factors. Cold Spring Harb Perspect Biol . 11 , a034066 (2019). 10.1101/cshperspect.a034066 PMC6442201 30420555

396. Tang Z MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1 Cell 2015 160 729 744 10.1016/j.cell.2015.01.028 25679764 PMC4564124 Tang, Z. et al. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1. Cell 160 , 729–744 (2015). 25679764 10.1016/j.cell.2015.01.028 PMC4564124

397. Morrison SF Central neural control of thermoregulation and brown adipose tissue Auton. Neurosci. 2016 196 14 24 10.1016/j.autneu.2016.02.010 26924538 PMC4846468 Morrison, S. F. Central neural control of thermoregulation and brown adipose tissue. Auton. Neurosci. 196 , 14–24 (2016). 26924538 10.1016/j.autneu.2016.02.010 PMC4846468

398. Douglas PM Heterotypic Signals from Neural HSF-1 Separate Thermotolerance from Longevity Cell Rep. 2015 12 1196 1204 10.1016/j.celrep.2015.07.026 26257177 PMC4889220 Douglas, P. M. et al. Heterotypic Signals from Neural HSF-1 Separate Thermotolerance from Longevity. Cell Rep. 12 , 1196–1204 (2015). 26257177 10.1016/j.celrep.2015.07.026 PMC4889220

399. Gildea HK Glia of C. elegans coordinate a protective organismal heat shock response independent of the neuronal thermosensory circuit Sci. Adv. 2022 8 eabq3970 10.1126/sciadv.abq3970 36490338 PMC9733925 Gildea, H. K. et al. Glia of C. elegans coordinate a protective organismal heat shock response independent of the neuronal thermosensory circuit. Sci. Adv. 8 , eabq3970 (2022). 36490338 10.1126/sciadv.abq3970 PMC9733925

400. Sala AJ Bott LC Brielmann RM Morimoto RI Embryo integrity regulates maternal proteostasis and stress resilience Genes Dev. 2020 34 678 687 10.1101/gad.335422.119 32217667 PMC7197353 Sala, A. J., Bott, L. C., Brielmann, R. M. & Morimoto, R. I. Embryo integrity regulates maternal proteostasis and stress resilience. Genes Dev. 34 , 678–687 (2020). 32217667 10.1101/gad.335422.119 PMC7197353

401. van Oosten-Hawle P Porter RS Morimoto RI Regulation of organismal proteostasis by transcellular chaperone signaling Cell 2013 153 1366 1378 10.1016/j.cell.2013.05.015 23746847 PMC3955170 van Oosten-Hawle, P., Porter, R. S. & Morimoto, R. I. Regulation of organismal proteostasis by transcellular chaperone signaling. Cell 153 , 1366–1378 (2013). 23746847 10.1016/j.cell.2013.05.015 PMC3955170

402. van Oosten-Hawle P Morimoto RI Transcellular chaperone signaling: an organismal strategy for integrated cell stress responses J. Exp. Biol. 2014 217 129 136 10.1242/jeb.091249 24353212 PMC3867495 van Oosten-Hawle, P. & Morimoto, R. I. Transcellular chaperone signaling: an organismal strategy for integrated cell stress responses. J. Exp. Biol. 217 , 129–136 (2014). 24353212 10.1242/jeb.091249 PMC3867495

403. Preissler, S. & Ron, D. Early events in the endoplasmic reticulum unfolded protein response. Cold Spring Harb Perspect Biol . 11 , a033894 (2019). 10.1101/cshperspect.a033894 PMC6442202 30396883

404. Hetz C Zhang K Kaufman RJ Mechanisms, regulation and functions of the unfolded protein response Nat. Rev. Mol. Cell Biol. 2020 21 421 438 10.1038/s41580-020-0250-z 32457508 PMC8867924 Hetz, C., Zhang, K. & Kaufman, R. J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 21 , 421–438 (2020). 32457508 10.1038/s41580-020-0250-z PMC8867924

405. Brewer JW Regulatory crosstalk within the mammalian unfolded protein response Cell Mol. Life Sci. 2014 71 1067 1079 10.1007/s00018-013-1490-2 24135849 PMC11113126 Brewer, J. W. Regulatory crosstalk within the mammalian unfolded protein response. Cell Mol. Life Sci. 71 , 1067–1079 (2014). 24135849 10.1007/s00018-013-1490-2 PMC11113126

406. Shen J Snapp EL Lippincott-Schwartz J Prywes R Stable binding of ATF6 to BiP in the endoplasmic reticulum stress response Mol. Cell Biol. 2005 25 921 932 10.1128/MCB.25.3.921-932.2005 15657421 PMC543992 Shen, J., Snapp, E. L., Lippincott-Schwartz, J. & Prywes, R. Stable binding of ATF6 to BiP in the endoplasmic reticulum stress response. Mol. Cell Biol. 25 , 921–932 (2005). 15657421 10.1128/MCB.25.3.921-932.2005 PMC543992

407. Chen Y Brandizzi F IRE1: ER stress sensor and cell fate executor Trends Cell Biol. 2013 23 547 555 10.1016/j.tcb.2013.06.005 23880584 PMC3818365 Chen, Y. & Brandizzi, F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 23 , 547–555 (2013). 23880584 10.1016/j.tcb.2013.06.005 PMC3818365

408. Ali MM Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response EMBO J. 2011 30 894 905 10.1038/emboj.2011.18 21317875 PMC3049214 Ali, M. M. et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 30 , 894–905 (2011). 21317875 10.1038/emboj.2011.18 PMC3049214

409. Grey, M. J. et al. IRE1beta negatively regulates IRE1alpha signaling in response to endoplasmic reticulum stress. J Cell Biol . 219 , e201904048 (2020). 10.1083/jcb.201904048 PMC7041686 31985747

410. Karagoz, G. E. et al. An unfolded protein-induced conformational switch activates mammalian IRE1. Elife . 6 , e30700 (2017). 10.7554/eLife.30700 PMC5699868 28971800

411. Belyy, V. et al. Endoplasmic reticulum stress activates human IRE1alpha through reversible assembly of inactive dimers into small oligomers. Elife . 11 , e74342 (2022). 10.7554/eLife.74342 PMC9217129 35730415

412. Tam AB Koong AC Niwa M Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD Cell Rep. 2014 9 850 858 10.1016/j.celrep.2014.09.016 25437541 PMC4486022 Tam, A. B., Koong, A. C. & Niwa, M. Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD. Cell Rep. 9 , 850–858 (2014). 25437541 10.1016/j.celrep.2014.09.016 PMC4486022

413. Volmer R van der Ploeg K Ron D Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains Proc. Natl. Acad. Sci. USA 2013 110 4628 4633 10.1073/pnas.1217611110 23487760 PMC3606975 Volmer, R., van der Ploeg, K. & Ron, D. Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc. Natl. Acad. Sci. USA 110 , 4628–4633 (2013). 23487760 10.1073/pnas.1217611110 PMC3606975

414. Martinon F Chen X Lee AH Glimcher LH TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages Nat. Immunol. 2010 11 411 418 10.1038/ni.1857 20351694 PMC3113706 Martinon, F., Chen, X., Lee, A. H. & Glimcher, L. H. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat. Immunol. 11 , 411–418 (2010). 20351694 10.1038/ni.1857 PMC3113706

415. Savic S TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes J. Autoimmun. 2014 50 59 66 10.1016/j.jaut.2013.11.002 24387801 PMC4012140 Savic, S. et al. TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. J. Autoimmun. 50 , 59–66 (2014). 24387801 10.1016/j.jaut.2013.11.002 PMC4012140

416. Lv X Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors Science 2023 381 eabn4180 10.1126/science.abn4180 37676964 PMC10720158 Lv, X. et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381 , eabn4180 (2023). 37676964 10.1126/science.abn4180 PMC10720158

417. Quwaider D RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation Exp. Hematol. Oncol. 2022 11 18 10.1186/s40164-022-00271-4 35361260 PMC8969279 Quwaider, D. et al. RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation. Exp. Hematol. Oncol. 11 , 18 (2022). 35361260 10.1186/s40164-022-00271-4 PMC8969279

418. Maurel M Chevet E Tavernier J Gerlo S Getting RIDD of RNA: IRE1 in cell fate regulation Trends Biochem Sci. 2014 39 245 254 10.1016/j.tibs.2014.02.008 24657016 Maurel, M., Chevet, E., Tavernier, J. & Gerlo, S. Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem Sci. 39 , 245–254 (2014). 24657016 10.1016/j.tibs.2014.02.008

419. Papaioannou, A. et al. Stress-induced tyrosine phosphorylation of RtcB modulates IRE1 activity and signaling outputs. Life Sci. Alliance 5 , e202201379 (2022). 10.26508/lsa.202201379 PMC8899846 35193953

420. Yoshida H Oku M Suzuki M Mori K pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response J. Cell Biol. 2006 172 565 575 10.1083/jcb.200508145 16461360 PMC2063676 Yoshida, H., Oku, M., Suzuki, M. & Mori, K. pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. J. Cell Biol. 172 , 565–575 (2006). 16461360 10.1083/jcb.200508145 PMC2063676

421. Yamamoto K Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-II J. Biochem 2004 136 343 350 10.1093/jb/mvh122 15598891 Yamamoto, K. et al. Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-II. J. Biochem 136 , 343–350 (2004). 15598891 10.1093/jb/mvh122

422. Lee AH Iwakoshi NN Glimcher LH XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response Mol. Cell Biol. 2003 23 7448 7459 10.1128/MCB.23.21.7448-7459.2003 14559994 PMC207643 Lee, A. H., Iwakoshi, N. N. & Glimcher, L. H. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol. Cell Biol. 23 , 7448–7459 (2003). 14559994 10.1128/MCB.23.21.7448-7459.2003 PMC207643

423. Adamson B A multiplexed single-cell crispr screening platform enables systematic dissection of the unfolded protein response Cell 2016 167 1867 1882.e1821 10.1016/j.cell.2016.11.048 27984733 PMC5315571 Adamson, B. et al. A multiplexed single-cell crispr screening platform enables systematic dissection of the unfolded protein response. Cell 167 , 1867–1882.e1821 (2016). 27984733 10.1016/j.cell.2016.11.048 PMC5315571

424. Reimold AM Plasma cell differentiation requires the transcription factor XBP-1 Nature 2001 412 300 307 10.1038/35085509 11460154 Reimold, A. M. et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412 , 300–307 (2001). 11460154 10.1038/35085509

425. Urano F Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1 Science 2000 287 664 666 10.1126/science.287.5453.664 10650002 Urano, F. et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287 , 664–666 (2000). 10650002 10.1126/science.287.5453.664

426. Nishitoh H ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats Genes Dev. 2002 16 1345 1355 10.1101/gad.992302 12050113 PMC186318 Nishitoh, H. et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 16 , 1345–1355 (2002). 12050113 10.1101/gad.992302 PMC186318

427. Yang Q Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNK EMBO Rep. 2006 7 622 627 10.1038/sj.embor.7400687 16680093 PMC1479600 Yang, Q. et al. Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNK. EMBO Rep. 7 , 622–627 (2006). 16680093 10.1038/sj.embor.7400687 PMC1479600

428. Dhanasekaran DN Reddy EP JNK signaling in apoptosis Oncogene 2008 27 6245 6251 10.1038/onc.2008.301 18931691 PMC3063296 Dhanasekaran, D. N. & Reddy, E. P. JNK signaling in apoptosis. Oncogene 27 , 6245–6251 (2008). 18931691 10.1038/onc.2008.301 PMC3063296

429. Tabas I Ron D Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress Nat. Cell Biol. 2011 13 184 190 10.1038/ncb0311-184 21364565 PMC3107571 Tabas, I. & Ron, D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13 , 184–190 (2011). 21364565 10.1038/ncb0311-184 PMC3107571

430. Xu Z miR-216b regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis Nat. Commun. 2016 7 11422 10.1038/ncomms11422 27173017 PMC4869177 Xu, Z. et al. miR-216b regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis. Nat. Commun. 7 , 11422 (2016). 27173017 10.1038/ncomms11422 PMC4869177

431. Rutkowski DT UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators Dev. Cell 2008 15 829 840 10.1016/j.devcel.2008.10.015 19081072 PMC2923556 Rutkowski, D. T. et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev. Cell 15 , 829–840 (2008). 19081072 10.1016/j.devcel.2008.10.015 PMC2923556

432. Nguyen DT Nck-dependent activation of extracellular signal-regulated kinase-1 and regulation of cell survival during endoplasmic reticulum stress Mol. Biol. Cell 2004 15 4248 4260 10.1091/mbc.e03-11-0851 15201339 PMC515356 Nguyen, D. T. et al. Nck-dependent activation of extracellular signal-regulated kinase-1 and regulation of cell survival during endoplasmic reticulum stress. Mol. Biol. Cell 15 , 4248–4260 (2004). 15201339 10.1091/mbc.E03-11-0851 PMC515356

433. Chaudhari N A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress Front Cell Neurosci. 2014 8 213 10.3389/fncel.2014.00213 25120434 PMC4114208 Chaudhari, N. et al. A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci. 8 , 213 (2014). 25120434 10.3389/fncel.2014.00213 PMC4114208

434. Zhu X Ubiquitination of inositol-requiring enzyme 1 (IRE1) by the E3 ligase CHIP mediates the IRE1/TRAF2/JNK pathway J. Biol. Chem. 2014 289 30567 30577 10.1074/jbc.M114.562868 25225294 PMC4215236 Zhu, X. et al. Ubiquitination of inositol-requiring enzyme 1 (IRE1) by the E3 ligase CHIP mediates the IRE1/TRAF2/JNK pathway. J. Biol. Chem. 289 , 30567–30577 (2014). 25225294 10.1074/jbc.M114.562868 PMC4215236

435. Hourihan JM Moronetti Mazzeo LE Fernandez-Cardenas LP Blackwell TK Cysteine Sulfenylation Directs IRE-1 to Activate the SKN-1/Nrf2 Antioxidant Response Mol. Cell 2016 63 553 566 10.1016/j.molcel.2016.07.019 27540856 PMC4996358 Hourihan, J. M., Moronetti Mazzeo, L. E., Fernandez-Cardenas, L. P. & Blackwell, T. K. Cysteine Sulfenylation Directs IRE-1 to Activate the SKN-1/Nrf2 Antioxidant Response. Mol. Cell 63 , 553–566 (2016). 27540856 10.1016/j.molcel.2016.07.019 PMC4996358

436. Bobrovnikova-Marjon E PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation Mol. Cell Biol. 2012 32 2268 2278 10.1128/MCB.00063-12 22493067 PMC3372262 Bobrovnikova-Marjon, E. et al. PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation. Mol. Cell Biol. 32 , 2268–2278 (2012). 22493067 10.1128/MCB.00063-12 PMC3372262

437. Wang P Li J Tao J Sha B The luminal domain of the ER stress sensor protein PERK binds misfolded proteins and thereby triggers PERK oligomerization J. Biol. Chem. 2018 293 4110 4121 10.1074/jbc.RA117.001294 29386355 PMC5857997 Wang, P., Li, J., Tao, J. & Sha, B. The luminal domain of the ER stress sensor protein PERK binds misfolded proteins and thereby triggers PERK oligomerization. J. Biol. Chem. 293 , 4110–4121 (2018). 29386355 10.1074/jbc.RA117.001294 PMC5857997

438. Komar, A. A. & Merrick, W. C. A Retrospective on eIF2A-and Not the Alpha Subunit of eIF2. Int. J. Mol. Sci . 21 , 2054 (2020). 10.3390/ijms21062054 PMC7139343 32192132

439. Hinnebusch AG Structural insights into the mechanism of scanning and start codon recognition in eukaryotic translation initiation Trends Biochem Sci. 2017 42 589 611 10.1016/j.tibs.2017.03.004 28442192 Hinnebusch, A. G. Structural insights into the mechanism of scanning and start codon recognition in eukaryotic translation initiation. Trends Biochem Sci. 42 , 589–611 (2017). 28442192 10.1016/j.tibs.2017.03.004

440. Jackson RJ Hellen CU Pestova TV The mechanism of eukaryotic translation initiation and principles of its regulation Nat. Rev. Mol. Cell Biol. 2010 11 113 127 10.1038/nrm2838 20094052 PMC4461372 Jackson, R. J., Hellen, C. U. & Pestova, T. V. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 11 , 113–127 (2010). 20094052 10.1038/nrm2838 PMC4461372

441. Proud CG eIF2 and the control of cell physiology Semin Cell Dev. Biol. 2005 16 3 12 10.1016/j.semcdb.2004.11.004 15659334 Proud, C. G. eIF2 and the control of cell physiology. Semin Cell Dev. Biol. 16 , 3–12 (2005). 15659334 10.1016/j.semcdb.2004.11.004

442. Harding HP Regulated translation initiation controls stress-induced gene expression in mammalian cells Mol. Cell 2000 6 1099 1108 10.1016/S1097-2765(00)00108-8 11106749 Harding, H. P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6 , 1099–1108 (2000). 11106749 10.1016/s1097-2765(00)00108-8

443. Lee YY Cevallos RC Jan E An upstream open reading frame regulates translation of GADD34 during cellular stresses that induce eIF2alpha phosphorylation J. Biol. Chem. 2009 284 6661 6673 10.1074/jbc.M806735200 19131336 PMC2652341 Lee, Y. Y., Cevallos, R. C. & Jan, E. An upstream open reading frame regulates translation of GADD34 during cellular stresses that induce eIF2alpha phosphorylation. J. Biol. Chem. 284 , 6661–6673 (2009). 19131336 10.1074/jbc.M806735200 PMC2652341

444. Palam LR Baird TD Wek RC Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation J. Biol. Chem. 2011 286 10939 10949 10.1074/jbc.M110.216093 21285359 PMC3064149 Palam, L. R., Baird, T. D. & Wek, R. C. Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. J. Biol. Chem. 286 , 10939–10949 (2011). 21285359 10.1074/jbc.M110.216093 PMC3064149

445. D’Antonio M Resetting translational homeostasis restores myelination in Charcot-Marie-Tooth disease type 1B mice J. Exp. Med 2013 210 821 838 10.1084/jem.20122005 23547100 PMC3620355 D’Antonio, M. et al. Resetting translational homeostasis restores myelination in Charcot-Marie-Tooth disease type 1B mice. J. Exp. Med 210 , 821–838 (2013). 23547100 10.1084/jem.20122005 PMC3620355

446. Boyce M A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress Science 2005 307 935 939 10.1126/science.1101902 15705855 Boyce, M. et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307 , 935–939 (2005). 15705855 10.1126/science.1101902

447. Han J ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death Nat. Cell Biol. 2013 15 481 490 10.1038/ncb2738 23624402 PMC3692270 Han, J. et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat. Cell Biol. 15 , 481–490 (2013). 23624402 10.1038/ncb2738 PMC3692270

448. Neill G Masson GR A stay of execution: ATF4 regulation and potential outcomes for the integrated stress response Front Mol. Neurosci. 2023 16 1112253 10.3389/fnmol.2023.1112253 36825279 PMC9941348 Neill, G. & Masson, G. R. A stay of execution: ATF4 regulation and potential outcomes for the integrated stress response. Front Mol. Neurosci. 16 , 1112253 (2023). 36825279 10.3389/fnmol.2023.1112253 PMC9941348

449. Bingle CD Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death J. Biol. Chem. 2000 275 22136 22146 10.1074/jbc.M909572199 10766760 Bingle, C. D. et al. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J. Biol. Chem. 275 , 22136–22146 (2000). 10766760 10.1074/jbc.M909572199

450. Song B Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes J. Clin. Invest 2008 118 3378 3389 10.1172/JCI34587 18776938 PMC2528909 Song, B. et al. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J. Clin. Invest 118 , 3378–3389 (2008). 18776938 10.1172/JCI34587 PMC2528909

451. Lin JH IRE1 signaling affects cell fate during the unfolded protein response Science 2007 318 944 949 10.1126/science.1146361 17991856 PMC3670588 Lin, J. H. et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 318 , 944–949 (2007). 17991856 10.1126/science.1146361 PMC3670588

452. Ohoka N TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death EMBO J. 2005 24 1243 1255 10.1038/sj.emboj.7600596 15775988 PMC556400 Ohoka, N. et al. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 24 , 1243–1255 (2005). 15775988 10.1038/sj.emboj.7600596 PMC556400

453. Cullinan SB Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival Mol. Cell Biol. 2003 23 7198 7209 10.1128/MCB.23.20.7198-7209.2003 14517290 PMC230321 Cullinan, S. B. et al. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell Biol. 23 , 7198–7209 (2003). 14517290 10.1128/MCB.23.20.7198-7209.2003 PMC230321

454. Kress JKC The integrated stress response effector ATF4 is an obligatory metabolic activator of NRF2 Cell Rep. 2023 42 112724 10.1016/j.celrep.2023.112724 37410595 Kress, J. K. C. et al. The integrated stress response effector ATF4 is an obligatory metabolic activator of NRF2. Cell Rep. 42 , 112724 (2023). 37410595 10.1016/j.celrep.2023.112724

455. Ma Q Role of nrf2 in oxidative stress and toxicity Annu Rev. Pharm. Toxicol. 2013 53 401 426 10.1146/annurev-pharmtox-011112-140320 PMC4680839 23294312 Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev. Pharm. Toxicol. 53 , 401–426 (2013). 10.1146/annurev-pharmtox-011112-140320 PMC4680839 23294312

456. Jiang HY Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses Mol. Cell Biol. 2003 23 5651 5663 10.1128/MCB.23.16.5651-5663.2003 12897138 PMC166326 Jiang, H. Y. et al. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol. Cell Biol. 23 , 5651–5663 (2003). 12897138 10.1128/MCB.23.16.5651-5663.2003 PMC166326

457. Li W Phosphorylation of LAMP2A by p38 MAPK couples ER stress to chaperone-mediated autophagy Nat. Commun. 2017 8 1763 10.1038/s41467-017-01609-x 29176575 PMC5701254 Li, W. et al. Phosphorylation of LAMP2A by p38 MAPK couples ER stress to chaperone-mediated autophagy. Nat. Commun. 8 , 1763 (2017). 29176575 10.1038/s41467-017-01609-x PMC5701254

458. Higa A Endoplasmic reticulum stress-activated transcription factor ATF6alpha requires the disulfide isomerase PDIA5 to modulate chemoresistance Mol. Cell Biol. 2014 34 1839 1849 10.1128/MCB.01484-13 24636989 PMC4019026 Higa, A. et al. Endoplasmic reticulum stress-activated transcription factor ATF6alpha requires the disulfide isomerase PDIA5 to modulate chemoresistance. Mol. Cell Biol. 34 , 1839–1849 (2014). 24636989 10.1128/MCB.01484-13 PMC4019026

459. Teske BF The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress Mol. Biol. Cell 2011 22 4390 4405 10.1091/mbc.e11-06-0510 21917591 PMC3216664 Teske, B. F. et al. The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Mol. Biol. Cell 22 , 4390–4405 (2011). 21917591 10.1091/mbc.E11-06-0510 PMC3216664

460. Shaffer AL XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation Immunity 2004 21 81 93 10.1016/j.immuni.2004.06.010 15345222 Shaffer, A. L. et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21 , 81–93 (2004). 15345222 10.1016/j.immuni.2004.06.010

461. Schewe DM Aguirre-Ghiso JA ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo Proc. Natl. Acad. Sci. USA 2008 105 10519 10524 10.1073/pnas.0800939105 18650380 PMC2492459 Schewe, D. M. & Aguirre-Ghiso, J. A. ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc. Natl. Acad. Sci. USA 105 , 10519–10524 (2008). 18650380 10.1073/pnas.0800939105 PMC2492459

462. Wu J ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress Dev. Cell 2007 13 351 364 10.1016/j.devcel.2007.07.005 17765679 Wu, J. et al. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev. Cell 13 , 351–364 (2007). 17765679 10.1016/j.devcel.2007.07.005

463. Jin JK ATF6 Decreases Myocardial Ischemia/Reperfusion Damage and Links ER Stress and Oxidative Stress Signaling Pathways in the Heart Circ. Res 2017 120 862 875 10.1161/CIRCRESAHA.116.310266 27932512 PMC5336510 Jin, J. K. et al. ATF6 Decreases Myocardial Ischemia/Reperfusion Damage and Links ER Stress and Oxidative Stress Signaling Pathways in the Heart. Circ. Res 120 , 862–875 (2017). 27932512 10.1161/CIRCRESAHA.116.310266 PMC5336510

464. Yamazaki H Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response J. Immunol. 2009 183 1480 1487 10.4049/jimmunol.0900017 19561103 PMC2762936 Yamazaki, H. et al. Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. J. Immunol. 183 , 1480–1487 (2009). 19561103 10.4049/jimmunol.0900017 PMC2762936

465. Pfanner N Warscheid B Wiedemann N Mitochondrial proteins: from biogenesis to functional networks Nat. Rev. Mol. Cell Biol. 2019 20 267 284 10.1038/s41580-018-0092-0 30626975 PMC6684368 Pfanner, N., Warscheid, B. & Wiedemann, N. Mitochondrial proteins: from biogenesis to functional networks. Nat. Rev. Mol. Cell Biol. 20 , 267–284 (2019). 30626975 10.1038/s41580-018-0092-0 PMC6684368

466. Song J Herrmann JM Becker T Quality control of the mitochondrial proteome Nat. Rev. Mol. Cell Biol. 2021 22 54 70 10.1038/s41580-020-00300-2 33093673 Song, J., Herrmann, J. M. & Becker, T. Quality control of the mitochondrial proteome. Nat. Rev. Mol. Cell Biol. 22 , 54–70 (2021). 33093673 10.1038/s41580-020-00300-2

467. Eckl EM Sensing, signaling and surviving mitochondrial stress Cell Mol. Life Sci. 2021 78 5925 5951 10.1007/s00018-021-03887-7 34228161 PMC8316193 Eckl, E. M. et al. Sensing, signaling and surviving mitochondrial stress. Cell Mol. Life Sci. 78 , 5925–5951 (2021). 34228161 10.1007/s00018-021-03887-7 PMC8316193

468. Liao PC Mitochondria-associated degradation pathway (MAD) function beyond the outer membrane Cell Rep. 2020 32 107902 10.1016/j.celrep.2020.107902 32668258 PMC7391283 Liao, P. C. et al. Mitochondria-associated degradation pathway (MAD) function beyond the outer membrane. Cell Rep. 32 , 107902 (2020). 32668258 10.1016/j.celrep.2020.107902 PMC7391283

469. Martensson CU Mitochondrial protein translocation-associated degradation Nature 2019 569 679 683 10.1038/s41586-019-1227-y 31118508 Martensson, C. U. et al. Mitochondrial protein translocation-associated degradation. Nature 569 , 679–683 (2019). 31118508 10.1038/s41586-019-1227-y

470. Wang X Chen XJ A cytosolic network suppressing mitochondria-mediated proteostatic stress and cell death Nature 2015 524 481 484 10.1038/nature14859 26192197 PMC4582408 Wang, X. & Chen, X. J. A cytosolic network suppressing mitochondria-mediated proteostatic stress and cell death. Nature 524 , 481–484 (2015). 26192197 10.1038/nature14859 PMC4582408

471. Wrobel L Mistargeted mitochondrial proteins activate a proteostatic response in the cytosol Nature 2015 524 485 488 10.1038/nature14951 26245374 Wrobel, L. et al. Mistargeted mitochondrial proteins activate a proteostatic response in the cytosol. Nature 524 , 485–488 (2015). 26245374 10.1038/nature14951

472. Weidberg, H. & Amon, A. MitoCPR-A surveillance pathway that protects mitochondria in response to protein import stress. Science 360 , eaan4146 (2018). 10.1126/science.aan4146 PMC6528467 29650645

473. Replogle JM Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq Cell 2022 185 2559 2575.e2528 10.1016/j.cell.2022.05.013 35688146 PMC9380471 Replogle, J. M. et al. Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell 185 , 2559–2575.e2528 (2022). 35688146 10.1016/j.cell.2022.05.013 PMC9380471

474. Gao F A defect in mitochondrial protein translation influences mitonuclear communication in the heart Nat. Commun. 2023 14 1595 10.1038/s41467-023-37291-5 36949106 PMC10033703 Gao, F. et al. A defect in mitochondrial protein translation influences mitonuclear communication in the heart. Nat. Commun. 14 , 1595 (2023). 36949106 10.1038/s41467-023-37291-5 PMC10033703

475. Ishimura, R. et al. Activation of GCN2 kinase by ribosome stalling links translation elongation with translation initiation. Elife 5 , e14295 (2016). 10.7554/eLife.14295 PMC4917338 27085088

476. Quiros PM Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals J. Cell Biol. 2017 216 2027 2045 10.1083/jcb.201702058 28566324 PMC5496626 Quiros, P. M. et al. Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals. J. Cell Biol. 216 , 2027–2045 (2017). 28566324 10.1083/jcb.201702058 PMC5496626

477. Guo X Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway Nature 2020 579 427 432 10.1038/s41586-020-2078-2 32132707 PMC7147832 Guo, X. et al. Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway. Nature 579 , 427–432 (2020). 32132707 10.1038/s41586-020-2078-2 PMC7147832

478. Zhao Q A mitochondrial specific stress response in mammalian cells EMBO J. 2002 21 4411 4419 10.1093/emboj/cdf445 12198143 PMC126185 Zhao, Q. et al. A mitochondrial specific stress response in mammalian cells. EMBO J. 21 , 4411–4419 (2002). 12198143 10.1093/emboj/cdf445 PMC126185

479. Fiorese CJ The transcription factor ATF5 mediates a mammalian mitochondrial UPR Curr. Biol. 2016 26 2037 2043 10.1016/j.cub.2016.06.002 27426517 PMC4980197 Fiorese, C. J. et al. The transcription factor ATF5 mediates a mammalian mitochondrial UPR. Curr. Biol. 26 , 2037–2043 (2016). 27426517 10.1016/j.cub.2016.06.002 PMC4980197

480. Sutandy FXR Gossner I Tascher G Munch C A cytosolic surveillance mechanism activates the mitochondrial UPR Nature 2023 618 849 854 10.1038/s41586-023-06142-0 37286597 PMC10284689 Sutandy, F. X. R., Gossner, I., Tascher, G. & Munch, C. A cytosolic surveillance mechanism activates the mitochondrial UPR. Nature 618 , 849–854 (2023). 37286597 10.1038/s41586-023-06142-0 PMC10284689

481. Kusuma, F. et al. PKR mediates the mitochondrial unfolded protein response through double-stranded RNA accumulation under mitochondrial stress. Int. J. Mol. Sci . 25 , 7738 (2024). 10.3390/ijms25147738 PMC11276775 39062980

482. Munch C The different axes of the mammalian mitochondrial unfolded protein response BMC Biol. 2018 16 81 10.1186/s12915-018-0548-x 30049264 PMC6060479 Munch, C. The different axes of the mammalian mitochondrial unfolded protein response. BMC Biol. 16 , 81 (2018). 30049264 10.1186/s12915-018-0548-x PMC6060479

483. Li TY Lysosomes mediate the mitochondrial UPR via mTORC1-dependent ATF4 phosphorylation Cell Discov. 2023 9 92 10.1038/s41421-023-00589-1 37679337 PMC10484937 Li, T. Y. et al. Lysosomes mediate the mitochondrial UPR via mTORC1-dependent ATF4 phosphorylation. Cell Discov. 9 , 92 (2023). 37679337 10.1038/s41421-023-00589-1 PMC10484937

484. Evaluation, I. f. H. M. a. GBD Compare http://vizhub.healthdata.org/gbd-compare (2021).

485. Scheltens P Alzheimer’s disease Lancet 2021 397 1577 1590 10.1016/S0140-6736(20)32205-4 33667416 PMC8354300 Scheltens, P. et al. Alzheimer’s disease. Lancet 397 , 1577–1590 (2021). 33667416 10.1016/S0140-6736(20)32205-4 PMC8354300

486. Jansen IE Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk Nat. Genet 2019 51 404 413 10.1038/s41588-018-0311-9 30617256 PMC6836675 Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet 51 , 404–413 (2019). 30617256 10.1038/s41588-018-0311-9 PMC6836675

487. Neugroschl, J. BMJ Best Practice - Alzheimer’s disease https://bestpractice.bmj.com/topics/en-gb/317 (2023).

488. Jack CR Jr. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease Alzheimers Dement 2018 14 535 562 10.1016/j.jalz.2018.02.018 29653606 PMC5958625 Jack, C. R. Jr. et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14 , 535–562 (2018). 29653606 10.1016/j.jalz.2018.02.018 PMC5958625

489. Chen GF Amyloid beta: structure, biology and structure-based therapeutic development Acta Pharm. Sin. 2017 38 1205 1235 10.1038/aps.2017.28 PMC5589967 28713158 Chen, G. F. et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharm. Sin. 38 , 1205–1235 (2017). 10.1038/aps.2017.28 PMC5589967 28713158

490. Díaz-Nido, J., Avila, J., Davies, R. W. & Morris, B. in Molecular Biology of the Neuron 0 (Oxford University Press, 2004).

491. Alzheimer A Stelzmann RA Schnitzlein HN Murtagh FR An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde Clin. Anat. 1995 8 429 431 10.1002/ca.980080612 8713166 Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde. Clin. Anat. 8 , 429–431 (1995). 8713166 10.1002/ca.980080612

492. Heneka MT Neuroinflammation in Alzheimer’s disease Lancet Neurol. 2015 14 388 405 10.1016/S1474-4422(15)70016-5 25792098 PMC5909703 Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14 , 388–405 (2015). 25792098 10.1016/S1474-4422(15)70016-5 PMC5909703

493. Yan MH Wang X Zhu X Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease Free Radic. Biol. Med 2013 62 90 101 10.1016/j.freeradbiomed.2012.11.014 23200807 PMC3744189 Yan, M. H., Wang, X. & Zhu, X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med 62 , 90–101 (2013). 23200807 10.1016/j.freeradbiomed.2012.11.014 PMC3744189

494. Targa Dias Anastacio H Matosin N Ooi L Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype? Transl. Psychiatry 2022 12 257 10.1038/s41398-022-02024-7 35732622 PMC9217953 Targa Dias Anastacio, H., Matosin, N. & Ooi, L. Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype?. Transl. Psychiatry 12 , 257 (2022). 35732622 10.1038/s41398-022-02024-7 PMC9217953

495. Collaborators, G. B. D. C. O. D. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021 Lancet 2024 403 2100 2132 10.1016/S0140-6736(24)00367-2 38582094 PMC11126520 Collaborators, G. B. D. C. O. D. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 403 , 2100–2132 (2024). 38582094 10.1016/S0140-6736(24)00367-2 PMC11126520

496. Bloem BR Okun MS Klein C Parkinson’s disease Lancet 2021 397 2284 2303 10.1016/S0140-6736(21)00218-X 33848468 Bloem, B. R., Okun, M. S. & Klein, C. Parkinson’s disease. Lancet 397 , 2284–2303 (2021). 33848468 10.1016/S0140-6736(21)00218-X

497. Postuma RB MDS clinical diagnostic criteria for Parkinson’s disease Mov. Disord. 2015 30 1591 1601 10.1002/mds.26424 26474316 Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30 , 1591–1601 (2015). 26474316 10.1002/mds.26424

498. Goedert M Spillantini MG Del Tredici K Braak H 100 years of Lewy pathology Nat. Rev. Neurol. 2013 9 13 24 10.1038/nrneurol.2012.242 23183883 Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9 , 13–24 (2013). 23183883 10.1038/nrneurol.2012.242

499. Martin I Dawson VL Dawson TM Recent advances in the genetics of Parkinson’s disease Annu Rev. Genomics Hum. Genet 2011 12 301 325 10.1146/annurev-genom-082410-101440 21639795 PMC4120236 Martin, I., Dawson, V. L. & Dawson, T. M. Recent advances in the genetics of Parkinson’s disease. Annu Rev. Genomics Hum. Genet 12 , 301–325 (2011). 21639795 10.1146/annurev-genom-082410-101440 PMC4120236

500. Vazquez-Velez GE Zoghbi HY Parkinson’s disease genetics and pathophysiology Annu Rev. Neurosci. 2021 44 87 108 10.1146/annurev-neuro-100720-034518 34236893 Vazquez-Velez, G. E. & Zoghbi, H. Y. Parkinson’s disease genetics and pathophysiology. Annu Rev. Neurosci. 44 , 87–108 (2021). 34236893 10.1146/annurev-neuro-100720-034518

501. Heymsfield, S. B. & Wadden, T. A. Mechanisms, pathophysiology, and management of obesity. N. Engl. J. Med. 376 , 254–266 (2017). 10.1056/NEJMra1514009 28099824

502. Ahmad E Type 2 diabetes Lancet 2022 400 1803 1820 10.1016/S0140-6736(22)01655-5 36332637 Ahmad, E. et al. Type 2 diabetes. Lancet 400 , 1803–1820 (2022). 36332637 10.1016/S0140-6736(22)01655-5

503. Bhupathiraju, S. N. & Hu, F. B. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ. Res. 118 , 1723–1735 (2016). 10.1161/CIRCRESAHA.115.306825 PMC4887150 27230638

504. Tomlinson DR Gardiner NJ Glucose neurotoxicity Nat. Rev. Neurosci. 2008 9 36 45 10.1038/nrn2294 18094705 Tomlinson, D. R. & Gardiner, N. J. Glucose neurotoxicity. Nat. Rev. Neurosci. 9 , 36–45 (2008). 18094705 10.1038/nrn2294

505. Sun J Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes Mol. Asp. Med. 2015 42 105 118 10.1016/j.mam.2015.01.001 PMC4404191 25579745 Sun, J. et al. Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes. Mol. Asp. Med. 42 , 105–118 (2015). 10.1016/j.mam.2015.01.001 PMC4404191 25579745

506. Harding HP Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival Mol. Cell 2001 7 1153 1163 10.1016/S1097-2765(01)00264-7 11430819 Harding, H. P. et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol. Cell 7 , 1153–1163 (2001). 11430819 10.1016/s1097-2765(01)00264-7

507. Hassler JR The IRE1alpha/XBP1s pathway is essential for the glucose response and protection of beta cells PLoS Biol. 2015 13 e1002277 10.1371/journal.pbio.1002277 26469762 PMC4607427 Hassler, J. R. et al. The IRE1alpha/XBP1s pathway is essential for the glucose response and protection of beta cells. PLoS Biol. 13 , e1002277 (2015). 26469762 10.1371/journal.pbio.1002277 PMC4607427

508. Seo J Atf4 regulates obesity, glucose homeostasis, and energy expenditure Diabetes 2009 58 2565 2573 10.2337/db09-0335 19690063 PMC2768187 Seo, J. et al. Atf4 regulates obesity, glucose homeostasis, and energy expenditure. Diabetes 58 , 2565–2573 (2009). 19690063 10.2337/db09-0335 PMC2768187

509. Zhu YL Aggregation and lack of secretion of most newly synthesized proinsulin in non-beta-cell lines Endocrinology 2004 145 3840 3849 10.1210/en.2003-1512 15117881 Zhu, Y. L. et al. Aggregation and lack of secretion of most newly synthesized proinsulin in non-beta-cell lines. Endocrinology 145 , 3840–3849 (2004). 15117881 10.1210/en.2003-1512

510. Ozcan U Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes Science 2006 313 1137 1140 10.1126/science.1128294 16931765 PMC4741373 Ozcan, U. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313 , 1137–1140 (2006). 16931765 10.1126/science.1128294 PMC4741373

511. Bachar-Wikstrom E Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes Diabetes 2013 62 1227 1237 10.2337/db12-1474 23274896 PMC3609555 Bachar-Wikstrom, E. et al. Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes 62 , 1227–1237 (2013). 23274896 10.2337/db12-1474 PMC3609555

512. Marzban L Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death Diabetes 2006 55 2192 2201 10.2337/db05-1566 16873681 Marzban, L. et al. Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death. Diabetes 55 , 2192–2201 (2006). 16873681 10.2337/db05-1566

513. Shigihara N Human IAPP-induced pancreatic beta cell toxicity and its regulation by autophagy J. Clin. Invest 2014 124 3634 3644 10.1172/JCI69866 25036706 PMC4109539 Shigihara, N. et al. Human IAPP-induced pancreatic beta cell toxicity and its regulation by autophagy. J. Clin. Invest 124 , 3634–3644 (2014). 25036706 10.1172/JCI69866 PMC4109539

514. Kim J Amyloidogenic peptide oligomer accumulation in autophagy-deficient beta cells induces diabetes J. Clin. Invest 2014 124 3311 3324 10.1172/JCI69625 25036705 PMC4109549 Kim, J. et al. Amyloidogenic peptide oligomer accumulation in autophagy-deficient beta cells induces diabetes. J. Clin. Invest 124 , 3311–3324 (2014). 25036705 10.1172/JCI69625 PMC4109549

515. Hur KY Jung HS Lee MS Role of autophagy in beta-cell function and mass Diab Obes. Metab. 2010 12 20 26 10.1111/j.1463-1326.2010.01278.x 21029296 Hur, K. Y., Jung, H. S. & Lee, M. S. Role of autophagy in beta-cell function and mass. Diab Obes. Metab. 12 , 20–26 (2010). 10.1111/j.1463-1326.2010.01278.x 21029296

516. Friedman SL Neuschwander-Tetri BA Rinella M Sanyal AJ Mechanisms of NAFLD development and therapeutic strategies Nat. Med 2018 24 908 922 10.1038/s41591-018-0104-9 29967350 PMC6553468 Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med 24 , 908–922 (2018). 29967350 10.1038/s41591-018-0104-9 PMC6553468

517. Younossi ZM Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 2016 64 73 84 10.1002/hep.28431 26707365 Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 , 73–84 (2016). 26707365 10.1002/hep.28431

518. Yang YY Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis Acta Pharm. Sin. 2022 43 1180 1190 10.1038/s41401-022-00860-3 PMC9061746 35190696 Yang, Y. Y. et al. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharm. Sin. 43 , 1180–1190 (2022). 10.1038/s41401-022-00860-3 PMC9061746 35190696

519. Gregor MF Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss Diabetes 2009 58 693 700 10.2337/db08-1220 19066313 PMC2646068 Gregor, M. F. et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 58 , 693–700 (2009). 19066313 10.2337/db08-1220 PMC2646068

520. Gonzalez-Rodriguez A Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD Cell Death Dis. 2014 5 e1179 10.1038/cddis.2014.162 24743734 PMC4001315 Gonzalez-Rodriguez, A. et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 5 , e1179 (2014). 24743734 10.1038/cddis.2014.162 PMC4001315

521. Fu S Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity Nature 2011 473 528 531 10.1038/nature09968 21532591 PMC3102791 Fu, S. et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473 , 528–531 (2011). 21532591 10.1038/nature09968 PMC3102791

522. Lebeaupin C Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease J. Hepatol. 2018 69 927 947 10.1016/j.jhep.2018.06.008 29940269 Lebeaupin, C. et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J. Hepatol. 69 , 927–947 (2018). 29940269 10.1016/j.jhep.2018.06.008

523. Flessa CM Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives Curr. Obes. Rep. 2021 10 134 161 10.1007/s13679-021-00431-3 33751456 Flessa, C. M. et al. Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives. Curr. Obes. Rep. 10 , 134–161 (2021). 33751456 10.1007/s13679-021-00431-3

524. Rao Y A novel HSF1 activator ameliorates non-alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation Br. J. Pharm. 2022 179 1411 1432 10.1111/bph.15727 34783017 Rao, Y. et al. A novel HSF1 activator ameliorates non-alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation. Br. J. Pharm. 179 , 1411–1432 (2022). 10.1111/bph.15727 34783017

525. Di Naso FC Obesity depresses the anti-inflammatory HSP70 pathway, contributing to NAFLD progression Obes. (Silver Spring) 2015 23 120 129 10.1002/oby.20919 25292174 Di Naso, F. C. et al. Obesity depresses the anti-inflammatory HSP70 pathway, contributing to NAFLD progression. Obes. (Silver Spring) 23 , 120–129 (2015). 10.1002/oby.20919 25292174

526. Kondo T Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases Endocr. Connect 2021 10 521 533 10.1530/EC-21-0084 33883285 PMC8183630 Kondo, T. et al. Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. Endocr. Connect 10 , 521–533 (2021). 33883285 10.1530/EC-21-0084 PMC8183630

527. Wu WKK Zhang L Chan MTV Autophagy, NAFLD and NAFLD-Related HCC Adv. Exp. Med Biol. 2018 1061 127 138 10.1007/978-981-10-8684-7_10 29956211 Wu, W. K. K., Zhang, L. & Chan, M. T. V. Autophagy, NAFLD and NAFLD-Related HCC. Adv. Exp. Med Biol. 1061 , 127–138 (2018). 29956211 10.1007/978-981-10-8684-7_10

528. Greaves M Maley CC Clonal evolution in cancer Nature 2012 481 306 313 10.1038/nature10762 22258609 PMC3367003 Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481 , 306–313 (2012). 22258609 10.1038/nature10762 PMC3367003

529. Tameire F Verginadis II Koumenis C Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy Semin Cancer Biol. 2015 33 3 15 10.1016/j.semcancer.2015.04.002 25920797 PMC4523493 Tameire, F., Verginadis, I. I. & Koumenis, C. Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy. Semin Cancer Biol. 33 , 3–15 (2015). 25920797 10.1016/j.semcancer.2015.04.002 PMC4523493

530. Wang M Kaufman RJ The impact of the endoplasmic reticulum protein-folding environment on cancer development Nat. Rev. Cancer 2014 14 581 597 10.1038/nrc3800 25145482 Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14 , 581–597 (2014). 25145482 10.1038/nrc3800

531. Cyran AM Zhitkovich A Heat shock proteins and HSF1 in cancer Front Oncol. 2022 12 860320 10.3389/fonc.2022.860320 35311075 PMC8924369 Cyran, A. M. & Zhitkovich, A. Heat shock proteins and HSF1 in cancer. Front Oncol. 12 , 860320 (2022). 35311075 10.3389/fonc.2022.860320 PMC8924369

532. Isaacs JS Hsp90 as a “Chaperone” of the epigenome: Insights and opportunities for cancer therapy Adv. Cancer Res 2016 129 107 140 10.1016/bs.acr.2015.09.003 26916003 Isaacs, J. S. Hsp90 as a “Chaperone” of the epigenome: Insights and opportunities for cancer therapy. Adv. Cancer Res 129 , 107–140 (2016). 26916003 10.1016/bs.acr.2015.09.003

533. Piao L Heat shock protein 70-mediated sensitization of cells to apoptosis by Carboxyl-Terminal Modulator Protein BMC Cell Biol. 2009 10 53 10.1186/1471-2121-10-53 19604401 PMC2729731 Piao, L. et al. Heat shock protein 70-mediated sensitization of cells to apoptosis by Carboxyl-Terminal Modulator Protein. BMC Cell Biol. 10 , 53 (2009). 19604401 10.1186/1471-2121-10-53 PMC2729731

534. Cande C Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria Biochimie 2002 84 215 222 10.1016/S0300-9084(02)01374-3 12022952 Cande, C. et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 84 , 215–222 (2002). 12022952 10.1016/s0300-9084(02)01374-3

535. Wang X Chen M Zhou J & Zhang, X. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review) Int J. Oncol. 2014 45 18 30 10.3892/ijo.2014.2399 24789222 Wang, X., Chen, M. & Zhou, J. & Zhang, X. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). Int J. Oncol. 45 , 18–30 (2014). 24789222 10.3892/ijo.2014.2399

536. Dey S Tameire F Koumenis C PERK-ing up autophagy during MYC-induced tumorigenesis Autophagy 2013 9 612 614 10.4161/auto.23486 23328692 PMC3627677 Dey, S., Tameire, F. & Koumenis, C. PERK-ing up autophagy during MYC-induced tumorigenesis. Autophagy 9 , 612–614 (2013). 23328692 10.4161/auto.23486 PMC3627677

537. Hart LS ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth J. Clin. Invest 2012 122 4621 4634 10.1172/JCI62973 23143306 PMC3533536 Hart, L. S. et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J. Clin. Invest 122 , 4621–4634 (2012). 23143306 10.1172/JCI62973 PMC3533536

538. Chen X Cubillos-Ruiz JR Endoplasmic reticulum stress signals in the tumour and its microenvironment Nat. Rev. Cancer 2021 21 71 88 10.1038/s41568-020-00312-2 33214692 PMC7927882 Chen, X. & Cubillos-Ruiz, J. R. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat. Rev. Cancer 21 , 71–88 (2021). 33214692 10.1038/s41568-020-00312-2 PMC7927882

539. Koritzinsky M Two phases of disulfide bond formation have differing requirements for oxygen J. Cell Biol. 2013 203 615 627 10.1083/jcb.201307185 24247433 PMC3840938 Koritzinsky, M. et al. Two phases of disulfide bond formation have differing requirements for oxygen. J. Cell Biol. 203 , 615–627 (2013). 24247433 10.1083/jcb.201307185 PMC3840938

540. Huber AL p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose Mol. Cell 2013 49 1049 1059 10.1016/j.molcel.2013.01.009 23395000 Huber, A. L. et al. p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose. Mol. Cell 49 , 1049–1059 (2013). 23395000 10.1016/j.molcel.2013.01.009

541. Verfaillie T Garg AD Agostinis P Targeting ER stress induced apoptosis and inflammation in cancer Cancer Lett. 2013 332 249 264 10.1016/j.canlet.2010.07.016 20732741 Verfaillie, T., Garg, A. D. & Agostinis, P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett. 332 , 249–264 (2013). 20732741 10.1016/j.canlet.2010.07.016

542. Cubillos-Ruiz JR Bettigole SE Glimcher LH Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer Cell 2017 168 692 706 10.1016/j.cell.2016.12.004 28187289 PMC5333759 Cubillos-Ruiz, J. R., Bettigole, S. E. & Glimcher, L. H. Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer. Cell 168 , 692–706 (2017). 28187289 10.1016/j.cell.2016.12.004 PMC5333759

543. Tameire F ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression Nat. Cell Biol. 2019 21 889 899 10.1038/s41556-019-0347-9 31263264 PMC6608727 Tameire, F. et al. ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nat. Cell Biol. 21 , 889–899 (2019). 31263264 10.1038/s41556-019-0347-9 PMC6608727

544. Pallmann N Stress-mediated reprogramming of prostate cancer one-carbon cycle drives disease progression Cancer Res 2021 81 4066 4078 10.1158/0008-5472.CAN-20-3956 34183356 Pallmann, N. et al. Stress-mediated reprogramming of prostate cancer one-carbon cycle drives disease progression. Cancer Res 81 , 4066–4078 (2021). 34183356 10.1158/0008-5472.CAN-20-3956

545. Dey S ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis J. Clin. Invest 2015 125 2592 2608 10.1172/JCI78031 26011642 PMC4563676 Dey, S. et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J. Clin. Invest 125 , 2592–2608 (2015). 26011642 10.1172/JCI78031 PMC4563676

546. Avivar-Valderas A PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment Mol. Cell Biol. 2011 31 3616 3629 10.1128/MCB.05164-11 21709020 PMC3165554 Avivar-Valderas, A. et al. PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. Mol. Cell Biol. 31 , 3616–3629 (2011). 21709020 10.1128/MCB.05164-11 PMC3165554

547. Rouschop KM The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5 J. Clin. Invest 2010 120 127 141 10.1172/JCI40027 20038797 PMC2798689 Rouschop, K. M. et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Invest 120 , 127–141 (2010). 20038797 10.1172/JCI40027 PMC2798689

548. Gentile D Esposito M Grumati P Metabolic adaption of cancer cells toward autophagy: Is there a role for ER-phagy? Front Mol. Biosci. 2022 9 930223 10.3389/fmolb.2022.930223 35992272 PMC9382244 Gentile, D., Esposito, M. & Grumati, P. Metabolic adaption of cancer cells toward autophagy: Is there a role for ER-phagy?. Front Mol. Biosci. 9 , 930223 (2022). 35992272 10.3389/fmolb.2022.930223 PMC9382244

549. Tang Q CRELD2, endoplasmic reticulum stress, and human diseases Front Endocrinol. (Lausanne) 2023 14 1117414 10.3389/fendo.2023.1117414 36936176 PMC10018036 Tang, Q. et al. CRELD2, endoplasmic reticulum stress, and human diseases. Front Endocrinol. (Lausanne) 14 , 1117414 (2023). 36936176 10.3389/fendo.2023.1117414 PMC10018036

550. Kuzu, O. F. & Saatcioglu, F. GeneSetR: A web server for gene set analysis based on genome-wide Perturb-Seq data. bioRxiv , 2023.2009.2018.558211, (2023).

551. Kern P Creld2 function during unfolded protein response is essential for liver metabolism homeostasis FASEB J. 2021 35 e21939 10.1096/fj.202002713RR 34549824 PMC12316087 Kern, P. et al. Creld2 function during unfolded protein response is essential for liver metabolism homeostasis. FASEB J. 35 , e21939 (2021). 34549824 10.1096/fj.202002713RR PMC12316087

552. Albig AR Roy TG Becenti DJ Schiemann WP Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis Angiogenesis 2007 10 197 216 10.1007/s10456-007-9075-z 17632767 Albig, A. R., Roy, T. G., Becenti, D. J. & Schiemann, W. P. Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis 10 , 197–216 (2007). 17632767 10.1007/s10456-007-9075-z

553. Boyle ST ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism Nat. Cell Biol. 2020 22 882 895 10.1038/s41556-020-0523-y 32451439 Boyle, S. T. et al. ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism. Nat. Cell Biol. 22 , 882–895 (2020). 32451439 10.1038/s41556-020-0523-y

554. Pittar A Enhanced RHO-ROCK signaling is associated with CRELD2 production and fibroblast recruitment in cutaneous squamous cell carcinoma Cytoskeleton (Hoboken) 2024 81 864 871 10.1002/cm.21894 38979935 PMC11615837 Pittar, A. et al. Enhanced RHO-ROCK signaling is associated with CRELD2 production and fibroblast recruitment in cutaneous squamous cell carcinoma. Cytoskeleton (Hoboken) 81 , 864–871 (2024). 38979935 10.1002/cm.21894 PMC11615837

555. Feng YX Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress Cancer Discov. 2014 4 702 715 10.1158/2159-8290.CD-13-0945 24705811 Feng, Y. X. et al. Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discov. 4 , 702–715 (2014). 24705811 10.1158/2159-8290.CD-13-0945

556. Recouvreux, M. V. et al. Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. J. Exp. Med . 217 , e14295 (2020). 10.1084/jem.20200388 PMC7478719 32510550

557. Wang Y The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway Cancer Res 2012 72 5396 5406 10.1158/0008-5472.CAN-12-0474 22915762 PMC3743425 Wang, Y. et al. The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway. Cancer Res 72 , 5396–5406 (2012). 22915762 10.1158/0008-5472.CAN-12-0474 PMC3743425

558. Mohamed E The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling Immunity 2020 52 668 682.e667 10.1016/j.immuni.2020.03.004 32294407 PMC7207019 Mohamed, E. et al. The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling. Immunity 52 , 668–682.e667 (2020). 32294407 10.1016/j.immuni.2020.03.004 PMC7207019

559. Thevenot PT The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors Immunity 2014 41 389 401 10.1016/j.immuni.2014.08.015 25238096 PMC4171711 Thevenot, P. T. et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41 , 389–401 (2014). 25238096 10.1016/j.immuni.2014.08.015 PMC4171711

560. Liu, M. et al. PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. J. Exp. Med . 219 , e20211498 (2022). 10.1084/jem.20211498 PMC8919616 35266960

561. Yu Q Type I interferons mediate pancreatic toxicities of PERK inhibition Proc. Natl. Acad. Sci. USA 2015 112 15420 15425 10.1073/pnas.1516362112 26627716 PMC4687574 Yu, Q. et al. Type I interferons mediate pancreatic toxicities of PERK inhibition. Proc. Natl. Acad. Sci. USA 112 , 15420–15425 (2015). 26627716 10.1073/pnas.1516362112 PMC4687574

562. Raines LN PERK is a critical metabolic hub for immunosuppressive function in macrophages Nat. Immunol. 2022 23 431 445 10.1038/s41590-022-01145-x 35228694 PMC9112288 Raines, L. N. et al. PERK is a critical metabolic hub for immunosuppressive function in macrophages. Nat. Immunol. 23 , 431–445 (2022). 35228694 10.1038/s41590-022-01145-x PMC9112288

563. Mandula JK Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses Cancer Cell 2022 40 1145 1160.e1149 10.1016/j.ccell.2022.08.016 36150390 PMC9561067 Mandula, J. K. et al. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell 40 , 1145–1160.e1149 (2022). 36150390 10.1016/j.ccell.2022.08.016 PMC9561067

564. Cao T Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8(+) T cells Cell 2024 187 2288 2304.e2227 10.1016/j.cell.2024.03.011 38565142 Cao, T. et al. Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8(+) T cells. Cell 187 , 2288–2304.e2227 (2024). 38565142 10.1016/j.cell.2024.03.011

565. Gao Y SEL1L preserves CD8(+) T-cell survival and homeostasis by fine-tuning PERK signaling and the IL-15 receptor-mediated mTORC1 axis Cell Mol. Immunol. 2023 20 1232 1250 10.1038/s41423-023-01078-x 37644166 PMC10541435 Gao, Y. et al. SEL1L preserves CD8(+) T-cell survival and homeostasis by fine-tuning PERK signaling and the IL-15 receptor-mediated mTORC1 axis. Cell Mol. Immunol. 20 , 1232–1250 (2023). 37644166 10.1038/s41423-023-01078-x PMC10541435

566. Unal B Targeting IRE1alpha reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer Nat. Commun. 2024 15 8895 10.1038/s41467-024-53039-1 39406723 PMC11480464 Unal, B. et al. Targeting IRE1alpha reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer. Nat. Commun. 15 , 8895 (2024). 39406723 10.1038/s41467-024-53039-1 PMC11480464

567. Sheng X IRE1alpha-XBP1s pathway promotes prostate cancer by activating c-MYC signaling Nat. Commun. 2019 10 323 10.1038/s41467-018-08152-3 30679434 PMC6345973 Sheng, X. et al. IRE1alpha-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat. Commun. 10 , 323 (2019). 30679434 10.1038/s41467-018-08152-3 PMC6345973

568. Zhao N Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer J. Clin. Invest 2018 128 1283 1299 10.1172/JCI95873 29480818 PMC5873887 Zhao, N. et al. Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J. Clin. Invest 128 , 1283–1299 (2018). 29480818 10.1172/JCI95873 PMC5873887

569. Romero-Ramirez L X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas Transl. Oncol. 2009 2 31 38 10.1593/tlo.08211 19252749 PMC2647700 Romero-Ramirez, L. et al. X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. Transl. Oncol. 2 , 31–38 (2009). 19252749 10.1593/tlo.08211 PMC2647700

570. Drogat B IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo Cancer Res 2007 67 6700 6707 10.1158/0008-5472.CAN-06-3235 17638880 Drogat, B. et al. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res 67 , 6700–6707 (2007). 17638880 10.1158/0008-5472.CAN-06-3235

571. Sheng X Divergent androgen regulation of unfolded protein response pathways drives prostate cancer EMBO Mol. Med. 2015 7 788 801 10.15252/emmm.201404509 25864123 PMC4459818 Sheng, X. et al. Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. EMBO Mol. Med. 7 , 788–801 (2015). 25864123 10.15252/emmm.201404509 PMC4459818

572. Crowley MJP Tumor-intrinsic IRE1alpha signaling controls protective immunity in lung cancer Nat. Commun. 2023 14 120 10.1038/s41467-022-35584-9 36624093 PMC9829901 Crowley, M. J. P. et al. Tumor-intrinsic IRE1alpha signaling controls protective immunity in lung cancer. Nat. Commun. 14 , 120 (2023). 36624093 10.1038/s41467-022-35584-9 PMC9829901

573. Song M IRE1alpha-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity Nature 2018 562 423 428 10.1038/s41586-018-0597-x 30305738 PMC6237282 Song, M. et al. IRE1alpha-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature 562 , 423–428 (2018). 30305738 10.1038/s41586-018-0597-x PMC6237282

574. Dong H The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc Nat. Immunol. 2019 20 865 878 10.1038/s41590-019-0388-z 31086333 PMC6588410 Dong, H. et al. The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc. Nat. Immunol. 20 , 865–878 (2019). 31086333 10.1038/s41590-019-0388-z PMC6588410

575. Di Conza G Tumor-induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity Nat. Immunol. 2021 22 1403 1415 10.1038/s41590-021-01047-4 34686867 PMC7611917 Di Conza, G. et al. Tumor-induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity. Nat. Immunol. 22 , 1403–1415 (2021). 34686867 10.1038/s41590-021-01047-4 PMC7611917

576. Chen X XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway Nature 2014 508 103 107 10.1038/nature13119 24670641 PMC4105133 Chen, X. et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 508 , 103–107 (2014). 24670641 10.1038/nature13119 PMC4105133

577. Xu L IRE1alpha silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer Cell 2024 187 7248 7266.e7234 10.1016/j.cell.2024.09.032 39419025 PMC11645245 Xu, L. et al. IRE1alpha silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell 187 , 7248–7266.e7234 (2024). 39419025 10.1016/j.cell.2024.09.032 PMC11645245

578. Logue SE Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy Nat. Commun. 2018 9 3267 10.1038/s41467-018-05763-8 30111846 PMC6093931 Logue, S. E. et al. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat. Commun. 9 , 3267 (2018). 30111846 10.1038/s41467-018-05763-8 PMC6093931

579. Guttman, O. et al. Antigen-derived peptides engage the ER stress sensor IRE1alpha to curb dendritic cell cross-presentation. J. Cell Biol . 221 , e202111068 (2022). 10.1083/jcb.202111068 PMC9036094 35446348

580. Martinez-Turtos A IRE1alpha overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response Oncoimmunology 2022 11 2116844 10.1080/2162402X.2022.2116844 36046811 PMC9423862 Martinez-Turtos, A. et al. IRE1alpha overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response. Oncoimmunology 11 , 2116844 (2022). 36046811 10.1080/2162402X.2022.2116844 PMC9423862

581. Liu CY ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer Mol. Oncol. 2018 12 1706 1717 10.1002/1878-0261.12365 30063110 PMC6166000 Liu, C. Y. et al. ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer. Mol. Oncol. 12 , 1706–1717 (2018). 30063110 10.1002/1878-0261.12365 PMC6166000

582. Sicari D Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6 Oncogene 2019 38 6184 6195 10.1038/s41388-019-0878-3 31312025 Sicari, D. et al. Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene 38 , 6184–6195 (2019). 31312025 10.1038/s41388-019-0878-3

583. Benedetti R ATF6 prevents DNA damage and cell death in colon cancer cells undergoing ER stress Cell Death Discov. 2022 8 295 10.1038/s41420-022-01085-3 35752616 PMC9233702 Benedetti, R. et al. ATF6 prevents DNA damage and cell death in colon cancer cells undergoing ER stress. Cell Death Discov. 8 , 295 (2022). 35752616 10.1038/s41420-022-01085-3 PMC9233702

584. Rodvold JJ ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway Cancer Res Commun. 2024 4 2734 2755 10.1158/2767-9764.CRC-24-0268 39324706 PMC11492184 Rodvold, J. J. et al. ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway. Cancer Res Commun. 4 , 2734–2755 (2024). 39324706 10.1158/2767-9764.CRC-24-0268 PMC11492184

585. Pachikov AN The non-canonical mechanism of ER stress-mediated progression of prostate cancer J. Exp. Clin. Cancer Res 2021 40 289 10.1186/s13046-021-02066-7 34521429 PMC8439065 Pachikov, A. N. et al. The non-canonical mechanism of ER stress-mediated progression of prostate cancer. J. Exp. Clin. Cancer Res . 40 , 289 (2021). 34521429 10.1186/s13046-021-02066-7 PMC8439065

586. Yu Y PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6 iScience 2023 26 106070 10.1016/j.isci.2023.106070 36824269 PMC9942123 Yu, Y. et al. PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6. iScience 26 , 106070 (2023). 36824269 10.1016/j.isci.2023.106070 PMC9942123

587. Kwon Y Identification of novel pathogenic roles of BLZF1/ATF6 in tumorigenesis of gastrointestinal stromal tumor showing Golgi-localized mutant KIT Cell Death Differ. 2023 30 2309 2321 10.1038/s41418-023-01220-2 37704840 PMC10589262 Kwon, Y. et al. Identification of novel pathogenic roles of BLZF1/ATF6 in tumorigenesis of gastrointestinal stromal tumor showing Golgi-localized mutant KIT. Cell Death Differ. 30 , 2309–2321 (2023). 37704840 10.1038/s41418-023-01220-2 PMC10589262

588. Lenders M Brand E Fabry disease: The current treatment landscape Drugs 2021 81 635 645 10.1007/s40265-021-01486-1 33721270 PMC8102455 Lenders, M. & Brand, E. Fabry disease: The current treatment landscape. Drugs 81 , 635–645 (2021). 33721270 10.1007/s40265-021-01486-1 PMC8102455

589. Pandey MK Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease Nature 2017 543 108 112 10.1038/nature21368 28225753 Pandey, M. K. et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543 , 108–112 (2017). 28225753 10.1038/nature21368

590. Lloyd-Evans E Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium Nat. Med 2008 14 1247 1255 10.1038/nm.1876 18953351 Lloyd-Evans, E. et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med . 14 , 1247–1255 (2008). 18953351 10.1038/nm.1876

591. Maurer MS Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy N. Engl. J. Med. 2018 379 1007 1016 10.1056/NEJMoa1805689 30145929 Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379 , 1007–1016 (2018). 30145929 10.1056/NEJMoa1805689

592. Coelho T Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial Neurology 2012 79 785 792 10.1212/WNL.0b013e3182661eb1 22843282 PMC4098875 Coelho, T. et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79 , 785–792 (2012). 22843282 10.1212/WNL.0b013e3182661eb1 PMC4098875

593. Sigurdson CJ Bartz JC Glatzel M Cellular and molecular mechanisms of prion disease Annu Rev. Pathol. 2019 14 497 516 10.1146/annurev-pathmechdis-012418-013109 30355150 PMC9071098 Sigurdson, C. J., Bartz, J. C. & Glatzel, M. Cellular and molecular mechanisms of prion disease. Annu Rev. Pathol. 14 , 497–516 (2019). 30355150 10.1146/annurev-pathmechdis-012418-013109 PMC9071098

594. Neylan KD Miller BL New approaches to the treatment of frontotemporal dementia Neurotherapeutics 2023 20 1055 1065 10.1007/s13311-023-01380-6 37157041 PMC10457270 Neylan, K. D. & Miller, B. L. New approaches to the treatment of frontotemporal dementia. Neurotherapeutics 20 , 1055–1065 (2023). 37157041 10.1007/s13311-023-01380-6 PMC10457270

595. Poewe W Multiple system atrophy Nat. Rev. Dis. Prim. 2022 8 56 10.1038/s41572-022-00382-6 36008429 Poewe, W. et al. Multiple system atrophy. Nat. Rev. Dis. Prim. 8 , 56 (2022). 36008429 10.1038/s41572-022-00382-6

596. Cortez L Sim V The therapeutic potential of chemical chaperones in protein folding diseases Prion 2014 8 197 202 10.4161/pri.28938 24818993 PMC4189890 Cortez, L. & Sim, V. The therapeutic potential of chemical chaperones in protein folding diseases. Prion 8 , 197–202 (2014). 24818993 10.4161/pri.28938 PMC4189890

597. Canchi DR Molecular mechanism for the preferential exclusion of TMAO from protein surfaces J. Phys. Chem. B 2012 116 12095 12104 10.1021/jp304298c 22970901 PMC3534762 Canchi, D. R. et al. Molecular mechanism for the preferential exclusion of TMAO from protein surfaces. J. Phys. Chem. B 116 , 12095–12104 (2012). 22970901 10.1021/jp304298c PMC3534762

598. Pepelnjak M In situ analysis of osmolyte mechanisms of proteome thermal stabilization Nat. Chem. Biol. 2024 20 1053 1065 10.1038/s41589-024-01568-7 38424171 PMC11288892 Pepelnjak, M. et al. In situ analysis of osmolyte mechanisms of proteome thermal stabilization. Nat. Chem. Biol. 20 , 1053–1065 (2024). 38424171 10.1038/s41589-024-01568-7 PMC11288892

599. Hafycz JM Strus E Naidoo N Reducing ER stress with chaperone therapy reverses sleep fragmentation and cognitive decline in aged mice Aging Cell 2022 21 e13598 10.1111/acel.13598 35488730 PMC9197403 Hafycz, J. M., Strus, E. & Naidoo, N. Reducing ER stress with chaperone therapy reverses sleep fragmentation and cognitive decline in aged mice. Aging Cell 21 , e13598 (2022). 35488730 10.1111/acel.13598 PMC9197403

600. Iannitti T Palmieri B Clinical and experimental applications of sodium phenylbutyrate Drugs R. D. 2011 11 227 249 10.2165/11591280-000000000-00000 21902286 PMC3586072 Iannitti, T. & Palmieri, B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R. D. 11 , 227–249 (2011). 21902286 10.2165/11591280-000000000-00000 PMC3586072

601. Paganoni S Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis N. Engl. J. Med. 2020 383 919 930 10.1056/NEJMoa1916945 32877582 PMC9134321 Paganoni, S. et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 383 , 919–930 (2020). 32877582 10.1056/NEJMoa1916945 PMC9134321

602. Khalaf K Tornese P Cocco A Albanese A Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases Transl. Neurodegener. 2022 11 33 10.1186/s40035-022-00307-z 35659112 PMC9166453 Khalaf, K., Tornese, P., Cocco, A. & Albanese, A. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl. Neurodegener. 11 , 33 (2022). 35659112 10.1186/s40035-022-00307-z PMC9166453

603. Paganoni S Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis Muscle Nerve 2021 63 31 39 10.1002/mus.27091 33063909 PMC7820979 Paganoni, S. et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 63 , 31–39 (2021). 33063909 10.1002/mus.27091 PMC7820979

604. Heo YA Sodium phenylbutyrate and ursodoxicoltaurine: First approval CNS Drugs 2022 36 1007 1013 10.1007/s40263-022-00945-x 35907175 Heo, Y. A. Sodium phenylbutyrate and ursodoxicoltaurine: First approval. CNS Drugs 36 , 1007–1013 (2022). 35907175 10.1007/s40263-022-00945-x

605. Ketabforoush A Sodium phenylbutyrate and tauroursodeoxycholic acid: A Story of hope turned to disappointment in amyotrophic lateral sclerosis treatment Clin. Drug Investig. 2024 44 495 512 10.1007/s40261-024-01371-1 38909349 Ketabforoush, A. et al. Sodium phenylbutyrate and tauroursodeoxycholic acid: A Story of hope turned to disappointment in amyotrophic lateral sclerosis treatment. Clin. Drug Investig. 44 , 495–512 (2024). 38909349 10.1007/s40261-024-01371-1

606. Markham A Migalastat: First global approval Drugs 2016 76 1147 1152 10.1007/s40265-016-0607-y 27351440 Markham, A. Migalastat: First global approval. Drugs 76 , 1147–1152 (2016). 27351440 10.1007/s40265-016-0607-y

607. McCafferty EH Scott LJ Migalastat: A review in fabry disease Drugs 2019 79 543 554 10.1007/s40265-019-01090-4 30875019 PMC6647464 McCafferty, E. H. & Scott, L. J. Migalastat: A review in fabry disease. Drugs 79 , 543–554 (2019). 30875019 10.1007/s40265-019-01090-4 PMC6647464

608. Keating D VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles N. Engl. J. Med 2018 379 1612 1620 10.1056/NEJMoa1807120 30334692 PMC6289290 Keating, D. et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med 379 , 1612–1620 (2018). 30334692 10.1056/NEJMoa1807120 PMC6289290

609. Milinic, T. et al. A dramatic decline in lung transplantation for cystic fibrosis in the United States. CHEST Pulmonary 166 , 100077 (2024). 10.1016/j.chpulm.2024.100077 PMC12352485 40821006

610. McNeill A Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells Brain 2014 137 1481 1495 10.1093/brain/awu020 24574503 PMC3999713 McNeill, A. et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137 , 1481–1495 (2014). 24574503 10.1093/brain/awu020 PMC3999713

611. Mullin S Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial JAMA Neurol. 2020 77 427 434 10.1001/jamaneurol.2019.4611 31930374 PMC6990847 Mullin, S. et al. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol. 77 , 427–434 (2020). 31930374 10.1001/jamaneurol.2019.4611 PMC6990847

612. Migdalska-Richards, A. et al. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse . 71 , e21967 (2017). 10.1002/syn.21967 PMC5485051 28295625

613. Silveira CRA Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial BMC Neurol. 2019 19 20 10.1186/s12883-019-1252-3 30738426 PMC6368728 Silveira, C. R. A. et al. Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 19 , 20 (2019). 30738426 10.1186/s12883-019-1252-3 PMC6368728

614. Bulawa CE Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Proc. Natl. Acad. Sci. USA 2012 109 9629 9634 10.1073/pnas.1121005109 22645360 PMC3386102 Bulawa, C. E. et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. USA 109 , 9629–9634 (2012). 22645360 10.1073/pnas.1121005109 PMC3386102

615. Yamaguchi K A designer molecular chaperone against transmissible spongiform encephalopathy slows disease progression in mice and macaques Nat. Biomed. Eng. 2019 3 206 219 10.1038/s41551-019-0349-8 30948810 Yamaguchi, K. et al. A designer molecular chaperone against transmissible spongiform encephalopathy slows disease progression in mice and macaques. Nat. Biomed. Eng. 3 , 206–219 (2019). 30948810 10.1038/s41551-019-0349-8

616. Kirkegaard T Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses Sci. Transl. Med. 2016 8 355ra118 10.1126/scitranslmed.aad9823 27605553 PMC6821533 Kirkegaard, T. et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci. Transl. Med. 8 , 355ra118 (2016). 27605553 10.1126/scitranslmed.aad9823 PMC6821533

617. Mengel E Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment J. Inherit. Metab. Dis. 2021 44 1463 1480 10.1002/jimd.12428 34418116 PMC9293014 Mengel, E. et al. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J. Inherit. Metab. Dis. 44 , 1463–1480 (2021). 34418116 10.1002/jimd.12428 PMC9293014

618. Kalmar B Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS J. Neurochem 2008 107 339 350 10.1111/j.1471-4159.2008.05595.x 18673445 Kalmar, B. et al. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J. Neurochem 107 , 339–350 (2008). 18673445 10.1111/j.1471-4159.2008.05595.x

619. Kieran D Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice Nat. Med 2004 10 402 405 10.1038/nm1021 15034571 Kieran, D. et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med . 10 , 402–405 (2004). 15034571 10.1038/nm1021

620. Benatar M Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial Lancet Neurol. 2024 23 687 699 10.1016/S1474-4422(24)00134-0 38782015 Benatar, M. et al. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol. 23 , 687–699 (2024). 38782015 10.1016/S1474-4422(24)00134-0

621. Wagner J Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease Acta Neuropathol. 2013 125 795 813 10.1007/s00401-013-1114-9 23604588 PMC3661926 Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol. 125 , 795–813 (2013). 23604588 10.1007/s00401-013-1114-9 PMC3661926

622. Wagner J Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies Acta Neuropathol. 2015 130 619 631 10.1007/s00401-015-1483-3 26439832 PMC4612332 Wagner, J. et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 130 , 619–631 (2015). 26439832 10.1007/s00401-015-1483-3 PMC4612332

623. Martinez Hernandez A The diphenylpyrazole compound anle138b blocks Abeta channels and rescues disease phenotypes in a mouse model for amyloid pathology EMBO Mol. Med 2018 10 32 47 10.15252/emmm.201707825 29208638 PMC5760857 Martinez Hernandez, A. et al. The diphenylpyrazole compound anle138b blocks Abeta channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Mol. Med 10 , 32–47 (2018). 29208638 10.15252/emmm.201707825 PMC5760857

624. Wegrzynowicz M Depopulation of dense alpha-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model Acta Neuropathol. 2019 138 575 595 10.1007/s00401-019-02023-x 31165254 PMC6778064 Wegrzynowicz, M. et al. Depopulation of dense alpha-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model. Acta Neuropathol. 138 , 575–595 (2019). 31165254 10.1007/s00401-019-02023-x PMC6778064

625. Levin J The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset Acta Neuropathol. 2014 127 779 780 10.1007/s00401-014-1265-3 24615514 PMC3984662 Levin, J. et al. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 127 , 779–780 (2014). 24615514 10.1007/s00401-014-1265-3 PMC3984662

626. Heras-Garvin A Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy Mov. Disord. 2019 34 255 263 10.1002/mds.27562 30452793 PMC6492169 Heras-Garvin, A. et al. Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov. Disord. 34 , 255–263 (2019). 30452793 10.1002/mds.27562 PMC6492169

627. Kocis P Elucidating the Abeta42 anti-aggregation mechanism of action of tramiprosate in alzheimer’s disease: Integrating molecular analytical methods, pharmacokinetic and clinical data CNS Drugs 2017 31 495 509 10.1007/s40263-017-0434-z 28435985 PMC5488121 Kocis, P. et al. Elucidating the Abeta42 anti-aggregation mechanism of action of tramiprosate in alzheimer’s disease: Integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs 31 , 495–509 (2017). 28435985 10.1007/s40263-017-0434-z PMC5488121

628. Gervais F Targeting soluble abeta peptide with tramiprosate for the treatment of brain amyloidosis Neurobiol. Aging 2007 28 537 547 10.1016/j.neurobiolaging.2006.02.015 16675063 Gervais, F. et al. Targeting soluble abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 28 , 537–547 (2007). 16675063 10.1016/j.neurobiolaging.2006.02.015

629. Hey JA Effects of oral ALZ-801/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: Results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early alzheimer’s disease Drugs 2024 84 811 823 10.1007/s40265-024-02067-8 38902571 PMC11289173 Hey, J. A. et al. Effects of oral ALZ-801/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: Results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early alzheimer’s disease. Drugs 84 , 811–823 (2024). 38902571 10.1007/s40265-024-02067-8 PMC11289173

630. Abushakra S APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE epsilon4/epsilon4 homozygotes with early Alzheimer’s disease: Trial design and baseline characteristics Alzheimers Dement (N. Y) 2024 10 e12498 10.1002/trc2.12498 39144121 PMC11322500 Abushakra, S. et al. APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE epsilon4/epsilon4 homozygotes with early Alzheimer’s disease: Trial design and baseline characteristics. Alzheimers Dement (N. Y) 10 , e12498 (2024). 39144121 10.1002/trc2.12498 PMC11322500

631. Shahpasand-Kroner H Molecular tweezers: Supramolecular hosts with broad-spectrum biological applications Pharm. Rev. 2023 75 263 308 10.1124/pharmrev.122.000654 36549866 PMC9976797 Shahpasand-Kroner, H. et al. Molecular tweezers: Supramolecular hosts with broad-spectrum biological applications. Pharm. Rev. 75 , 263–308 (2023). 36549866 10.1124/pharmrev.122.000654 PMC9976797

632. Acharya S Molecular basis for preventing alpha-synuclein aggregation by a molecular tweezer J. Biol. Chem. 2014 289 10727 10737 10.1074/jbc.M113.524520 24567327 PMC4036189 Acharya, S. et al. Molecular basis for preventing alpha-synuclein aggregation by a molecular tweezer. J. Biol. Chem. 289 , 10727–10737 (2014). 24567327 10.1074/jbc.M113.524520 PMC4036189

633. Prabhudesai S A novel “molecular tweezer” inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo Neurotherapeutics 2012 9 464 476 10.1007/s13311-012-0105-1 22373667 PMC3337029 Prabhudesai, S. et al. A novel “molecular tweezer” inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 9 , 464–476 (2012). 22373667 10.1007/s13311-012-0105-1 PMC3337029

634. Di J The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice Alzheimers Res Ther. 2021 13 6 10.1186/s13195-020-00743-x 33397489 PMC7784007 Di, J. et al. The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. Alzheimers Res Ther. 13 , 6 (2021). 33397489 10.1186/s13195-020-00743-x PMC7784007

635. Sinha S Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins J. Am. Chem. Soc. 2011 133 16958 16969 10.1021/ja206279b 21916458 PMC3210512 Sinha, S. et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J. Am. Chem. Soc. 133 , 16958–16969 (2011). 21916458 10.1021/ja206279b PMC3210512

636. Attar A Bitan G Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by “molecular tweezers” - from the test tube to animal models Curr. Pharm. Des. 2014 20 2469 2483 10.2174/13816128113199990496 23859557 PMC4261945 Attar, A. & Bitan, G. Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by “molecular tweezers” - from the test tube to animal models. Curr. Pharm. Des. 20 , 2469–2483 (2014). 23859557 10.2174/13816128113199990496 PMC4261945

637. Attar A Protection of primary neurons and mouse brain from Alzheimer’s pathology by molecular tweezers Brain 2012 135 3735 3748 10.1093/brain/aws289 23183235 PMC3525056 Attar, A. et al. Protection of primary neurons and mouse brain from Alzheimer’s pathology by molecular tweezers. Brain 135 , 3735–3748 (2012). 23183235 10.1093/brain/aws289 PMC3525056

638. Bengoa-Vergniory N CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease Nat. Commun. 2020 11 4885 10.1038/s41467-020-18689-x 32985503 PMC7522721 Bengoa-Vergniory, N. et al. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease. Nat. Commun. 11 , 4885 (2020). 32985503 10.1038/s41467-020-18689-x PMC7522721

639. Perni M A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity Proc. Natl. Acad. Sci. USA 2017 114 E1009 E1017 10.1073/pnas.1610586114 28096355 PMC5307473 Perni, M. et al. A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity. Proc. Natl. Acad. Sci. USA 114 , E1009–E1017 (2017). 28096355 10.1073/pnas.1610586114 PMC5307473

640. Limbocker R Squalamine and Its Derivatives Modulate the Aggregation of Amyloid-beta and alpha-Synuclein and Suppress the Toxicity of Their Oligomers Front Neurosci. 2021 15 680026 10.3389/fnins.2021.680026 34220435 PMC8249941 Limbocker, R. et al. Squalamine and Its Derivatives Modulate the Aggregation of Amyloid-beta and alpha-Synuclein and Suppress the Toxicity of Their Oligomers. Front Neurosci. 15 , 680026 (2021). 34220435 10.3389/fnins.2021.680026 PMC8249941

641. West CL Squalamine restores the function of the enteric nervous system in mouse models of parkinson’s disease J. Parkinsons Dis. 2020 10 1477 1491 10.3233/JPD-202076 32925094 West, C. L. et al. Squalamine restores the function of the enteric nervous system in mouse models of parkinson’s disease. J. Parkinsons Dis. 10 , 1477–1491 (2020). 32925094 10.3233/JPD-202076

642. Camilleri M Oral ENT-01 targets enteric neurons to treat constipation in parkinson disease: A randomized controlled trial Ann. Intern Med 2022 175 1666 1674 10.7326/M22-1438 36343348 Camilleri, M. et al. Oral ENT-01 targets enteric neurons to treat constipation in parkinson disease: A randomized controlled trial. Ann. Intern Med 175 , 1666–1674 (2022). 36343348 10.7326/M22-1438

643. Loeffler DA Antibody-mediated clearance of brain amyloid-beta: Mechanisms of action, effects of natural and monoclonal anti-abeta antibodies, and downstream effects J. Alzheimers Dis. Rep. 2023 7 873 899 10.3233/ADR-230025 37662616 PMC10473157 Loeffler, D. A. Antibody-mediated clearance of brain amyloid-beta: Mechanisms of action, effects of natural and monoclonal anti-abeta antibodies, and downstream effects. J. Alzheimers Dis. Rep. 7 , 873–899 (2023). 37662616 10.3233/ADR-230025 PMC10473157

644. van Dyck CH Lecanemab in early Alzheimer’s disease N. Engl. J. Med. 2023 388 9 21 10.1056/NEJMoa2212948 36449413 van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388 , 9–21 (2023). 36449413 10.1056/NEJMoa2212948

645. Mintun MA Donanemab in early Alzheimer’s disease N. Engl. J. Med. 2021 384 1691 1704 10.1056/NEJMoa2100708 33720637 Mintun, M. A. et al. Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 384 , 1691–1704 (2021). 33720637 10.1056/NEJMoa2100708

646. Budd Haeberlein S TWo Randomized Phase 3 Studies Of Aducanumab In Early Alzheimer’s disease J. Prev. Alzheimers Dis. 2022 9 197 210 10.14283/jpad.2022.30 35542991 Budd Haeberlein, S. et al. TWo Randomized Phase 3 Studies Of Aducanumab In Early Alzheimer’s disease. J. Prev. Alzheimers Dis. 9 , 197–210 (2022). 35542991 10.14283/jpad.2022.30

647. Coerver K Practical considerations in the administration of aducanumab for the neurologist Neurol. Clin. Pr. 2022 12 169 175 10.1212/CPJ.0000000000001144 PMC9208401 35733944 Coerver, K. et al. Practical considerations in the administration of aducanumab for the neurologist. Neurol. Clin. Pr. 12 , 169–175 (2022). 10.1212/CPJ.0000000000001144 PMC9208401 35733944

648. Honig LS Trial of solanezumab for mild dementia due to Alzheimer’s disease N. Engl. J. Med 2018 378 321 330 10.1056/NEJMoa1705971 29365294 Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med 378 , 321–330 (2018). 29365294 10.1056/NEJMoa1705971

649. Ostrowitzki S Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials JAMA Neurol. 2022 79 1113 1121 10.1001/jamaneurol.2022.2909 36121669 PMC9486635 Ostrowitzki, S. et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials. JAMA Neurol. 79 , 1113–1121 (2022). 36121669 10.1001/jamaneurol.2022.2909 PMC9486635

650. Salloway S Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease N. Engl. J. Med 2014 370 322 333 10.1056/NEJMoa1304839 24450891 PMC4159618 Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med . 370 , 322–333 (2014). 24450891 10.1056/NEJMoa1304839 PMC4159618

651. Pagano G Trial of prasinezumab in early-stage Parkinson’s disease N. Engl. J. Med 2022 387 421 432 10.1056/NEJMoa2202867 35921451 Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson’s disease. N. Engl. J. Med 387 , 421–432 (2022). 35921451 10.1056/NEJMoa2202867

652. Pagano G Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease Nat. Med 2024 30 1096 1103 10.1038/s41591-024-02886-y 38622249 PMC11031390 Pagano, G. et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease. Nat. Med 30 , 1096–1103 (2024). 38622249 10.1038/s41591-024-02886-y PMC11031390

653. Piller C Picture imperfect Science 2024 385 1406 1412 10.1126/science.adt3535 39325884 Piller, C. Picture imperfect. Science 385 , 1406–1412 (2024). 39325884 10.1126/science.adt3535

654. Kasza A Dihydropyridine derivatives modulate heat shock responses and have a neuroprotective effect in a transgenic mouse model of Alzheimer’s disease J. Alzheimers Dis. 2016 53 557 571 10.3233/JAD-150860 27163800 PMC4969717 Kasza, A. et al. Dihydropyridine derivatives modulate heat shock responses and have a neuroprotective effect in a transgenic mouse model of Alzheimer’s disease. J. Alzheimers Dis. 53 , 557–571 (2016). 27163800 10.3233/JAD-150860 PMC4969717

655. Roe MS Dihydropyridines allosterically modulate Hsp90 providing a novel mechanism for heat shock protein co-induction and neuroprotection Front Mol. Biosci. 2018 5 51 10.3389/fmolb.2018.00051 29930942 PMC6000670 Roe, M. S. et al. Dihydropyridines allosterically modulate Hsp90 providing a novel mechanism for heat shock protein co-induction and neuroprotection. Front Mol. Biosci. 5 , 51 (2018). 29930942 10.3389/fmolb.2018.00051 PMC6000670

656. Roe, S. M. et al. The crystal structure of the Hsp90-LA1011 complex and the mechanism by which LA1011 may improve the prognosis of Alzheimer’s disease. Biomolecules 13 , 1051 (2023). 10.3390/biom13071051 PMC10377191 37509087

657. Lee S Sulforaphane upregulates the heat shock protein co-chaperone CHIP and clears amyloid-beta and tau in a mouse model of Alzheimer’s disease Mol. Nutr. Food Res 2018 62 e1800240 10.1002/mnfr.201800240 29714053 Lee, S. et al. Sulforaphane upregulates the heat shock protein co-chaperone CHIP and clears amyloid-beta and tau in a mouse model of Alzheimer’s disease. Mol. Nutr. Food Res 62 , e1800240 (2018). 29714053 10.1002/mnfr.201800240

658. Otoo, R. A. & Allen, A. R. Sulforaphane’s multifaceted potential: From neuroprotection to anticancer action. Molecules 28 , 6902 (2023). 10.3390/molecules28196902 PMC10574530 37836745

659. Kim HV Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model Amyloid 2013 20 7 12 10.3109/13506129.2012.751367 23253046 Kim, H. V. et al. Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model. Amyloid 20 , 7–12 (2013). 23253046 10.3109/13506129.2012.751367

660. Zhang R Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer’s disease-like lesions Int J. Mol. Sci. 2014 15 14396 14410 10.3390/ijms150814396 25196440 PMC4159858 Zhang, R. et al. Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer’s disease-like lesions. Int J. Mol. Sci. 15 , 14396–14410 (2014). 25196440 10.3390/ijms150814396 PMC4159858

661. Zhang R Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid beta deposits and peroxidation in mice with Alzheimer-like lesions Am. J. Alzheimers Dis. Other Demen 2015 30 183 191 10.1177/1533317514542645 25024455 PMC10852928 Zhang, R. et al. Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid beta deposits and peroxidation in mice with Alzheimer-like lesions. Am. J. Alzheimers Dis. Other Demen 30 , 183–191 (2015). 25024455 10.1177/1533317514542645 PMC10852928

662. Luo W Heat shock protein 90 in neurodegenerative diseases Mol. Neurodegener. 2010 5 24 10.1186/1750-1326-5-24 20525284 PMC2896944 Luo, W. et al. Heat shock protein 90 in neurodegenerative diseases. Mol. Neurodegener. 5 , 24 (2010). 20525284 10.1186/1750-1326-5-24 PMC2896944

663. Wang B A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer’s mouse model via an HSF1-mediated mechanism Mol. Psychiatry 2017 22 990 1001 10.1038/mp.2016.104 27457810 PMC5323357 Wang, B. et al. A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer’s mouse model via an HSF1-mediated mechanism. Mol. Psychiatry 22 , 990–1001 (2017). 27457810 10.1038/mp.2016.104 PMC5323357

664. Chen Y Hsp90 chaperone inhibitor 17-AAG attenuates Abeta-induced synaptic toxicity and memory impairment J. Neurosci. 2014 34 2464 2470 10.1523/JNEUROSCI.0151-13.2014 24523537 PMC3921421 Chen, Y. et al. Hsp90 chaperone inhibitor 17-AAG attenuates Abeta-induced synaptic toxicity and memory impairment. J. Neurosci. 34 , 2464–2470 (2014). 24523537 10.1523/JNEUROSCI.0151-13.2014 PMC3921421

665. Weickert S The mechanism of Hsp90-induced oligomerizaton of Tau Sci. Adv. 2020 6 eaax6999 10.1126/sciadv.aax6999 32201713 PMC7069708 Weickert, S. et al. The mechanism of Hsp90-induced oligomerizaton of Tau. Sci. Adv. 6 , eaax6999 (2020). 32201713 10.1126/sciadv.aax6999 PMC7069708

666. Moll A Hsp multichaperone complex buffers pathologically modified Tau Nat. Commun. 2022 13 3668 10.1038/s41467-022-31396-z 35760815 PMC9237115 Moll, A. et al. Hsp multichaperone complex buffers pathologically modified Tau. Nat. Commun. 13 , 3668 (2022). 35760815 10.1038/s41467-022-31396-z PMC9237115

667. Dickey CA The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins J. Clin. Invest 2007 117 648 658 10.1172/JCI29715 17304350 PMC1794119 Dickey, C. A. et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest 117 , 648–658 (2007). 17304350 10.1172/JCI29715 PMC1794119

668. Rodriguez-Ramos A Gonzalez JA Fanarraga ML Enhanced Inhibition of Amyloid Formation by Heat Shock Protein 90 Immobilized on Nanoparticles ACS Chem. Neurosci. 2023 14 2811 2817 10.1021/acschemneuro.3c00370 37471620 PMC10401628 Rodriguez-Ramos, A., Gonzalez, J. A. & Fanarraga, M. L. Enhanced Inhibition of Amyloid Formation by Heat Shock Protein 90 Immobilized on Nanoparticles. ACS Chem. Neurosci. 14 , 2811–2817 (2023). 37471620 10.1021/acschemneuro.3c00370 PMC10401628

669. Yang H Heat shock protein inspired nanochaperones restore amyloid-beta homeostasis for preventative therapy of Alzheimer’s disease Adv. Sci. (Weinh.) 2019 6 1901844 31763156 10.1002/advs.201901844 PMC6864524 Yang, H. et al. Heat shock protein inspired nanochaperones restore amyloid-beta homeostasis for preventative therapy of Alzheimer’s disease. Adv. Sci. (Weinh.) 6 , 1901844 (2019). 31763156 10.1002/advs.201901844 PMC6864524

670. Caballero AB Gamez P Nanochaperone-based strategies to control protein aggregation linked to conformational diseases Angew. Chem. Int Ed. Engl. 2021 60 41 52 10.1002/anie.202007924 32706460 Caballero, A. B. & Gamez, P. Nanochaperone-based strategies to control protein aggregation linked to conformational diseases. Angew. Chem. Int Ed. Engl. 60 , 41–52 (2021). 32706460 10.1002/anie.202007924

671. Xu L Harnessing nanochaperone-mediated autophagy for selective clearance of pathogenic tau protein in Alzheimer’s disease Adv. Mater. 2024 36 e2313869 10.1002/adma.202313869 38688523 Xu, L. et al. Harnessing nanochaperone-mediated autophagy for selective clearance of pathogenic tau protein in Alzheimer’s disease. Adv. Mater. 36 , e2313869 (2024). 38688523 10.1002/adma.202313869

672. Jin Y Saatcioglu F Targeting the unfolded protein response in hormone-regulated cancers Trends Cancer 2020 6 160 171 10.1016/j.trecan.2019.12.001 32061305 Jin, Y. & Saatcioglu, F. Targeting the unfolded protein response in hormone-regulated cancers. Trends Cancer 6 , 160–171 (2020). 32061305 10.1016/j.trecan.2019.12.001

673. Halliday M Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity Cell Death Dis. 2015 6 e1672 10.1038/cddis.2015.49 25741597 PMC4385927 Halliday, M. et al. Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis. 6 , e1672 (2015). 25741597 10.1038/cddis.2015.49 PMC4385927

674. Moreno JA Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration Nature 2012 485 507 511 10.1038/nature11058 22622579 PMC3378208 Moreno, J. A. et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 485 , 507–511 (2012). 22622579 10.1038/nature11058 PMC3378208

675. Ma T Suppression of eIF2alpha kinases alleviates Alzheimer’s disease-related plasticity and memory deficits Nat. Neurosci. 2013 16 1299 1305 10.1038/nn.3486 23933749 PMC3756900 Ma, T. et al. Suppression of eIF2alpha kinases alleviates Alzheimer’s disease-related plasticity and memory deficits. Nat. Neurosci. 16 , 1299–1305 (2013). 23933749 10.1038/nn.3486 PMC3756900

676. Devi L Ohno M PERK mediates eIF2alpha phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer’s disease Neurobiol. Aging 2014 35 2272 2281 10.1016/j.neurobiolaging.2014.04.031 24889041 PMC4127890 Devi, L. & Ohno, M. PERK mediates eIF2alpha phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer’s disease. Neurobiol. Aging 35 , 2272–2281 (2014). 24889041 10.1016/j.neurobiolaging.2014.04.031 PMC4127890

677. Moreno JA Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice Sci. Transl. Med 2013 5 206ra138 10.1126/scitranslmed.3006767 24107777 Moreno, J. A. et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci. Transl. Med 5 , 206ra138 (2013). 24107777 10.1126/scitranslmed.3006767

678. Radford H PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia Acta Neuropathol. 2015 130 633 642 10.1007/s00401-015-1487-z 26450683 PMC4612323 Radford, H. et al. PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol. 130 , 633–642 (2015). 26450683 10.1007/s00401-015-1487-z PMC4612323

679. Mercado G Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson’s disease Neurobiol. Dis. 2018 112 136 148 10.1016/j.nbd.2018.01.004 29355603 Mercado, G. et al. Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson’s disease. Neurobiol. Dis. 112 , 136–148 (2018). 29355603 10.1016/j.nbd.2018.01.004

680. Kim HJ Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models Nat. Genet 2014 46 152 160 10.1038/ng.2853 24336168 PMC3934366 Kim, H. J. et al. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet 46 , 152–160 (2014). 24336168 10.1038/ng.2853 PMC3934366

681. Hughes, D. T. et al. Targeting the kinase insert loop of PERK selectively modulates PERK signaling without systemic toxicity in mice. Sci. Signal . 13 , eabb4749 (2020). 10.1126/scisignal.abb4749 32788341

682. Sidrauski C Pharmacological brake-release of mRNA translation enhances cognitive memory Elife 2013 2 e00498 10.7554/eLife.00498 23741617 PMC3667625 Sidrauski, C. et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife 2 , e00498 (2013). 23741617 10.7554/eLife.00498 PMC3667625

683. Sekine Y Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound Science 2015 348 1027 1030 10.1126/science.aaa6986 25858979 PMC4538794 Sekine, Y. et al. Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound. Science 348 , 1027–1030 (2015). 25858979 10.1126/science.aaa6986 PMC4538794

684. Bugallo R Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis Cell Death Dis. 2020 11 397 10.1038/s41419-020-2601-2 32457286 PMC7250913 Bugallo, R. et al. Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis. Cell Death Dis. 11 , 397 (2020). 32457286 10.1038/s41419-020-2601-2 PMC7250913

685. Halliday M Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice Brain 2017 140 1768 1783 10.1093/brain/awx074 28430857 PMC5445255 Halliday, M. et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain 140 , 1768–1783 (2017). 28430857 10.1093/brain/awx074 PMC5445255

686. Albert-Gasco H Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration Brain 2024 147 649 664 10.1093/brain/awad313 37703312 PMC10834243 Albert-Gasco, H. et al. Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration. Brain 147 , 649–664 (2024). 37703312 10.1093/brain/awad313 PMC10834243

687. Camargos EF Nobrega OT Trazodone to change the risk of neurodegeneration: bedside to bench Brain 2017 140 e47 10.1093/brain/awx149 28641375 Camargos, E. F. & Nobrega, O. T. Trazodone to change the risk of neurodegeneration: bedside to bench. Brain 140 , e47 (2017). 28641375 10.1093/brain/awx149

688. Camargos EF Trazodone and cognitive performance in Alzheimer disease J. Clin. Psychopharmacol. 2015 35 88 89 10.1097/JCP.0000000000000237 25379952 Camargos, E. F. et al. Trazodone and cognitive performance in Alzheimer disease. J. Clin. Psychopharmacol. 35 , 88–89 (2015). 25379952 10.1097/JCP.0000000000000237

689. Halliday M Mallucci GR Reply: Trazodone to change the risk of neurodegeneration: bedside to bench Brain 2017 140 e48 10.1093/brain/awx150 28641370 Halliday, M. & Mallucci, G. R. Reply: Trazodone to change the risk of neurodegeneration: bedside to bench. Brain 140 , e48 (2017). 28641370 10.1093/brain/awx150

690. Na D A multi-layered network model identifies Akt1 as a common modulator of neurodegeneration Mol. Syst. Biol. 2023 19 e11801 10.15252/msb.202311801 37984409 PMC10698508 Na, D. et al. A multi-layered network model identifies Akt1 as a common modulator of neurodegeneration. Mol. Syst. Biol. 19 , e11801 (2023). 37984409 10.15252/msb.202311801 PMC10698508

691. Cisse M The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model Mol. Psychiatry 2017 22 1562 1575 10.1038/mp.2016.152 27646263 PMC5658671 Cisse, M. et al. The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. Mol. Psychiatry 22 , 1562–1575 (2017). 27646263 10.1038/mp.2016.152 PMC5658671

692. Sado M Protective effect against Parkinson’s disease-related insults through the activation of XBP1 Brain Res. 2009 1257 16 24 10.1016/j.brainres.2008.11.104 19135031 Sado, M. et al. Protective effect against Parkinson’s disease-related insults through the activation of XBP1. Brain Res. 1257 , 16–24 (2009). 19135031 10.1016/j.brainres.2008.11.104

693. Valdes P Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1 Proc. Natl. Acad. Sci. USA 2014 111 6804 6809 10.1073/pnas.1321845111 24753614 PMC4020088 Valdes, P. et al. Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc. Natl. Acad. Sci. USA 111 , 6804–6809 (2014). 24753614 10.1073/pnas.1321845111 PMC4020088

694. Zuleta A AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington’s disease Biochem Biophys. Res. Commun. 2012 420 558 563 10.1016/j.bbrc.2012.03.033 22445760 Zuleta, A. et al. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington’s disease. Biochem Biophys. Res. Commun. 420 , 558–563 (2012). 22445760 10.1016/j.bbrc.2012.03.033

695. Duran-Aniotz C The unfolded protein response transcription factor XBP1s ameliorates Alzheimer’s disease by improving synaptic function and proteostasis Mol. Ther. 2023 31 2240 2256 10.1016/j.ymthe.2023.03.028 37016577 PMC10362463 Duran-Aniotz, C. et al. The unfolded protein response transcription factor XBP1s ameliorates Alzheimer’s disease by improving synaptic function and proteostasis. Mol. Ther. 31 , 2240–2256 (2023). 37016577 10.1016/j.ymthe.2023.03.028 PMC10362463

696. Casas-Tinto S The ER stress factor XBP1s prevents amyloid-beta neurotoxicity Hum. Mol. Genet 2011 20 2144 2160 10.1093/hmg/ddr100 21389082 PMC3090193 Casas-Tinto, S. et al. The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Hum. Mol. Genet 20 , 2144–2160 (2011). 21389082 10.1093/hmg/ddr100 PMC3090193

697. Waldherr SM Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau Nat. Commun. 2019 10 4443 10.1038/s41467-019-12070-3 31570707 PMC6768869 Waldherr, S. M. et al. Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau. Nat. Commun. 10 , 4443 (2019). 31570707 10.1038/s41467-019-12070-3 PMC6768869

698. Cabral-Miranda F Unfolded protein response IRE1/XBP1 signaling is required for healthy mammalian brain aging EMBO J. 2022 41 e111952 10.15252/embj.2022111952 36314651 PMC9670206 Cabral-Miranda, F. et al. Unfolded protein response IRE1/XBP1 signaling is required for healthy mammalian brain aging. EMBO J. 41 , e111952 (2022). 36314651 10.15252/embj.2022111952 PMC9670206

699. Hetz C XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy Genes Dev. 2009 23 2294 2306 10.1101/gad.1830709 19762508 PMC2758741 Hetz, C. et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 23 , 2294–2306 (2009). 19762508 10.1101/gad.1830709 PMC2758741

700. Vidal RL Targeting the UPR transcription factor XBP1 protects against Huntington’s disease through the regulation of FoxO1 and autophagy Hum. Mol. Genet 2012 21 2245 2262 10.1093/hmg/dds040 22337954 PMC3335312 Vidal, R. L. et al. Targeting the UPR transcription factor XBP1 protects against Huntington’s disease through the regulation of FoxO1 and autophagy. Hum. Mol. Genet 21 , 2245–2262 (2012). 22337954 10.1093/hmg/dds040 PMC3335312

701. Duran-Aniotz C IRE1 signaling exacerbates Alzheimer’s disease pathogenesis Acta Neuropathol. 2017 134 489 506 10.1007/s00401-017-1694-x 28341998 Duran-Aniotz, C. et al. IRE1 signaling exacerbates Alzheimer’s disease pathogenesis. Acta Neuropathol. 134 , 489–506 (2017). 28341998 10.1007/s00401-017-1694-x

702. Kovaleva V MANF regulates neuronal survival and UPR through its ER-located receptor IRE1alpha Cell Rep. 2023 42 112066 10.1016/j.celrep.2023.112066 36739529 Kovaleva, V. et al. MANF regulates neuronal survival and UPR through its ER-located receptor IRE1alpha. Cell Rep. 42 , 112066 (2023). 36739529 10.1016/j.celrep.2023.112066

703. Ghosh R Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress Cell 2014 158 534 548 10.1016/j.cell.2014.07.002 25018104 PMC4244221 Ghosh, R. et al. Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress. Cell 158 , 534–548 (2014). 25018104 10.1016/j.cell.2014.07.002 PMC4244221

704. Aman Y Autophagy in healthy aging and disease Nat. Aging 2021 1 634 650 10.1038/s43587-021-00098-4 34901876 PMC8659158 Aman, Y. et al. Autophagy in healthy aging and disease. Nat. Aging 1 , 634–650 (2021). 34901876 10.1038/s43587-021-00098-4 PMC8659158

705. Kocot AM Wroblewska B Nutritional strategies for autophagy activation and health consequences of autophagy impairment Nutrition 2022 103-104 111686 10.1016/j.nut.2022.111686 35843038 Kocot, A. M. & Wroblewska, B. Nutritional strategies for autophagy activation and health consequences of autophagy impairment. Nutrition 103-104 , 111686 (2022). 35843038 10.1016/j.nut.2022.111686

706. Mulcahy Levy JM Thorburn A Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients Cell Death Differ. 2020 27 843 857 10.1038/s41418-019-0474-7 31836831 PMC7206017 Mulcahy Levy, J. M. & Thorburn, A. Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ. 27 , 843–857 (2020). 31836831 10.1038/s41418-019-0474-7 PMC7206017

707. Mizushima N Levine B Autophagy in mammalian development and differentiation Nat. Cell Biol. 2010 12 823 830 10.1038/ncb0910-823 20811354 PMC3127249 Mizushima, N. & Levine, B. Autophagy in mammalian development and differentiation. Nat. Cell Biol. 12 , 823–830 (2010). 20811354 10.1038/ncb0910-823 PMC3127249

708. Pyo JO Overexpression of Atg5 in mice activates autophagy and extends lifespan Nat. Commun. 2013 4 2300 10.1038/ncomms3300 23939249 PMC3753544 Pyo, J. O. et al. Overexpression of Atg5 in mice activates autophagy and extends lifespan. Nat. Commun. 4 , 2300 (2013). 23939249 10.1038/ncomms3300 PMC3753544

709. Pickford F The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice J. Clin. Invest 2008 118 2190 2199 18497889 10.1172/JCI33585 PMC2391284 Pickford, F. et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest 118 , 2190–2199 (2008). 18497889 10.1172/JCI33585 PMC2391284

710. Fernandez AF Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice Nature 2018 558 136 140 10.1038/s41586-018-0162-7 29849149 PMC5992097 Fernandez, A. F. et al. Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature 558 , 136–140 (2018). 29849149 10.1038/s41586-018-0162-7 PMC5992097

711. Djajadikerta A Autophagy induction as a therapeutic strategy for neurodegenerative diseases J. Mol. Biol. 2020 432 2799 2821 10.1016/j.jmb.2019.12.035 31887286 Djajadikerta, A. et al. Autophagy induction as a therapeutic strategy for neurodegenerative diseases. J. Mol. Biol. 432 , 2799–2821 (2020). 31887286 10.1016/j.jmb.2019.12.035

712. Dong X Novel Bcl-2 inhibitors selectively disrupt the autophagy-specific Bcl-2-beclin 1 protein-protein interaction ACS Med. Chem. Lett. 2022 13 1510 1516 10.1021/acsmedchemlett.2c00309 36105331 PMC9465831 Dong, X. et al. Novel Bcl-2 inhibitors selectively disrupt the autophagy-specific Bcl-2-beclin 1 protein-protein interaction. ACS Med. Chem. Lett. 13 , 1510–1516 (2022). 36105331 10.1021/acsmedchemlett.2c00309 PMC9465831

713. Takahashi D AUTACs: Cargo-specific degraders using selective autophagy Mol. Cell 2019 76 797 810.e710 10.1016/j.molcel.2019.09.009 31606272 Takahashi, D. et al. AUTACs: Cargo-specific degraders using selective autophagy. Mol. Cell 76 , 797–810.e710 (2019). 31606272 10.1016/j.molcel.2019.09.009

714. Macauley SL Combination therapies for lysosomal storage diseases: A complex answer to a simple problem Pediatr. Endocrinol. Rev. 2016 13 639 648 27491211 PMC5374980 Macauley, S. L. Combination therapies for lysosomal storage diseases: A complex answer to a simple problem. Pediatr. Endocrinol. Rev. 13 , 639–648 (2016). 27491211 PMC5374980

715. Kido J Sugawara K Nakamura K Gene therapy for lysosomal storage diseases: Current clinical trial prospects Front Genet 2023 14 1064924 10.3389/fgene.2023.1064924 36713078 PMC9880060 Kido, J., Sugawara, K. & Nakamura, K. Gene therapy for lysosomal storage diseases: Current clinical trial prospects. Front Genet 14 , 1064924 (2023). 36713078 10.3389/fgene.2023.1064924 PMC9880060

716. Patterson MC Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update Mol. Genet Metab. 2012 106 330 344 10.1016/j.ymgme.2012.03.012 22572546 Patterson, M. C. et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol. Genet Metab. 106 , 330–344 (2012). 22572546 10.1016/j.ymgme.2012.03.012

717. Sohn YB Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome) Orphanet J. Rare Dis. 2013 8 42 10.1186/1750-1172-8-42 23497636 PMC3614543 Sohn, Y. B. et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J. Rare Dis. 8 , 42 (2013). 23497636 10.1186/1750-1172-8-42 PMC3614543

718. Okuyama T A Phase 2/3 Trial of Pabinafusp Alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II Mol. Ther. 2021 29 671 679 10.1016/j.ymthe.2020.09.039 33038326 PMC7854283 Okuyama, T. et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol. Ther. 29 , 671–679 (2021). 33038326 10.1016/j.ymthe.2020.09.039 PMC7854283

719. Bourdenx M Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases Autophagy 2016 12 472 483 10.1080/15548627.2015.1136769 26761717 PMC4835967 Bourdenx, M. et al. Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases. Autophagy 12 , 472–483 (2016). 26761717 10.1080/15548627.2015.1136769 PMC4835967

720. Koh JY Lysosomal dysfunction in proteinopathic neurodegenerative disorders: possible therapeutic roles of cAMP and zinc Mol. Brain 2019 12 18 10.1186/s13041-019-0439-2 30866990 PMC6417073 Koh, J. Y. et al. Lysosomal dysfunction in proteinopathic neurodegenerative disorders: possible therapeutic roles of cAMP and zinc. Mol. Brain 12 , 18 (2019). 30866990 10.1186/s13041-019-0439-2 PMC6417073

721. Mannick JB Lamming DW Targeting the biology of aging with mTOR inhibitors Nat. Aging 2023 3 642 660 10.1038/s43587-023-00416-y 37142830 PMC10330278 Mannick, J. B. & Lamming, D. W. Targeting the biology of aging with mTOR inhibitors. Nat. Aging 3 , 642–660 (2023). 37142830 10.1038/s43587-023-00416-y PMC10330278

722. Ravikumar B Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease Nat. Genet 2004 36 585 595 10.1038/ng1362 15146184 Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet 36 , 585–595 (2004). 15146184 10.1038/ng1362

723. Santulli G Totary-Jain H Tailoring mTOR-based therapy: molecular evidence and clinical challenges Pharmacogenomics 2013 14 1517 1526 10.2217/pgs.13.143 24024901 PMC4186793 Santulli, G. & Totary-Jain, H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics 14 , 1517–1526 (2013). 24024901 10.2217/pgs.13.143 PMC4186793

724. Mao, B. et al. Overview of Research into mTOR Inhibitors. Molecules 27 , 5295 (2022). 10.3390/molecules27165295 PMC9413691 36014530

725. Tezil T Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy NPJ Aging Mech. Dis. 2019 5 7 10.1038/s41514-019-0037-7 31602311 PMC6775102 Tezil, T. et al. Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy. NPJ Aging Mech. Dis. 5 , 7 (2019). 31602311 10.1038/s41514-019-0037-7 PMC6775102

726. Arotcarena, M. L., Teil, M. & Dehay, B. Autophagy in synucleinopathy: The Overwhelmed and Defective Machinery. Cells 8 , 565 (2019). 10.3390/cells8060565 PMC6627933 31181865

727. Welch WJ Brown CR Influence of molecular and chemical chaperones on protein folding Cell Stress Chaperones 1996 1 109 115 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2 9222596 PMC248462 Welch, W. J. & Brown, C. R. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1 , 109–115 (1996). 9222596 10.1379/1466-1268(1996)001<0109:iomacc>2.3.co;2 PMC248462

728. Ingolfsson HI Phytochemicals perturb membranes and promiscuously alter protein function ACS Chem. Biol. 2014 9 1788 1798 10.1021/cb500086e 24901212 PMC4136704 Ingolfsson, H. I. et al. Phytochemicals perturb membranes and promiscuously alter protein function. ACS Chem. Biol. 9 , 1788–1798 (2014). 24901212 10.1021/cb500086e PMC4136704

729. Chan MM Chen R Fong D Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations Cancer Lett. 2018 433 53 64 10.1016/j.canlet.2018.06.034 29960048 PMC7117025 Chan, M. M., Chen, R. & Fong, D. Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations. Cancer Lett. 433 , 53–64 (2018). 29960048 10.1016/j.canlet.2018.06.034 PMC7117025

730. Longo VD Di Tano M Mattson MP Guidi N Intermittent and periodic fasting, longevity and disease Nat. Aging 2021 1 47 59 10.1038/s43587-020-00013-3 35310455 PMC8932957 Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging 1 , 47–59 (2021). 35310455 10.1038/s43587-020-00013-3 PMC8932957

731. Wong SQ Kumar AV Mills J Lapierre LR Autophagy in aging and longevity Hum. Genet 2020 139 277 290 10.1007/s00439-019-02031-7 31144030 PMC6884674 Wong, S. Q., Kumar, A. V., Mills, J. & Lapierre, L. R. Autophagy in aging and longevity. Hum. Genet 139 , 277–290 (2020). 31144030 10.1007/s00439-019-02031-7 PMC6884674

732. Garcia-Prat L Autophagy maintains stemness by preventing senescence Nature 2016 529 37 42 10.1038/nature16187 26738589 Garcia-Prat, L. et al. Autophagy maintains stemness by preventing senescence. Nature 529 , 37–42 (2016). 26738589 10.1038/nature16187

733. Eisenberg T Cardioprotection and lifespan extension by the natural polyamine spermidine Nat. Med 2016 22 1428 1438 10.1038/nm.4222 27841876 PMC5806691 Eisenberg, T. et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat. Med 22 , 1428–1438 (2016). 27841876 10.1038/nm.4222 PMC5806691

734. Li W EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages Biochem Pharm. 2011 81 1152 1163 10.1016/j.bcp.2011.02.015 21371444 PMC3072446 Li, W. et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharm. 81 , 1152–1163 (2011). 21371444 10.1016/j.bcp.2011.02.015 PMC3072446

735. Park D Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition Sci. Rep. 2016 6 21772 10.1038/srep21772 26902888 PMC4763238 Park, D. et al. Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition. Sci. Rep. 6 , 21772 (2016). 26902888 10.1038/srep21772 PMC4763238

736. Brakedal B The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease Cell Metab. 2022 34 396 407.e396 10.1016/j.cmet.2022.02.001 35235774 Brakedal, B. et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab. 34 , 396–407.e396 (2022). 35235774 10.1016/j.cmet.2022.02.001

737. Rautiainen S Manson JE Lichtenstein AH Sesso HD Dietary supplements and disease prevention - a global overview Nat. Rev. Endocrinol. 2016 12 407 420 10.1038/nrendo.2016.54 27150288 Rautiainen, S., Manson, J. E., Lichtenstein, A. H. & Sesso, H. D. Dietary supplements and disease prevention - a global overview. Nat. Rev. Endocrinol. 12 , 407–420 (2016). 27150288 10.1038/nrendo.2016.54

738. Farkona S Diamandis EP Blasutig IM Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016 14 73 10.1186/s12916-016-0623-5 27151159 PMC4858828 Farkona, S., Diamandis, E. P. & Blasutig, I. M. Cancer immunotherapy: the beginning of the end of cancer?. BMC Med 14 , 73 (2016). 27151159 10.1186/s12916-016-0623-5 PMC4858828

739. Khalil DN Smith EL Brentjens RJ Wolchok JD The future of cancer treatment: immunomodulation, CARs and combination immunotherapy Nat. Rev. Clin. Oncol. 2016 13 394 10.1038/nrclinonc.2016.65 27118494 PMC5558237 Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13 , 394 (2016). 27118494 10.1038/nrclinonc.2016.65 PMC5558237

740. Hegde PS Chen DS Top 10 Challenges in Cancer Immunotherapy Immunity 2020 52 17 35 10.1016/j.immuni.2019.12.011 31940268 Hegde, P. S. & Chen, D. S. Top 10 Challenges in Cancer Immunotherapy. Immunity 52 , 17–35 (2020). 31940268 10.1016/j.immuni.2019.12.011

741. Samstein RM Tumor mutational load predicts survival after immunotherapy across multiple cancer types Nat. Genet 2019 51 202 206 10.1038/s41588-018-0312-8 30643254 PMC6365097 Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet 51 , 202–206 (2019). 30643254 10.1038/s41588-018-0312-8 PMC6365097

742. Wei SC Duffy CR Allison JP Fundamental mechanisms of immune checkpoint blockade therapy Cancer Discov. 2018 8 1069 1086 10.1158/2159-8290.CD-18-0367 30115704 Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8 , 1069–1086 (2018). 30115704 10.1158/2159-8290.CD-18-0367

743. Haslam, A., Gill, J. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw. Open 3 , e200423 (2020). 10.1001/jamanetworkopen.2020.0423 PMC7063495 32150268

744. Mercier R LaPointe P The role of cellular proteostasis in antitumor immunity J. Biol. Chem. 2022 298 101930 10.1016/j.jbc.2022.101930 35421375 PMC9108985 Mercier, R. & LaPointe, P. The role of cellular proteostasis in antitumor immunity. J. Biol. Chem. 298 , 101930 (2022). 35421375 10.1016/j.jbc.2022.101930 PMC9108985

745. Zavareh RB HSP90 inhibition enhances cancer immunotherapy by modulating the surface expression of multiple immune checkpoint proteins Cell Chem. Biol. 2021 28 158 168.e155 10.1016/j.chembiol.2020.10.005 33113406 Zavareh, R. B. et al. HSP90 inhibition enhances cancer immunotherapy by modulating the surface expression of multiple immune checkpoint proteins. Cell Chem. Biol. 28 , 158–168.e155 (2021). 33113406 10.1016/j.chembiol.2020.10.005

746. Xu X Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation Nat. Commun. 2024 15 4237 10.1038/s41467-024-48597-3 38762492 PMC11102475 Xu, X. et al. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation. Nat. Commun. 15 , 4237 (2024). 38762492 10.1038/s41467-024-48597-3 PMC11102475

747. Jaeger AM Rebalancing protein homeostasis enhances tumor antigen presentation Clin. Cancer Res 2019 25 6392 6405 10.1158/1078-0432.CCR-19-0596 31213460 PMC6825536 Jaeger, A. M. et al. Rebalancing protein homeostasis enhances tumor antigen presentation. Clin. Cancer Res 25 , 6392–6405 (2019). 31213460 10.1158/1078-0432.CCR-19-0596 PMC6825536

748. Gilardini Montani MS KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 alpha-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression Br. J. Cancer 2020 123 298 306 10.1038/s41416-020-0872-0 32418990 PMC7374093 Gilardini Montani, M. S. et al. KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 alpha-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression. Br. J. Cancer 123 , 298–306 (2020). 32418990 10.1038/s41416-020-0872-0 PMC7374093

749. Batista A IRE1alpha regulates macrophage polarization, PD-L1 expression, and tumor survival PLoS Biol. 2020 18 e3000687 10.1371/journal.pbio.3000687 32520957 PMC7307794 Batista, A. et al. IRE1alpha regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biol. 18 , e3000687 (2020). 32520957 10.1371/journal.pbio.3000687 PMC7307794

750. Liu J Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages Hepatology 2019 70 241 258 10.1002/hep.30607 30854665 PMC6597282 Liu, J. et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages. Hepatology 70 , 241–258 (2019). 30854665 10.1002/hep.30607 PMC6597282

751. Liu L Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity Cell Rep. Med 2023 4 101206 10.1016/j.xcrm.2023.101206 37769655 PMC10591028 Liu, L. et al. Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. Cell Rep. Med 4 , 101206 (2023). 37769655 10.1016/j.xcrm.2023.101206 PMC10591028

752. Lin J Targeting the IRE1alpha/XBP1s pathway suppresses CARM1-expressing ovarian cancer Nat. Commun. 2021 12 5321 10.1038/s41467-021-25684-3 34493732 PMC8423755 Lin, J. et al. Targeting the IRE1alpha/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat. Commun. 12 , 5321 (2021). 34493732 10.1038/s41467-021-25684-3 PMC8423755

753. Chu Y Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance Nat. Med 2023 29 1550 1562 10.1038/s41591-023-02371-y 37248301 PMC11421770 Chu, Y. et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat. Med 29 , 1550–1562 (2023). 37248301 10.1038/s41591-023-02371-y PMC11421770

754. Guan X Androgen receptor activity in T cells limits checkpoint blockade efficacy Nature 2022 606 791 796 10.1038/s41586-022-04522-6 35322234 PMC10294141 Guan, X. et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606 , 791–796 (2022). 35322234 10.1038/s41586-022-04522-6 PMC10294141